assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id,aidx
1,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019,,,CLD0
2,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219,,,CLD0
3,15453,,B,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019,,,CLD0
4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,Striatum,,Membrane,104729,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249,2435.0,,CLD0
5,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219,,,CLD0
6,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219,,,CLD0
7,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219,,,CLD0
8,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219,,,CLD0
9,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219,,,CLD0
10,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219,,,CLD0
11,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219,,,CLD0
12,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219,,,CLD0
13,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218,,,CLD0
14,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218,,,CLD0
15,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218,,,CLD0
16,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218,,,CLD0
17,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122,D,9,Expert,1,,CHEMBL884521,,BAO_0000357,,,CLD0
18,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357,,,CLD0
19,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019,,,CLD0
20,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357,,,CLD0
21,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357,,,CLD0
22,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357,,,CLD0
23,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357,,,CLD0
24,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357,,,CLD0
25,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,Endothelial cell,,22226,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219,,,CLD0
26,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357,,,CLD0
27,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357,,,CLD0
28,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219,,,CLD0
29,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357,,,CLD0
30,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357,,,CLD0
31,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357,,,CLD0
32,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357,,,CLD0
33,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357,,,CLD0
34,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357,,,CLD0
35,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357,,,CLD0
36,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019,,,CLD0
37,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019,,,CLD0
38,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019,,,CLD0
39,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225,,,CLD0
40,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225,,,CLD0
41,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615153,,BAO_0000225,,,CLD0
42,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615154,,BAO_0000225,,,CLD0
43,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019,,,CLD0
44,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019,,,CLD0
45,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019,,,CLD0
46,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019,,,CLD0
47,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,Testis,,,12971,D,9,Expert,1,,CHEMBL615159,,BAO_0000221,473.0,,CLD0
48,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,Testis,,,12971,D,9,Expert,1,,CHEMBL615172,,BAO_0000221,473.0,,CLD0
49,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615173,,BAO_0000019,,,CLD0
50,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615174,,BAO_0000019,,,CLD0
51,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019,,,CLD0
52,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357,,,CLD0
53,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357,,,CLD0
54,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357,,,CLD0
55,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membrane,104740,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249,,,CLD0
56,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219,,,CLD0
57,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocyte,,104835,D,7,Autocuration,1,,CHEMBL615180,1758.0,BAO_0000219,,,CLD0
58,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocyte,,104821,D,7,Autocuration,1,,CHEMBL615181,1758.0,BAO_0000219,,,CLD0
59,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocyte,,104848,D,7,Autocuration,1,,CHEMBL615182,1758.0,BAO_0000219,,,CLD0
60,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219,,,CLD0
61,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219,,,CLD0
62,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219,,,CLD0
63,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219,,,CLD0
64,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219,,,CLD0
65,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219,,,CLD0
66,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219,,,CLD0
67,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219,,,CLD0
68,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219,,,CLD0
69,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219,,,CLD0
70,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219,,,CLD0
71,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219,,,CLD0
72,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219,,,CLD0
73,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219,,,CLD0
74,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219,,,CLD0
75,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219,,,CLD0
76,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219,,,CLD0
77,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,SCLC,,22226,U,0,Intermediate,1,,CHEMBL615198,333.0,BAO_0000219,,,CLD0
78,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121,D,9,Expert,1,,CHEMBL615199,,BAO_0000357,,,CLD0
79,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615200,,BAO_0000357,,,CLD0
80,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615201,,BAO_0000357,,,CLD0
81,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615202,,BAO_0000357,,,CLD0
82,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsome,11231,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251,,,CLD0
83,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsome,11231,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251,,,CLD0
84,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsome,11231,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251,,,CLD0
85,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsome,11231,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251,,,CLD0
86,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsome,12083,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251,2107.0,,CLD0
87,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019,,,CLD0
88,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019,,,CLD0
89,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019,,,CLD0
90,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12083,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251,2107.0,,CLD0
91,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12083,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251,2107.0,,CLD0
92,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12083,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251,2107.0,,CLD0
93,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615213,,BAO_0000357,,,CLD0
94,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615273,,BAO_0000357,,,CLD0
95,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219,,,CLD0
96,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219,,,CLD0
97,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219,,,CLD0
98,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219,,,CLD0
99,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219,,,CLD0
100,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606,N,1,Expert,1,,CHEMBL883130,,BAO_0000218,,,CLD0
101,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219,,,CLD0
102,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219,,,CLD0
103,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219,,,CLD0
104,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615329,5553.0,BAO_0000218,,,CLD0
105,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615330,5553.0,BAO_0000218,,,CLD0
106,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,HepG2 2.2.15,,50606,N,1,Expert,1,,CHEMBL615331,5553.0,BAO_0000218,,,CLD0
107,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615332,5553.0,BAO_0000218,,,CLD0
108,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615333,5553.0,BAO_0000218,,,CLD0
109,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615334,5553.0,BAO_0000218,,,CLD0
110,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615335,5553.0,BAO_0000218,,,CLD0
111,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615336,5553.0,BAO_0000218,,,CLD0
112,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615337,5553.0,BAO_0000218,,,CLD0
113,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615338,5553.0,BAO_0000218,,,CLD0
114,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615339,5553.0,BAO_0000218,,,CLD0
115,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2 2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615340,5553.0,BAO_0000218,,,CLD0
116,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219,,,CLD0
117,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsome,22226,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251,,,CLD0
118,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019,,,CLD0
119,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219,,,CLD0
120,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219,,,CLD0
121,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219,,,CLD0
122,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219,,,CLD0
123,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219,,,CLD0
124,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219,,,CLD0
125,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219,,,CLD0
126,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219,,,CLD0
127,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219,,,CLD0
128,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,116833,D,5,Expert,1,,CHEMBL615352,,BAO_0000220,,,CLD0
129,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,Brain,,,116833,D,5,Intermediate,1,,CHEMBL615353,,BAO_0000220,955.0,,CLD0
130,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615354,,BAO_0000220,,,CLD0
131,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615355,,BAO_0000220,,,CLD0
132,3260,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220,,,CLD0
133,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019,,,CLD0
134,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219,,,CLD0
135,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219,,,CLD0
136,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019,,,CLD0
137,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357,,,CLD0
138,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218,948.0,,CLD0
139,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019,,,CLD0
140,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615363,,BAO_0000019,,,CLD0
141,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357,,,CLD0
142,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615365,,BAO_0000019,,,CLD0
143,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219,,,CLD0
144,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219,,,CLD0
145,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219,,,CLD0
146,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019,,,CLD0
147,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019,,,CLD0
148,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357,,,CLD0
149,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CEM/MTX,,22226,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000219,,,CLD0
150,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CEM/MTX,,22226,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000219,,,CLD0
151,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219,,,CLD0
152,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219,,,CLD0
153,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219,,,CLD0
154,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219,,,CLD0
155,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,CEM/MTX,,22226,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000219,,,CLD0
156,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CEM/MTX,,22226,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000219,,,CLD0
157,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249,,,CLD0
158,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218,,,CLD0
159,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human alphaherpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218,,,CLD0
160,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,Human alphaherpesvirus 3,10335.0,,,HEL,,50527,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218,,,CLD0
161,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,Human alphaherpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218,,,CLD0
162,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,Human alphaherpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218,,,CLD0
163,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218,,,CLD0
164,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019,,,CLD0
165,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143,H,8,Expert,1,,CHEMBL615377,,BAO_0000249,,,CLD0
166,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077,H,8,Expert,1,,CHEMBL615378,,BAO_0000357,,,CLD0
167,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219,,,CLD0
168,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,RBL,,12166,D,9,Expert,1,,CHEMBL615380,,BAO_0000219,,,CLD0
169,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357,,,CLD0
170,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357,,,CLD0
171,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357,,,CLD0
172,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357,,,CLD0
173,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357,,,CLD0
174,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357,,,CLD0
175,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357,,,CLD0
176,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357,,,CLD0
177,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357,,,CLD0
178,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357,,,CLD0
179,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357,,,CLD0
180,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357,,,CLD0
181,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357,,,CLD0
182,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357,,,CLD0
183,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357,,,CLD0
184,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019,,,CLD0
185,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219,,,CLD0
186,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,NSCLC,,22226,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000219,,,CLD0
187,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357,,,CLD0
188,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357,,,CLD0
189,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357,,,CLD0
190,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357,,,CLD0
191,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357,,,CLD0
192,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347,D,9,Expert,1,,CHEMBL615228,,BAO_0000019,,,CLD0
193,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615229,,BAO_0000357,,,CLD0
194,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120,D,9,Expert,1,,CHEMBL615230,,BAO_0000221,2369.0,,CLD0
195,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615231,,BAO_0000357,,,CLD0
196,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL884520,,BAO_0000357,,,CLD0
197,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615232,,BAO_0000357,,,CLD0
198,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019,,,CLD0
199,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357,,,CLD0
200,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357,,,CLD0
201,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019,,,CLD0
202,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019,,,CLD0
203,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019,,,CLD0
204,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019,,,CLD0
205,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019,,,CLD0
206,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019,,,CLD0
207,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835,H,8,Expert,1,,CHEMBL615241,,BAO_0000019,,,CLD0
208,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601,H,8,Expert,1,,CHEMBL615242,,BAO_0000357,,,CLD0
209,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019,,,CLD0
210,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019,,,CLD0
211,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019,,,CLD0
212,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019,,,CLD0
213,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019,,,CLD0
214,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019,,,CLD0
215,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357,,,CLD0
216,11966,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357,,,CLD0
217,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019,,,CLD0
218,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,Plasma,,,12052,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000366,1969.0,,CLD0
219,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Expert,1,,CHEMBL828340,,BAO_0000019,,,CLD0
220,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019,,,CLD0
221,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019,,,CLD0
222,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019,,,CLD0
223,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019,,,CLD0
224,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019,,,CLD0
225,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019,,,CLD0
226,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219,,,CLD0
227,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219,,,CLD0
228,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219,,,CLD0
229,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M/CDDP,,80007,N,1,Intermediate,1,,CHEMBL615262,,BAO_0000219,,,CLD0
230,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41McisR,,80007,N,1,Expert,1,,CHEMBL615263,5599.0,BAO_0000219,,,CLD0
231,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41McisR,,80007,N,1,Expert,1,,CHEMBL838393,5599.0,BAO_0000219,,,CLD0
232,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41McisR,,80007,N,1,Intermediate,1,,CHEMBL615264,5599.0,BAO_0000219,,,CLD0
233,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84,D,9,Expert,1,,CHEMBL615265,,BAO_0000357,,,CLD0
234,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68,D,9,Expert,1,,CHEMBL615266,,BAO_0000357,,,CLD0
235,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68,H,8,Expert,1,,CHEMBL615267,,BAO_0000357,,,CLD0
236,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615268,,BAO_0000357,,,CLD0
237,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615269,,BAO_0000357,,,CLD0
238,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615270,,BAO_0000357,,,CLD0
239,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357,,,CLD0
240,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357,,,CLD0
241,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357,,,CLD0
242,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357,,,CLD0
243,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357,,,CLD0
244,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357,,,CLD0
245,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357,,,CLD0
246,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019,,,CLD0
247,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357,,,CLD0
248,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357,,,CLD0
249,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357,,,CLD0
250,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019,,,CLD0
251,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019,,,CLD0
252,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019,,,CLD0
253,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019,,,CLD0
254,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019,,,CLD0
255,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357,,,CLD0
256,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019,,,CLD0
257,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357,,,CLD0
258,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019,,,CLD0
259,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019,,,CLD0
260,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249,H,8,Expert,1,,CHEMBL615701,,BAO_0000357,,,CLD0
261,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019,,,CLD0
262,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019,,,CLD0
263,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019,,,CLD0
264,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019,,,CLD0
265,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019,,,CLD0
266,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221,2116.0,,CLD0
267,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL615708,,BAO_0000019,,,CLD0
268,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357,,,CLD0
269,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22221,N,1,Autocuration,1,,CHEMBL615710,,BAO_0000218,,,CLD0
270,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019,,,CLD0
271,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL615712,,BAO_0000357,,,CLD0
272,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL836325,,BAO_0000357,,,CLD0
273,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019,,,CLD0
274,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357,,,CLD0
275,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019,,,CLD0
276,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019,,,CLD0
277,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019,,,CLD0
278,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,Frontal cortex,,,10577,H,8,Expert,1,,CHEMBL881818,,BAO_0000221,1870.0,,CLD0
279,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL884540,,BAO_0000357,,,CLD0
280,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224,,,CLD0
281,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224,,,CLD0
282,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membrane,104744,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249,,,CLD0
283,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membrane,104744,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249,,,CLD0
284,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000221,956.0,,CLD0
285,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019,,,CLD0
286,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221,10000000.0,,CLD0
287,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221,10000000.0,,CLD0
288,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221,10000000.0,,CLD0
289,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218,,,CLD0
290,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019,,,CLD0
291,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219,,,CLD0
292,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357,,,CLD0
293,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL615730,,BAO_0000019,,,CLD0
294,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,Tail,,,12687,H,8,Expert,1,,CHEMBL615731,,BAO_0000221,2415.0,,CLD0
295,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,Tail,,,12687,H,8,Expert,1,,CHEMBL615732,,BAO_0000221,2415.0,,CLD0
296,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,Artery,,,12687,H,8,Expert,1,,CHEMBL615733,,BAO_0000221,1637.0,,CLD0
297,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,Tail,,,12687,H,8,Expert,1,,CHEMBL615734,,BAO_0000221,2415.0,,CLD0
298,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,Tail,,,12687,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000221,2415.0,,CLD0
299,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,Tail,,,12687,H,8,Expert,1,,CHEMBL615736,,BAO_0000221,2415.0,,CLD0
300,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221,2116.0,,CLD0
301,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221,2116.0,,CLD0
302,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221,2116.0,,CLD0
303,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357,,,CLD0
304,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL615279,,BAO_0000019,,,CLD0
305,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL615280,,BAO_0000357,,,CLD0
306,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019,,,CLD0
307,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019,,,CLD0
308,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019,,,CLD0
309,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219,,,CLD0
310,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019,,,CLD0
311,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019,,,CLD0
312,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocyte,,104703,D,7,Autocuration,1,,CHEMBL615287,1758.0,BAO_0000219,,,CLD0
313,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220,,,CLD0
314,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220,,,CLD0
315,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219,,,CLD0
316,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219,,,CLD0
317,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,A2780 ADR,,22226,U,0,Autocuration,1,,CHEMBL615291,5594.0,BAO_0000219,,,CLD0
318,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225,,,CLD0
319,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225,,,CLD0
320,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225,,,CLD0
321,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225,,,CLD0
322,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22221,N,1,Autocuration,1,,CHEMBL825021,,BAO_0000019,,,CLD0
323,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22221,N,1,Autocuration,1,,CHEMBL615296,,BAO_0000019,,,CLD0
324,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019,,,CLD0
325,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22221,N,1,Autocuration,1,,CHEMBL615298,,BAO_0000019,,,CLD0
326,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22221,N,1,Autocuration,1,,CHEMBL615299,,BAO_0000019,,,CLD0
327,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22221,N,1,Autocuration,1,,CHEMBL615300,,BAO_0000019,,,CLD0
328,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357,,,CLD0
329,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241,D,9,Expert,1,,CHEMBL615302,,BAO_0000357,,,CLD0
330,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019,,,CLD0
331,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019,,,CLD0
332,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019,,,CLD0
333,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,Heart,,,12132,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218,948.0,,CLD0
334,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,Liver,,,12132,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218,2107.0,,CLD0
335,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,Liver,,,12132,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218,2107.0,,CLD0
336,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,Liver,,,12132,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218,2107.0,,CLD0
337,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,Liver,,,22226,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000221,2107.0,,CLD0
338,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,Liver,,,12132,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000221,2107.0,,CLD0
339,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019,,,CLD0
340,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019,,,CLD0
341,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019,,,CLD0
342,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019,,,CLD0
343,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218,,,CLD0
344,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,Heart,,,12132,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218,948.0,,CLD0
345,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,Liver,,,12132,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218,2107.0,,CLD0
346,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218,,,CLD0
347,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019,,,CLD0
348,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019,,,CLD0
349,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019,,,CLD0
350,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357,,,CLD0
351,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357,,,CLD0
352,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357,,,CLD0
353,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357,,,CLD0
354,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357,,,CLD0
355,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357,,,CLD0
356,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357,,,CLD0
357,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357,,,CLD0
358,166,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357,,,CLD0
359,3548,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019,,,CLD0
360,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251,2107.0,,CLD0
361,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251,2107.0,,CLD0
362,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251,2107.0,,CLD0
363,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251,2107.0,,CLD0
364,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251,2107.0,,CLD0
365,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251,2107.0,,CLD0
366,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251,2107.0,,CLD0
367,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251,2107.0,,CLD0
368,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251,2107.0,,CLD0
369,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251,2107.0,,CLD0
370,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,12236,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251,2107.0,,CLD0
371,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224,,,CLD0
372,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224,,,CLD0
373,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224,,,CLD0
374,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612,D,9,Expert,1,,CHEMBL615427,,BAO_0000357,,,CLD0
375,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219,,,CLD0
376,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219,,,CLD0
377,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219,,,CLD0
378,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019,,,CLD0
379,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218,,,CLD0
380,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218,,,CLD0
381,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,rhinovirus B14,12131.0,,,,,12464,H,8,Expert,1,,CHEMBL615434,,BAO_0000019,,,CLD0
382,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218,,,CLD0
383,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218,,,CLD0
384,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218,,,CLD0
385,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,rhinovirus B14,12131.0,,,,,12464,H,8,Expert,1,,CHEMBL615438,,BAO_0000019,,,CLD0
386,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,rhinovirus B14,12131.0,,,,,12464,H,8,Expert,1,,CHEMBL615439,,BAO_0000019,,,CLD0
387,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,rhinovirus B14,12131.0,,,,,12464,H,8,Expert,1,,CHEMBL615440,,BAO_0000019,,,CLD0
388,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,rhinovirus B14,12131.0,,,,,12464,H,8,Expert,1,,CHEMBL615441,,BAO_0000019,,,CLD0
389,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218,,,CLD0
390,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218,,,CLD0
391,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218,,,CLD0
392,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218,,,CLD0
393,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464,H,8,Expert,1,,CHEMBL615643,,BAO_0000357,,,CLD0
394,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019,,,CLD0
395,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218,,,CLD0
396,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218,,,CLD0
397,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218,,,CLD0
398,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218,,,CLD0
399,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218,,,CLD0
400,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218,,,CLD0
401,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,Lung,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218,2048.0,,CLD0
402,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,Lung,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218,2048.0,,CLD0
403,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,Lung,3LL cell line,,80620,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218,2048.0,,CLD0
404,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219,,,CLD0
405,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219,,,CLD0
406,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219,,,CLD0
407,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219,,,CLD0
408,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219,,,CLD0
409,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219,,,CLD0
410,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219,,,CLD0
411,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219,,,CLD0
412,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219,,,CLD0
413,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219,,,CLD0
414,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219,,,CLD0
415,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219,,,CLD0
416,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219,,,CLD0
417,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219,,,CLD0
418,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219,,,CLD0
419,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219,,,CLD0
420,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219,,,CLD0
421,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219,,,CLD0
422,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219,,,CLD0
423,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219,,,CLD0
424,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219,,,CLD0
425,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219,,,CLD0
426,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219,,,CLD0
427,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219,,,CLD0
428,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219,,,CLD0
429,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219,,,CLD0
430,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219,,,CLD0
431,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,M5076,,22226,U,0,Autocuration,1,,CHEMBL615591,516.0,BAO_0000218,,,CLD0
432,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,M5076,,22226,U,0,Autocuration,1,,CHEMBL615592,516.0,BAO_0000218,,,CLD0
433,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,Capsule,,,22226,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218,3893.0,,CLD0
434,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,Capsule,,,22226,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218,3893.0,,CLD0
435,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219,,,CLD0
436,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219,,,CLD0
437,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219,,,CLD0
438,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219,,,CLD0
439,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219,,,CLD0
440,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219,,,CLD0
441,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219,,,CLD0
442,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219,,,CLD0
443,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219,,,CLD0
444,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219,,,CLD0
445,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219,,,CLD0
446,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219,,,CLD0
447,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219,,,CLD0
448,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219,,,CLD0
449,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219,,,CLD0
450,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219,,,CLD0
451,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219,,,CLD0
452,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219,,,CLD0
453,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218,,,CLD0
454,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,BALB/c3T3,,104860,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219,,,CLD0
455,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219,,,CLD0
456,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219,,,CLD0
457,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219,,,CLD0
458,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,S-3T3,,11169,H,8,Expert,1,,CHEMBL615688,,BAO_0000219,,,CLD0
459,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219,,,CLD0
460,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219,,,CLD0
461,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,S-3T3,,11169,H,8,Expert,1,,CHEMBL615691,,BAO_0000219,,,CLD0
462,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,S-3T3,,11169,H,8,Expert,1,,CHEMBL615692,,BAO_0000219,,,CLD0
463,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219,,,CLD0
464,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219,,,CLD0
465,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219,,,CLD0
466,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219,,,CLD0
467,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219,,,CLD0
468,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219,,,CLD0
469,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219,,,CLD0
470,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219,,,CLD0
471,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219,,,CLD0
472,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219,,,CLD0
473,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219,,,CLD0
474,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219,,,CLD0
475,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219,,,CLD0
476,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219,,,CLD0
477,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219,,,CLD0
478,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219,,,CLD0
479,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219,,,CLD0
480,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219,,,CLD0
481,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219,,,CLD0
482,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219,,,CLD0
483,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219,,,CLD0
484,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219,,,CLD0
485,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218,,,CLD0
486,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219,,,CLD0
487,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219,,,CLD0
488,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219,,,CLD0
489,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219,,,CLD0
490,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218,,,CLD0
491,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218,,,CLD0
492,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219,,,CLD0
493,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219,,,CLD0
494,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219,,,CLD0
495,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219,,,CLD0
496,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219,,,CLD0
497,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218,,,CLD0
498,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218,,,CLD0
499,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218,,,CLD0
500,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218,,,CLD0
501,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218,,,CLD0
502,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218,,,CLD0
503,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218,,,CLD0
504,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218,,,CLD0
505,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218,,,CLD0
506,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218,,,CLD0
507,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218,,,CLD0
508,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218,,,CLD0
509,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219,,,CLD0
510,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219,,,CLD0
511,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219,,,CLD0
512,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218,,,CLD0
513,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218,,,CLD0
514,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218,,,CLD0
515,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218,,,CLD0
516,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218,,,CLD0
517,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219,,,CLD0
518,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219,,,CLD0
519,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219,,,CLD0
520,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219,,,CLD0
521,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219,,,CLD0
522,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219,,,CLD0
523,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219,,,CLD0
524,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219,,,CLD0
525,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219,,,CLD0
526,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219,,,CLD0
527,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219,,,CLD0
528,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219,,,CLD0
529,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219,,,CLD0
530,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219,,,CLD0
531,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219,,,CLD0
532,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219,,,CLD0
533,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219,,,CLD0
534,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219,,,CLD0
535,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019,,,CLD0
536,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019,,,CLD0
537,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019,,,CLD0
538,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615559,,BAO_0000019,,,CLD0
539,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019,,,CLD0
540,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019,,,CLD0
541,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL857062,,BAO_0000019,,,CLD0
542,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL615562,,BAO_0000019,,,CLD0
543,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019,,,CLD0
544,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357,,,CLD0
545,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019,,,CLD0
546,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019,,,CLD0
547,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615567,,BAO_0000019,,,CLD0
548,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019,,,CLD0
549,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357,,,CLD0
550,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019,,,CLD0
551,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019,,,CLD0
552,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224,,,CLD0
553,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019,,,CLD0
554,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019,,,CLD0
555,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019,,,CLD0
556,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357,,,CLD0
557,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357,,,CLD0
558,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221,10000000.0,,CLD0
559,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615579,,BAO_0000357,,,CLD0
560,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615580,,BAO_0000357,,,CLD0
561,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615581,,BAO_0000019,,,CLD0
562,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221,10000000.0,,CLD0
563,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221,10000000.0,,CLD0
564,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221,10000000.0,,CLD0
565,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221,10000000.0,,CLD0
566,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221,10000000.0,,CLD0
567,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221,10000000.0,,CLD0
568,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221,10000000.0,,CLD0
569,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221,10000000.0,,CLD0
570,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221,10000000.0,,CLD0
571,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membrane,10576,D,9,Expert,1,,CHEMBL615589,,BAO_0000249,,,CLD0
572,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615442,,BAO_0000221,10000000.0,,CLD0
573,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221,10000000.0,,CLD0
574,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221,10000000.0,,CLD0
575,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615445,,BAO_0000221,10000000.0,,CLD0
576,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221,10000000.0,,CLD0
577,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219,,,CLD0
578,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615448,,BAO_0000221,10000000.0,,CLD0
579,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615449,,BAO_0000221,10000000.0,,CLD0
580,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219,,,CLD0
581,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615451,,BAO_0000221,10000000.0,,CLD0
582,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357,,,CLD0
583,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221,10000000.0,,CLD0
584,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221,10000000.0,,CLD0
585,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221,10000000.0,,CLD0
586,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221,10000000.0,,CLD0
587,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221,10000000.0,,CLD0
588,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615458,,BAO_0000218,10000000.0,,CLD0
589,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615459,,BAO_0000221,10000000.0,,CLD0
590,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219,,,CLD0
591,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019,,,CLD0
592,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019,,,CLD0
593,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221,10000000.0,,CLD0
594,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221,2116.0,,CLD0
595,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221,2116.0,,CLD0
596,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221,2116.0,,CLD0
597,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221,2116.0,,CLD0
598,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221,2116.0,,CLD0
599,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221,2116.0,,CLD0
600,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357,,,CLD0
601,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357,,,CLD0
602,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357,,,CLD0
603,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221,10000000.0,,CLD0
604,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221,10000000.0,,CLD0
605,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218,,,CLD0
606,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357,,,CLD0
607,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219,,,CLD0
608,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219,,,CLD0
609,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019,,,CLD0
610,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219,,,CLD0
611,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219,,,CLD0
612,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219,,,CLD0
613,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219,,,CLD0
614,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219,,,CLD0
615,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219,,,CLD0
616,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219,,,CLD0
617,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219,,,CLD0
618,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219,,,CLD0
619,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219,,,CLD0
620,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219,,,CLD0
621,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219,,,CLD0
622,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019,,,CLD0
623,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019,,,CLD0
624,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615696,308.0,BAO_0000219,,,CLD0
625,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219,,,CLD0
626,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219,,,CLD0
627,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219,,,CLD0
628,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219,,,CLD0
629,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219,,,CLD0
630,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219,,,CLD0
631,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219,,,CLD0
632,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219,,,CLD0
633,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219,,,CLD0
634,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615982,,BAO_0000019,,,CLD0
635,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615983,,BAO_0000019,,,CLD0
636,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615984,,BAO_0000019,,,CLD0
637,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615985,,BAO_0000019,,,CLD0
638,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219,,,CLD0
639,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219,,,CLD0
640,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219,,,CLD0
641,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219,,,CLD0
642,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219,,,CLD0
643,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219,,,CLD0
644,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219,,,CLD0
645,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219,,,CLD0
646,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219,,,CLD0
647,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219,,,CLD0
648,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219,,,CLD0
649,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219,,,CLD0
650,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019,,,CLD0
651,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019,,,CLD0
652,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019,,,CLD0
653,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219,,,CLD0
654,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616002,,BAO_0000019,,,CLD0
655,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616003,,BAO_0000019,,,CLD0
656,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616004,,BAO_0000019,,,CLD0
657,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616005,,BAO_0000019,,,CLD0
658,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019,,,CLD0
659,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616007,,BAO_0000019,,,CLD0
660,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019,,,CLD0
661,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019,,,CLD0
662,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616010,,BAO_0000019,,,CLD0
663,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616011,,BAO_0000019,,,CLD0
664,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615740,,BAO_0000019,,,CLD0
665,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019,,,CLD0
666,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615742,,BAO_0000019,,,CLD0
667,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019,,,CLD0
668,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219,,,CLD0
669,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219,,,CLD0
670,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357,,,CLD0
671,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357,,,CLD0
672,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019,,,CLD0
673,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019,,,CLD0
674,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019,,,CLD0
675,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616259,,BAO_0000019,,,CLD0
676,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019,,,CLD0
677,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616261,,BAO_0000019,,,CLD0
678,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616262,,BAO_0000019,,,CLD0
679,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616263,,BAO_0000019,,,CLD0
680,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616264,,BAO_0000019,,,CLD0
681,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616265,,BAO_0000019,,,CLD0
682,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616266,,BAO_0000019,,,CLD0
683,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616267,,BAO_0000019,,,CLD0
684,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616268,,BAO_0000019,,,CLD0
685,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616269,,BAO_0000357,,,CLD0
686,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219,,,CLD0
687,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105,H,8,Expert,1,,CHEMBL616270,722.0,BAO_0000219,,,CLD0
688,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219,,,CLD0
689,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219,,,CLD0
690,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616273,,BAO_0000357,,,CLD0
691,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616274,,BAO_0000357,,,CLD0
692,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219,,,CLD0
693,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219,,,CLD0
694,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218,955.0,,CLD0
695,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218,955.0,,CLD0
696,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218,955.0,,CLD0
697,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218,955.0,,CLD0
698,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218,955.0,,CLD0
699,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218,955.0,,CLD0
700,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218,955.0,,CLD0
701,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218,955.0,,CLD0
702,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218,955.0,,CLD0
703,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218,955.0,,CLD0
704,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218,955.0,,CLD0
705,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218,955.0,,CLD0
706,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218,955.0,,CLD0
707,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218,955.0,,CLD0
708,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218,955.0,,CLD0
709,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218,955.0,,CLD0
710,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218,955.0,,CLD0
711,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218,955.0,,CLD0
712,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218,955.0,,CLD0
713,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019,,,CLD0
714,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,Membrane,11923,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249,1898.0,,CLD0
715,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019,,,CLD0
716,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019,,,CLD0
717,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL615620,,BAO_0000019,,,CLD0
718,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357,,,CLD0
719,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357,,,CLD0
720,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019,,,CLD0
721,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019,,,CLD0
722,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019,,,CLD0
723,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019,,,CLD0
724,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019,,,CLD0
725,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019,,,CLD0
726,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019,,,CLD0
727,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357,,,CLD0
728,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL615630,,BAO_0000221,178.0,,CLD0
729,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219,,,CLD0
730,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218,,,CLD0
731,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357,,,CLD0
732,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218,,,CLD0
733,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Expert,1,,CHEMBL615635,,BAO_0000019,,,CLD0
734,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL615636,,BAO_0000357,,,CLD0
735,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615637,,BAO_0000357,,,CLD0
736,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219,,,CLD0
737,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219,,,CLD0
738,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219,,,CLD0
739,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000221,178.0,,CLD0
740,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219,,,CLD0
741,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357,,,CLD0
742,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219,,,CLD0
743,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357,,,CLD0
744,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019,,,CLD0
745,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357,,,CLD0
746,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357,,,CLD0
747,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219,,,CLD0
748,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019,,,CLD0
749,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000221,2367.0,,CLD0
750,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019,,,CLD0
751,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019,,,CLD0
752,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019,,,CLD0
753,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357,,,CLD0
754,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615856,,BAO_0000019,,,CLD0
755,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615857,,BAO_0000019,,,CLD0
756,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615858,,BAO_0000019,,,CLD0
757,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615859,,BAO_0000221,10000000.0,,CLD0
758,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357,,,CLD0
759,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,22226,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000221,7318.0,,CLD0
760,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,22226,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000221,7318.0,,CLD0
761,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,22226,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000221,7318.0,,CLD0
762,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,22226,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000221,7318.0,,CLD0
763,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221,10000000.0,,CLD0
764,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221,10000000.0,,CLD0
765,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221,10000000.0,,CLD0
766,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,Frontal cortex,,Membrane,104744,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249,1870.0,,CLD0
767,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,Brain,,,104744,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249,955.0,,CLD0
768,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,104744,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000221,1870.0,,CLD0
769,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,104744,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000221,1870.0,,CLD0
770,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224,,,CLD0
771,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221,10000000.0,,CLD0
772,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221,10000000.0,,CLD0
773,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224,,,CLD0
774,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019,,,CLD0
775,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249,,,CLD0
776,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000221,956.0,,CLD0
777,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000221,956.0,,CLD0
778,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221,955.0,,CLD0
779,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221,955.0,,CLD0
780,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019,,,CLD0
781,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224,,,CLD0
782,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224,,,CLD0
783,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224,,,CLD0
784,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224,,,CLD0
785,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224,,,CLD0
786,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000221,956.0,,CLD0
787,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000221,956.0,,CLD0
788,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224,,,CLD0
789,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019,,,CLD0
790,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221,955.0,,CLD0
791,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221,955.0,,CLD0
792,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224,,,CLD0
793,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221,955.0,,CLD0
794,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000221,956.0,,CLD0
795,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019,,,CLD0
796,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019,,,CLD0
797,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,Prefrontal cortex,,,104744,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000221,451.0,,CLD0
798,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019,,,CLD0
799,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019,,,CLD0
800,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221,955.0,,CLD0
801,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104744,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000221,956.0,,CLD0
802,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,Synaptosomes,104744,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220,955.0,,CLD0
803,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221,955.0,,CLD0
804,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019,,,CLD0
805,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019,,,CLD0
806,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615785,,BAO_0000357,,,CLD0
807,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249,,,CLD0
808,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218,,,CLD0
809,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218,,,CLD0
810,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019,,,CLD0
811,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218,,,CLD0
812,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218,,,CLD0
813,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019,,,CLD0
814,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,GH4ZD10,,10576,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219,,,CLD0
815,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,GH4ZD10,,51,H,8,Expert,1,,CHEMBL615815,,BAO_0000219,,,CLD0
816,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,GH4ZD10,,10576,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219,,,CLD0
817,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615817,,BAO_0000249,955.0,,CLD0
818,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221,10000000.0,,CLD0
819,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221,10000000.0,,CLD0
820,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,Hippocampus,,Membrane,10576,H,8,Expert,1,,CHEMBL615820,,BAO_0000249,10000000.0,,CLD0
821,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615821,,BAO_0000221,10000000.0,,CLD0
822,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615822,,BAO_0000221,10000000.0,,CLD0
823,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615823,,BAO_0000221,10000000.0,,CLD0
824,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615824,,BAO_0000221,10000000.0,,CLD0
825,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615825,,BAO_0000221,10000000.0,,CLD0
826,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615826,,BAO_0000357,,,CLD0
827,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,Membrane,10576,H,8,Expert,1,,CHEMBL615827,,BAO_0000249,10000000.0,,CLD0
828,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,Membrane,10576,H,8,Expert,1,,CHEMBL615828,,BAO_0000249,10000000.0,,CLD0
829,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615829,,BAO_0000221,10000000.0,,CLD0
830,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221,10000000.0,,CLD0
831,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615831,,BAO_0000221,10000000.0,,CLD0
832,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357,,,CLD0
833,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019,,,CLD0
834,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221,10000000.0,,CLD0
835,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,Hippocampus,,Membrane,10576,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249,10000000.0,,CLD0
836,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249,10000000.0,,CLD0
837,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL615837,,BAO_0000221,955.0,,CLD0
838,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL615838,,BAO_0000221,955.0,,CLD0
839,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615839,,BAO_0000249,10000000.0,,CLD0
840,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019,,,CLD0
841,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,Cerebral cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249,956.0,,CLD0
842,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615405,,BAO_0000221,10000000.0,,CLD0
843,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,Frontal cortex,,,10576,H,8,Expert,1,,CHEMBL615406,,BAO_0000221,1870.0,,CLD0
844,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615900,,BAO_0000221,10000000.0,,CLD0
845,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615901,,BAO_0000221,10000000.0,,CLD0
846,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615902,,BAO_0000357,,,CLD0
847,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221,10000000.0,,CLD0
848,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357,,,CLD0
849,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615905,,BAO_0000357,,,CLD0
850,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019,,,CLD0
851,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019,,,CLD0
852,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL615908,,BAO_0000221,956.0,,CLD0
853,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221,10000000.0,,CLD0
854,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019,,,CLD0
855,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019,,,CLD0
856,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019,,,CLD0
857,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL615913,,BAO_0000221,956.0,,CLD0
858,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615914,,BAO_0000357,,,CLD0
859,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221,10000000.0,,CLD0
860,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357,,,CLD0
861,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615917,,BAO_0000357,,,CLD0
862,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615918,,BAO_0000357,,,CLD0
863,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615919,,BAO_0000249,10000000.0,,CLD0
864,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615920,,BAO_0000221,10000000.0,,CLD0
865,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357,,,CLD0
866,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615922,,BAO_0000357,,,CLD0
867,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL881290,,BAO_0000249,,,CLD0
868,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221,10000000.0,,CLD0
869,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221,10000000.0,,CLD0
870,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221,10000000.0,,CLD0
871,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615926,,BAO_0000357,,,CLD0
872,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615927,,BAO_0000019,,,CLD0
873,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221,10000000.0,,CLD0
874,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615929,,BAO_0000357,,,CLD0
875,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221,10000000.0,,CLD0
876,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219,,,CLD0
877,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219,,,CLD0
878,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219,,,CLD0
879,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357,,,CLD0
880,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357,,,CLD0
881,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019,,,CLD0
882,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219,,,CLD0
883,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357,,,CLD0
884,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357,,,CLD0
885,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357,,,CLD0
886,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357,,,CLD0
887,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357,,,CLD0
888,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357,,,CLD0
889,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219,,,CLD0
890,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,Jugular vein,,,51,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000221,4711.0,,CLD0
891,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357,,,CLD0
892,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL835002,,BAO_0000019,,,CLD0
893,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019,,,CLD0
894,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219,,,CLD0
895,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219,,,CLD0
896,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615807,,BAO_0000357,,,CLD0
897,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357,,,CLD0
898,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615809,,BAO_0000357,,,CLD0
899,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219,,,CLD0
900,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357,,,CLD0
901,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219,,,CLD0
902,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219,,,CLD0
903,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357,,,CLD0
904,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219,,,CLD0
905,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219,,,CLD0
906,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357,,,CLD0
907,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219,,,CLD0
908,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019,,,CLD0
909,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357,,,CLD0
910,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615759,,BAO_0000357,,,CLD0
911,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357,,,CLD0
912,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219,,,CLD0
913,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357,,,CLD0
914,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357,,,CLD0
915,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357,,,CLD0
916,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357,,,CLD0
917,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219,,,CLD0
918,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019,,,CLD0
919,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357,,,CLD0
920,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615768,,BAO_0000357,,,CLD0
921,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357,,,CLD0
922,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615770,,BAO_0000357,,,CLD0
923,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357,,,CLD0
924,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615772,,BAO_0000357,,,CLD0
925,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357,,,CLD0
926,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615774,,BAO_0000357,,,CLD0
927,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357,,,CLD0
928,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357,,,CLD0
929,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615777,,BAO_0000357,,,CLD0
930,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,AK,,51,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219,,,CLD0
931,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615779,,BAO_0000357,,,CLD0
932,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357,,,CLD0
933,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357,,,CLD0
934,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357,,,CLD0
935,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219,,,CLD0
936,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219,,,CLD0
937,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019,,,CLD0
938,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019,,,CLD0
939,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019,,,CLD0
940,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019,,,CLD0
941,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219,,,CLD0
942,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357,,,CLD0
943,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357,,,CLD0
944,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357,,,CLD0
945,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616124,,BAO_0000357,,,CLD0
946,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616125,,BAO_0000357,,,CLD0
947,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Expert,1,,CHEMBL616126,,BAO_0000357,,,CLD0
948,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219,,,CLD0
949,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616128,,BAO_0000019,,,CLD0
950,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357,,,CLD0
951,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616130,,BAO_0000357,,,CLD0
952,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357,,,CLD0
953,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219,,,CLD0
954,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219,,,CLD0
955,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357,,,CLD0
956,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357,,,CLD0
957,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616136,,BAO_0000357,,,CLD0
958,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019,,,CLD0
959,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019,,,CLD0
960,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357,,,CLD0
961,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616139,,BAO_0000357,,,CLD0
962,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616140,308.0,BAO_0000219,,,CLD0
963,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616141,,BAO_0000019,,,CLD0
964,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357,,,CLD0
965,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357,,,CLD0
966,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219,,,CLD0
967,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219,,,CLD0
968,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219,,,CLD0
969,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219,,,CLD0
970,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019,,,CLD0
971,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019,,,CLD0
972,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019,,,CLD0
973,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218,,,CLD0
974,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,ovary,,51,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000219,,,CLD0
975,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019,,,CLD0
976,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019,,,CLD0
977,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357,,,CLD0
978,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219,,,CLD0
979,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616022,,BAO_0000019,,,CLD0
980,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019,,,CLD0
981,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019,,,CLD0
982,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019,,,CLD0
983,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219,,,CLD0
984,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019,,,CLD0
985,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616028,,BAO_0000019,,,CLD0
986,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616029,,BAO_0000019,,,CLD0
987,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219,,,CLD0
988,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616031,449.0,BAO_0000219,,,CLD0
989,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616032,,BAO_0000019,,,CLD0
990,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616033,,BAO_0000019,,,CLD0
991,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019,,,CLD0
992,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019,,,CLD0
993,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019,,,CLD0
994,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019,,,CLD0
995,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019,,,CLD0
996,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019,,,CLD0
997,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019,,,CLD0
998,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219,,,CLD0
999,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219,,,CLD0
1000,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219,,,CLD0
1001,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019,,,CLD0
1002,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616045,308.0,BAO_0000219,,,CLD0
1003,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219,,,CLD0
1004,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219,,,CLD0
1005,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219,,,CLD0
1006,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219,,,CLD0
1007,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219,,,CLD0
1008,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,HA7,,51,H,8,Expert,1,,CHEMBL616051,,BAO_0000219,,,CLD0
1009,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,HA7,,51,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219,,,CLD0
1010,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616213,308.0,BAO_0000219,,,CLD0
1011,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,Ha7,,51,H,8,Expert,1,,CHEMBL616214,,BAO_0000219,,,CLD0
1012,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,Ha7,,51,H,8,Expert,1,,CHEMBL616215,,BAO_0000219,,,CLD0
1013,12861,Binding activity radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357,,,CLD0
1014,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019,,,CLD0
1015,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357,,,CLD0
1016,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357,,,CLD0
1017,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357,,,CLD0
1018,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL833493,,BAO_0000357,,,CLD0
1019,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357,,,CLD0
1020,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219,,,CLD0
1021,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019,,,CLD0
1022,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019,,,CLD0
1023,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,ovary,,51,H,8,Expert,1,,CHEMBL616225,,BAO_0000219,,,CLD0
1024,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219,,,CLD0
1025,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219,,,CLD0
1026,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219,,,CLD0
1027,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219,,,CLD0
1028,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219,,,CLD0
1029,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219,,,CLD0
1030,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357,,,CLD0
1031,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219,,,CLD0
1032,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219,,,CLD0
1033,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219,,,CLD0
1034,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357,,,CLD0
1035,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219,,,CLD0
1036,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616237,,BAO_0000019,,,CLD0
1037,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219,,,CLD0
1038,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219,,,CLD0
1039,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219,,,CLD0
1040,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219,,,CLD0
1041,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219,,,CLD0
1042,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219,,,CLD0
1043,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616244,,BAO_0000357,,,CLD0
1044,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357,,,CLD0
1045,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357,,,CLD0
1046,5254,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357,,,CLD0
1047,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357,,,CLD0
1048,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357,,,CLD0
1049,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357,,,CLD0
1050,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357,,,CLD0
1051,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218,,,CLD0
1052,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218,,,CLD0
1053,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218,,,CLD0
1054,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616255,,BAO_0000218,,,CLD0
1055,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL832872,,BAO_0000218,,,CLD0
1056,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616256,,BAO_0000218,,,CLD0
1057,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616257,,BAO_0000218,,,CLD0
1058,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616258,,BAO_0000218,,,CLD0
1059,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616384,,BAO_0000218,,,CLD0
1060,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221,10000000.0,,CLD0
1061,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863,H,8,Expert,1,,CHEMBL616386,,BAO_0000357,,,CLD0
1062,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616387,,BAO_0000221,10000000.0,,CLD0
1063,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221,10000000.0,,CLD0
1064,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616389,,BAO_0000221,10000000.0,,CLD0
1065,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221,10000000.0,,CLD0
1066,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357,,,CLD0
1067,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616392,,BAO_0000221,10000000.0,,CLD0
1068,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357,,,CLD0
1069,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357,,,CLD0
1070,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,Brain,,,51,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000221,955.0,,CLD0
1071,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357,,,CLD0
1072,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,Brain,,,51,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000221,955.0,,CLD0
1073,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,Brain,,,51,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000221,955.0,,CLD0
1074,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019,,,CLD0
1075,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616399,,BAO_0000357,,,CLD0
1076,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357,,,CLD0
1077,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616400,,BAO_0000019,,,CLD0
1078,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019,,,CLD0
1079,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL616402,,BAO_0000019,,,CLD0
1080,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616403,,BAO_0000019,,,CLD0
1081,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221,10000000.0,,CLD0
1082,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,Frontal cortex,,Membrane,51,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249,1870.0,,CLD0
1083,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019,,,CLD0
1084,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,Cortex,,,51,H,8,Expert,1,,CHEMBL616407,,BAO_0000221,1851.0,,CLD0
1085,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019,,,CLD0
1086,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,Hippocampus,,Membrane,10576,D,9,Expert,1,,CHEMBL616409,,BAO_0000249,10000000.0,,CLD0
1087,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616410,,BAO_0000221,10000000.0,,CLD0
1088,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357,,,CLD0
1089,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membrane,10576,D,9,Expert,1,,CHEMBL616412,,BAO_0000249,,,CLD0
1090,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membrane,10576,D,9,Expert,1,,CHEMBL616413,,BAO_0000249,10000000.0,,CLD0
1091,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221,10000000.0,,CLD0
1092,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616415,,BAO_0000221,10000000.0,,CLD0
1093,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019,,,CLD0
1094,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616417,,BAO_0000357,,,CLD0
1095,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357,,,CLD0
1096,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219,,,CLD0
1097,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357,,,CLD0
1098,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249,,,CLD0
1099,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249,,,CLD0
1100,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membrane,10576,H,8,Expert,1,,CHEMBL616423,,BAO_0000249,,,CLD0
1101,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616424,,BAO_0000357,,,CLD0
1102,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616425,,BAO_0000357,,,CLD0
1103,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616426,,BAO_0000357,,,CLD0
1104,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221,10000000.0,,CLD0
1105,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221,10000000.0,,CLD0
1106,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221,10000000.0,,CLD0
1107,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616052,,BAO_0000357,,,CLD0
1108,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357,,,CLD0
1109,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,Cerebral cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249,956.0,,CLD0
1110,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357,,,CLD0
1111,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357,,,CLD0
1112,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616057,,BAO_0000019,,,CLD0
1113,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616058,,BAO_0000221,955.0,,CLD0
1114,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221,955.0,,CLD0
1115,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249,,,CLD0
1116,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616061,,BAO_0000221,10000000.0,,CLD0
1117,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616062,,BAO_0000221,10000000.0,,CLD0
1118,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249,,,CLD0
1119,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249,2435.0,,CLD0
1120,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membrane,10576,D,9,Expert,1,,CHEMBL616065,,BAO_0000249,,,CLD0
1121,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,Cerebral cortex,,Membrane,10576,D,9,Expert,1,,CHEMBL616066,,BAO_0000249,956.0,,CLD0
1122,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221,10000000.0,,CLD0
1123,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221,10000000.0,,CLD0
1124,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221,10000000.0,,CLD0
1125,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616070,,BAO_0000249,10000000.0,,CLD0
1126,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221,10000000.0,,CLD0
1127,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616072,,BAO_0000221,10000000.0,,CLD0
1128,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221,10000000.0,,CLD0
1129,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221,10000000.0,,CLD0
1130,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,Frontal cortex,,,10576,H,8,Expert,1,,CHEMBL616075,,BAO_0000221,1870.0,,CLD0
1131,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357,,,CLD0
1132,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616077,,BAO_0000019,,,CLD0
1133,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616078,,BAO_0000019,,,CLD0
1134,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616079,,BAO_0000019,,,CLD0
1135,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219,,,CLD0
1136,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357,,,CLD0
1137,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616082,,BAO_0000221,10000000.0,,CLD0
1138,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221,10000000.0,,CLD0
1139,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,10576,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000221,956.0,,CLD0
1140,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,Frontal cortex,,,10576,H,8,Expert,1,,CHEMBL616085,,BAO_0000221,1870.0,,CLD0
1141,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,Cerebral cortex,,,10576,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000221,956.0,,CLD0
1142,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221,10000000.0,,CLD0
1143,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616088,,BAO_0000357,,,CLD0
1144,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019,,,CLD0
1145,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616090,,BAO_0000357,,,CLD0
1146,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357,,,CLD0
1147,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249,2435.0,,CLD0
1148,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357,,,CLD0
1149,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218,,,CLD0
1150,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221,955.0,,CLD0
1151,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616096,,BAO_0000357,,,CLD0
1152,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616097,,BAO_0000249,955.0,,CLD0
1153,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membrane,10576,D,9,Expert,1,,CHEMBL616098,,BAO_0000249,,,CLD0
1154,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221,10000000.0,,CLD0
1155,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221,10000000.0,,CLD0
1156,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616101,,BAO_0000357,,,CLD0
1157,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,Cerebral cortex,,Membrane,10576,H,8,Expert,1,,CHEMBL616102,,BAO_0000249,956.0,,CLD0
1158,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357,,,CLD0
1159,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL616104,,BAO_0000221,956.0,,CLD0
1160,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616105,,BAO_0000019,,,CLD0
1161,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616106,,BAO_0000019,,,CLD0
1162,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,Cerebral cortex,,,10576,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000221,956.0,,CLD0
1163,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616108,,BAO_0000357,,,CLD0
1164,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616109,,BAO_0000221,10000000.0,,CLD0
1165,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357,,,CLD0
1166,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219,,,CLD0
1167,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616112,,BAO_0000019,,,CLD0
1168,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221,10000000.0,,CLD0
1169,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019,,,CLD0
1170,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019,,,CLD0
1171,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357,,,CLD0
1172,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615844,,BAO_0000221,955.0,,CLD0
1173,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615939,,BAO_0000221,10000000.0,,CLD0
1174,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615940,,BAO_0000019,,,CLD0
1175,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615941,,BAO_0000221,10000000.0,,CLD0
1176,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221,10000000.0,,CLD0
1177,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221,10000000.0,,CLD0
1178,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221,10000000.0,,CLD0
1179,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221,10000000.0,,CLD0
1180,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221,10000000.0,,CLD0
1181,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221,10000000.0,,CLD0
1182,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221,10000000.0,,CLD0
1183,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221,10000000.0,,CLD0
1184,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221,10000000.0,,CLD0
1185,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221,10000000.0,,CLD0
1186,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221,10000000.0,,CLD0
1187,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221,10000000.0,,CLD0
1188,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221,10000000.0,,CLD0
1189,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615955,,BAO_0000221,10000000.0,,CLD0
1190,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221,10000000.0,,CLD0
1191,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221,10000000.0,,CLD0
1192,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,Frontal cortex,,,10576,H,8,Expert,1,,CHEMBL615958,,BAO_0000221,1870.0,,CLD0
1193,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,Frontal cortex,,,10576,H,8,Expert,1,,CHEMBL615959,,BAO_0000221,1870.0,,CLD0
1194,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,Frontal cortex,,,10576,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000221,1870.0,,CLD0
1195,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,Frontal cortex,,,10576,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000221,1870.0,,CLD0
1196,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615962,,BAO_0000221,955.0,,CLD0
1197,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,Striatum,,Membrane,10576,H,8,Expert,1,,CHEMBL615963,,BAO_0000019,2435.0,,CLD0
1198,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,Striatum,,Membrane,10576,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019,2435.0,,CLD0
1199,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,Striatum,,Membrane,10576,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019,2435.0,,CLD0
1200,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219,,,CLD0
1201,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615967,,BAO_0000249,,,CLD0
1202,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL615968,,BAO_0000221,956.0,,CLD0
1203,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218,,,CLD0
1204,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218,,,CLD0
1205,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615971,,BAO_0000357,,,CLD0
1206,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,Hippocampus,,Membrane,10576,H,8,Expert,1,,CHEMBL615972,,BAO_0000249,10000000.0,,CLD0
1207,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249,10000000.0,,CLD0
1208,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249,10000000.0,,CLD0
1209,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219,,,CLD0
1210,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615976,,BAO_0000249,10000000.0,,CLD0
1211,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL872106,,BAO_0000221,10000000.0,,CLD0
1212,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357,,,CLD0
1213,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357,,,CLD0
1214,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357,,,CLD0
1215,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357,,,CLD0
1216,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357,,,CLD0
1217,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357,,,CLD0
1218,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357,,,CLD0
1219,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357,,,CLD0
1220,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357,,,CLD0
1221,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357,,,CLD0
1222,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357,,,CLD0
1223,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357,,,CLD0
1224,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357,,,CLD0
1225,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357,,,CLD0
1226,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357,,,CLD0
1227,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019,,,CLD0
1228,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357,,,CLD0
1229,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357,,,CLD0
1230,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019,,,CLD0
1231,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221,10000000.0,,CLD0
1232,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615874,,BAO_0000019,,,CLD0
1233,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219,,,CLD0
1234,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019,,,CLD0
1235,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019,,,CLD0
1236,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357,,,CLD0
1237,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615879,,BAO_0000357,,,CLD0
1238,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615880,,BAO_0000357,,,CLD0
1239,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019,,,CLD0
1240,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615882,,BAO_0000019,,,CLD0
1241,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218,,,CLD0
1242,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218,,,CLD0
1243,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218,,,CLD0
1244,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218,,,CLD0
1245,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218,,,CLD0
1246,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218,,,CLD0
1247,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218,,,CLD0
1248,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218,,,CLD0
1249,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218,,,CLD0
1250,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218,,,CLD0
1251,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218,,,CLD0
1252,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218,,,CLD0
1253,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218,,,CLD0
1254,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218,,,CLD0
1255,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218,,,CLD0
1256,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membrane,10576,D,9,Expert,1,,CHEMBL615898,,BAO_0000249,,,CLD0
1257,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019,,,CLD0
1258,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019,,,CLD0
1259,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357,,,CLD0
1260,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249,,,CLD0
1261,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616294,,BAO_0000221,10000000.0,,CLD0
1262,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249,10000000.0,,CLD0
1263,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221,955.0,,CLD0
1264,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019,,,CLD0
1265,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019,,,CLD0
1266,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019,,,CLD0
1267,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019,,,CLD0
1268,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616608,,BAO_0000019,,,CLD0
1269,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019,,,CLD0
1270,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616610,,BAO_0000019,,,CLD0
1271,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019,,,CLD0
1272,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616612,,BAO_0000019,,,CLD0
1273,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019,,,CLD0
1274,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616614,,BAO_0000019,,,CLD0
1275,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019,,,CLD0
1276,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616616,,BAO_0000019,,,CLD0
1277,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019,,,CLD0
1278,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019,,,CLD0
1279,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019,,,CLD0
1280,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616620,,BAO_0000019,,,CLD0
1281,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616621,,BAO_0000019,,,CLD0
1282,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019,,,CLD0
1283,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616146,,BAO_0000019,,,CLD0
1284,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019,,,CLD0
1285,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019,,,CLD0
1286,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019,,,CLD0
1287,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019,,,CLD0
1288,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221,10000000.0,,CLD0
1289,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616150,,BAO_0000221,10000000.0,,CLD0
1290,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,Hippocampus,,Membrane,10576,D,9,Expert,1,,CHEMBL616151,,BAO_0000249,10000000.0,,CLD0
1291,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL872873,,BAO_0000221,10000000.0,,CLD0
1292,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221,10000000.0,,CLD0
1293,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221,10000000.0,,CLD0
1294,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL884861,,BAO_0000249,,,CLD0
1295,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357,,,CLD0
1296,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019,,,CLD0
1297,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL616674,,BAO_0000221,956.0,,CLD0
1298,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357,,,CLD0
1299,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221,10000000.0,,CLD0
1300,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221,10000000.0,,CLD0
1301,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221,10000000.0,,CLD0
1302,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616679,,BAO_0000357,,,CLD0
1303,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616680,,BAO_0000221,10000000.0,,CLD0
1304,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221,10000000.0,,CLD0
1305,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221,10000000.0,,CLD0
1306,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221,10000000.0,,CLD0
1307,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221,10000000.0,,CLD0
1308,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221,10000000.0,,CLD0
1309,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221,955.0,,CLD0
1310,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357,,,CLD0
1311,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357,,,CLD0
1312,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221,10000000.0,,CLD0
1313,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357,,,CLD0
1314,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616691,,BAO_0000357,,,CLD0
1315,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616692,,BAO_0000221,10000000.0,,CLD0
1316,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,Cortex,,,10576,H,8,Expert,1,,CHEMBL616693,,BAO_0000249,1851.0,,CLD0
1317,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616694,,BAO_0000221,955.0,,CLD0
1318,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221,10000000.0,,CLD0
1319,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357,,,CLD0
1320,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357,,,CLD0
1321,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357,,,CLD0
1322,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616949,,BAO_0000019,,,CLD0
1323,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221,10000000.0,,CLD0
1324,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357,,,CLD0
1325,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616951,,BAO_0000221,955.0,,CLD0
1326,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616952,,BAO_0000221,955.0,,CLD0
1327,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616953,,BAO_0000357,,,CLD0
1328,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357,,,CLD0
1329,14875,GTPgammaS radioligand binding assay,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357,,,CLD0
1330,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357,,,CLD0
1331,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019,,,CLD0
1332,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019,,,CLD0
1333,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357,,,CLD0
1334,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357,,,CLD0
1335,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019,,,CLD0
1336,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219,,,CLD0
1337,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219,,,CLD0
1338,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616524,,BAO_0000357,,,CLD0
1339,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219,,,CLD0
1340,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019,,,CLD0
1341,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019,,,CLD0
1342,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616527,,BAO_0000357,,,CLD0
1343,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616528,,BAO_0000219,,,CLD0
1344,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357,,,CLD0
1345,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357,,,CLD0
1346,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616531,,BAO_0000357,,,CLD0
1347,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357,,,CLD0
1348,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357,,,CLD0
1349,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616534,,BAO_0000357,,,CLD0
1350,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616535,,BAO_0000357,,,CLD0
1351,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357,,,CLD0
1352,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357,,,CLD0
1353,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219,,,CLD0
1354,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616539,,BAO_0000019,,,CLD0
1355,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616540,,BAO_0000019,,,CLD0
1356,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357,,,CLD0
1357,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616430,,BAO_0000357,,,CLD0
1358,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,106,D,9,Expert,1,,CHEMBL616431,643.0,BAO_0000219,,,CLD0
1359,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616432,,BAO_0000357,,,CLD0
1360,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616433,,BAO_0000357,,,CLD0
1361,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616434,,BAO_0000357,,,CLD0
1362,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219,,,CLD0
1363,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616436,,BAO_0000019,,,CLD0
1364,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219,,,CLD0
1365,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219,,,CLD0
1366,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219,,,CLD0
1367,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616440,,BAO_0000357,,,CLD0
1368,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219,,,CLD0
1369,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616442,,BAO_0000357,,,CLD0
1370,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357,,,CLD0
1371,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219,,,CLD0
1372,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616445,,BAO_0000357,,,CLD0
1373,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616446,,BAO_0000357,,,CLD0
1374,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219,,,CLD0
1375,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357,,,CLD0
1376,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219,,,CLD0
1377,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219,,,CLD0
1378,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219,,,CLD0
1379,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219,,,CLD0
1380,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219,,,CLD0
1381,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219,,,CLD0
1382,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219,,,CLD0
1383,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616455,,BAO_0000357,,,CLD0
1384,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219,,,CLD0
1385,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357,,,CLD0
1386,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219,,,CLD0
1387,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219,,,CLD0
1388,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616460,,BAO_0000019,,,CLD0
1389,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616461,,BAO_0000019,,,CLD0
1390,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219,,,CLD0
1391,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219,,,CLD0
1392,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019,,,CLD0
1393,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219,,,CLD0
1394,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357,,,CLD0
1395,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000221,7318.0,,CLD0
1396,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000221,7318.0,,CLD0
1397,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000221,7318.0,,CLD0
1398,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000221,7318.0,,CLD0
1399,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616188,,BAO_0000357,,,CLD0
1400,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Intermediate,1,,CHEMBL873475,,BAO_0000357,,,CLD0
1401,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577,D,9,Expert,1,,CHEMBL616189,,BAO_0000221,2435.0,,CLD0
1402,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616190,,BAO_0000357,,,CLD0
1403,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357,,,CLD0
1404,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357,,,CLD0
1405,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357,,,CLD0
1406,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357,,,CLD0
1407,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357,,,CLD0
1408,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357,,,CLD0
1409,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249,10000000.0,,CLD0
1410,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,Cerebral cortex,,,10576,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000221,956.0,,CLD0
1411,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221,10000000.0,,CLD0
1412,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616200,,BAO_0000221,10000000.0,,CLD0
1413,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616201,,BAO_0000221,10000000.0,,CLD0
1414,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616202,,BAO_0000221,10000000.0,,CLD0
1415,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616203,,BAO_0000221,10000000.0,,CLD0
1416,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616204,,BAO_0000221,10000000.0,,CLD0
1417,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616205,,BAO_0000221,10000000.0,,CLD0
1418,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616206,,BAO_0000221,10000000.0,,CLD0
1419,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,Cerebral cortex,,Membrane,10576,H,8,Expert,1,,CHEMBL616207,,BAO_0000249,956.0,,CLD0
1420,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,Cerebral cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249,956.0,,CLD0
1421,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,Cerebral cortex,,,10576,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249,956.0,,CLD0
1422,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616210,,BAO_0000357,,,CLD0
1423,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616211,,BAO_0000221,10000000.0,,CLD0
1424,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221,10000000.0,,CLD0
1425,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616505,,BAO_0000221,10000000.0,,CLD0
1426,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019,,,CLD0
1427,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221,10000000.0,,CLD0
1428,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616507,,BAO_0000221,10000000.0,,CLD0
1429,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249,,,CLD0
1430,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221,10000000.0,,CLD0
1431,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616305,,BAO_0000221,10000000.0,,CLD0
1432,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221,10000000.0,,CLD0
1433,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357,,,CLD0
1434,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL881829,,BAO_0000221,10000000.0,,CLD0
1435,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616308,,BAO_0000357,,,CLD0
1436,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019,955.0,,CLD0
1437,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616310,,BAO_0000019,955.0,,CLD0
1438,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219,,,CLD0
1439,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616312,,BAO_0000357,,,CLD0
1440,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357,,,CLD0
1441,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616314,,BAO_0000221,10000000.0,,CLD0
1442,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221,10000000.0,,CLD0
1443,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221,10000000.0,,CLD0
1444,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221,10000000.0,,CLD0
1445,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,Frontal cortex,,,10576,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000221,1870.0,,CLD0
1446,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616570,,BAO_0000357,,,CLD0
1447,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357,,,CLD0
1448,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221,10000000.0,,CLD0
1449,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL616573,,BAO_0000249,956.0,,CLD0
1450,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616574,,BAO_0000357,,,CLD0
1451,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616575,,BAO_0000221,10000000.0,,CLD0
1452,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221,10000000.0,,CLD0
1453,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357,,,CLD0
1454,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249,10000000.0,,CLD0
1455,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249,10000000.0,,CLD0
1456,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616579,,BAO_0000357,,,CLD0
1457,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616580,,BAO_0000019,,,CLD0
1458,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019,,,CLD0
1459,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221,10000000.0,,CLD0
1460,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616583,,BAO_0000221,10000000.0,,CLD0
1461,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616584,,BAO_0000221,10000000.0,,CLD0
1462,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616585,,BAO_0000357,,,CLD0
1463,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616586,,BAO_0000221,10000000.0,,CLD0
1464,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221,10000000.0,,CLD0
1465,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221,10000000.0,,CLD0
1466,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221,10000000.0,,CLD0
1467,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616590,,BAO_0000221,10000000.0,,CLD0
1468,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219,,,CLD0
1469,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616592,,BAO_0000357,,,CLD0
1470,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357,,,CLD0
1471,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219,,,CLD0
1472,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,Cerebral cortex,,Membrane,10576,H,8,Expert,1,,CHEMBL616595,,BAO_0000249,956.0,,CLD0
1473,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357,,,CLD0
1474,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221,10000000.0,,CLD0
1475,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616598,,BAO_0000221,10000000.0,,CLD0
1476,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membrane,10576,D,9,Expert,1,,CHEMBL616599,,BAO_0000249,,,CLD0
1477,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membrane,10576,D,9,Expert,1,,CHEMBL616600,,BAO_0000249,10000000.0,,CLD0
1478,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000221,1851.0,,CLD0
1479,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000221,1851.0,,CLD0
1480,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000221,1851.0,,CLD0
1481,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000221,1851.0,,CLD0
1482,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249,,,CLD0
1483,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249,,,CLD0
1484,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,10576,D,9,Expert,1,,CHEMBL616318,,BAO_0000221,1870.0,,CLD0
1485,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221,10000000.0,,CLD0
1486,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221,10000000.0,,CLD0
1487,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616321,,BAO_0000221,10000000.0,,CLD0
1488,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019,,,CLD0
1489,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019,,,CLD0
1490,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357,,,CLD0
1491,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221,10000000.0,,CLD0
1492,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221,10000000.0,,CLD0
1493,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221,10000000.0,,CLD0
1494,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357,,,CLD0
1495,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,Frontal cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249,1870.0,,CLD0
1496,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,Frontal cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249,1870.0,,CLD0
1497,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,Frontal cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249,1870.0,,CLD0
1498,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,Frontal cortex,,Membrane,10576,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249,1870.0,,CLD0
1499,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,Frontal cortex,,,10576,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249,1870.0,,CLD0
1500,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,Membrane,10576,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249,955.0,,CLD0
1501,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,Frontal cortex,,,10576,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000221,1870.0,,CLD0
1502,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,Cerebral cortex,,,10576,H,8,Expert,1,,CHEMBL616334,,BAO_0000221,956.0,,CLD0
1503,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221,10000000.0,,CLD0
1504,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000221,1851.0,,CLD0
1505,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616337,,BAO_0000249,,,CLD0
1506,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000221,1851.0,,CLD0
1507,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydroxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221,10000000.0,,CLD0
1508,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221,10000000.0,,CLD0
1509,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357,,,CLD0
1510,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616342,,BAO_0000357,,,CLD0
1511,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,10576,D,9,Expert,1,,CHEMBL616343,,BAO_0000221,1870.0,,CLD0
1512,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616344,,BAO_0000019,,,CLD0
1513,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616345,,BAO_0000357,,,CLD0
1514,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616346,,BAO_0000019,,,CLD0
1515,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221,10000000.0,,CLD0
1516,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616348,,BAO_0000019,,,CLD0
1517,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616349,,BAO_0000357,,,CLD0
1518,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,Membrane,10576,D,9,Expert,1,,CHEMBL616152,,BAO_0000249,1870.0,,CLD0
1519,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,Frontal cortex,,,10576,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249,1870.0,,CLD0
1520,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616154,,BAO_0000019,,,CLD0
1521,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,10576,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000221,956.0,,CLD0
1522,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616156,,BAO_0000221,10000000.0,,CLD0
1523,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616157,,BAO_0000221,10000000.0,,CLD0
1524,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221,10000000.0,,CLD0
1525,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357,,,CLD0
1526,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616160,,BAO_0000357,,,CLD0
1527,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,Cortex,,,10576,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000221,1851.0,,CLD0
1528,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019,,,CLD0
1529,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL616163,,BAO_0000357,,,CLD0
1530,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,Hippocampus,,Membrane,10626,H,8,Expert,1,,CHEMBL616164,,BAO_0000249,10000000.0,,CLD0
1531,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221,955.0,,CLD0
1532,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,Hippocampus,,Membrane,51,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019,10000000.0,,CLD0
1533,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019,,,CLD0
1534,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221,955.0,,CLD0
1535,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000221,955.0,,CLD0
1536,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357,,,CLD0
1537,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616360,,BAO_0000357,,,CLD0
1538,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616361,,BAO_0000357,,,CLD0
1539,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357,,,CLD0
1540,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249,,,CLD0
1541,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357,,,CLD0
1542,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357,,,CLD0
1543,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616366,,BAO_0000357,,,CLD0
1544,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL872906,,BAO_0000357,,,CLD0
1545,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357,,,CLD0
1546,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357,,,CLD0
1547,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357,,,CLD0
1548,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616370,,BAO_0000357,,,CLD0
1549,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616371,,BAO_0000357,,,CLD0
1550,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219,,,CLD0
1551,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616373,449.0,BAO_0000219,,,CLD0
1552,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218,,,CLD0
1553,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221,10000000.0,,CLD0
1554,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357,,,CLD0
1555,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL857064,,BAO_0000357,,,CLD0
1556,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357,,,CLD0
1557,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357,,,CLD0
1558,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357,,,CLD0
1559,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357,,,CLD0
1560,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357,,,CLD0
1561,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357,,,CLD0
1562,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357,,,CLD0
1563,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219,,,CLD0
1564,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357,,,CLD0
1565,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357,,,CLD0
1566,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357,,,CLD0
1567,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357,,,CLD0
1568,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357,,,CLD0
1569,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616559,,BAO_0000357,,,CLD0
1570,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357,,,CLD0
1571,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357,,,CLD0
1572,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219,,,CLD0
1573,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219,,,CLD0
1574,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357,,,CLD0
1575,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357,,,CLD0
1576,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218,,,CLD0
1577,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357,,,CLD0
1578,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357,,,CLD0
1579,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616990,,BAO_0000357,,,CLD0
1580,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357,,,CLD0
1581,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357,,,CLD0
1582,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357,,,CLD0
1583,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Expert,1,,CHEMBL616994,,BAO_0000221,7318.0,,CLD0
1584,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000221,7318.0,,CLD0
1585,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219,,,CLD0
1586,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218,,,CLD0
1587,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218,,,CLD0
1588,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,Artery,,,106,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000221,1637.0,,CLD0
1589,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,Iliac artery,,,106,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000221,5609.0,,CLD0
1590,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019,,,CLD0
1591,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019,,,CLD0
1592,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019,,,CLD0
1593,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019,,,CLD0
1594,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019,,,CLD0
1595,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL617005,,BAO_0000019,,,CLD0
1596,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219,,,CLD0
1597,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219,,,CLD0
1598,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357,,,CLD0
1599,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019,,,CLD0
1600,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219,,,CLD0
1601,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219,,,CLD0
1602,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219,,,CLD0
1603,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219,,,CLD0
1604,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219,,,CLD0
1605,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616631,,BAO_0000019,,,CLD0
1606,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019,,,CLD0
1607,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616633,,BAO_0000357,,,CLD0
1608,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219,,,CLD0
1609,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357,,,CLD0
1610,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL885358,,BAO_0000357,,,CLD0
1611,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219,,,CLD0
1612,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219,,,CLD0
1613,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357,,,CLD0
1614,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219,,,CLD0
1615,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219,,,CLD0
1616,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219,,,CLD0
1617,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219,,,CLD0
1618,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219,,,CLD0
1619,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357,,,CLD0
1620,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357,,,CLD0
1621,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,105,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000221,7318.0,,CLD0
1622,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,105,H,8,Expert,1,,CHEMBL616647,,BAO_0000221,7318.0,,CLD0
1623,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357,,,CLD0
1624,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357,,,CLD0
1625,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357,,,CLD0
1626,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616512,,BAO_0000357,,,CLD0
1627,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357,,,CLD0
1628,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000221,2435.0,,CLD0
1629,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616515,,BAO_0000357,,,CLD0
1630,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019,,,CLD0
1631,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357,,,CLD0
1632,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357,,,CLD0
1633,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357,,,CLD0
1634,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357,,,CLD0
1635,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357,,,CLD0
1636,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357,,,CLD0
1637,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357,,,CLD0
1638,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357,,,CLD0
1639,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000221,2435.0,,CLD0
1640,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019,,,CLD0
1641,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357,,,CLD0
1642,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357,,,CLD0
1643,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,Frontal cortex,,Membrane,105,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249,1870.0,,CLD0
1644,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,Frontal cortex,,Membrane,105,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249,1870.0,,CLD0
1645,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616737,,BAO_0000019,,,CLD0
1646,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019,,,CLD0
1647,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616739,,BAO_0000019,,,CLD0
1648,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616740,,BAO_0000019,,,CLD0
1649,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616741,,BAO_0000019,,,CLD0
1650,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219,,,CLD0
1651,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019,,,CLD0
1652,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019,,,CLD0
1653,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019,,,CLD0
1654,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019,,,CLD0
1655,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019,,,CLD0
1656,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019,,,CLD0
1657,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019,,,CLD0
1658,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357,,,CLD0
1659,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357,,,CLD0
1660,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218,,,CLD0
1661,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218,,,CLD0
1662,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218,,,CLD0
1663,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218,,,CLD0
1664,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019,,,CLD0
1665,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357,,,CLD0
1666,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019,,,CLD0
1667,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000221,2435.0,,CLD0
1668,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357,,,CLD0
1669,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357,,,CLD0
1670,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357,,,CLD0
1671,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616662,,BAO_0000019,,,CLD0
1672,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019,,,CLD0
1673,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019,,,CLD0
1674,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219,,,CLD0
1675,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219,,,CLD0
1676,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219,,,CLD0
1677,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219,,,CLD0
1678,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219,,,CLD0
1679,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219,,,CLD0
1680,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219,,,CLD0
1681,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219,,,CLD0
1682,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219,,,CLD0
1683,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219,,,CLD0
1684,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019,,,CLD0
1685,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219,,,CLD0
1686,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219,,,CLD0
1687,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219,,,CLD0
1688,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105,H,8,Expert,1,,CHEMBL617048,,BAO_0000019,,,CLD0
1689,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019,,,CLD0
1690,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616898,,BAO_0000019,,,CLD0
1691,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219,,,CLD0
1692,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019,,,CLD0
1693,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616900,449.0,BAO_0000219,,,CLD0
1694,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219,,,CLD0
1695,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357,,,CLD0
1696,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219,,,CLD0
1697,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219,,,CLD0
1698,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357,,,CLD0
1699,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219,,,CLD0
1700,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219,,,CLD0
1701,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219,,,CLD0
1702,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219,,,CLD0
1703,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219,,,CLD0
1704,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219,,,CLD0
1705,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219,,,CLD0
1706,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357,,,CLD0
1707,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219,,,CLD0
1708,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219,,,CLD0
1709,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019,,,CLD0
1710,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616917,,BAO_0000357,,,CLD0
1711,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357,,,CLD0
1712,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616919,,BAO_0000219,,,CLD0
1713,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357,,,CLD0
1714,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357,,,CLD0
1715,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357,,,CLD0
1716,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616922,,BAO_0000357,,,CLD0
1717,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357,,,CLD0
1718,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616924,,BAO_0000357,,,CLD0
1719,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL875909,,BAO_0000357,,,CLD0
1720,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357,,,CLD0
1721,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357,,,CLD0
1722,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357,,,CLD0
1723,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219,,,CLD0
1724,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616929,449.0,BAO_0000219,,,CLD0
1725,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616930,,BAO_0000357,,,CLD0
1726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616931,,BAO_0000019,,,CLD0
1727,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357,,,CLD0
1728,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616933,,BAO_0000357,,,CLD0
1729,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,105,D,9,Expert,1,,CHEMBL616934,643.0,BAO_0000219,,,CLD0
1730,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616935,,BAO_0000357,,,CLD0
1731,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357,,,CLD0
1732,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616937,,BAO_0000357,,,CLD0
1733,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616938,,BAO_0000357,,,CLD0
1734,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019,,,CLD0
1735,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616940,,BAO_0000019,,,CLD0
1736,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616941,,BAO_0000357,,,CLD0
1737,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219,,,CLD0
1738,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219,,,CLD0
1739,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219,,,CLD0
1740,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019,,,CLD0
1741,12861,Binding activity radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357,,,CLD0
1742,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019,,,CLD0
1743,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219,,,CLD0
1744,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357,,,CLD0
1745,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357,,,CLD0
1746,14499,The ionization constant (pKa) for the compound measured potentiometrically,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357,,,CLD0
1747,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616854,,BAO_0000357,,,CLD0
1748,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219,,,CLD0
1749,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219,,,CLD0
1750,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219,,,CLD0
1751,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357,,,CLD0
1752,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219,,,CLD0
1753,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219,,,CLD0
1754,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219,,,CLD0
1755,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219,,,CLD0
1756,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219,,,CLD0
1757,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219,,,CLD0
1758,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616544,,BAO_0000357,,,CLD0
1759,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219,,,CLD0
1760,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357,,,CLD0
1761,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219,,,CLD0
1762,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219,,,CLD0
1763,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616549,,BAO_0000019,,,CLD0
1764,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616550,,BAO_0000019,,,CLD0
1765,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357,,,CLD0
1766,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357,,,CLD0
1767,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357,,,CLD0
1768,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019,,,CLD0
1769,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,Cortex,,,10577,H,8,Expert,1,,CHEMBL616553,,BAO_0000221,1851.0,,CLD0
1770,9098,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357,,,CLD0
1771,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,Frontal cortex,,,10577,H,8,Expert,1,,CHEMBL616555,,BAO_0000221,1870.0,,CLD0
1772,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616556,,BAO_0000019,,,CLD0
1773,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,Globus pallidus,,,10577,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000221,1875.0,,CLD0
1774,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,Frontal cortex,,,10577,H,8,Expert,1,,CHEMBL616558,,BAO_0000221,1870.0,,CLD0
1775,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616749,,BAO_0000019,,,CLD0
1776,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357,,,CLD0
1777,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357,,,CLD0
1778,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,Striatum,,Membrane,10577,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249,2435.0,,CLD0
1779,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000221,2435.0,,CLD0
1780,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616754,,BAO_0000357,,,CLD0
1781,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019,,,CLD0
1782,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000221,2435.0,,CLD0
1783,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000221,2435.0,,CLD0
1784,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000221,2435.0,,CLD0
1785,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,Striatum,,Membrane,10577,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249,2435.0,,CLD0
1786,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357,,,CLD0
1787,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000221,2435.0,,CLD0
1788,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000221,2435.0,,CLD0
1789,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,Cerebral cortex,,,10577,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000221,956.0,,CLD0
1790,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL872909,,BAO_0000357,,,CLD0
1791,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357,,,CLD0
1792,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616765,,BAO_0000357,,,CLD0
1793,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000221,2435.0,,CLD0
1794,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000221,2435.0,,CLD0
1795,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357,,,CLD0
1796,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357,,,CLD0
1797,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019,,,CLD0
1798,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019,,,CLD0
1799,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000221,2435.0,,CLD0
1800,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616773,,BAO_0000019,,,CLD0
1801,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019,,,CLD0
1802,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357,,,CLD0
1803,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249,,,CLD0
1804,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357,,,CLD0
1805,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357,,,CLD0
1806,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,Striatum,,Membrane,10577,D,9,Expert,1,,CHEMBL616779,,BAO_0000249,2435.0,,CLD0
1807,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616780,,BAO_0000357,,,CLD0
1808,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,Cerebral cortex,,,10577,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000221,956.0,,CLD0
1809,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357,,,CLD0
1810,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357,,,CLD0
1811,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577,H,8,Expert,1,,CHEMBL616784,,BAO_0000221,2435.0,,CLD0
1812,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357,,,CLD0
1813,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,Membrane,10577,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249,955.0,,CLD0
1814,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,Frontal cortex,,,10577,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000221,1870.0,,CLD0
1815,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,Membrane,10577,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249,955.0,,CLD0
1816,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357,,,CLD0
1817,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357,,,CLD0
1818,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,10577,D,9,Expert,1,,CHEMBL616790,,BAO_0000221,1870.0,,CLD0
1819,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616791,,BAO_0000357,,,CLD0
1820,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019,,,CLD0
1821,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,Striatum,,Membrane,10577,D,9,Expert,1,,CHEMBL616793,,BAO_0000249,2435.0,,CLD0
1822,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357,,,CLD0
1823,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357,,,CLD0
1824,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104686,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000221,956.0,,CLD0
1825,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357,,,CLD0
1826,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249,,,CLD0
1827,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357,,,CLD0
1828,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357,,,CLD0
1829,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357,,,CLD0
1830,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357,,,CLD0
1831,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357,,,CLD0
1832,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL857068,,BAO_0000357,,,CLD0
1833,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357,,,CLD0
1834,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357,,,CLD0
1835,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357,,,CLD0
1836,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357,,,CLD0
1837,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357,,,CLD0
1838,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357,,,CLD0
1839,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357,,,CLD0
1840,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224,,,CLD0
1841,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357,,,CLD0
1842,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357,,,CLD0
1843,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,Choroid plexus,,,108,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000221,1886.0,,CLD0
1844,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357,,,CLD0
1845,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357,,,CLD0
1846,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357,,,CLD0
1847,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357,,,CLD0
1848,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616819,,BAO_0000357,,,CLD0
1849,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616820,,BAO_0000357,,,CLD0
1850,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616821,,BAO_0000019,,,CLD0
1851,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357,,,CLD0
1852,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,108,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000221,7318.0,,CLD0
1853,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357,,,CLD0
1854,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357,,,CLD0
1855,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357,,,CLD0
1856,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616827,,BAO_0000019,,,CLD0
1857,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357,,,CLD0
1858,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357,,,CLD0
1859,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019,,,CLD0
1860,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616831,,BAO_0000357,,,CLD0
1861,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019,,,CLD0
1862,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019,,,CLD0
1863,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616834,,BAO_0000019,,,CLD0
1864,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019,,,CLD0
1865,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357,,,CLD0
1866,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249,,,CLD0
1867,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL616836,,BAO_0000357,,,CLD0
1868,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357,,,CLD0
1869,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,12689,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000221,1870.0,,CLD0
1870,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219,,,CLD0
1871,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357,,,CLD0
1872,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357,,,CLD0
1873,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357,,,CLD0
1874,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357,,,CLD0
1875,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357,,,CLD0
1876,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357,,,CLD0
1877,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357,,,CLD0
1878,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357,,,CLD0
1879,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357,,,CLD0
1880,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,105,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000221,7318.0,,CLD0
1881,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224,,,CLD0
1882,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224,,,CLD0
1883,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019,,,CLD0
1884,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019,,,CLD0
1885,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249,955.0,,CLD0
1886,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221,955.0,,CLD0
1887,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224,,,CLD0
1888,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224,,,CLD0
1889,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000221,1870.0,,CLD0
1890,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224,,,CLD0
1891,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224,,,CLD0
1892,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224,,,CLD0
1893,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000221,955.0,,CLD0
1894,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000221,955.0,,CLD0
1895,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000221,955.0,,CLD0
1896,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000221,955.0,,CLD0
1897,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000221,955.0,,CLD0
1898,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019,,,CLD0
1899,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019,,,CLD0
1900,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000221,1870.0,,CLD0
1901,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000221,955.0,,CLD0
1902,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000221,955.0,,CLD0
1903,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019,,,CLD0
1904,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019,,,CLD0
1905,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221,955.0,,CLD0
1906,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221,955.0,,CLD0
1907,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249,,,CLD0
1908,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249,,,CLD0
1909,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224,,,CLD0
1910,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249,,,CLD0
1911,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224,,,CLD0
1912,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224,,,CLD0
1913,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224,,,CLD0
1914,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224,,,CLD0
1915,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019,,,CLD0
1916,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224,,,CLD0
1917,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224,,,CLD0
1918,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224,,,CLD0
1919,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224,,,CLD0
1920,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224,,,CLD0
1921,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019,,,CLD0
1922,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104686,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000221,956.0,,CLD0
1923,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224,,,CLD0
1924,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224,,,CLD0
1925,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224,,,CLD0
1926,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224,,,CLD0
1927,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249,,,CLD0
1928,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249,,,CLD0
1929,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224,,,CLD0
1930,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019,,,CLD0
1931,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224,,,CLD0
1932,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224,,,CLD0
1933,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224,,,CLD0
1934,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019,,,CLD0
1935,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019,,,CLD0
1936,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019,,,CLD0
1937,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219,,,CLD0
1938,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249,,,CLD0
1939,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224,,,CLD0
1940,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,Brain,,Brain membranes,104686,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249,955.0,,CLD0
1941,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219,,,CLD0
1942,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224,,,CLD0
1943,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224,,,CLD0
1944,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224,,,CLD0
1945,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249,,,CLD0
1946,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249,,,CLD0
1947,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000221,1515.0,,CLD0
1948,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019,,,CLD0
1949,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224,,,CLD0
1950,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357,,,CLD0
1951,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357,,,CLD0
1952,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617559,,BAO_0000357,,,CLD0
1953,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617560,,BAO_0000357,,,CLD0
1954,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249,,,CLD0
1955,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249,,,CLD0
1956,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000221,2435.0,,CLD0
1957,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019,,,CLD0
1958,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617565,,BAO_0000019,,,CLD0
1959,12861,Binding activity radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357,,,CLD0
1960,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019,,,CLD0
1961,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL875911,,BAO_0000019,,,CLD0
1962,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019,,,CLD0
1963,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249,,,CLD0
1964,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617569,,BAO_0000019,,,CLD0
1965,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617570,,BAO_0000249,,,CLD0
1966,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357,,,CLD0
1967,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357,,,CLD0
1968,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617573,,BAO_0000357,,,CLD0
1969,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,105,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000221,7318.0,,CLD0
1970,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617575,,BAO_0000357,,,CLD0
1971,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357,,,CLD0
1972,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019,,,CLD0
1973,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019,,,CLD0
1974,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357,,,CLD0
1975,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,Frontal cortex,,,10578,H,8,Expert,1,,CHEMBL617580,,BAO_0000221,1870.0,,CLD0
1976,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249,,,CLD0
1977,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357,,,CLD0
1978,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617583,,BAO_0000019,,,CLD0
1979,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357,,,CLD0
1980,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357,,,CLD0
1981,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357,,,CLD0
1982,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357,,,CLD0
1983,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357,,,CLD0
1984,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357,,,CLD0
1985,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357,,,CLD0
1986,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357,,,CLD0
1987,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357,,,CLD0
1988,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219,,,CLD0
1989,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL617592,,BAO_0000357,,,CLD0
1990,15250,,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357,,,CLD0
1991,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219,,,CLD0
1992,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219,,,CLD0
1993,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219,,,CLD0
1994,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219,,,CLD0
1995,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,Saphenous vein,,,105,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000221,7318.0,,CLD0
1996,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357,,,CLD0
1997,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617599,,BAO_0000357,,,CLD0
1998,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357,,,CLD0
1999,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219,,,CLD0
2000,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219,,,CLD0
2001,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019,,,CLD0
2002,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019,,,CLD0
2003,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019,,,CLD0
2004,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019,,,CLD0
2005,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019,,,CLD0
2006,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357,,,CLD0
2007,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357,,,CLD0
2008,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357,,,CLD0
2009,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617304,,BAO_0000357,,,CLD0
2010,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219,,,CLD0
2011,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,COS,,105,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219,,,CLD0
2012,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357,,,CLD0
2013,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,105,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000221,7318.0,,CLD0
2014,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357,,,CLD0
2015,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357,,,CLD0
2016,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357,,,CLD0
2017,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357,,,CLD0
2018,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357,,,CLD0
2019,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617314,,BAO_0000357,,,CLD0
2020,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019,,,CLD0
2021,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219,,,CLD0
2022,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219,,,CLD0
2023,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219,,,CLD0
2024,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,Saphenous vein,,,106,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000221,7318.0,,CLD0
2025,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL617320,,BAO_0000357,,,CLD0
2026,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL617321,,BAO_0000357,,,CLD0
2027,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL617322,,BAO_0000357,,,CLD0
2028,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357,,,CLD0
2029,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357,,,CLD0
2030,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219,,,CLD0
2031,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219,,,CLD0
2032,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219,,,CLD0
2033,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019,,,CLD0
2034,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219,,,CLD0
2035,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616869,,BAO_0000357,,,CLD0
2036,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219,,,CLD0
2037,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219,,,CLD0
2038,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219,,,CLD0
2039,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219,,,CLD0
2040,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219,,,CLD0
2041,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357,,,CLD0
2042,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,106,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000221,7318.0,,CLD0
2043,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357,,,CLD0
2044,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357,,,CLD0
2045,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL857976,,BAO_0000357,,,CLD0
2046,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219,,,CLD0
2047,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616844,,BAO_0000357,,,CLD0
2048,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357,,,CLD0
2049,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616846,,BAO_0000357,,,CLD0
2050,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357,,,CLD0
2051,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019,,,CLD0
2052,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357,,,CLD0
2053,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357,,,CLD0
2054,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019,,,CLD0
2055,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219,,,CLD0
2056,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357,,,CLD0
2057,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219,,,CLD0
2058,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219,,,CLD0
2059,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219,,,CLD0
2060,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357,,,CLD0
2061,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219,,,CLD0
2062,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357,,,CLD0
2063,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219,,,CLD0
2064,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357,,,CLD0
2065,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357,,,CLD0
2066,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219,,,CLD0
2067,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219,,,CLD0
2068,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219,,,CLD0
2069,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357,,,CLD0
2070,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357,,,CLD0
2071,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357,,,CLD0
2072,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357,,,CLD0
2073,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019,,,CLD0
2074,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616718,,BAO_0000019,,,CLD0
2075,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019,,,CLD0
2076,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019,,,CLD0
2077,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616720,,BAO_0000019,,,CLD0
2078,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357,,,CLD0
2079,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219,,,CLD0
2080,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357,,,CLD0
2081,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219,,,CLD0
2082,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357,,,CLD0
2083,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357,,,CLD0
2084,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357,,,CLD0
2085,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357,,,CLD0
2086,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357,,,CLD0
2087,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Expert,1,,CHEMBL616730,,BAO_0000019,,,CLD0
2088,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357,,,CLD0
2089,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357,,,CLD0
2090,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219,,,CLD0
2091,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219,,,CLD0
2092,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357,,,CLD0
2093,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219,,,CLD0
2094,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357,,,CLD0
2095,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219,,,CLD0
2096,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219,,,CLD0
2097,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219,,,CLD0
2098,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357,,,CLD0
2099,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357,,,CLD0
2100,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357,,,CLD0
2101,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019,,,CLD0
2102,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019,,,CLD0
2103,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019,,,CLD0
2104,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019,,,CLD0
2105,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218,,,CLD0
2106,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019,,,CLD0
2107,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,Frontal cortex,,,17005,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000221,1870.0,,CLD0
2108,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019,,,CLD0
2109,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,Frontal cortex,,,22226,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000221,1870.0,,CLD0
2110,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,Frontal cortex,,,22226,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000221,1870.0,,CLD0
2111,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,Frontal cortex,,,22226,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000221,1870.0,,CLD0
2112,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,Frontal cortex,,,104784,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000221,1870.0,,CLD0
2113,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,Frontal cortex,,,104784,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000221,1870.0,,CLD0
2114,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,Frontal cortex,,,104784,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000221,1870.0,,CLD0
2115,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224,,,CLD0
2116,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224,,,CLD0
2117,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224,,,CLD0
2118,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357,,,CLD0
2119,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218,,,CLD0
2120,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,Cerebral cortex,,,104826,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000221,956.0,,CLD0
2121,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224,,,CLD0
2122,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,Cerebral cortex,,,104826,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000221,956.0,,CLD0
2123,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218,,,CLD0
2124,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,Cerebral cortex,,,104826,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000221,956.0,,CLD0
2125,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224,,,CLD0
2126,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224,,,CLD0
2127,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224,,,CLD0
2128,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,Cerebral cortex,,,104826,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000221,956.0,,CLD0
2129,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224,,,CLD0
2130,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224,,,CLD0
2131,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221,955.0,,CLD0
2132,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,Brain,,,22226,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221,955.0,,CLD0
2133,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357,,,CLD0
2134,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019,,,CLD0
2135,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019,,,CLD0
2136,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019,,,CLD0
2137,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224,,,CLD0
2138,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019,,,CLD0
2139,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019,,,CLD0
2140,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019,,,CLD0
2141,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019,,,CLD0
2142,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019,,,CLD0
2143,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224,,,CLD0
2144,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224,,,CLD0
2145,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224,,,CLD0
2146,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224,,,CLD0
2147,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224,,,CLD0
2148,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224,,,CLD0
2149,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224,,,CLD0
2150,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224,,,CLD0
2151,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224,,,CLD0
2152,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224,,,CLD0
2153,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224,,,CLD0
2154,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019,,,CLD0
2155,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019,,,CLD0
2156,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221,10000000.0,,CLD0
2157,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221,10000000.0,,CLD0
2158,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221,955.0,,CLD0
2159,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,Cortex,,,104686,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000221,1851.0,,CLD0
2160,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,Frontal cortex,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249,1870.0,,CLD0
2161,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,Frontal cortex,,Membrane,104686,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249,1870.0,,CLD0
2162,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019,,,CLD0
2163,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000221,1870.0,,CLD0
2164,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221,955.0,,CLD0
2165,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membrane,104686,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249,,,CLD0
2166,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221,955.0,,CLD0
2167,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,Tail,,,104686,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000221,2415.0,,CLD0
2168,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019,,,CLD0
2169,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019,,,CLD0
2170,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019,,,CLD0
2171,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019,,,CLD0
2172,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019,,,CLD0
2173,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,Synaptosomes,104686,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220,955.0,,CLD0
2174,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000221,1870.0,,CLD0
2175,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249,955.0,,CLD0
2176,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000221,1870.0,,CLD0
2177,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000221,1870.0,,CLD0
2178,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019,,,CLD0
2179,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000221,1870.0,,CLD0
2180,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000221,1870.0,,CLD0
2181,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,Tail,,,104686,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000221,2415.0,,CLD0
2182,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,Cortex,,,104686,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000221,1851.0,,CLD0
2183,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,Aorta,,,104686,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000221,947.0,,CLD0
2184,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019,,,CLD0
2185,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019,,,CLD0
2186,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,104686,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000221,1870.0,,CLD0
2187,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224,,,CLD0
2188,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,Cerebral cortex,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249,956.0,,CLD0
2189,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,Cerebral cortex,,,104686,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000221,956.0,,CLD0
2190,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,Cerebral cortex,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000221,956.0,,CLD0
2191,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224,,,CLD0
2192,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221,955.0,,CLD0
2193,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,Tail,,,104686,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000221,2415.0,,CLD0
2194,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,105075,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000221,1870.0,,CLD0
2195,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,105075,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000221,1870.0,,CLD0
2196,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,105075,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000221,1870.0,,CLD0
2197,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,105075,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000221,1870.0,,CLD0
2198,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,105075,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000221,1870.0,,CLD0
2199,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,105075,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000221,1870.0,,CLD0
2200,9523,Hill coefficient of compound was determined,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224,,,CLD0
2201,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019,,,CLD0
2202,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,Cerebral cortex,,,104686,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000221,956.0,,CLD0
2203,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,Cerebral cortex,,,12687,H,8,Expert,1,,CHEMBL617029,,BAO_0000221,956.0,,CLD0
2204,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,Cerebral cortex,,,12687,H,8,Expert,1,,CHEMBL875908,,BAO_0000221,956.0,,CLD0
2205,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357,,,CLD0
2206,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000221,1870.0,,CLD0
2207,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019,,,CLD0
2208,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224,,,CLD0
2209,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224,,,CLD0
2210,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224,,,CLD0
2211,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019,,,CLD0
2212,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224,,,CLD0
2213,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,CHO,,22226,U,0,Autocuration,1,,CHEMBL617038,449.0,BAO_0000219,,,CLD0
2214,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,CHO,,104784,H,4,Autocuration,1,,CHEMBL617039,449.0,BAO_0000219,,,CLD0
2215,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224,,,CLD0
2216,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224,,,CLD0
2217,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224,,,CLD0
2218,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224,,,CLD0
2219,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249,,,CLD0
2220,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224,,,CLD0
2221,17066,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224,,,CLD0
2222,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224,,,CLD0
2223,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224,,,CLD0
2224,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224,,,CLD0
2225,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224,,,CLD0
2226,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224,,,CLD0
2227,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224,,,CLD0
2228,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224,,,CLD0
2229,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019,,,CLD0
2230,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224,,,CLD0
2231,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357,,,CLD0
2232,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357,,,CLD0
2233,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224,,,CLD0
2234,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224,,,CLD0
2235,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224,,,CLD0
2236,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357,,,CLD0
2237,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357,,,CLD0
2238,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357,,,CLD0
2239,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357,,,CLD0
2240,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357,,,CLD0
2241,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357,,,CLD0
2242,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357,,,CLD0
2243,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357,,,CLD0
2244,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218,,,CLD0
2245,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224,,,CLD0
2246,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219,,,CLD0
2247,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219,,,CLD0
2248,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219,,,CLD0
2249,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219,,,CLD0
2250,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224,,,CLD0
2251,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224,,,CLD0
2252,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357,,,CLD0
2253,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224,,,CLD0
2254,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617198,,BAO_0000357,,,CLD0
2255,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL873476,,BAO_0000357,,,CLD0
2256,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,Frontal cortex,,,17005,H,8,Expert,1,,CHEMBL617199,,BAO_0000221,1870.0,,CLD0
2257,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357,,,CLD0
2258,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357,,,CLD0
2259,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357,,,CLD0
2260,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357,,,CLD0
2261,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357,,,CLD0
2262,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219,,,CLD0
2263,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219,,,CLD0
2264,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219,,,CLD0
2265,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219,,,CLD0
2266,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219,,,CLD0
2267,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219,,,CLD0
2268,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219,,,CLD0
2269,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357,,,CLD0
2270,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617056,,BAO_0000357,,,CLD0
2271,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219,,,CLD0
2272,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,BEK,,107,H,8,Expert,1,,CHEMBL617058,,BAO_0000219,,,CLD0
2273,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357,,,CLD0
2274,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219,,,CLD0
2275,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219,,,CLD0
2276,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219,,,CLD0
2277,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219,,,CLD0
2278,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019,,,CLD0
2279,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019,,,CLD0
2280,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219,,,CLD0
2281,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219,,,CLD0
2282,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019,,,CLD0
2283,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019,,,CLD0
2284,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019,,,CLD0
2285,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357,,,CLD0
2286,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357,,,CLD0
2287,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357,,,CLD0
2288,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357,,,CLD0
2289,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357,,,CLD0
2290,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219,,,CLD0
2291,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357,,,CLD0
2292,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617077,,BAO_0000019,,,CLD0
2293,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617078,,BAO_0000357,,,CLD0
2294,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617079,,BAO_0000357,,,CLD0
2295,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357,,,CLD0
2296,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219,,,CLD0
2297,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,BEK,,107,H,8,Expert,1,,CHEMBL617082,,BAO_0000219,,,CLD0
2298,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357,,,CLD0
2299,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357,,,CLD0
2300,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617085,,BAO_0000357,,,CLD0
2301,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357,,,CLD0
2302,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,GF6,,107,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219,,,CLD0
2303,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357,,,CLD0
2304,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357,,,CLD0
2305,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,COS-7,,107,H,8,Expert,1,,CHEMBL617090,643.0,BAO_0000219,,,CLD0
2306,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357,,,CLD0
2307,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219,,,CLD0
2308,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019,,,CLD0
2309,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357,,,CLD0
2310,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617517,,BAO_0000357,,,CLD0
2311,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219,,,CLD0
2312,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357,,,CLD0
2313,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617520,,BAO_0000357,,,CLD0
2314,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357,,,CLD0
2315,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617522,,BAO_0000357,,,CLD0
2316,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357,,,CLD0
2317,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357,,,CLD0
2318,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000221,1870.0,,CLD0
2319,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019,,,CLD0
2320,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224,,,CLD0
2321,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019,,,CLD0
2322,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019,,,CLD0
2323,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,Caudal artery,,,104686,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000221,3086.0,,CLD0
2324,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000221,1870.0,,CLD0
2325,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000221,1870.0,,CLD0
2326,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019,,,CLD0
2327,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000221,1870.0,,CLD0
2328,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224,,,CLD0
2329,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224,,,CLD0
2330,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224,,,CLD0
2331,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224,,,CLD0
2332,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219,,,CLD0
2333,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224,,,CLD0
2334,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224,,,CLD0
2335,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224,,,CLD0
2336,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224,,,CLD0
2337,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219,,,CLD0
2338,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219,,,CLD0
2339,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019,,,CLD0
2340,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019,,,CLD0
2341,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019,,,CLD0
2342,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224,,,CLD0
2343,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224,,,CLD0
2344,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000221,1870.0,,CLD0
2345,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000221,1870.0,,CLD0
2346,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224,,,CLD0
2347,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224,,,CLD0
2348,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224,,,CLD0
2349,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019,,,CLD0
2350,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,Tissue,,,104686,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019,479.0,,CLD0
2351,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,Tissue,,,104686,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019,479.0,,CLD0
2352,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224,,,CLD0
2353,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218,,,CLD0
2354,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221,955.0,,CLD0
2355,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224,,,CLD0
2356,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019,,,CLD0
2357,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019,,,CLD0
2358,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000221,1870.0,,CLD0
2359,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224,,,CLD0
2360,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224,,,CLD0
2361,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224,,,CLD0
2362,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019,,,CLD0
2363,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000221,2435.0,,CLD0
2364,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019,,,CLD0
2365,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019,,,CLD0
2366,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224,,,CLD0
2367,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224,,,CLD0
2368,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019,,,CLD0
2369,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019,,,CLD0
2370,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019,,,CLD0
2371,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019,,,CLD0
2372,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019,,,CLD0
2373,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019,,,CLD0
2374,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249,,,CLD0
2375,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019,,,CLD0
2376,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019,,,CLD0
2377,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019,,,CLD0
2378,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019,,,CLD0
2379,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019,,,CLD0
2380,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019,,,CLD0
2381,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019,,,CLD0
2382,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019,,,CLD0
2383,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019,,,CLD0
2384,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019,,,CLD0
2385,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019,,,CLD0
2386,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019,,,CLD0
2387,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019,,,CLD0
2388,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019,,,CLD0
2389,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019,,,CLD0
2390,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,Striatum,,Membrane,104686,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249,2435.0,,CLD0
2391,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249,,,CLD0
2392,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224,,,CLD0
2393,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224,,,CLD0
2394,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224,,,CLD0
2395,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019,,,CLD0
2396,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224,,,CLD0
2397,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019,,,CLD0
2398,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019,,,CLD0
2399,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019,,,CLD0
2400,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,Prefrontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617678,,BAO_0000221,451.0,,CLD0
2401,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224,,,CLD0
2402,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224,,,CLD0
2403,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019,955.0,,CLD0
2404,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221,955.0,,CLD0
2405,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224,,,CLD0
2406,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224,,,CLD0
2407,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224,,,CLD0
2408,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104686,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000221,956.0,,CLD0
2409,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224,,,CLD0
2410,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224,,,CLD0
2411,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019,,,CLD0
2412,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019,,,CLD0
2413,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218,,,CLD0
2414,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218,,,CLD0
2415,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218,,,CLD0
2416,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218,,,CLD0
2417,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL857985,,BAO_0000221,955.0,,CLD0
2418,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617695,,BAO_0000019,,,CLD0
2419,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,Cortex,,,12687,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000221,1851.0,,CLD0
2420,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357,,,CLD0
2421,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,12687,D,9,Expert,1,,CHEMBL617257,,BAO_0000221,1870.0,,CLD0
2422,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617258,,BAO_0000357,,,CLD0
2423,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617259,,BAO_0000019,,,CLD0
2424,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357,,,CLD0
2425,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617261,,BAO_0000357,,,CLD0
2426,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000221,1870.0,,CLD0
2427,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,Cerebral cortex,,,12687,H,8,Expert,1,,CHEMBL617263,,BAO_0000221,956.0,,CLD0
2428,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,Tissue,,,12687,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019,479.0,,CLD0
2429,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617265,,BAO_0000019,,,CLD0
2430,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,Frontal cortex,,Membrane,12687,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249,1870.0,,CLD0
2431,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000221,1870.0,,CLD0
2432,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,Frontal cortex,,,12687,H,8,Expert,1,,CHEMBL617268,,BAO_0000221,1870.0,,CLD0
2433,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219,,,CLD0
2434,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617323,,BAO_0000357,,,CLD0
2435,15577,Serotonergic activity of the compound.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357,,,CLD0
2436,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,Frontal cortex,,Membrane,12687,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249,1870.0,,CLD0
2437,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617326,,BAO_0000019,,,CLD0
2438,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617327,,BAO_0000249,,,CLD0
2439,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,Cortex,,,12687,D,9,Expert,1,,CHEMBL617328,,BAO_0000221,1851.0,,CLD0
2440,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,Cortex,,,12687,D,9,Expert,1,,CHEMBL617329,,BAO_0000221,1851.0,,CLD0
2441,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,Cortex,,,12687,D,9,Expert,1,,CHEMBL617330,,BAO_0000221,1851.0,,CLD0
2442,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357,,,CLD0
2443,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357,,,CLD0
2444,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617333,,BAO_0000357,,,CLD0
2445,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357,,,CLD0
2446,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357,,,CLD0
2447,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357,,,CLD0
2448,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357,,,CLD0
2449,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617338,,BAO_0000357,,,CLD0
2450,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357,,,CLD0
2451,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617340,,BAO_0000357,,,CLD0
2452,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357,,,CLD0
2453,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617342,,BAO_0000357,,,CLD0
2454,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617343,,BAO_0000357,,,CLD0
2455,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219,,,CLD0
2456,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617345,,BAO_0000357,,,CLD0
2457,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617346,,BAO_0000357,,,CLD0
2458,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357,,,CLD0
2459,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357,,,CLD0
2460,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357,,,CLD0
2461,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019,,,CLD0
2462,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL872339,,BAO_0000357,,,CLD0
2463,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357,,,CLD0
2464,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617352,,BAO_0000357,,,CLD0
2465,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357,,,CLD0
2466,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357,,,CLD0
2467,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357,,,CLD0
2468,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219,,,CLD0
2469,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357,,,CLD0
2470,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357,,,CLD0
2471,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617359,,BAO_0000357,,,CLD0
2472,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357,,,CLD0
2473,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357,,,CLD0
2474,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357,,,CLD0
2475,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617362,,BAO_0000357,,,CLD0
2476,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357,,,CLD0
2477,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357,,,CLD0
2478,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224,,,CLD0
2479,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224,,,CLD0
2480,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224,,,CLD0
2481,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224,,,CLD0
2482,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357,,,CLD0
2483,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219,,,CLD0
2484,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219,,,CLD0
2485,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357,,,CLD0
2486,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617373,,BAO_0000357,,,CLD0
2487,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019,,,CLD0
2488,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019,,,CLD0
2489,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019,,,CLD0
2490,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019,,,CLD0
2491,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019,,,CLD0
2492,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019,,,CLD0
2493,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357,,,CLD0
2494,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357,,,CLD0
2495,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357,,,CLD0
2496,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357,,,CLD0
2497,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617384,,BAO_0000357,,,CLD0
2498,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617385,,BAO_0000357,,,CLD0
2499,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019,,,CLD0
2500,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019,,,CLD0
2501,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219,,,CLD0
2502,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219,,,CLD0
2503,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219,,,CLD0
2504,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224,,,CLD0
2505,12861,Binding activity radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357,,,CLD0
2506,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019,,,CLD0
2507,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219,,,CLD0
2508,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219,,,CLD0
2509,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219,,,CLD0
2510,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219,,,CLD0
2511,5254,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357,,,CLD0
2512,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357,,,CLD0
2513,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219,,,CLD0
2514,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219,,,CLD0
2515,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219,,,CLD0
2516,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219,,,CLD0
2517,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617404,,BAO_0000357,,,CLD0
2518,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219,,,CLD0
2519,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219,,,CLD0
2520,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219,,,CLD0
2521,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617254,,BAO_0000357,,,CLD0
2522,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219,,,CLD0
2523,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219,,,CLD0
2524,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219,,,CLD0
2525,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219,,,CLD0
2526,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219,,,CLD0
2527,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219,,,CLD0
2528,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219,,,CLD0
2529,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219,,,CLD0
2530,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219,,,CLD0
2531,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219,,,CLD0
2532,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219,,,CLD0
2533,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219,,,CLD0
2534,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219,,,CLD0
2535,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219,,,CLD0
2536,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219,,,CLD0
2537,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219,,,CLD0
2538,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL616888,,BAO_0000357,,,CLD0
2539,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219,,,CLD0
2540,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219,,,CLD0
2541,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219,,,CLD0
2542,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219,,,CLD0
2543,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219,,,CLD0
2544,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219,,,CLD0
2545,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219,,,CLD0
2546,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019,,,CLD0
2547,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357,,,CLD0
2548,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357,,,CLD0
2549,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357,,,CLD0
2550,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,Aorta,,,107,H,8,Expert,1,,CHEMBL617101,,BAO_0000221,947.0,,CLD0
2551,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,Aorta,,,107,H,8,Expert,1,,CHEMBL617102,,BAO_0000221,947.0,,CLD0
2552,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,107,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000221,7318.0,,CLD0
2553,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617104,,BAO_0000357,,,CLD0
2554,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219,,,CLD0
2555,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019,,,CLD0
2556,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019,,,CLD0
2557,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000221,945.0,,CLD0
2558,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687,D,9,Expert,1,,CHEMBL875910,,BAO_0000221,945.0,,CLD0
2559,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019,,,CLD0
2560,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219,,,CLD0
2561,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019,,,CLD0
2562,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019,,,CLD0
2563,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357,,,CLD0
2564,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357,,,CLD0
2565,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617112,,BAO_0000019,,,CLD0
2566,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357,,,CLD0
2567,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357,,,CLD0
2568,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357,,,CLD0
2569,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219,,,CLD0
2570,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019,,,CLD0
2571,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357,,,CLD0
2572,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617119,,BAO_0000357,,,CLD0
2573,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617120,,BAO_0000357,,,CLD0
2574,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617121,,BAO_0000219,,,CLD0
2575,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219,,,CLD0
2576,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,Cerebral cortex,,,12687,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000221,956.0,,CLD0
2577,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,Frontal cortex,,,12687,H,8,Expert,1,,CHEMBL617124,,BAO_0000221,1870.0,,CLD0
2578,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617600,,BAO_0000249,,,CLD0
2579,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617601,,BAO_0000357,,,CLD0
2580,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL882923,,BAO_0000019,,,CLD0
2581,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357,,,CLD0
2582,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,Cortex,,,12687,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019,1851.0,,CLD0
2583,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357,,,CLD0
2584,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,Frontal cortex,,,12687,H,8,Expert,1,,CHEMBL617605,,BAO_0000221,1870.0,,CLD0
2585,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,Cerebral cortex,,,12687,H,8,Expert,1,,CHEMBL617606,,BAO_0000221,956.0,,CLD0
2586,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Frontal cortex,,,12687,D,9,Expert,1,,CHEMBL617607,,BAO_0000221,1870.0,,CLD0
2587,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249,,,CLD0
2588,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,Cerebral cortex,,,12687,D,9,Expert,1,,CHEMBL617456,,BAO_0000221,956.0,,CLD0
2589,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617457,,BAO_0000357,,,CLD0
2590,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617458,,BAO_0000357,,,CLD0
2591,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617459,,BAO_0000019,,,CLD0
2592,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617460,,BAO_0000357,,,CLD0
2593,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617461,,BAO_0000357,,,CLD0
2594,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617462,,BAO_0000019,,,CLD0
2595,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357,,,CLD0
2596,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019,,,CLD0
2597,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019,,,CLD0
2598,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL617466,,BAO_0000221,955.0,,CLD0
2599,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000221,1870.0,,CLD0
2600,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,Cerebral cortex,,,12687,H,8,Expert,1,,CHEMBL617468,,BAO_0000221,956.0,,CLD0
2601,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000221,1870.0,,CLD0
2602,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019,,,CLD0
2603,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019,,,CLD0
2604,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219,,,CLD0
2605,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617473,,BAO_0000357,,,CLD0
2606,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617474,,BAO_0000019,,,CLD0
2607,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617475,,BAO_0000019,,,CLD0
2608,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221,955.0,,CLD0
2609,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617477,,BAO_0000357,,,CLD0
2610,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219,,,CLD0
2611,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221,,,CLD0
2612,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357,,,CLD0
2613,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617481,,BAO_0000357,,,CLD0
2614,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,Frontal cortex,,,12687,H,8,Expert,1,,CHEMBL617482,,BAO_0000221,1870.0,,CLD0
2615,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019,,,CLD0
2616,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357,,,CLD0
2617,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219,,,CLD0
2618,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621530,,BAO_0000357,,,CLD0
2619,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621531,,BAO_0000357,,,CLD0
2620,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621532,,BAO_0000019,,,CLD0
2621,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621533,,BAO_0000357,,,CLD0
2622,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219,,,CLD0
2623,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019,,,CLD0
2624,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357,,,CLD0
2625,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357,,,CLD0
2626,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621538,,BAO_0000357,,,CLD0
2627,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019,,,CLD0
2628,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000221,1870.0,,CLD0
2629,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019,,,CLD0
2630,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,Frontal cortex,,Membrane,12687,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000221,1870.0,,CLD0
2631,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621543,,BAO_0000357,,,CLD0
2632,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621544,,BAO_0000357,,,CLD0
2633,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621545,,BAO_0000357,,,CLD0
2634,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357,,,CLD0
2635,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357,,,CLD0
2636,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219,,,CLD0
2637,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357,,,CLD0
2638,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357,,,CLD0
2639,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357,,,CLD0
2640,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618695,,BAO_0000357,,,CLD0
2641,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357,,,CLD0
2642,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL618697,,BAO_0000357,,,CLD0
2643,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357,,,CLD0
2644,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357,,,CLD0
2645,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357,,,CLD0
2646,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219,,,CLD0
2647,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618896,,BAO_0000357,,,CLD0
2648,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000221,5383.0,,CLD0
2649,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357,,,CLD0
2650,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357,,,CLD0
2651,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357,,,CLD0
2652,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,Prefrontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000221,451.0,,CLD0
2653,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357,,,CLD0
2654,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687,D,9,Expert,1,,CHEMBL618903,,BAO_0000221,10000000.0,,CLD0
2655,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357,,,CLD0
2656,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357,,,CLD0
2657,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357,,,CLD0
2658,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219,,,CLD0
2659,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000221,1870.0,,CLD0
2660,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357,,,CLD0
2661,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,Cerebral cortex,,,12687,H,8,Expert,1,,CHEMBL617910,,BAO_0000221,956.0,,CLD0
2662,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221,955.0,,CLD0
2663,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249,,,CLD0
2664,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249,,,CLD0
2665,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617913,,BAO_0000019,,,CLD0
2666,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617914,,BAO_0000249,,,CLD0
2667,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249,,,CLD0
2668,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249,,,CLD0
2669,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617917,,BAO_0000019,,,CLD0
2670,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,Tissue,,,12687,H,8,Expert,1,,CHEMBL617918,,BAO_0000019,479.0,,CLD0
2671,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,Tissue,,,12687,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019,479.0,,CLD0
2672,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,Cerebral cortex,,,12687,D,9,Expert,1,,CHEMBL617920,,BAO_0000221,956.0,,CLD0
2673,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617921,,BAO_0000019,,,CLD0
2674,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102,D,5,Expert,1,,CHEMBL617922,,BAO_0000224,,,CLD0
2675,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357,,,CLD0
2676,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357,,,CLD0
2677,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357,,,CLD0
2678,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617926,,BAO_0000357,,,CLD0
2679,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357,,,CLD0
2680,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357,,,CLD0
2681,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,Cortex,,,12687,D,9,Expert,1,,CHEMBL617929,,BAO_0000221,1851.0,,CLD0
2682,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617930,,BAO_0000019,,,CLD0
2683,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019,,,CLD0
2684,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019,,,CLD0
2685,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219,,,CLD0
2686,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019,,,CLD0
2687,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019,,,CLD0
2688,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357,,,CLD0
2689,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,Cerebral cortex,,,12687,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000221,956.0,,CLD0
2690,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,Frontal cortex,,,12687,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000221,1870.0,,CLD0
2691,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218,,,CLD0
2692,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218,,,CLD0
2693,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218,,,CLD0
2694,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617942,,BAO_0000357,,,CLD0
2695,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617943,,BAO_0000357,,,CLD0
2696,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617944,,BAO_0000224,,,CLD0
2697,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617945,,BAO_0000224,,,CLD0
2698,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075,H,4,Expert,1,,CHEMBL617946,,BAO_0000224,,,CLD0
2699,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357,,,CLD0
2700,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617948,,BAO_0000357,,,CLD0
2701,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019,,,CLD0
2702,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019,,,CLD0
2703,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,Tail,,,12687,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000221,2415.0,,CLD0
2704,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617951,,BAO_0000221,1515.0,,CLD0
2705,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617952,,BAO_0000221,1515.0,,CLD0
2706,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000221,1515.0,,CLD0
2707,12861,Binding activity radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357,,,CLD0
2708,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617955,,BAO_0000019,,,CLD0
2709,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019,,,CLD0
2710,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,Cortex,,,12687,H,8,Expert,1,,CHEMBL617270,,BAO_0000019,1851.0,,CLD0
2711,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219,,,CLD0
2712,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219,,,CLD0
2713,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019,,,CLD0
2714,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,Cortex,,,12687,D,9,Expert,1,,CHEMBL617274,,BAO_0000221,1851.0,,CLD0
2715,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357,,,CLD0
2716,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357,,,CLD0
2717,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357,,,CLD0
2718,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO-k,,108,H,8,Expert,1,,CHEMBL617278,,BAO_0000219,,,CLD0
2719,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,CHO-k,,108,H,8,Expert,1,,CHEMBL617279,,BAO_0000219,,,CLD0
2720,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO-k,,108,H,8,Expert,1,,CHEMBL617280,,BAO_0000219,,,CLD0
2721,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357,,,CLD0
2722,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357,,,CLD0
2723,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617283,,BAO_0000019,,,CLD0
2724,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617284,,BAO_0000019,,,CLD0
2725,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219,,,CLD0
2726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019,,,CLD0
2727,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617287,,BAO_0000357,,,CLD0
2728,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617288,,BAO_0000357,,,CLD0
2729,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357,,,CLD0
2730,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357,,,CLD0
2731,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357,,,CLD0
2732,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219,,,CLD0
2733,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219,,,CLD0
2734,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219,,,CLD0
2735,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219,,,CLD0
2736,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,CHO-k,,108,H,8,Expert,1,,CHEMBL617295,,BAO_0000219,,,CLD0
2737,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357,,,CLD0
2738,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019,,,CLD0
2739,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219,,,CLD0
2740,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219,,,CLD0
2741,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219,,,CLD0
2742,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357,,,CLD0
2743,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219,,,CLD0
2744,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219,,,CLD0
2745,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219,,,CLD0
2746,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617508,,BAO_0000357,,,CLD0
2747,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219,,,CLD0
2748,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219,,,CLD0
2749,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219,,,CLD0
2750,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357,,,CLD0
2751,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219,,,CLD0
2752,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219,,,CLD0
2753,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219,,,CLD0
2754,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219,,,CLD0
2755,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219,,,CLD0
2756,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219,,,CLD0
2757,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219,,,CLD0
2758,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219,,,CLD0
2759,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219,,,CLD0
2760,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219,,,CLD0
2761,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219,,,CLD0
2762,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219,,,CLD0
2763,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219,,,CLD0
2764,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219,,,CLD0
2765,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617762,,BAO_0000357,,,CLD0
2766,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357,,,CLD0
2767,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219,,,CLD0
2768,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219,,,CLD0
2769,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219,,,CLD0
2770,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019,,,CLD0
2771,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221,10000000.0,,CLD0
2772,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219,,,CLD0
2773,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219,,,CLD0
2774,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357,,,CLD0
2775,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000221,945.0,,CLD0
2776,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000221,945.0,,CLD0
2777,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219,,,CLD0
2778,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219,,,CLD0
2779,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219,,,CLD0
2780,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219,,,CLD0
2781,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019,,,CLD0
2782,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000221,945.0,,CLD0
2783,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689,D,9,Expert,1,,CHEMBL617853,,BAO_0000221,945.0,,CLD0
2784,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617854,,BAO_0000357,,,CLD0
2785,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL873477,,BAO_0000357,,,CLD0
2786,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617855,,BAO_0000357,,,CLD0
2787,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617856,,BAO_0000019,,,CLD0
2788,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019,,,CLD0
2789,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249,,,CLD0
2790,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357,,,CLD0
2791,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357,,,CLD0
2792,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357,,,CLD0
2793,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617862,,BAO_0000019,,,CLD0
2794,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019,,,CLD0
2795,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249,,,CLD0
2796,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249,,,CLD0
2797,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617650,,BAO_0000019,,,CLD0
2798,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617651,,BAO_0000019,,,CLD0
2799,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357,,,CLD0
2800,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019,,,CLD0
2801,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357,,,CLD0
2802,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019,,,CLD0
2803,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019,,,CLD0
2804,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617656,,BAO_0000357,,,CLD0
2805,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357,,,CLD0
2806,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357,,,CLD0
2807,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617659,,BAO_0000357,,,CLD0
2808,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617838,,BAO_0000357,,,CLD0
2809,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,Brain,,Brain membranes,12689,D,9,Expert,1,,CHEMBL617839,,BAO_0000249,955.0,,CLD0
2810,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357,,,CLD0
2811,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,Cortex,,,12689,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000221,1851.0,,CLD0
2812,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,SR-3T3,,12689,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000219,,,CLD0
2813,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,SR-3T3,,12689,H,8,Expert,1,,CHEMBL617842,,BAO_0000219,,,CLD0
2814,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219,,,CLD0
2815,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617844,,BAO_0000357,,,CLD0
2816,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617845,,BAO_0000357,,,CLD0
2817,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219,,,CLD0
2818,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357,,,CLD0
2819,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617848,,BAO_0000357,,,CLD0
2820,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357,,,CLD0
2821,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621507,,BAO_0000357,,,CLD0
2822,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621508,,BAO_0000357,,,CLD0
2823,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,Cortex,,,12689,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000221,1851.0,,CLD0
2824,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,Cortex,,,12689,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000221,1851.0,,CLD0
2825,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019,,,CLD0
2826,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219,,,CLD0
2827,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357,,,CLD0
2828,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621514,,BAO_0000357,,,CLD0
2829,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,A-9,,12689,H,8,Expert,1,,CHEMBL621515,,BAO_0000219,,,CLD0
2830,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,J1,,12689,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219,,,CLD0
2831,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000221,5383.0,,CLD0
2832,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357,,,CLD0
2833,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,Prefrontal cortex,,,12689,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000221,451.0,,CLD0
2834,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357,,,CLD0
2835,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357,,,CLD0
2836,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357,,,CLD0
2837,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,A-9,,12689,H,8,Expert,1,,CHEMBL621523,,BAO_0000219,,,CLD0
2838,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357,,,CLD0
2839,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL621525,,BAO_0000357,,,CLD0
2840,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357,,,CLD0
2841,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357,,,CLD0
2842,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,J1,,12689,H,8,Expert,1,,CHEMBL621527,,BAO_0000219,,,CLD0
2843,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617865,,BAO_0000019,,,CLD0
2844,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357,,,CLD0
2845,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019,,,CLD0
2846,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357,,,CLD0
2847,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617488,,BAO_0000357,,,CLD0
2848,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357,,,CLD0
2849,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,SR-3T3,,12689,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000219,,,CLD0
2850,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,SR-3T3,,12689,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000219,,,CLD0
2851,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,Cortex,,,12689,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000221,1851.0,,CLD0
2852,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,Cortex,,,12689,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000221,1851.0,,CLD0
2853,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357,,,CLD0
2854,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617495,,BAO_0000019,,,CLD0
2855,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357,,,CLD0
2856,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219,,,CLD0
2857,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357,,,CLD0
2858,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357,,,CLD0
2859,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019,,,CLD0
2860,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357,,,CLD0
2861,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617502,,BAO_0000357,,,CLD0
2862,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357,,,CLD0
2863,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357,,,CLD0
2864,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357,,,CLD0
2865,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617407,,BAO_0000019,,,CLD0
2866,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357,,,CLD0
2867,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357,,,CLD0
2868,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357,,,CLD0
2869,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357,,,CLD0
2870,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019,,,CLD0
2871,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617774,,BAO_0000357,,,CLD0
2872,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219,,,CLD0
2873,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219,,,CLD0
2874,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219,,,CLD0
2875,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219,,,CLD0
2876,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219,,,CLD0
2877,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219,,,CLD0
2878,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219,,,CLD0
2879,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219,,,CLD0
2880,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219,,,CLD0
2881,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357,,,CLD0
2882,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219,,,CLD0
2883,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219,,,CLD0
2884,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219,,,CLD0
2885,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219,,,CLD0
2886,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219,,,CLD0
2887,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219,,,CLD0
2888,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219,,,CLD0
2889,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219,,,CLD0
2890,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Expert,1,,CHEMBL617608,,BAO_0000357,,,CLD0
2891,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219,,,CLD0
2892,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219,,,CLD0
2893,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219,,,CLD0
2894,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219,,,CLD0
2895,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219,,,CLD0
2896,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019,,,CLD0
2897,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617615,,BAO_0000221,945.0,,CLD0
2898,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL858114,,BAO_0000221,945.0,,CLD0
2899,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000221,945.0,,CLD0
2900,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617617,,BAO_0000221,945.0,,CLD0
2901,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688,D,9,Expert,1,,CHEMBL875914,,BAO_0000019,,,CLD0
2902,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000221,945.0,,CLD0
2903,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617619,,BAO_0000221,945.0,,CLD0
2904,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019,,,CLD0
2905,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019,,,CLD0
2906,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019,,,CLD0
2907,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617623,,BAO_0000221,945.0,,CLD0
2908,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617624,,BAO_0000221,945.0,,CLD0
2909,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617625,,BAO_0000221,945.0,,CLD0
2910,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617626,,BAO_0000221,945.0,,CLD0
2911,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000221,945.0,,CLD0
2912,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617628,,BAO_0000221,945.0,,CLD0
2913,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000221,945.0,,CLD0
2914,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000221,945.0,,CLD0
2915,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617630,,BAO_0000221,945.0,,CLD0
2916,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000221,1515.0,,CLD0
2917,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357,,,CLD0
2918,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688,H,8,Expert,1,,CHEMBL617633,,BAO_0000357,,,CLD0
2919,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357,,,CLD0
2920,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357,,,CLD0
2922,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000221,945.0,,CLD0
2923,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357,,,CLD0
2924,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357,,,CLD0
2925,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357,,,CLD0
2926,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357,,,CLD0
2927,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357,,,CLD0
2928,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357,,,CLD0
2929,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357,,,CLD0
2930,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357,,,CLD0
2931,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617646,,BAO_0000357,,,CLD0
2932,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357,,,CLD0
2933,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357,,,CLD0
2934,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357,,,CLD0
2935,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357,,,CLD0
2936,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617877,,BAO_0000357,,,CLD0
2937,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617878,,BAO_0000357,,,CLD0
2938,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357,,,CLD0
2939,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019,,,CLD0
2940,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000221,2435.0,,CLD0
2941,5254,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357,,,CLD0
2942,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219,,,CLD0
2943,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219,,,CLD0
2944,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219,,,CLD0
2945,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219,,,CLD0
2946,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219,,,CLD0
2947,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617887,,BAO_0000357,,,CLD0
2948,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357,,,CLD0
2949,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,CHO-k,,108,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000219,,,CLD0
2950,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357,,,CLD0
2951,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357,,,CLD0
2952,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357,,,CLD0
2953,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219,,,CLD0
2954,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219,,,CLD0
2955,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219,,,CLD0
2956,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219,,,CLD0
2957,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617897,,BAO_0000357,,,CLD0
2958,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019,,,CLD0
2959,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019,,,CLD0
2960,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219,,,CLD0
2961,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019,,,CLD0
2962,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019,,,CLD0
2963,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019,,,CLD0
2964,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357,,,CLD0
2965,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357,,,CLD0
2966,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357,,,CLD0
2967,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357,,,CLD0
2968,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357,,,CLD0
2969,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219,,,CLD0
2970,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620618,,BAO_0000019,,,CLD0
2971,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620619,,BAO_0000357,,,CLD0
2972,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620620,,BAO_0000357,,,CLD0
2973,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357,,,CLD0
2974,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,Cerebral cortex,,Membrane,104698,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249,956.0,,CLD0
2975,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223,,,CLD0
2976,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,Cortex,,,104698,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000221,1851.0,,CLD0
2977,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,Cortex,,,104698,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000221,1851.0,,CLD0
2978,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019,,,CLD0
2979,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,NG-108,,104698,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219,,,CLD0
2980,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019,,,CLD0
2981,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019,,,CLD0
2982,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223,,,CLD0
2983,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223,,,CLD0
2984,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223,,,CLD0
2985,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249,956.0,,CLD0
2986,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249,956.0,,CLD0
2987,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membrane,104698,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249,,,CLD0
2988,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223,,,CLD0
2989,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,Entorhinal cortex,,,104698,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000221,2728.0,,CLD0
2990,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223,,,CLD0
2991,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223,,,CLD0
2992,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000221,956.0,,CLD0
2993,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019,,,CLD0
2994,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249,,,CLD0
2995,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223,,,CLD0
2996,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000221,956.0,,CLD0
2997,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019,,,CLD0
2998,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019,,,CLD0
2999,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249,,,CLD0
3000,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249,,,CLD0
3001,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019,,,CLD0
3002,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,Entorhinal cortex,,,104698,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000221,2728.0,,CLD0
3003,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,Brain,,Membrane,104698,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249,955.0,,CLD0
3004,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223,,,CLD0
3005,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221,955.0,,CLD0
3006,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000221,955.0,,CLD0
3007,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223,,,CLD0
3008,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223,,,CLD0
3009,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223,,,CLD0
3010,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223,,,CLD0
3011,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223,,,CLD0
3012,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019,,,CLD0
3013,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019,,,CLD0
3014,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223,,,CLD0
3015,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019,,,CLD0
3016,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218,,,CLD0
3017,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218,,,CLD0
3018,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218,,,CLD0
3019,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218,,,CLD0
3020,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218,,,CLD0
3021,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218,,,CLD0
3022,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218,,,CLD0
3023,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218,,,CLD0
3024,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218,,,CLD0
3025,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218,,,CLD0
3026,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218,,,CLD0
3027,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218,,,CLD0
3028,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218,,,CLD0
3029,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218,,,CLD0
3030,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218,,,CLD0
3031,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218,,,CLD0
3032,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218,,,CLD0
3033,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218,,,CLD0
3034,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000221,948.0,,CLD0
3035,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019,,,CLD0
3036,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019,,,CLD0
3037,12861,Binding activity radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223,,,CLD0
3038,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,Brain,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249,955.0,,CLD0
3039,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,Brain,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249,955.0,,CLD0
3040,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357,,,CLD0
3041,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357,,,CLD0
3042,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357,,,CLD0
3043,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357,,,CLD0
3044,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357,,,CLD0
3045,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620663,,BAO_0000357,,,CLD0
3046,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357,,,CLD0
3047,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620665,,BAO_0000357,,,CLD0
3048,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357,,,CLD0
3049,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357,,,CLD0
3050,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620668,,BAO_0000357,,,CLD0
3051,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357,,,CLD0
3052,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620670,,BAO_0000357,,,CLD0
3053,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357,,,CLD0
3054,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357,,,CLD0
3055,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357,,,CLD0
3056,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357,,,CLD0
3057,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357,,,CLD0
3058,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357,,,CLD0
3059,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357,,,CLD0
3060,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL621383,,BAO_0000357,,,CLD0
3061,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357,,,CLD0
3062,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,Area postrema,,,144,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000221,2162.0,,CLD0
3063,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357,,,CLD0
3064,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Expert,1,,CHEMBL617990,,BAO_0000019,,,CLD0
3065,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221,2116.0,,CLD0
3066,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019,,,CLD0
3067,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019,,,CLD0
3068,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221,2116.0,,CLD0
3069,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221,2116.0,,CLD0
3070,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000221,1155.0,,CLD0
3071,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000221,1155.0,,CLD0
3072,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000221,1155.0,,CLD0
3073,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000221,1155.0,,CLD0
3074,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000221,1155.0,,CLD0
3075,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000221,1155.0,,CLD0
3076,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221,2116.0,,CLD0
3077,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221,2116.0,,CLD0
3078,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221,2116.0,,CLD0
3079,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221,2116.0,,CLD0
3080,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221,2116.0,,CLD0
3081,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223,,,CLD0
3082,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221,2116.0,,CLD0
3083,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221,2116.0,,CLD0
3084,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221,2116.0,,CLD0
3085,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221,2116.0,,CLD0
3086,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221,2116.0,,CLD0
3087,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221,2116.0,,CLD0
3088,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221,2116.0,,CLD0
3089,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221,2116.0,,CLD0
3090,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221,2116.0,,CLD0
3091,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221,2116.0,,CLD0
3092,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221,2116.0,,CLD0
3093,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221,2116.0,,CLD0
3094,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019,,,CLD0
3095,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357,,,CLD0
3096,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714,D,5,Expert,1,,CHEMBL617835,,BAO_0000223,,,CLD0
3097,6013,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223,,,CLD0
3098,12861,Binding activity radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223,,,CLD0
3099,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019,,,CLD0
3100,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223,,,CLD0
3101,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223,,,CLD0
3102,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223,,,CLD0
3103,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019,,,CLD0
3104,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219,,,CLD0
3105,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,Tail,,,105030,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218,2415.0,,CLD0
3106,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,NG 108-15,,105030,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000219,,,CLD0
3107,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224,,,CLD0
3108,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224,,,CLD0
3109,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,NG 108-15,,105030,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000219,,,CLD0
3110,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019,,,CLD0
3111,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218,,,CLD0
3112,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,N1E 115,,105030,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219,,,CLD0
3113,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,Cortex,,,105030,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019,1851.0,,CLD0
3114,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,Cortex,,,105030,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019,1851.0,,CLD0
3115,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224,,,CLD0
3116,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,N1E,,105030,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219,,,CLD0
3117,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,N1E,,105030,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219,,,CLD0
3118,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224,,,CLD0
3119,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,NIE-115,,105030,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219,,,CLD0
3120,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219,,,CLD0
3121,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019,,,CLD0
3122,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,NG,,11765,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219,,,CLD0
3123,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357,,,CLD0
3124,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019,,,CLD0
3125,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357,,,CLD0
3126,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357,,,CLD0
3127,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223,,,CLD0
3128,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223,,,CLD0
3129,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223,,,CLD0
3130,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019,,,CLD0
3131,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019,,,CLD0
3132,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,Vagus nerve,,,104714,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000221,1759.0,,CLD0
3133,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221,2116.0,,CLD0
3134,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019,,,CLD0
3135,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,Vagus nerve,,,104714,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000221,1759.0,,CLD0
3136,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019,,,CLD0
3137,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,Vagus nerve,,,104714,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000221,1759.0,,CLD0
3138,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219,,,CLD0
3139,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,Cerebral cortex,,,104698,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000221,956.0,,CLD0
3140,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,Frontal cortex,,,12020,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000221,1870.0,,CLD0
3141,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357,,,CLD0
3142,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019,,,CLD0
3143,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000221,956.0,,CLD0
3144,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218,948.0,,CLD0
3145,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000221,948.0,,CLD0
3146,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000221,948.0,,CLD0
3147,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000221,948.0,,CLD0
3148,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000221,948.0,,CLD0
3149,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019,,,CLD0
3150,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019,,,CLD0
3151,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019,,,CLD0
3152,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019,,,CLD0
3153,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218,,,CLD0
3154,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218,,,CLD0
3155,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218,,,CLD0
3156,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019,,,CLD0
3157,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218,,,CLD0
3158,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,Vagus nerve,,,104698,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000221,1759.0,,CLD0
3159,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019,,,CLD0
3160,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019,,,CLD0
3161,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223,,,CLD0
3162,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000221,956.0,,CLD0
3163,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,Cerebral cortex,,,104698,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000221,956.0,,CLD0
3164,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249,,,CLD0
3165,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,Cortex,,,104698,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019,1851.0,,CLD0
3166,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249,955.0,,CLD0
3167,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221,955.0,,CLD0
3168,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249,,,CLD0
3169,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249,,,CLD0
3170,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019,,,CLD0
3171,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019,,,CLD0
3172,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019,,,CLD0
3173,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223,,,CLD0
3174,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019,,,CLD0
3175,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membrane,104698,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249,,,CLD0
3176,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019,,,CLD0
3177,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223,,,CLD0
3178,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223,,,CLD0
3179,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219,,,CLD0
3180,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219,,,CLD0
3181,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019,,,CLD0
3182,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019,,,CLD0
3183,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019,,,CLD0
3184,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019,,,CLD0
3185,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019,,,CLD0
3186,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019,,,CLD0
3187,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019,,,CLD0
3188,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218,,,CLD0
3189,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218,,,CLD0
3190,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218,,,CLD0
3191,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218,,,CLD0
3192,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218,,,CLD0
3193,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218,,,CLD0
3194,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218,,,CLD0
3195,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218,,,CLD0
3196,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218,,,CLD0
3197,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218,,,CLD0
3198,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218,,,CLD0
3199,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218,,,CLD0
3200,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218,,,CLD0
3201,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218,,,CLD0
3202,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218,,,CLD0
3203,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218,,,CLD0
3204,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218,,,CLD0
3205,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218,,,CLD0
3206,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218,,,CLD0
3207,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218,,,CLD0
3208,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218,,,CLD0
3209,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218,,,CLD0
3210,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218,,,CLD0
3211,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218,,,CLD0
3212,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218,,,CLD0
3213,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218,,,CLD0
3214,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218,,,CLD0
3215,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218,,,CLD0
3216,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218,,,CLD0
3217,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218,,,CLD0
3218,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218,,,CLD0
3219,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218,,,CLD0
3220,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218,,,CLD0
3221,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218,,,CLD0
3222,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218,,,CLD0
3223,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218,,,CLD0
3224,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218,,,CLD0
3225,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218,,,CLD0
3226,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218,,,CLD0
3227,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218,,,CLD0
3228,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019,,,CLD0
3229,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019,,,CLD0
3230,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223,,,CLD0
3231,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019,,,CLD0
3232,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698,H,6,Intermediate,1,,CHEMBL618918,,BAO_0000221,10000000.0,,CLD0
3233,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019,,,CLD0
3234,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019,,,CLD0
3235,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223,,,CLD0
3236,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL618922,433.0,BAO_0000219,,,CLD0
3237,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019,,,CLD0
3238,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019,,,CLD0
3239,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019,,,CLD0
3240,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019,,,CLD0
3241,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221,2116.0,,CLD0
3242,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221,2116.0,,CLD0
3243,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221,2116.0,,CLD0
3244,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221,2116.0,,CLD0
3245,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221,2116.0,,CLD0
3246,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221,2116.0,,CLD0
3247,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221,2116.0,,CLD0
3248,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221,2116.0,,CLD0
3249,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221,2116.0,,CLD0
3250,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221,2116.0,,CLD0
3251,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221,2116.0,,CLD0
3252,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221,2116.0,,CLD0
3253,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221,2116.0,,CLD0
3254,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221,2116.0,,CLD0
3255,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221,2116.0,,CLD0
3256,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221,2116.0,,CLD0
3257,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221,2116.0,,CLD0
3258,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221,2116.0,,CLD0
3259,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357,,,CLD0
3260,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,Membrane,20033,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249,2435.0,,CLD0
3261,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,Membrane,20033,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249,2435.0,,CLD0
3262,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000221,2435.0,,CLD0
3263,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000221,2435.0,,CLD0
3264,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000221,2435.0,,CLD0
3265,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000221,2435.0,,CLD0
3266,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221,2116.0,,CLD0
3267,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221,2116.0,,CLD0
3268,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221,2116.0,,CLD0
3269,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357,,,CLD0
3270,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357,,,CLD0
3271,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019,,,CLD0
3272,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019,,,CLD0
3273,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019,,,CLD0
3274,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357,,,CLD0
3275,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000221,2435.0,,CLD0
3276,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357,2435.0,,CLD0
3277,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,Membrane,20033,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249,2435.0,,CLD0
3278,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,Membrane,20033,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249,2435.0,,CLD0
3279,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221,2116.0,,CLD0
3280,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Expert,1,,CHEMBL619081,,BAO_0000357,,,CLD0
3281,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357,,,CLD0
3282,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357,,,CLD0
3283,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357,,,CLD0
3284,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221,2116.0,,CLD0
3285,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221,2116.0,,CLD0
3286,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221,2116.0,,CLD0
3287,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221,2116.0,,CLD0
3288,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221,2116.0,,CLD0
3289,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,Colon,,,20033,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000221,1155.0,,CLD0
3290,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357,,,CLD0
3291,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019,,,CLD0
3292,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357,,,CLD0
3293,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019,,,CLD0
3294,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219,,,CLD0
3295,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,Striatum,,Membrane,20033,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019,2435.0,,CLD0
3296,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357,,,CLD0
3297,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357,,,CLD0
3298,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000221,2435.0,,CLD0
3299,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221,10000000.0,,CLD0
3300,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357,,,CLD0
3301,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357,,,CLD0
3302,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221,2116.0,,CLD0
3303,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357,,,CLD0
3304,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357,,,CLD0
3305,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019,,,CLD0
3306,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219,,,CLD0
3307,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357,,,CLD0
3308,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357,,,CLD0
3309,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219,,,CLD0
3310,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357,,,CLD0
3311,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357,,,CLD0
3312,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,COS-7,,10622,H,8,Autocuration,1,,CHEMBL619013,643.0,BAO_0000219,,,CLD0
3313,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357,,,CLD0
3314,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000221,2081.0,,CLD0
3315,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000221,2081.0,,CLD0
3316,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357,,,CLD0
3317,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221,10000000.0,,CLD0
3318,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221,10000000.0,,CLD0
3319,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,Saphenous vein,,,168,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000221,7318.0,,CLD0
3320,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619020,,BAO_0000357,,,CLD0
3321,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,Muscularis mucosa,,,10623,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000221,6676.0,,CLD0
3322,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357,,,CLD0
3323,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357,,,CLD0
3324,670,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019,,,CLD0
3325,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,Muscularis mucosa,,,10623,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000221,6676.0,,CLD0
3326,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619026,,BAO_0000019,,,CLD0
3327,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,Muscularis mucosa,,,10623,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000221,6676.0,,CLD0
3328,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,Muscularis mucosa,,,10623,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000221,6676.0,,CLD0
3329,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,Muscularis mucosa,,,10623,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000221,6676.0,,CLD0
3330,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019,,,CLD0
3331,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619031,,BAO_0000357,,,CLD0
3332,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019,,,CLD0
3333,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619033,,BAO_0000357,,,CLD0
3334,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,Muscularis mucosa,,,10623,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000221,6676.0,,CLD0
3335,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357,,,CLD0
3336,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357,,,CLD0
3337,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619037,,BAO_0000019,,,CLD0
3338,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,Membrane,10623,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249,2435.0,,CLD0
3339,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,Striatum,,Membrane,10623,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249,2435.0,,CLD0
3340,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,Membrane,10623,H,8,Expert,1,,CHEMBL619040,,BAO_0000249,2435.0,,CLD0
3341,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623,D,9,Expert,1,,CHEMBL619041,,BAO_0000221,2435.0,,CLD0
3342,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000221,2435.0,,CLD0
3343,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,Membrane,10623,H,8,Expert,1,,CHEMBL619043,,BAO_0000249,2435.0,,CLD0
3344,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619044,,BAO_0000221,2435.0,,CLD0
3345,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619045,,BAO_0000249,2435.0,,CLD0
3346,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,Membrane,10623,H,8,Expert,1,,CHEMBL619046,,BAO_0000249,2435.0,,CLD0
3347,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,Striatum,,Membrane,10623,H,8,Expert,1,,CHEMBL619047,,BAO_0000249,2435.0,,CLD0
3348,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221,955.0,,CLD0
3349,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019,,,CLD0
3350,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019,,,CLD0
3351,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019,,,CLD0
3352,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019,,,CLD0
3353,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019,,,CLD0
3354,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620592,,BAO_0000357,,,CLD0
3355,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,Membrane,10623,H,8,Expert,1,,CHEMBL620593,,BAO_0000249,2435.0,,CLD0
3356,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,Esophagus,,,10623,D,9,Expert,1,,CHEMBL620594,,BAO_0000221,1043.0,,CLD0
3357,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,Esophagus,,,10623,H,8,Expert,1,,CHEMBL875079,,BAO_0000221,1043.0,,CLD0
3358,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,Esophagus,,,10623,H,8,Expert,1,,CHEMBL620595,,BAO_0000221,1043.0,,CLD0
3359,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,Esophagus,,,10623,D,9,Expert,1,,CHEMBL620596,,BAO_0000221,1043.0,,CLD0
3360,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019,,,CLD0
3361,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620598,,BAO_0000019,,,CLD0
3362,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620599,,BAO_0000218,,,CLD0
3363,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019,,,CLD0
3364,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,Muscularis mucosa,,,168,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000221,6676.0,,CLD0
3365,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,Colon,,,168,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000221,1155.0,,CLD0
3366,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357,,,CLD0
3367,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357,,,CLD0
3368,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357,,,CLD0
3369,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357,,,CLD0
3370,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019,,,CLD0
3371,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357,,,CLD0
3372,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019,,,CLD0
3373,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019,,,CLD0
3374,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357,,,CLD0
3375,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357,,,CLD0
3376,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357,,,CLD0
3377,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357,,,CLD0
3378,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620615,,BAO_0000357,,,CLD0
3379,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,Brain,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249,955.0,,CLD0
3380,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,Brain,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249,955.0,,CLD0
3381,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,Brain,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249,955.0,,CLD0
3382,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,Cortex,,,104698,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019,1851.0,,CLD0
3383,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019,,,CLD0
3384,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221,10000000.0,,CLD0
3385,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019,,,CLD0
3386,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019,,,CLD0
3387,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019,,,CLD0
3388,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223,,,CLD0
3389,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223,,,CLD0
3390,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019,,,CLD0
3391,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249,,,CLD0
3392,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019,,,CLD0
3393,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019,,,CLD0
3394,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019,,,CLD0
3395,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019,,,CLD0
3396,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249,,,CLD0
3397,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223,,,CLD0
3398,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223,,,CLD0
3399,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223,,,CLD0
3400,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL619646,,BAO_0000249,10000000.0,,CLD0
3401,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221,955.0,,CLD0
3402,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019,,,CLD0
3403,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019,,,CLD0
3404,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218,,,CLD0
3405,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019,955.0,,CLD0
3406,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357,,,CLD0
3407,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019,955.0,,CLD0
3408,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019,955.0,,CLD0
3409,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019,,,CLD0
3410,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019,,,CLD0
3411,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249,955.0,,CLD0
3412,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019,,,CLD0
3413,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Expert,1,,CHEMBL620727,,BAO_0000357,,,CLD0
3414,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223,,,CLD0
3415,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019,,,CLD0
3416,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019,,,CLD0
3417,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223,,,CLD0
3418,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223,,,CLD0
3419,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000221,1155.0,,CLD0
3420,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000221,1155.0,,CLD0
3421,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000221,1155.0,,CLD0
3422,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223,,,CLD0
3423,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019,,,CLD0
3424,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223,,,CLD0
3425,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019,,,CLD0
3426,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019,,,CLD0
3427,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019,,,CLD0
3428,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223,,,CLD0
3429,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019,,,CLD0
3430,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019,,,CLD0
3431,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019,,,CLD0
3432,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223,,,CLD0
3433,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223,,,CLD0
3434,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019,,,CLD0
3435,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223,,,CLD0
3436,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223,,,CLD0
3437,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,NG,,104714,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219,,,CLD0
3438,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223,,,CLD0
3439,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219,,,CLD0
3440,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019,,,CLD0
3441,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219,,,CLD0
3442,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223,,,CLD0
3443,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223,,,CLD0
3444,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,NG 108-15,,104714,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219,,,CLD0
3445,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223,,,CLD0
3446,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019,,,CLD0
3447,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000221,1155.0,,CLD0
3448,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000221,1155.0,,CLD0
3449,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000221,1155.0,,CLD0
3450,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000221,1155.0,,CLD0
3451,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223,,,CLD0
3452,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223,,,CLD0
3453,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223,,,CLD0
3454,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223,,,CLD0
3455,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223,,,CLD0
3456,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223,,,CLD0
3457,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL873478,,BAO_0000357,,,CLD0
3458,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223,,,CLD0
3459,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357,,,CLD0
3460,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357,,,CLD0
3461,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357,,,CLD0
3462,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223,,,CLD0
3463,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223,,,CLD0
3464,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223,,,CLD0
3465,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019,,,CLD0
3466,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357,,,CLD0
3467,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357,,,CLD0
3468,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357,,,CLD0
3469,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357,,,CLD0
3470,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019,,,CLD0
3471,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357,,,CLD0
3472,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357,,,CLD0
3473,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019,,,CLD0
3474,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357,,,CLD0
3475,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019,,,CLD0
3476,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019,,,CLD0
3477,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223,,,CLD0
3478,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357,,,CLD0
3479,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019,,,CLD0
3480,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357,,,CLD0
3481,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocyte,,12020,D,9,Expert,1,,CHEMBL619059,1758.0,BAO_0000219,,,CLD0
3482,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocyte,,12020,D,9,Expert,1,,CHEMBL619060,1758.0,BAO_0000219,,,CLD0
3483,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocyte,,12020,D,9,Expert,1,,CHEMBL875095,1758.0,BAO_0000219,,,CLD0
3484,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221,2116.0,,CLD0
3485,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221,2116.0,,CLD0
3486,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019,,,CLD0
3487,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221,2116.0,,CLD0
3488,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,Colon,,,20033,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000221,1155.0,,CLD0
3489,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221,2116.0,,CLD0
3490,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221,2116.0,,CLD0
3491,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357,,,CLD0
3492,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224,,,CLD0
3493,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224,,,CLD0
3494,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221,2116.0,,CLD0
3495,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224,,,CLD0
3496,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224,,,CLD0
3497,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,Cortex,,,104841,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000221,1851.0,,CLD0
3498,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,Cortex,,,104841,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000221,1851.0,,CLD0
3499,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619169,,BAO_0000219,2081.0,,CLD0
3500,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619170,,BAO_0000219,2081.0,,CLD0
3501,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019,,,CLD0
3502,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619172,,BAO_0000219,2081.0,,CLD0
3503,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019,,,CLD0
3504,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019,,,CLD0
3505,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019,,,CLD0
3506,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224,,,CLD0
3507,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019,,,CLD0
3508,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224,,,CLD0
3509,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224,,,CLD0
3510,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000221,945.0,,CLD0
3511,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000221,945.0,,CLD0
3512,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019,,,CLD0
3513,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224,,,CLD0
3514,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224,,,CLD0
3515,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221,10000000.0,,CLD0
3516,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198,H,8,Expert,1,,CHEMBL619186,,BAO_0000357,,,CLD0
3517,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019,,,CLD0
3518,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Cortex,,,104705,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000221,1851.0,,CLD0
3519,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224,,,CLD0
3520,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198,D,9,Expert,1,,CHEMBL619190,,BAO_0000221,955.0,,CLD0
3521,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198,D,9,Expert,1,,CHEMBL619191,,BAO_0000221,2037.0,,CLD0
3522,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019,,,CLD0
3523,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224,,,CLD0
3524,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,Frontal cortex,,,22226,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000221,1870.0,,CLD0
3525,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224,,,CLD0
3526,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224,,,CLD0
3527,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000221,945.0,,CLD0
3528,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,HEK293,,121,D,9,Expert,1,,CHEMBL619198,722.0,BAO_0000219,,,CLD0
3529,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,HEK293,,121,D,9,Expert,1,,CHEMBL875081,722.0,BAO_0000219,,,CLD0
3530,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357,,,CLD0
3531,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121,H,8,Expert,1,,CHEMBL884710,,BAO_0000357,,,CLD0
3532,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019,,,CLD0
3533,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019,,,CLD0
3534,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019,,,CLD0
3535,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019,,,CLD0
3536,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219,,,CLD0
3537,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL619204,,BAO_0000019,,,CLD0
3538,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249,10000000.0,,CLD0
3539,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357,,,CLD0
3540,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL619207,,BAO_0000249,10000000.0,,CLD0
3541,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000221,2435.0,,CLD0
3542,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000221,2435.0,,CLD0
3543,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000221,2435.0,,CLD0
3544,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000221,2435.0,,CLD0
3545,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000221,2435.0,,CLD0
3546,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000221,2435.0,,CLD0
3547,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000221,2435.0,,CLD0
3548,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000221,2435.0,,CLD0
3549,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000221,2435.0,,CLD0
3550,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000221,2435.0,,CLD0
3551,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000221,2435.0,,CLD0
3552,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000221,349.0,,CLD0
3553,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000221,349.0,,CLD0
3554,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000221,349.0,,CLD0
3555,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000221,349.0,,CLD0
3556,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000221,349.0,,CLD0
3557,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000221,349.0,,CLD0
3558,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000221,349.0,,CLD0
3559,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620694,,BAO_0000357,,,CLD0
3560,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019,,,CLD0
3561,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357,,,CLD0
3562,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620696,,BAO_0000357,,,CLD0
3563,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357,,,CLD0
3564,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357,,,CLD0
3565,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357,,,CLD0
3566,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357,,,CLD0
3567,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219,,,CLD0
3568,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219,,,CLD0
3569,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219,,,CLD0
3570,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219,,,CLD0
3571,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219,,,CLD0
3572,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219,,,CLD0
3573,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219,,,CLD0
3574,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219,,,CLD0
3575,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620708,,BAO_0000357,,,CLD0
3576,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357,,,CLD0
3577,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620710,,BAO_0000357,,,CLD0
3578,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219,,,CLD0
3579,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620712,,BAO_0000357,,,CLD0
3580,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620713,,BAO_0000357,,,CLD0
3581,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620714,,BAO_0000357,,,CLD0
3582,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620715,,BAO_0000357,,,CLD0
3583,6013,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357,,,CLD0
3584,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620717,,BAO_0000357,,,CLD0
3585,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357,,,CLD0
3586,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357,,,CLD0
3587,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219,,,CLD0
3588,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219,,,CLD0
3589,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219,,,CLD0
3590,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618076,,BAO_0000357,,,CLD0
3591,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618077,,BAO_0000357,,,CLD0
3592,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618078,,BAO_0000357,,,CLD0
3593,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL881821,,BAO_0000357,,,CLD0
3594,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618079,,BAO_0000357,,,CLD0
3595,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625,H,8,Expert,1,,CHEMBL618080,,BAO_0000357,,,CLD0
3596,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219,,,CLD0
3597,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219,,,CLD0
3598,4820,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618083,,BAO_0000357,,,CLD0
3599,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL618084,,BAO_0000357,,,CLD0
3600,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618085,,BAO_0000357,,,CLD0
3601,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618086,,BAO_0000357,,,CLD0
3602,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357,,,CLD0
3603,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357,,,CLD0
3604,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357,,,CLD0
3605,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,Colon,,,104714,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000221,1155.0,,CLD0
3606,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223,,,CLD0
3607,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618090,,BAO_0000357,,,CLD0
3608,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618091,,BAO_0000357,,,CLD0
3609,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357,,,CLD0
3610,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618093,,BAO_0000357,,,CLD0
3611,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219,,,CLD0
3612,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618095,,BAO_0000357,,,CLD0
3613,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL875093,,BAO_0000357,,,CLD0
3614,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618096,,BAO_0000357,,,CLD0
3615,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618118,,BAO_0000357,,,CLD0
3616,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618119,,BAO_0000357,,,CLD0
3617,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618120,,BAO_0000357,,,CLD0
3618,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357,,,CLD0
3619,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219,,,CLD0
3620,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357,,,CLD0
3621,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219,,,CLD0
3622,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357,,,CLD0
3623,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219,,,CLD0
3624,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618236,,BAO_0000019,,,CLD0
3625,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618237,,BAO_0000019,,,CLD0
3626,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219,,,CLD0
3627,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618239,,BAO_0000357,,,CLD0
3628,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019,,,CLD0
3629,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357,,,CLD0
3630,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219,,,CLD0
3631,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019,,,CLD0
3632,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357,,,CLD0
3633,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL619951,,BAO_0000357,,,CLD0
3634,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219,,,CLD0
3635,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219,,,CLD0
3636,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219,,,CLD0
3637,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219,,,CLD0
3638,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219,,,CLD0
3639,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219,,,CLD0
3640,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219,,,CLD0
3641,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219,,,CLD0
3642,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219,,,CLD0
3643,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219,,,CLD0
3644,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357,,,CLD0
3645,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219,,,CLD0
3646,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357,,,CLD0
3647,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620784,,BAO_0000357,,,CLD0
3648,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219,,,CLD0
3649,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357,,,CLD0
3650,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219,,,CLD0
3651,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219,,,CLD0
3652,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219,,,CLD0
3653,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219,,,CLD0
3654,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219,,,CLD0
3655,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219,,,CLD0
3656,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620792,449.0,BAO_0000219,,,CLD0
3657,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357,,,CLD0
3658,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357,,,CLD0
3659,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219,,,CLD0
3660,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620796,,BAO_0000357,,,CLD0
3661,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357,,,CLD0
3662,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620798,,BAO_0000019,,,CLD0
3663,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357,,,CLD0
3664,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620800,,BAO_0000357,,,CLD0
3665,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357,,,CLD0
3666,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357,,,CLD0
3667,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357,,,CLD0
3668,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620803,,BAO_0000019,,,CLD0
3669,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620804,,BAO_0000019,,,CLD0
3670,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357,,,CLD0
3671,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357,,,CLD0
3672,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357,,,CLD0
3673,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357,,,CLD0
3674,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357,,,CLD0
3675,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357,,,CLD0
3676,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620811,,BAO_0000357,,,CLD0
3677,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357,,,CLD0
3678,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357,,,CLD0
3679,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357,,,CLD0
3680,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620815,,BAO_0000357,,,CLD0
3681,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219,,,CLD0
3682,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357,,,CLD0
3683,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357,,,CLD0
3684,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219,,,CLD0
3685,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620820,,BAO_0000357,,,CLD0
3686,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219,,,CLD0
3687,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620822,,BAO_0000357,,,CLD0
3688,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620823,,BAO_0000357,,,CLD0
3689,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620824,,BAO_0000357,,,CLD0
3690,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219,,,CLD0
3691,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357,,,CLD0
3692,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357,,,CLD0
3693,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357,,,CLD0
3694,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357,,,CLD0
3695,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357,,,CLD0
3696,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219,,,CLD0
3697,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620831,,BAO_0000019,,,CLD0
3698,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620832,,BAO_0000019,,,CLD0
3699,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL621548,,BAO_0000357,,,CLD0
3700,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019,,,CLD0
3701,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357,,,CLD0
3702,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219,,,CLD0
3703,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019,,,CLD0
3704,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357,,,CLD0
3705,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357,,,CLD0
3706,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219,,,CLD0
3707,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219,,,CLD0
3708,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219,,,CLD0
3709,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618161,,BAO_0000357,,,CLD0
3710,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219,,,CLD0
3711,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618163,,BAO_0000357,,,CLD0
3712,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357,,,CLD0
3713,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618165,,BAO_0000219,,,CLD0
3714,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219,,,CLD0
3715,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219,,,CLD0
3716,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219,,,CLD0
3717,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219,,,CLD0
3718,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219,,,CLD0
3719,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219,,,CLD0
3720,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219,,,CLD0
3721,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619893,722.0,BAO_0000219,,,CLD0
3722,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219,,,CLD0
3723,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209,H,8,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219,,,CLD0
3724,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Intermediate,1,,CHEMBL619896,,BAO_0000357,,,CLD0
3725,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219,,,CLD0
3726,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219,,,CLD0
3727,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219,,,CLD0
3728,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219,,,CLD0
3729,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219,,,CLD0
3730,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219,,,CLD0
3731,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219,,,CLD0
3732,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219,,,CLD0
3733,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357,,,CLD0
3734,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022,D,9,Expert,1,,CHEMBL620735,,BAO_0000357,,,CLD0
3735,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019,,,CLD0
3736,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219,,,CLD0
3737,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219,,,CLD0
3738,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219,,,CLD0
3739,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219,,,CLD0
3740,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219,,,CLD0
3741,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219,,,CLD0
3742,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219,,,CLD0
3743,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219,,,CLD0
3744,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219,,,CLD0
3745,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219,,,CLD0
3746,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219,,,CLD0
3747,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219,,,CLD0
3748,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219,,,CLD0
3749,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620750,,BAO_0000357,,,CLD0
3750,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620751,,BAO_0000357,,,CLD0
3751,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620752,,BAO_0000357,,,CLD0
3752,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL872929,449.0,BAO_0000219,,,CLD0
3753,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620753,,BAO_0000357,,,CLD0
3754,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620754,,BAO_0000357,,,CLD0
3755,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923,D,9,Expert,1,,CHEMBL620755,449.0,BAO_0000219,,,CLD0
3756,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620756,,BAO_0000357,,,CLD0
3757,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620757,,BAO_0000357,,,CLD0
3758,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620758,449.0,BAO_0000219,,,CLD0
3759,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620759,449.0,BAO_0000219,,,CLD0
3760,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620760,449.0,BAO_0000219,,,CLD0
3761,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620761,449.0,BAO_0000219,,,CLD0
3762,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620762,,BAO_0000221,2116.0,,CLD0
3763,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620763,,BAO_0000221,2116.0,,CLD0
3764,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620764,,BAO_0000221,2116.0,,CLD0
3765,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membrane,11923,D,9,Expert,1,,CHEMBL857990,,BAO_0000249,,,CLD0
3766,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620765,,BAO_0000357,,,CLD0
3767,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620766,,BAO_0000357,,,CLD0
3768,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,Membrane,11923,H,8,Expert,1,,CHEMBL620767,,BAO_0000221,1898.0,,CLD0
3769,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620768,,BAO_0000357,,,CLD0
3770,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,Membrane,11923,H,8,Expert,1,,CHEMBL619051,,BAO_0000249,1898.0,,CLD0
3771,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL619052,,BAO_0000357,,,CLD0
3772,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619053,722.0,BAO_0000219,,,CLD0
3773,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619703,722.0,BAO_0000219,,,CLD0
3774,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Autocuration,1,,CHEMBL619704,722.0,BAO_0000219,,,CLD0
3775,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619851,,BAO_0000357,,,CLD0
3776,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619852,,BAO_0000357,,,CLD0
3777,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619853,,BAO_0000357,,,CLD0
3778,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL619854,,BAO_0000357,,,CLD0
3779,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619855,,BAO_0000357,,,CLD0
3780,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619856,,BAO_0000357,,,CLD0
3781,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619857,,BAO_0000357,,,CLD0
3782,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619858,,BAO_0000019,,,CLD0
3783,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619859,,BAO_0000357,,,CLD0
3784,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619860,,BAO_0000357,,,CLD0
3785,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619861,,BAO_0000357,,,CLD0
3786,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619862,,BAO_0000357,,,CLD0
3787,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619863,,BAO_0000357,,,CLD0
3788,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619864,,BAO_0000357,,,CLD0
3789,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872928,,BAO_0000357,,,CLD0
3790,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619865,,BAO_0000357,,,CLD0
3791,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619866,,BAO_0000357,,,CLD0
3792,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619867,,BAO_0000357,,,CLD0
3793,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619868,,BAO_0000221,2116.0,,CLD0
3794,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619869,,BAO_0000019,,,CLD0
3795,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619870,,BAO_0000019,,,CLD0
3796,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619871,,BAO_0000357,,,CLD0
3797,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619872,,BAO_0000357,,,CLD0
3798,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619873,,BAO_0000357,,,CLD0
3799,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619874,,BAO_0000221,178.0,,CLD0
3800,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619875,,BAO_0000221,178.0,,CLD0
3801,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619876,,BAO_0000357,,,CLD0
3802,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619877,,BAO_0000357,,,CLD0
3803,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL619878,,BAO_0000219,,,CLD0
3804,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619879,,BAO_0000221,178.0,,CLD0
3805,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619880,,BAO_0000357,,,CLD0
3806,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619881,,BAO_0000221,178.0,,CLD0
3807,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619882,,BAO_0000221,178.0,,CLD0
3808,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619883,,BAO_0000221,178.0,,CLD0
3809,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619884,,BAO_0000221,178.0,,CLD0
3810,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619885,,BAO_0000357,,,CLD0
3811,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619886,,BAO_0000221,178.0,,CLD0
3812,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619887,,BAO_0000221,178.0,,CLD0
3813,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875097,,BAO_0000019,,,CLD0
3814,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618001,,BAO_0000219,,,CLD0
3815,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618002,,BAO_0000219,,,CLD0
3816,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618003,,BAO_0000219,,,CLD0
3817,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618004,,BAO_0000219,,,CLD0
3818,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618005,,BAO_0000219,,,CLD0
3819,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618006,,BAO_0000357,,,CLD0
3820,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875086,,BAO_0000019,,,CLD0
3821,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL618007,,BAO_0000221,178.0,,CLD0
3822,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618008,,BAO_0000357,,,CLD0
3823,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618009,,BAO_0000219,,,CLD0
3824,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618010,,BAO_0000357,,,CLD0
3825,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618011,,BAO_0000357,,,CLD0
3826,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618012,,BAO_0000357,,,CLD0
3827,12780,Tested against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL882927,,BAO_0000357,,,CLD0
3828,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618013,,BAO_0000357,,,CLD0
3829,12780,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618014,,BAO_0000357,,,CLD0
3830,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618015,,BAO_0000357,,,CLD0
3831,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618016,,BAO_0000019,,,CLD0
3832,13165,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618017,,BAO_0000357,,,CLD0
3833,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618018,,BAO_0000019,,,CLD0
3834,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875087,,BAO_0000219,,,CLD0
3835,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618019,,BAO_0000219,,,CLD0
3836,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618020,,BAO_0000019,,,CLD0
3837,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618021,,BAO_0000019,,,CLD0
3838,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618022,,BAO_0000221,178.0,,CLD0
3839,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618023,,BAO_0000357,,,CLD0
3840,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618024,,BAO_0000221,178.0,,CLD0
3841,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL873950,,BAO_0000019,,,CLD0
3842,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618025,,BAO_0000357,,,CLD0
3843,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618026,,BAO_0000219,,,CLD0
3844,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618027,,BAO_0000219,,,CLD0
3845,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618028,,BAO_0000219,,,CLD0
3846,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618029,,BAO_0000219,,,CLD0
3847,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618030,,BAO_0000357,,,CLD0
3848,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618031,,BAO_0000357,,,CLD0
3849,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618032,,BAO_0000357,,,CLD0
3850,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618033,,BAO_0000357,,,CLD0
3851,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618034,,BAO_0000357,,,CLD0
3852,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875088,,BAO_0000357,,,CLD0
3853,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618035,,BAO_0000019,,,CLD0
3854,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618036,,BAO_0000019,,,CLD0
3855,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618037,,BAO_0000357,,,CLD0
3856,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618038,,BAO_0000357,,,CLD0
3857,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618761,,BAO_0000019,,,CLD0
3858,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618762,,BAO_0000357,,,CLD0
3859,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618763,,BAO_0000357,,,CLD0
3860,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618764,,BAO_0000357,,,CLD0
3861,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL618765,,BAO_0000357,,,CLD0
3862,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618766,,BAO_0000357,,,CLD0
3863,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618767,,BAO_0000357,,,CLD0
3864,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619380,,BAO_0000357,,,CLD0
3865,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL619381,,BAO_0000357,,,CLD0
3866,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087,D,9,Expert,1,,CHEMBL619382,,BAO_0000357,,,CLD0
3867,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619383,,BAO_0000357,,,CLD0
3868,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619384,,BAO_0000019,,,CLD0
3869,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619385,,BAO_0000019,,,CLD0
3870,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55,H,8,Autocuration,1,,CHEMBL882928,,BAO_0000019,,,CLD0
3871,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619386,,BAO_0000019,,,CLD0
3872,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619387,,BAO_0000019,,,CLD0
3873,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619388,,BAO_0000019,,,CLD0
3874,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619389,,BAO_0000019,,,CLD0
3875,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619390,,BAO_0000019,,,CLD0
3876,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619391,,BAO_0000019,,,CLD0
3877,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619392,,BAO_0000019,,,CLD0
3878,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619393,,BAO_0000221,178.0,,CLD0
3879,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619394,,BAO_0000019,,,CLD0
3880,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619395,702.0,BAO_0000219,,,CLD0
3881,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619396,702.0,BAO_0000219,,,CLD0
3882,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619397,,BAO_0000357,,,CLD0
3883,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619398,,BAO_0000357,,,CLD0
3884,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619399,,BAO_0000357,,,CLD0
3885,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619400,663.0,BAO_0000219,,,CLD0
3886,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619401,,BAO_0000019,,,CLD0
3887,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619402,,BAO_0000019,,,CLD0
3888,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166,D,9,Expert,1,,CHEMBL619403,663.0,BAO_0000219,,,CLD0
3889,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619404,663.0,BAO_0000219,,,CLD0
3890,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619405,663.0,BAO_0000219,,,CLD0
3891,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619406,702.0,BAO_0000219,,,CLD0
3892,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL619407,702.0,BAO_0000219,,,CLD0
3893,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619408,,BAO_0000357,,,CLD0
3894,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619409,702.0,BAO_0000219,,,CLD0
3895,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619410,702.0,BAO_0000219,,,CLD0
3896,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619753,702.0,BAO_0000219,,,CLD0
3897,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619754,702.0,BAO_0000219,,,CLD0
3898,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619903,,BAO_0000357,,,CLD0
3899,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619904,,BAO_0000357,,,CLD0
3900,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619905,,BAO_0000357,,,CLD0
3901,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619906,,BAO_0000019,,,CLD0
3902,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619907,,BAO_0000019,,,CLD0
3903,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619908,,BAO_0000019,,,CLD0
3904,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619909,,BAO_0000019,,,CLD0
3905,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619910,702.0,BAO_0000219,,,CLD0
3906,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL882929,702.0,BAO_0000219,,,CLD0
3907,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619911,702.0,BAO_0000219,,,CLD0
3908,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619912,,BAO_0000019,,,CLD0
3909,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619913,,BAO_0000357,,,CLD0
3910,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619914,702.0,BAO_0000219,,,CLD0
3911,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619915,702.0,BAO_0000219,,,CLD0
3912,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619916,702.0,BAO_0000219,,,CLD0
3913,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619917,,BAO_0000218,,,CLD0
3914,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619918,,BAO_0000357,,,CLD0
3915,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619919,,BAO_0000218,,,CLD0
3916,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883710,702.0,BAO_0000219,,,CLD0
3917,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619920,,BAO_0000221,178.0,,CLD0
3918,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619921,,BAO_0000357,,,CLD0
3919,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619922,,BAO_0000019,,,CLD0
3920,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619923,,BAO_0000219,,,CLD0
3921,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619924,702.0,BAO_0000219,,,CLD0
3922,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,RBL,,12166,H,8,Expert,1,,CHEMBL619925,,BAO_0000219,,,CLD0
3923,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619926,702.0,BAO_0000219,,,CLD0
3924,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619927,702.0,BAO_0000219,,,CLD0
3925,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619928,702.0,BAO_0000219,,,CLD0
3926,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619929,702.0,BAO_0000219,,,CLD0
3927,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875089,702.0,BAO_0000219,,,CLD0
3928,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619930,702.0,BAO_0000219,,,CLD0
3929,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619931,702.0,BAO_0000219,,,CLD0
3930,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619932,702.0,BAO_0000219,,,CLD0
3931,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619933,702.0,BAO_0000219,,,CLD0
3932,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619934,702.0,BAO_0000219,,,CLD0
3933,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619935,702.0,BAO_0000219,,,CLD0
3934,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619936,702.0,BAO_0000219,,,CLD0
3935,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619937,702.0,BAO_0000219,,,CLD0
3936,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619938,702.0,BAO_0000219,,,CLD0
3937,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619939,702.0,BAO_0000219,,,CLD0
3938,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619940,702.0,BAO_0000219,,,CLD0
3939,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875090,702.0,BAO_0000219,,,CLD0
3940,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619941,702.0,BAO_0000219,,,CLD0
3941,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619942,702.0,BAO_0000219,,,CLD0
3942,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883711,702.0,BAO_0000219,,,CLD0
3943,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619943,702.0,BAO_0000219,,,CLD0
3944,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619944,702.0,BAO_0000219,,,CLD0
3945,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619945,702.0,BAO_0000219,,,CLD0
3946,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619946,702.0,BAO_0000219,,,CLD0
3947,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619947,702.0,BAO_0000219,,,CLD0
3948,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619948,702.0,BAO_0000219,,,CLD0
3949,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619949,702.0,BAO_0000219,,,CLD0
3950,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619950,,BAO_0000019,,,CLD0
3951,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618050,,BAO_0000019,,,CLD0
3952,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL875091,663.0,BAO_0000219,,,CLD0
3953,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL618051,663.0,BAO_0000219,,,CLD0
3954,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618052,702.0,BAO_0000219,,,CLD0
3955,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL618053,663.0,BAO_0000219,,,CLD0
3956,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL618054,,BAO_0000019,,,CLD0
3957,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618055,702.0,BAO_0000219,,,CLD0
3958,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618056,702.0,BAO_0000219,,,CLD0
3959,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618057,,BAO_0000357,,,CLD0
3960,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618058,702.0,BAO_0000219,,,CLD0
3961,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618059,702.0,BAO_0000219,,,CLD0
3962,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL618060,,BAO_0000019,,,CLD0
3963,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618061,702.0,BAO_0000219,,,CLD0
3964,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618062,,BAO_0000019,,,CLD0
3965,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618063,702.0,BAO_0000219,,,CLD0
3966,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618064,,BAO_0000357,,,CLD0
3967,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618065,702.0,BAO_0000219,,,CLD0
3968,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618066,702.0,BAO_0000219,,,CLD0
3969,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618067,702.0,BAO_0000219,,,CLD0
3970,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618068,702.0,BAO_0000219,,,CLD0
3971,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618069,702.0,BAO_0000219,,,CLD0
3972,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618070,702.0,BAO_0000219,,,CLD0
3973,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL618071,,BAO_0000221,349.0,,CLD0
3974,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL619247,,BAO_0000221,349.0,,CLD0
3975,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825,H,8,Autocuration,1,,CHEMBL619248,,BAO_0000019,,,CLD0
3976,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619249,,BAO_0000221,10000000.0,,CLD0
3977,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619250,,BAO_0000221,10000000.0,,CLD0
3978,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL619251,,BAO_0000019,,,CLD0
3979,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619252,,BAO_0000221,178.0,,CLD0
3980,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619253,,BAO_0000221,178.0,,CLD0
3981,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619254,,BAO_0000219,,,CLD0
3982,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619255,,BAO_0000219,,,CLD0
3983,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619256,,BAO_0000219,,,CLD0
3984,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL875418,,BAO_0000219,,,CLD0
3985,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619257,,BAO_0000219,,,CLD0
3986,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL619258,,BAO_0000219,,,CLD0
3987,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,PMNL,,17140,H,8,Expert,1,,CHEMBL619259,424.0,BAO_0000219,,,CLD0
3988,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619260,,BAO_0000357,,,CLD0
3989,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619261,,BAO_0000218,178.0,,CLD0
3990,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619263,,BAO_0000218,178.0,,CLD0
3991,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619264,,BAO_0000218,178.0,,CLD0
3992,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619265,,BAO_0000218,178.0,,CLD0
3993,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619266,,BAO_0000218,178.0,,CLD0
3994,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619902,,BAO_0000218,178.0,,CLD0
3995,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620058,,BAO_0000218,178.0,,CLD0
3996,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620059,,BAO_0000218,178.0,,CLD0
3997,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620060,,BAO_0000218,178.0,,CLD0
3998,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620061,,BAO_0000218,178.0,,CLD0
3999,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620062,,BAO_0000218,178.0,,CLD0
4000,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620063,,BAO_0000218,178.0,,CLD0
4001,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620064,,BAO_0000218,178.0,,CLD0
4002,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620065,,BAO_0000218,178.0,,CLD0
4003,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620066,,BAO_0000218,178.0,,CLD0
4004,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620067,,BAO_0000218,178.0,,CLD0
4005,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620068,,BAO_0000218,178.0,,CLD0
4006,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620069,,BAO_0000218,178.0,,CLD0
4007,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620070,,BAO_0000218,178.0,,CLD0
4008,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620071,,BAO_0000218,178.0,,CLD0
4009,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620072,,BAO_0000218,178.0,,CLD0
4010,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620036,,BAO_0000218,178.0,,CLD0
4011,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857702,,BAO_0000218,178.0,,CLD0
4012,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620037,,BAO_0000218,178.0,,CLD0
4013,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620038,,BAO_0000218,178.0,,CLD0
4014,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620039,,BAO_0000218,178.0,,CLD0
4015,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620040,,BAO_0000218,178.0,,CLD0
4016,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620041,,BAO_0000218,178.0,,CLD0
4017,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620042,,BAO_0000218,178.0,,CLD0
4018,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620043,,BAO_0000218,178.0,,CLD0
4019,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620044,,BAO_0000218,178.0,,CLD0
4020,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620045,,BAO_0000218,178.0,,CLD0
4021,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620046,,BAO_0000218,178.0,,CLD0
4022,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620047,,BAO_0000218,178.0,,CLD0
4023,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620048,,BAO_0000218,178.0,,CLD0
4024,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857703,,BAO_0000218,178.0,,CLD0
4025,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620049,,BAO_0000218,178.0,,CLD0
4026,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620050,,BAO_0000218,178.0,,CLD0
4027,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620051,,BAO_0000218,178.0,,CLD0
4028,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619213,,BAO_0000218,178.0,,CLD0
4029,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619214,,BAO_0000218,178.0,,CLD0
4030,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619804,,BAO_0000218,178.0,,CLD0
4031,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619805,,BAO_0000218,178.0,,CLD0
4032,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619806,,BAO_0000218,178.0,,CLD0
4033,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619807,,BAO_0000218,178.0,,CLD0
4034,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619808,,BAO_0000218,178.0,,CLD0
4035,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619809,,BAO_0000218,,,CLD0
4036,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619810,,BAO_0000218,,,CLD0
4037,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619811,,BAO_0000218,,,CLD0
4038,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620769,,BAO_0000218,,,CLD0
4039,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620770,,BAO_0000218,,,CLD0
4040,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620771,,BAO_0000218,,,CLD0
4041,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620772,,BAO_0000218,,,CLD0
4042,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620773,,BAO_0000218,,,CLD0
4043,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620774,,BAO_0000357,,,CLD0
4044,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL620775,,BAO_0000357,,,CLD0
4045,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620776,,BAO_0000357,,,CLD0
4046,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620777,,BAO_0000218,178.0,,CLD0
4047,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620778,,BAO_0000357,,,CLD0
4048,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620779,,BAO_0000357,,,CLD0
4049,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621500,,BAO_0000019,,,CLD0
4050,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621501,,BAO_0000019,,,CLD0
4051,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618098,,BAO_0000019,,,CLD0
4052,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618099,,BAO_0000019,,,CLD0
4053,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618100,,BAO_0000357,,,CLD0
4054,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618101,,BAO_0000357,,,CLD0
4055,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618102,,BAO_0000357,,,CLD0
4056,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618103,,BAO_0000357,,,CLD0
4057,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618104,,BAO_0000357,,,CLD0
4058,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL883712,,BAO_0000219,,,CLD0
4059,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618105,,BAO_0000357,,,CLD0
4060,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618106,,BAO_0000357,,,CLD0
4061,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618107,,BAO_0000357,,,CLD0
4062,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618108,,BAO_0000357,,,CLD0
4063,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618109,,BAO_0000357,,,CLD0
4064,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618110,,BAO_0000357,,,CLD0
4065,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL618111,,BAO_0000357,,,CLD0
4066,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618112,,BAO_0000019,,,CLD0
4067,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618113,,BAO_0000019,,,CLD0
4068,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618114,,BAO_0000357,,,CLD0
4069,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55,H,8,Expert,1,,CHEMBL620871,,BAO_0000221,2116.0,,CLD0
4070,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620872,,BAO_0000221,178.0,,CLD0
4071,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620873,,BAO_0000221,178.0,,CLD0
4072,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620874,,BAO_0000357,,,CLD0
4073,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL620875,,BAO_0000357,,,CLD0
4074,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620876,,BAO_0000251,2107.0,,CLD0
4075,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620877,,BAO_0000251,2107.0,,CLD0
4076,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL857854,,BAO_0000251,2107.0,,CLD0
4077,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620878,,BAO_0000251,2107.0,,CLD0
4078,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620879,,BAO_0000251,2107.0,,CLD0
4079,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620880,,BAO_0000251,2107.0,,CLD0
4080,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620881,,BAO_0000251,2107.0,,CLD0
4081,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620882,,BAO_0000251,2107.0,,CLD0
4082,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620883,,BAO_0000251,2107.0,,CLD0
4083,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620884,,BAO_0000251,2107.0,,CLD0
4084,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620885,,BAO_0000251,2107.0,,CLD0
4085,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620886,,BAO_0000251,2107.0,,CLD0
4086,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620887,,BAO_0000251,2107.0,,CLD0
4087,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618039,,BAO_0000251,2107.0,,CLD0
4088,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618040,,BAO_0000251,2107.0,,CLD0
4089,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618041,,BAO_0000251,2107.0,,CLD0
4090,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL618216,,BAO_0000251,2107.0,,CLD0
4091,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL618217,,BAO_0000251,2107.0,,CLD0
4092,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618218,,BAO_0000251,2107.0,,CLD0
4093,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618219,,BAO_0000251,2107.0,,CLD0
4094,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618220,,BAO_0000251,2107.0,,CLD0
4095,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618221,,BAO_0000251,2107.0,,CLD0
4096,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618222,,BAO_0000251,2107.0,,CLD0
4097,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618223,,BAO_0000251,2107.0,,CLD0
4098,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618224,,BAO_0000251,2107.0,,CLD0
4099,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618225,,BAO_0000251,2107.0,,CLD0
4100,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618226,,BAO_0000251,2107.0,,CLD0
4101,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618227,,BAO_0000251,2107.0,,CLD0
4102,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618228,,BAO_0000251,2107.0,,CLD0
4103,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618229,,BAO_0000251,2107.0,,CLD0
4104,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618230,,BAO_0000251,2107.0,,CLD0
4105,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618231,,BAO_0000251,2107.0,,CLD0
4106,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618232,,BAO_0000251,2107.0,,CLD0
4107,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618233,,BAO_0000251,2107.0,,CLD0
4108,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618234,,BAO_0000251,2107.0,,CLD0
4109,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618235,,BAO_0000251,2107.0,,CLD0
4110,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618115,,BAO_0000251,2107.0,,CLD0
4111,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618116,,BAO_0000251,2107.0,,CLD0
4112,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL618117,,BAO_0000251,2107.0,,CLD0
4113,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619968,,BAO_0000251,2107.0,,CLD0
4114,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619969,,BAO_0000251,2107.0,,CLD0
4115,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619970,,BAO_0000251,2107.0,,CLD0
4116,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619971,,BAO_0000251,2107.0,,CLD0
4117,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619972,,BAO_0000251,2107.0,,CLD0
4118,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619973,,BAO_0000251,2107.0,,CLD0
4119,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619974,,BAO_0000251,2107.0,,CLD0
4120,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619975,,BAO_0000251,2107.0,,CLD0
4121,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL619976,,BAO_0000251,2107.0,,CLD0
4122,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL619977,,BAO_0000251,2107.0,,CLD0
4123,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL619978,,BAO_0000251,2107.0,,CLD0
4124,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL619979,,BAO_0000251,2107.0,,CLD0
4125,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL619980,,BAO_0000251,2107.0,,CLD0
4126,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22226,U,0,Autocuration,1,,CHEMBL619981,,BAO_0000251,2107.0,,CLD0
4127,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619982,741.0,BAO_0000219,,,CLD0
4128,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698,N,1,Intermediate,1,,CHEMBL619983,993.0,BAO_0000219,,,CLD0
4129,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620031,391.0,BAO_0000219,,,CLD0
4130,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620032,391.0,BAO_0000219,,,CLD0
4131,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620033,505.0,BAO_0000219,,,CLD0
4132,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620034,505.0,BAO_0000219,,,CLD0
4133,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL620035,1119.0,BAO_0000219,,,CLD0
4134,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618318,1119.0,BAO_0000219,,,CLD0
4135,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618319,1119.0,BAO_0000219,,,CLD0
4136,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618320,1119.0,BAO_0000219,,,CLD0
4137,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618321,1119.0,BAO_0000219,,,CLD0
4138,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL883118,1119.0,BAO_0000219,,,CLD0
4139,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883795,391.0,BAO_0000219,,,CLD0
4140,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618322,391.0,BAO_0000219,,,CLD0
4141,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618323,391.0,BAO_0000219,,,CLD0
4142,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618324,391.0,BAO_0000219,,,CLD0
4143,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618325,391.0,BAO_0000219,,,CLD0
4144,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL875416,391.0,BAO_0000219,,,CLD0
4145,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618326,391.0,BAO_0000219,,,CLD0
4146,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618327,391.0,BAO_0000219,,,CLD0
4147,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619215,391.0,BAO_0000219,,,CLD0
4148,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619216,391.0,BAO_0000219,,,CLD0
4149,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619217,391.0,BAO_0000219,,,CLD0
4150,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619218,391.0,BAO_0000219,,,CLD0
4151,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619219,391.0,BAO_0000219,,,CLD0
4152,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619220,391.0,BAO_0000219,,,CLD0
4153,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619221,391.0,BAO_0000219,,,CLD0
4154,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619222,391.0,BAO_0000219,,,CLD0
4155,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857454,391.0,BAO_0000219,,,CLD0
4156,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619223,702.0,BAO_0000219,,,CLD0
4157,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619224,702.0,BAO_0000219,,,CLD0
4158,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619225,,BAO_0000019,,,CLD0
4159,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619226,702.0,BAO_0000219,,,CLD0
4160,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619227,702.0,BAO_0000219,,,CLD0
4161,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619228,,BAO_0000357,,,CLD0
4162,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619229,,BAO_0000219,,,CLD0
4163,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619230,702.0,BAO_0000219,,,CLD0
4164,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,RBL,,12166,H,8,Autocuration,1,,CHEMBL619231,,BAO_0000219,,,CLD0
4165,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619232,,BAO_0000357,,,CLD0
4166,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619233,,BAO_0000357,,,CLD0
4167,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619234,,BAO_0000357,,,CLD0
4168,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619235,,BAO_0000357,,,CLD0
4169,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619236,,BAO_0000019,,,CLD0
4170,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619237,702.0,BAO_0000219,,,CLD0
4171,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619238,,BAO_0000357,,,CLD0
4172,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619239,,BAO_0000357,,,CLD0
4173,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619240,,BAO_0000357,,,CLD0
4174,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875417,,BAO_0000019,,,CLD0
4175,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619241,702.0,BAO_0000219,,,CLD0
4176,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619242,,BAO_0000019,,,CLD0
4177,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883796,702.0,BAO_0000219,,,CLD0
4178,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619243,,BAO_0000357,,,CLD0
4179,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619244,,BAO_0000357,,,CLD0
4180,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619245,,BAO_0000019,,,CLD0
4181,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619246,,BAO_0000019,,,CLD0
4182,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619984,702.0,BAO_0000219,,,CLD0
4183,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619985,702.0,BAO_0000219,,,CLD0
4184,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619986,702.0,BAO_0000219,,,CLD0
4185,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619987,702.0,BAO_0000219,,,CLD0
4186,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619988,,BAO_0000218,,,CLD0
4187,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619989,702.0,BAO_0000219,,,CLD0
4188,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619990,702.0,BAO_0000219,,,CLD0
4189,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619991,,BAO_0000219,,,CLD0
4190,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619992,,BAO_0000219,,,CLD0
4191,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619993,,BAO_0000218,,,CLD0
4192,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619994,663.0,BAO_0000219,,,CLD0
4193,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619995,663.0,BAO_0000219,,,CLD0
4194,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619996,,BAO_0000019,,,CLD0
4195,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619997,,BAO_0000019,,,CLD0
4196,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619998,,BAO_0000019,,,CLD0
4197,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,RBI-1,,12166,H,8,Expert,1,,CHEMBL619999,,BAO_0000219,,,CLD0
4198,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,RBI-1,,12166,H,8,Autocuration,1,,CHEMBL620000,,BAO_0000219,,,CLD0
4199,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620001,702.0,BAO_0000219,,,CLD0
4200,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620002,,BAO_0000357,,,CLD0
4201,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620003,702.0,BAO_0000219,,,CLD0
4202,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620004,702.0,BAO_0000219,,,CLD0
4203,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL874063,,BAO_0000357,,,CLD0
4204,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620005,702.0,BAO_0000219,,,CLD0
4205,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620006,702.0,BAO_0000219,,,CLD0
4206,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620007,702.0,BAO_0000219,,,CLD0
4207,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620008,702.0,BAO_0000219,,,CLD0
4208,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620009,702.0,BAO_0000219,,,CLD0
4209,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620010,702.0,BAO_0000219,,,CLD0
4210,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620011,702.0,BAO_0000219,,,CLD0
4211,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620677,702.0,BAO_0000219,,,CLD0
4212,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620678,702.0,BAO_0000219,,,CLD0
4213,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620679,702.0,BAO_0000219,,,CLD0
4214,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620680,702.0,BAO_0000219,,,CLD0
4215,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620838,,BAO_0000357,,,CLD0
4216,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620839,,BAO_0000357,,,CLD0
4217,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620840,,BAO_0000357,,,CLD0
4218,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620841,702.0,BAO_0000219,,,CLD0
4219,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620842,702.0,BAO_0000219,,,CLD0
4220,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620843,702.0,BAO_0000219,,,CLD0
4221,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620844,702.0,BAO_0000219,,,CLD0
4222,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620845,702.0,BAO_0000219,,,CLD0
4223,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620846,,BAO_0000019,,,CLD0
4224,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873951,,BAO_0000357,,,CLD0
4225,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620847,,BAO_0000357,,,CLD0
4226,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620848,702.0,BAO_0000219,,,CLD0
4227,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620849,702.0,BAO_0000219,,,CLD0
4228,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620850,702.0,BAO_0000219,,,CLD0
4229,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620851,702.0,BAO_0000219,,,CLD0
4230,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620852,702.0,BAO_0000219,,,CLD0
4231,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875098,702.0,BAO_0000219,,,CLD0
4232,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620853,702.0,BAO_0000219,,,CLD0
4233,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620854,,BAO_0000019,,,CLD0
4234,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620855,702.0,BAO_0000219,,,CLD0
4235,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL839884,702.0,BAO_0000219,,,CLD0
4236,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620856,702.0,BAO_0000219,,,CLD0
4237,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620857,702.0,BAO_0000219,,,CLD0
4238,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620858,,BAO_0000019,,,CLD0
4239,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620859,,BAO_0000019,,,CLD0
4240,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620860,,BAO_0000019,,,CLD0
4241,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620861,,BAO_0000019,,,CLD0
4242,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620862,,BAO_0000357,,,CLD0
4243,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620863,,BAO_0000357,,,CLD0
4244,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620864,,BAO_0000019,,,CLD0
4245,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620865,702.0,BAO_0000219,,,CLD0
4246,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620866,702.0,BAO_0000219,,,CLD0
4247,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620867,663.0,BAO_0000219,,,CLD0
4248,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620868,663.0,BAO_0000219,,,CLD0
4249,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620869,663.0,BAO_0000219,,,CLD0
4250,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873952,,BAO_0000019,,,CLD0
4251,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875099,,BAO_0000357,,,CLD0
4252,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620870,663.0,BAO_0000219,,,CLD0
4253,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,RBI-1,,12166,H,8,Autocuration,1,,CHEMBL618261,,BAO_0000219,,,CLD0
4254,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,RBI-1,,12166,H,8,Autocuration,1,,CHEMBL618262,,BAO_0000219,,,CLD0
4255,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,RBI-1,,12166,H,8,Autocuration,1,,CHEMBL619428,,BAO_0000219,,,CLD0
4256,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,RBI-1,,12166,H,8,Autocuration,1,,CHEMBL619429,,BAO_0000219,,,CLD0
4257,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,RBI-1,,12166,H,8,Autocuration,1,,CHEMBL619430,,BAO_0000219,,,CLD0
4258,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620017,702.0,BAO_0000219,,,CLD0
4259,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620018,702.0,BAO_0000219,,,CLD0
4260,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620019,702.0,BAO_0000219,,,CLD0
4261,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620020,702.0,BAO_0000219,,,CLD0
4262,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620021,702.0,BAO_0000219,,,CLD0
4263,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620022,702.0,BAO_0000219,,,CLD0
4264,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620023,702.0,BAO_0000219,,,CLD0
4265,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620024,702.0,BAO_0000219,,,CLD0
4266,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620025,702.0,BAO_0000219,,,CLD0
4267,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620026,702.0,BAO_0000219,,,CLD0
4268,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620027,702.0,BAO_0000219,,,CLD0
4269,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620028,,BAO_0000019,,,CLD0
4270,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620029,,BAO_0000357,,,CLD0
4271,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620030,,BAO_0000357,,,CLD0
4272,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875415,702.0,BAO_0000219,,,CLD0
4273,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618256,702.0,BAO_0000219,,,CLD0
4274,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618257,702.0,BAO_0000219,,,CLD0
4275,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618258,702.0,BAO_0000219,,,CLD0
4276,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618259,702.0,BAO_0000219,,,CLD0
4277,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618260,,BAO_0000019,,,CLD0
4278,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618215,702.0,BAO_0000219,,,CLD0
4279,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618390,702.0,BAO_0000219,,,CLD0
4280,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618391,702.0,BAO_0000219,,,CLD0
4281,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618392,702.0,BAO_0000219,,,CLD0
4282,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618393,702.0,BAO_0000219,,,CLD0
4283,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618394,,BAO_0000219,,,CLD0
4284,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618395,702.0,BAO_0000219,,,CLD0
4285,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618396,702.0,BAO_0000219,,,CLD0
4286,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL858253,702.0,BAO_0000219,,,CLD0
4287,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Autocuration,1,,CHEMBL618397,,BAO_0000019,,,CLD0
4288,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL618398,,BAO_0000357,,,CLD0
4289,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618399,,BAO_0000019,,,CLD0
4290,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618400,,BAO_0000357,,,CLD0
4291,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618401,,BAO_0000357,,,CLD0
4292,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618402,,BAO_0000357,,,CLD0
4293,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55,H,8,Autocuration,1,,CHEMBL876400,702.0,BAO_0000219,,,CLD0
4294,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618403,,BAO_0000357,,,CLD0
4295,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618404,,BAO_0000357,,,CLD0
4296,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618405,,BAO_0000357,,,CLD0
4297,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618406,,BAO_0000357,,,CLD0
4298,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL618407,,BAO_0000019,,,CLD0
4299,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618408,,BAO_0000357,,,CLD0
4300,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618409,,BAO_0000357,,,CLD0
4301,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618410,,BAO_0000357,,,CLD0
4302,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618411,,BAO_0000357,,,CLD0
4303,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618412,,BAO_0000357,,,CLD0
4304,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618413,702.0,BAO_0000219,,,CLD0
4305,11089,,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618414,,BAO_0000357,,,CLD0
4306,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618415,,BAO_0000357,,,CLD0
4307,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618416,,BAO_0000019,,,CLD0
4308,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL876401,,BAO_0000357,,,CLD0
4309,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Expert,1,,CHEMBL618417,,BAO_0000357,,,CLD0
4310,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618418,,BAO_0000357,,,CLD0
4311,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618419,,BAO_0000357,,,CLD0
4312,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618420,,BAO_0000357,,,CLD0
4313,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618421,,BAO_0000357,,,CLD0
4314,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618422,,BAO_0000019,,,CLD0
4315,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618423,,BAO_0000019,,,CLD0
4316,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618424,,BAO_0000019,,,CLD0
4317,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284,S,2,Intermediate,1,,CHEMBL618425,,BAO_0000220,,,CLD0
4318,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL618426,,BAO_0000019,,,CLD0
4319,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623,N,1,Expert,1,,CHEMBL618427,390.0,BAO_0000219,,,CLD0
4320,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618428,345.0,BAO_0000219,,,CLD0
4321,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618429,345.0,BAO_0000219,,,CLD0
4322,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618430,345.0,BAO_0000219,,,CLD0
4323,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618431,345.0,BAO_0000219,,,CLD0
4324,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL883799,345.0,BAO_0000219,,,CLD0
4325,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618432,345.0,BAO_0000219,,,CLD0
4326,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618433,345.0,BAO_0000219,,,CLD0
4327,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443,D,9,Expert,1,,CHEMBL618434,,BAO_0000357,,,CLD0
4328,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240,H,8,Expert,1,,CHEMBL618435,407.0,BAO_0000219,,,CLD0
4329,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL876402,,BAO_0000357,,,CLD0
4330,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618436,,BAO_0000019,,,CLD0
4331,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618437,,BAO_0000218,,,CLD0
4332,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL618438,,BAO_0000357,,,CLD0
4333,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,17045,H,8,Expert,1,,CHEMBL883800,,BAO_0000251,2107.0,,CLD0
4334,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,17045,H,8,Expert,1,,CHEMBL618439,,BAO_0000251,2107.0,,CLD0
4335,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,NCI,,22226,U,0,Intermediate,1,,CHEMBL618440,1188.0,BAO_0000219,,,CLD0
4336,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,NCI,,22226,U,0,Intermediate,1,,CHEMBL618441,1188.0,BAO_0000219,,,CLD0
4337,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Expert,1,,CHEMBL618442,,BAO_0000019,,,CLD0
4338,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Autocuration,1,,CHEMBL618443,,BAO_0000019,,,CLD0
4339,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938,H,8,Expert,1,,CHEMBL619158,,BAO_0000019,,,CLD0
4340,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938,H,8,Autocuration,1,,CHEMBL620974,,BAO_0000019,,,CLD0
4341,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938,H,8,Autocuration,1,,CHEMBL620975,,BAO_0000357,,,CLD0
4342,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL620976,,BAO_0000019,,,CLD0
4343,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22221,N,1,Expert,1,,CHEMBL620977,,BAO_0000019,,,CLD0
4344,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620978,542.0,BAO_0000219,,,CLD0
4345,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620979,542.0,BAO_0000219,,,CLD0
4346,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620980,542.0,BAO_0000219,,,CLD0
4347,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620981,542.0,BAO_0000219,,,CLD0
4348,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620982,542.0,BAO_0000219,,,CLD0
4349,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620983,542.0,BAO_0000219,,,CLD0
4350,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620984,,BAO_0000019,,,CLD0
4351,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620985,,BAO_0000019,,,CLD0
4352,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275,H,8,Expert,1,,CHEMBL620986,,BAO_0000357,,,CLD0
4353,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620987,,BAO_0000218,,,CLD0
4354,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620988,,BAO_0000218,,,CLD0
4355,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620989,,BAO_0000218,,,CLD0
4356,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620990,,BAO_0000218,,,CLD0
4357,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Intermediate,1,,CHEMBL620991,,BAO_0000218,,,CLD0
4358,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620992,850.0,BAO_0000218,,,CLD0
4359,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620993,850.0,BAO_0000218,,,CLD0
4360,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620994,850.0,BAO_0000218,,,CLD0
4361,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620995,850.0,BAO_0000218,,,CLD0
4362,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620996,850.0,BAO_0000218,,,CLD0
4363,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL875581,850.0,BAO_0000218,,,CLD0
4364,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620997,,BAO_0000218,,,CLD0
4365,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620998,,BAO_0000218,,,CLD0
4366,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620999,,BAO_0000218,,,CLD0
4367,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621000,,BAO_0000218,,,CLD0
4368,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621001,,BAO_0000218,,,CLD0
4369,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621002,,BAO_0000218,,,CLD0
4370,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621003,,BAO_0000218,,,CLD0
4371,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621004,,BAO_0000218,,,CLD0
4372,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621005,,BAO_0000218,,,CLD0
4373,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621006,,BAO_0000218,,,CLD0
4374,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621007,,BAO_0000218,,,CLD0
4375,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621008,,BAO_0000218,,,CLD0
4376,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621009,,BAO_0000218,,,CLD0
4377,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL857705,,BAO_0000218,,,CLD0
4378,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619828,,BAO_0000218,,,CLD0
4379,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619829,,BAO_0000218,,,CLD0
4380,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619830,,BAO_0000218,,,CLD0
4381,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619831,,BAO_0000218,,,CLD0
4382,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619832,,BAO_0000218,,,CLD0
4383,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619833,,BAO_0000218,,,CLD0
4384,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619834,,BAO_0000218,,,CLD0
4385,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619835,,BAO_0000218,,,CLD0
4386,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619836,,BAO_0000218,,,CLD0
4387,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619837,850.0,BAO_0000218,,,CLD0
4388,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619838,,BAO_0000218,,,CLD0
4389,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619839,,BAO_0000218,,,CLD0
4390,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619840,850.0,BAO_0000218,,,CLD0
4391,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619841,850.0,BAO_0000218,,,CLD0
4392,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL857704,850.0,BAO_0000218,,,CLD0
4393,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619842,850.0,BAO_0000218,,,CLD0
4394,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL619843,850.0,BAO_0000218,,,CLD0
4395,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619844,,BAO_0000019,,,CLD0
4396,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL857855,,BAO_0000251,2107.0,,CLD0
4397,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619845,,BAO_0000251,2107.0,,CLD0
4398,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619846,,BAO_0000251,2107.0,,CLD0
4399,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619847,,BAO_0000251,2107.0,,CLD0
4400,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL619848,,BAO_0000251,2107.0,,CLD0
4401,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620893,,BAO_0000251,2107.0,,CLD0
4402,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620894,,BAO_0000251,2107.0,,CLD0
4403,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620895,,BAO_0000251,2107.0,,CLD0
4404,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620896,,BAO_0000251,2107.0,,CLD0
4405,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620897,,BAO_0000251,2107.0,,CLD0
4406,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620898,,BAO_0000251,2107.0,,CLD0
4407,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsome,22221,N,1,Autocuration,1,,CHEMBL620899,,BAO_0000251,2107.0,,CLD0
4408,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620900,,BAO_0000218,1969.0,,CLD0
4409,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL620901,,BAO_0000218,2107.0,,CLD0
4410,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620902,,BAO_0000218,,,CLD0
4411,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620903,,BAO_0000218,1969.0,,CLD0
4412,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620904,,BAO_0000218,1969.0,,CLD0
4413,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620905,,BAO_0000218,1969.0,,CLD0
4414,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620906,,BAO_0000218,1969.0,,CLD0
4415,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875420,,BAO_0000218,1969.0,,CLD0
4416,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620907,,BAO_0000218,1969.0,,CLD0
4417,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620908,,BAO_0000218,1969.0,,CLD0
4418,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620909,,BAO_0000218,1969.0,,CLD0
4419,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620910,,BAO_0000218,1969.0,,CLD0
4420,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620911,,BAO_0000218,1969.0,,CLD0
4421,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620912,,BAO_0000218,1969.0,,CLD0
4422,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620913,,BAO_0000218,,,CLD0
4423,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620914,,BAO_0000218,,,CLD0
4424,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620915,,BAO_0000218,,,CLD0
4425,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620916,,BAO_0000218,,,CLD0
4426,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620917,,BAO_0000218,,,CLD0
4427,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620918,,BAO_0000218,,,CLD0
4428,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620919,,BAO_0000218,,,CLD0
4429,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620920,,BAO_0000218,1969.0,,CLD0
4430,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620921,,BAO_0000218,1969.0,,CLD0
4431,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620922,,BAO_0000218,1969.0,,CLD0
4432,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620923,,BAO_0000218,,,CLD0
4433,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620924,,BAO_0000218,1969.0,,CLD0
4434,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (umol/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620925,,BAO_0000218,,,CLD0
4435,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620926,,BAO_0000218,,,CLD0
4436,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620927,,BAO_0000218,,,CLD0
4437,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620928,,BAO_0000218,,,CLD0
4438,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620929,,BAO_0000218,,,CLD0
4439,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620930,,BAO_0000218,1969.0,,CLD0
4440,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620931,,BAO_0000218,1969.0,,CLD0
4441,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620932,,BAO_0000218,1969.0,,CLD0
4442,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620933,,BAO_0000218,,,CLD0
4443,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620934,,BAO_0000218,,,CLD0
4444,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620935,,BAO_0000218,,,CLD0
4445,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620936,,BAO_0000218,,,CLD0
4446,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620937,,BAO_0000218,,,CLD0
4447,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620938,,BAO_0000218,,,CLD0
4448,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620939,,BAO_0000218,,,CLD0
4449,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620940,,BAO_0000218,,,CLD0
4450,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620941,,BAO_0000218,,,CLD0
4451,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620942,,BAO_0000218,,,CLD0
4452,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620943,,BAO_0000218,,,CLD0
4453,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620944,,BAO_0000218,,,CLD0
4454,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620945,,BAO_0000218,,,CLD0
4455,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620946,,BAO_0000218,,,CLD0
4456,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620947,,BAO_0000218,,,CLD0
4457,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620948,,BAO_0000218,,,CLD0
4458,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620949,,BAO_0000218,,,CLD0
4459,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620950,,BAO_0000218,,,CLD0
4460,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620951,,BAO_0000218,,,CLD0
4461,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620952,,BAO_0000218,,,CLD0
4462,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875421,,BAO_0000218,,,CLD0
4463,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620953,,BAO_0000218,,,CLD0
4464,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873491,,BAO_0000218,,,CLD0
4465,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620954,,BAO_0000218,,,CLD0
4466,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620955,,BAO_0000218,1969.0,,CLD0
4467,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618097,,BAO_0000218,1969.0,,CLD0
4468,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618268,,BAO_0000218,1969.0,,CLD0
4469,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618269,,BAO_0000218,1969.0,,CLD0
4470,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618270,,BAO_0000218,1969.0,,CLD0
4471,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618271,,BAO_0000218,,,CLD0
4472,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873493,,BAO_0000218,,,CLD0
4473,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621031,,BAO_0000218,,,CLD0
4474,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621032,,BAO_0000218,,,CLD0
4475,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621033,,BAO_0000218,,,CLD0
4476,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621034,,BAO_0000218,1969.0,,CLD0
4477,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621035,,BAO_0000218,,,CLD0
4478,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621036,,BAO_0000218,1969.0,,CLD0
4479,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621037,,BAO_0000218,1969.0,,CLD0
4480,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619812,,BAO_0000218,,,CLD0
4481,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619813,,BAO_0000218,,,CLD0
4482,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873335,,BAO_0000218,,,CLD0
4483,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619814,,BAO_0000218,,,CLD0
4484,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619815,,BAO_0000218,,,CLD0
4485,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619816,,BAO_0000218,,,CLD0
4486,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619817,,BAO_0000218,,,CLD0
4487,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL619818,,BAO_0000218,,,CLD0
4488,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619819,,BAO_0000218,1969.0,,CLD0
4489,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619820,,BAO_0000218,,,CLD0
4490,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875419,,BAO_0000218,,,CLD0
4491,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619821,,BAO_0000218,1969.0,,CLD0
4492,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619822,,BAO_0000218,,,CLD0
4493,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619823,,BAO_0000218,,,CLD0
4494,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619824,,BAO_0000218,,,CLD0
4495,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619825,,BAO_0000218,,,CLD0
4496,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619826,,BAO_0000218,,,CLD0
4497,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL619827,,BAO_0000218,2048.0,,CLD0
4498,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618167,,BAO_0000218,,,CLD0
4499,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618168,,BAO_0000221,178.0,,CLD0
4500,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL618169,,BAO_0000221,955.0,,CLD0
4501,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Heart,,,22224,U,0,Autocuration,1,,CHEMBL618170,,BAO_0000221,948.0,,CLD0
4502,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224,U,0,Autocuration,1,,CHEMBL618171,,BAO_0000221,160.0,,CLD0
4503,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL618172,,BAO_0000221,2113.0,,CLD0
4504,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618173,,BAO_0000221,2107.0,,CLD0
4505,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL618174,,BAO_0000221,2048.0,,CLD0
4506,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875408,,BAO_0000221,2106.0,,CLD0
4507,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL839827,,BAO_0000218,,,CLD0
4508,5689,Partition coefficient was measured in octanol/pH7.4 phosphate buffer as -log (counts per min ),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL618175,,BAO_0000100,,,CLD0
4509,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618176,,BAO_0000218,,,CLD0
4510,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618177,,BAO_0000218,,,CLD0
4511,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618178,,BAO_0000218,,,CLD0
4512,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618179,,BAO_0000218,,,CLD0
4513,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873489,,BAO_0000019,,,CLD0
4514,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618180,,BAO_0000019,,,CLD0
4515,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618181,,BAO_0000218,,,CLD0
4516,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618182,,BAO_0000218,,,CLD0
4517,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618183,,BAO_0000218,1969.0,,CLD0
4518,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618184,,BAO_0000218,2048.0,,CLD0
4519,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618185,,BAO_0000218,2048.0,,CLD0
4520,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618186,,BAO_0000218,2048.0,,CLD0
4521,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618187,,BAO_0000218,2048.0,,CLD0
4522,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618188,,BAO_0000218,2048.0,,CLD0
4523,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL875409,,BAO_0000218,2048.0,,CLD0
4524,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618189,,BAO_0000218,2048.0,,CLD0
4525,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618190,,BAO_0000218,178.0,,CLD0
4526,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618191,,BAO_0000218,178.0,,CLD0
4527,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618192,,BAO_0000218,178.0,,CLD0
4528,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL618193,,BAO_0000218,1474.0,,CLD0
4529,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL618194,,BAO_0000218,1474.0,,CLD0
4530,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL618195,,BAO_0000218,1474.0,,CLD0
4531,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618196,,BAO_0000218,955.0,,CLD0
4532,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618197,,BAO_0000218,955.0,,CLD0
4533,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618198,,BAO_0000218,955.0,,CLD0
4534,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618199,,BAO_0000218,948.0,,CLD0
4535,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618200,,BAO_0000218,948.0,,CLD0
4536,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618201,,BAO_0000218,948.0,,CLD0
4537,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618202,,BAO_0000218,160.0,,CLD0
4538,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618203,,BAO_0000218,160.0,,CLD0
4539,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618204,,BAO_0000218,160.0,,CLD0
4540,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618205,,BAO_0000218,2113.0,,CLD0
4541,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618206,,BAO_0000218,2113.0,,CLD0
4542,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618207,,BAO_0000218,2113.0,,CLD0
4543,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618208,,BAO_0000218,2107.0,,CLD0
4544,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618932,,BAO_0000218,2107.0,,CLD0
4545,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618933,,BAO_0000218,2107.0,,CLD0
4546,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618934,,BAO_0000218,2048.0,,CLD0
4547,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618935,,BAO_0000218,2048.0,,CLD0
4548,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618936,,BAO_0000218,2048.0,,CLD0
4549,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618937,,BAO_0000218,2385.0,,CLD0
4550,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618938,,BAO_0000218,2385.0,,CLD0
4551,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL619104,,BAO_0000218,2385.0,,CLD0
4552,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619105,,BAO_0000218,2106.0,,CLD0
4553,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619106,,BAO_0000218,2106.0,,CLD0
4554,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619107,,BAO_0000218,2106.0,,CLD0
4555,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL875410,,BAO_0000218,945.0,,CLD0
4556,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619108,,BAO_0000218,945.0,,CLD0
4557,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619109,,BAO_0000218,945.0,,CLD0
4558,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619110,,BAO_0000218,,,CLD0
4559,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619111,,BAO_0000218,,,CLD0
4560,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619112,,BAO_0000218,,,CLD0
4561,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619113,,BAO_0000218,,,CLD0
4562,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619114,,BAO_0000218,,,CLD0
4563,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619115,,BAO_0000218,,,CLD0
4564,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619116,478.0,BAO_0000219,,,CLD0
4565,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619117,478.0,BAO_0000219,,,CLD0
4566,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619118,478.0,BAO_0000219,,,CLD0
4567,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619119,478.0,BAO_0000219,,,CLD0
4568,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619120,478.0,BAO_0000219,,,CLD0
4569,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619121,478.0,BAO_0000219,,,CLD0
4570,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619122,478.0,BAO_0000219,,,CLD0
4571,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619123,478.0,BAO_0000219,,,CLD0
4572,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619124,478.0,BAO_0000219,,,CLD0
4573,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619125,478.0,BAO_0000219,,,CLD0
4574,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875411,478.0,BAO_0000219,,,CLD0
4575,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619126,478.0,BAO_0000219,,,CLD0
4576,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619127,478.0,BAO_0000219,,,CLD0
4577,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619128,478.0,BAO_0000219,,,CLD0
4578,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619129,478.0,BAO_0000219,,,CLD0
4579,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619130,478.0,BAO_0000219,,,CLD0
4580,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619131,478.0,BAO_0000219,,,CLD0
4581,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619132,478.0,BAO_0000219,,,CLD0
4582,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619133,478.0,BAO_0000218,,,CLD0
4583,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619134,478.0,BAO_0000219,,,CLD0
4584,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619135,478.0,BAO_0000219,,,CLD0
4585,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619136,478.0,BAO_0000219,,,CLD0
4586,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619137,478.0,BAO_0000219,,,CLD0
4587,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883713,478.0,BAO_0000219,,,CLD0
4588,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875412,478.0,BAO_0000219,,,CLD0
4589,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619138,478.0,BAO_0000218,,,CLD0
4590,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619262,478.0,BAO_0000218,,,CLD0
4591,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619139,478.0,BAO_0000219,,,CLD0
4592,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619140,478.0,BAO_0000219,,,CLD0
4593,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619141,478.0,BAO_0000219,,,CLD0
4594,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619142,478.0,BAO_0000219,,,CLD0
4595,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619143,478.0,BAO_0000219,,,CLD0
4596,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619144,478.0,BAO_0000219,,,CLD0
4597,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619145,478.0,BAO_0000219,,,CLD0
4598,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619146,478.0,BAO_0000219,,,CLD0
4599,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619147,478.0,BAO_0000219,,,CLD0
4600,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619148,478.0,BAO_0000219,,,CLD0
4601,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619149,478.0,BAO_0000219,,,CLD0
4602,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619150,478.0,BAO_0000219,,,CLD0
4603,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619151,478.0,BAO_0000219,,,CLD0
4604,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883794,478.0,BAO_0000219,,,CLD0
4605,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619152,478.0,BAO_0000219,,,CLD0
4606,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619153,478.0,BAO_0000219,,,CLD0
4607,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619154,478.0,BAO_0000219,,,CLD0
4608,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619155,478.0,BAO_0000219,,,CLD0
4609,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619156,478.0,BAO_0000219,,,CLD0
4610,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619157,478.0,BAO_0000219,,,CLD0
4611,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619797,478.0,BAO_0000219,,,CLD0
4612,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619798,,BAO_0000218,,,CLD0
4613,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619799,,BAO_0000218,,,CLD0
4614,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619800,,BAO_0000218,,,CLD0
4615,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619801,,BAO_0000218,,,CLD0
4616,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619802,,BAO_0000218,,,CLD0
4617,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619803,,BAO_0000218,,,CLD0
4618,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619965,,BAO_0000218,,,CLD0
4619,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619966,,BAO_0000218,,,CLD0
4620,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619967,,BAO_0000218,,,CLD0
4621,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620073,,BAO_0000218,,,CLD0
4622,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620074,,BAO_0000218,,,CLD0
4623,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620075,,BAO_0000218,,,CLD0
4624,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620076,,BAO_0000218,,,CLD0
4625,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620077,,BAO_0000218,,,CLD0
4626,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620078,,BAO_0000218,,,CLD0
4627,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620079,,BAO_0000218,,,CLD0
4628,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620080,,BAO_0000218,,,CLD0
4629,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620081,,BAO_0000218,,,CLD0
4630,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620082,,BAO_0000218,,,CLD0
4631,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620083,,BAO_0000218,,,CLD0
4632,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620084,,BAO_0000218,,,CLD0
4633,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620085,,BAO_0000218,,,CLD0
4634,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874595,,BAO_0000218,,,CLD0
4635,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873352,,BAO_0000218,,,CLD0
4636,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620086,,BAO_0000218,,,CLD0
4637,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620087,,BAO_0000218,,,CLD0
4638,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620088,,BAO_0000218,,,CLD0
4639,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620089,,BAO_0000218,,,CLD0
4640,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620090,,BAO_0000218,,,CLD0
4641,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620091,,BAO_0000218,,,CLD0
4642,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620092,,BAO_0000251,,,CLD0
4643,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620093,,BAO_0000251,,,CLD0
4644,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620094,,BAO_0000251,,,CLD0
4645,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620095,,BAO_0000251,,,CLD0
4646,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620096,,BAO_0000218,1969.0,,CLD0
4647,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620097,,BAO_0000218,1969.0,,CLD0
4648,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620098,,BAO_0000366,1969.0,,CLD0
4649,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL620099,,BAO_0000218,2113.0,,CLD0
4650,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL620100,,BAO_0000218,2113.0,,CLD0
4651,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620101,,BAO_0000019,,,CLD0
4652,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620102,,BAO_0000019,,,CLD0
4653,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620103,,BAO_0000366,1969.0,,CLD0
4654,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620104,,BAO_0000366,1969.0,,CLD0
4655,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874596,,BAO_0000218,,,CLD0
4656,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873490,,BAO_0000218,,,CLD0
4657,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620105,,BAO_0000019,,,CLD0
4658,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620780,,BAO_0000218,,,CLD0
4659,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620781,,BAO_0000218,,,CLD0
4660,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620956,,BAO_0000218,1969.0,,CLD0
4661,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620957,,BAO_0000218,1088.0,,CLD0
4662,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620958,,BAO_0000218,1088.0,,CLD0
4663,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620959,,BAO_0000218,,,CLD0
4664,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620960,,BAO_0000218,,,CLD0
4665,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620961,,BAO_0000218,,,CLD0
4666,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620962,,BAO_0000218,1969.0,,CLD0
4667,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620963,,BAO_0000218,1969.0,,CLD0
4668,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620964,,BAO_0000218,,,CLD0
4669,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620965,,BAO_0000218,,,CLD0
4670,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620966,,BAO_0000218,,,CLD0
4671,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620967,,BAO_0000221,178.0,,CLD0
4672,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620968,,BAO_0000019,,,CLD0
4673,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874597,,BAO_0000019,,,CLD0
4674,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620969,,BAO_0000019,,,CLD0
4675,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620970,,BAO_0000019,,,CLD0
4676,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235,D,9,Expert,1,,CHEMBL620971,,BAO_0000357,,,CLD0
4677,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620972,,BAO_0000218,,,CLD0
4678,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620973,,BAO_0000019,,,CLD0
4679,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618243,,BAO_0000019,,,CLD0
4680,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618244,,BAO_0000221,2107.0,,CLD0
4681,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618245,,BAO_0000221,2107.0,,CLD0
4682,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618246,,BAO_0000221,2107.0,,CLD0
4683,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618247,,BAO_0000221,2107.0,,CLD0
4684,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618248,,BAO_0000218,,,CLD0
4685,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618249,,BAO_0000221,1088.0,,CLD0
4686,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618250,,BAO_0000019,,,CLD0
4687,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874598,,BAO_0000019,,,CLD0
4688,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618251,,BAO_0000019,,,CLD0
4689,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618252,,BAO_0000019,,,CLD0
4690,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618253,,BAO_0000019,,,CLD0
4691,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618254,,BAO_0000019,,,CLD0
4692,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618255,,BAO_0000019,,,CLD0
4693,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618983,,BAO_0000251,2107.0,,CLD0
4694,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618984,,BAO_0000366,1969.0,,CLD0
4695,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618985,,BAO_0000366,1969.0,,CLD0
4696,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618986,,BAO_0000366,1969.0,,CLD0
4697,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618987,,BAO_0000366,1969.0,,CLD0
4698,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618988,,BAO_0000366,1969.0,,CLD0
4699,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618989,,BAO_0000251,2107.0,,CLD0
4700,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618990,,BAO_0000251,2107.0,,CLD0
4701,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618991,,BAO_0000251,2107.0,,CLD0
4702,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL876725,,BAO_0000251,,,CLD0
4703,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618992,,BAO_0000251,,,CLD0
4704,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618993,,BAO_0000251,,,CLD0
4705,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618994,,BAO_0000251,2107.0,,CLD0
4706,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618995,,BAO_0000251,2107.0,,CLD0
4707,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618996,,BAO_0000251,2107.0,,CLD0
4708,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618997,,BAO_0000251,2107.0,,CLD0
4709,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618998,,BAO_0000251,2107.0,,CLD0
4710,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618999,,BAO_0000218,,,CLD0
4711,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620223,,BAO_0000218,,,CLD0
4712,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620224,,BAO_0000218,,,CLD0
4713,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620225,,BAO_0000366,1969.0,,CLD0
4714,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620226,,BAO_0000366,1969.0,,CLD0
4715,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620227,,BAO_0000221,1088.0,,CLD0
4716,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876726,,BAO_0000221,1088.0,,CLD0
4717,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620228,,BAO_0000221,1088.0,,CLD0
4718,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620229,,BAO_0000221,1088.0,,CLD0
4719,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620230,,BAO_0000218,,,CLD0
4720,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620231,,BAO_0000218,,,CLD0
4721,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620232,,BAO_0000218,,,CLD0
4722,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620233,,BAO_0000218,,,CLD0
4723,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,S9 Microsomes,50594,N,1,Intermediate,1,,CHEMBL620234,,BAO_0000218,,,CLD0
4724,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,S9 Microsomes,50594,N,1,Intermediate,1,,CHEMBL620235,,BAO_0000218,,,CLD0
4725,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,S9 Microsomes,50594,N,1,Intermediate,1,,CHEMBL620236,,BAO_0000218,,,CLD0
4726,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,Microsomes,50594,N,1,Intermediate,1,,CHEMBL620237,,BAO_0000218,2107.0,,CLD0
4727,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,Plasma,HSA,,22228,M,3,Intermediate,1,,CHEMBL620238,,BAO_0000219,1969.0,,CLD0
4728,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594,N,1,Intermediate,1,,CHEMBL620239,,BAO_0000218,2369.0,,CLD0
4729,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620240,,BAO_0000218,955.0,,CLD0
4730,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620241,,BAO_0000218,955.0,,CLD0
4731,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL876727,,BAO_0000218,948.0,,CLD0
4732,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620242,,BAO_0000218,2113.0,,CLD0
4733,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620243,,BAO_0000218,,,CLD0
4734,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL620244,,BAO_0000218,1088.0,,CLD0
4735,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620245,,BAO_0000218,1977.0,,CLD0
4736,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620246,,BAO_0000218,1977.0,,CLD0
4737,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620247,,BAO_0000218,1977.0,,CLD0
4738,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620248,,BAO_0000218,1969.0,,CLD0
4739,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL873497,,BAO_0000218,1969.0,,CLD0
4740,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620249,,BAO_0000218,1969.0,,CLD0
4741,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620250,,BAO_0000218,,,CLD0
4742,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620251,,BAO_0000218,,,CLD0
4743,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620252,,BAO_0000218,,,CLD0
4744,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620253,,BAO_0000218,,,CLD0
4745,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620254,,BAO_0000218,,,CLD0
4746,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620255,,BAO_0000218,,,CLD0
4747,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620256,,BAO_0000218,,,CLD0
4748,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876728,,BAO_0000218,,,CLD0
4749,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620257,,BAO_0000218,,,CLD0
4750,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620258,,BAO_0000218,,,CLD0
4751,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620259,,BAO_0000218,,,CLD0
4752,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620260,,BAO_0000218,,,CLD0
4753,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620261,,BAO_0000218,178.0,,CLD0
4754,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620262,,BAO_0000218,,,CLD0
4755,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620263,,BAO_0000218,,,CLD0
4756,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620264,,BAO_0000218,,,CLD0
4757,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620265,,BAO_0000218,,,CLD0
4758,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620266,,BAO_0000218,,,CLD0
4759,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620267,,BAO_0000218,,,CLD0
4760,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619364,,BAO_0000218,1977.0,,CLD0
4761,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619365,,BAO_0000218,1977.0,,CLD0
4762,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL619366,,BAO_0000218,955.0,,CLD0
4763,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL619367,,BAO_0000218,2113.0,,CLD0
4764,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619368,,BAO_0000218,2107.0,,CLD0
4765,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL619369,,BAO_0000218,2048.0,,CLD0
4766,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876729,,BAO_0000218,2106.0,,CLD0
4767,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619370,,BAO_0000218,,,CLD0
4768,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619371,,BAO_0000218,,,CLD0
4769,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619372,,BAO_0000218,,,CLD0
4770,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620012,,BAO_0000218,,,CLD0
4771,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620013,,BAO_0000218,,,CLD0
4772,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620014,478.0,BAO_0000219,,,CLD0
4773,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620015,478.0,BAO_0000219,,,CLD0
4774,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621010,478.0,BAO_0000219,,,CLD0
4775,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621011,478.0,BAO_0000219,,,CLD0
4776,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621012,478.0,BAO_0000219,,,CLD0
4777,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621013,478.0,BAO_0000219,,,CLD0
4778,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621014,478.0,BAO_0000219,,,CLD0
4779,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618154,481.0,BAO_0000219,,,CLD0
4780,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618155,478.0,BAO_0000219,,,CLD0
4781,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618156,481.0,BAO_0000219,,,CLD0
4782,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618157,481.0,BAO_0000219,,,CLD0
4783,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618328,478.0,BAO_0000219,,,CLD0
4784,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618329,478.0,BAO_0000219,,,CLD0
4785,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618330,478.0,BAO_0000219,,,CLD0
4786,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618331,478.0,BAO_0000219,,,CLD0
4787,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618332,478.0,BAO_0000219,,,CLD0
4788,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618333,478.0,BAO_0000219,,,CLD0
4789,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618334,481.0,BAO_0000219,,,CLD0
4790,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618335,478.0,BAO_0000219,,,CLD0
4791,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,PC-12,,11736,D,9,Expert,1,,CHEMBL618336,342.0,BAO_0000219,,,CLD0
4792,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,PC-12,,11736,H,8,Expert,1,,CHEMBL618337,342.0,BAO_0000219,,,CLD0
4793,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,PC-12,,11736,D,9,Expert,1,,CHEMBL618338,342.0,BAO_0000219,,,CLD0
4794,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618339,722.0,BAO_0000219,,,CLD0
4795,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618340,722.0,BAO_0000219,,,CLD0
4796,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,Fibroblast,,11831,D,9,Expert,1,,CHEMBL618341,442.0,BAO_0000219,,,CLD0
4797,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,Fibroblast,,11831,H,8,Expert,1,,CHEMBL618342,442.0,BAO_0000219,,,CLD0
4798,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,Fibroblast,,11831,D,9,Expert,1,,CHEMBL618343,442.0,BAO_0000219,,,CLD0
4799,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280,H,8,Expert,1,,CHEMBL621038,,BAO_0000357,,,CLD0
4800,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cell,,22226,U,0,Autocuration,1,,CHEMBL621039,574.0,BAO_0000219,,,CLD0
4801,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cell,,22226,U,0,Autocuration,1,,CHEMBL621040,574.0,BAO_0000219,,,CLD0
4802,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621041,455.0,BAO_0000219,,,CLD0
4803,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621042,455.0,BAO_0000219,,,CLD0
4804,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621043,455.0,BAO_0000219,,,CLD0
4805,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Expert,1,,CHEMBL621044,455.0,BAO_0000219,,,CLD0
4806,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621045,455.0,BAO_0000219,,,CLD0
4807,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621046,455.0,BAO_0000219,,,CLD0
4808,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621047,455.0,BAO_0000219,,,CLD0
4809,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621048,797.0,BAO_0000219,,,CLD0
4810,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL883798,797.0,BAO_0000219,,,CLD0
4811,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621049,797.0,BAO_0000219,,,CLD0
4812,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621050,797.0,BAO_0000219,,,CLD0
4813,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621051,797.0,BAO_0000219,,,CLD0
4814,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621052,797.0,BAO_0000219,,,CLD0
4815,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621053,797.0,BAO_0000219,,,CLD0
4816,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621054,797.0,BAO_0000219,,,CLD0
4817,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621055,,BAO_0000218,,,CLD0
4818,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876398,,BAO_0000218,,,CLD0
4819,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621056,,BAO_0000218,,,CLD0
4820,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621057,,BAO_0000218,1969.0,,CLD0
4821,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621058,,BAO_0000218,1969.0,,CLD0
4822,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621059,,BAO_0000218,,,CLD0
4823,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621060,,BAO_0000218,,,CLD0
4824,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621061,,BAO_0000218,,,CLD0
4825,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621062,,BAO_0000218,,,CLD0
4826,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621063,,BAO_0000218,,,CLD0
4827,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621064,,BAO_0000218,,,CLD0
4828,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621065,,BAO_0000218,,,CLD0
4829,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621066,,BAO_0000218,,,CLD0
4830,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621067,,BAO_0000218,,,CLD0
4831,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621068,,BAO_0000218,,,CLD0
4832,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876399,,BAO_0000218,,,CLD0
4833,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621069,,BAO_0000218,,,CLD0
4834,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621070,,BAO_0000218,,,CLD0
4835,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621071,,BAO_0000218,,,CLD0
4836,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621072,,BAO_0000218,,,CLD0
4837,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618209,,BAO_0000218,,,CLD0
4838,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618210,,BAO_0000218,1969.0,,CLD0
4839,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618211,,BAO_0000366,1969.0,,CLD0
4840,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618212,,BAO_0000218,,,CLD0
4841,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618213,,BAO_0000019,,,CLD0
4842,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618214,,BAO_0000019,,,CLD0
4843,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873492,,BAO_0000218,,,CLD0
4844,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618272,,BAO_0000218,,,CLD0
4845,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618273,,BAO_0000218,,,CLD0
4846,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618274,,BAO_0000218,1969.0,,CLD0
4847,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618275,,BAO_0000218,,,CLD0
4848,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618276,,BAO_0000218,,,CLD0
4849,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618277,,BAO_0000019,,,CLD0
4850,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618278,,BAO_0000218,,,CLD0
4851,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618279,,BAO_0000218,1969.0,,CLD0
4852,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618280,,BAO_0000019,,,CLD0
4853,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618281,,BAO_0000218,,,CLD0
4854,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618282,,BAO_0000218,1969.0,,CLD0
4855,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618283,,BAO_0000019,,,CLD0
4856,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618284,,BAO_0000019,,,CLD0
4857,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618285,,BAO_0000218,,,CLD0
4858,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618286,,BAO_0000019,,,CLD0
4859,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618287,,BAO_0000218,,,CLD0
4860,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618288,,BAO_0000218,,,CLD0
4861,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876393,,BAO_0000218,,,CLD0
4862,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618289,,BAO_0000218,,,CLD0
4863,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618290,,BAO_0000218,,,CLD0
4864,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618291,,BAO_0000019,,,CLD0
4865,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618292,,BAO_0000019,,,CLD0
4866,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618293,,BAO_0000019,,,CLD0
4867,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618294,,BAO_0000218,,,CLD0
4868,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618295,,BAO_0000218,,,CLD0
4869,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618296,,BAO_0000218,,,CLD0
4870,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618297,,BAO_0000218,,,CLD0
4871,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618298,,BAO_0000221,1088.0,,CLD0
4872,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618299,,BAO_0000221,1088.0,,CLD0
4873,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618300,,BAO_0000221,1088.0,,CLD0
4874,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618301,,BAO_0000221,1088.0,,CLD0
4875,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618302,,BAO_0000221,1088.0,,CLD0
4876,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876394,,BAO_0000221,1088.0,,CLD0
4877,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618303,,BAO_0000221,1088.0,,CLD0
4878,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618304,,BAO_0000221,1088.0,,CLD0
4879,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618305,,BAO_0000218,,,CLD0
4880,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618306,,BAO_0000218,,,CLD0
4881,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618307,,BAO_0000366,1969.0,,CLD0
4882,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618308,,BAO_0000366,1969.0,,CLD0
4883,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618309,,BAO_0000366,1969.0,,CLD0
4884,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618310,,BAO_0000366,1969.0,,CLD0
4885,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873353,,BAO_0000366,1969.0,,CLD0
4886,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618311,,BAO_0000366,1969.0,,CLD0
4887,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618312,,BAO_0000366,1969.0,,CLD0
4888,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618313,,BAO_0000366,1969.0,,CLD0
4889,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618314,,BAO_0000019,,,CLD0
4890,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618315,,BAO_0000019,,,CLD0
4891,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618316,,BAO_0000366,1969.0,,CLD0
4892,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618317,,BAO_0000366,1969.0,,CLD0
4893,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620138,,BAO_0000366,1969.0,,CLD0
4894,17599,Partition coefficient (logP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL858280,,BAO_0000100,,,CLD0
4895,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620139,,BAO_0000019,,,CLD0
4896,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620140,,BAO_0000251,2107.0,,CLD0
4897,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL620141,,BAO_0000221,2107.0,,CLD0
4898,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL620142,,BAO_0000221,2107.0,,CLD0
4899,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL620143,,BAO_0000221,2107.0,,CLD0
4900,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620144,,BAO_0000251,,,CLD0
4901,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620145,,BAO_0000251,,,CLD0
4902,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620146,,BAO_0000251,,,CLD0
4903,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620147,,BAO_0000251,2107.0,,CLD0
4904,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620148,,BAO_0000251,2107.0,,CLD0
4905,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL620149,,BAO_0000251,2107.0,,CLD0
4906,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876412,,BAO_0000019,,,CLD0
4907,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619352,,BAO_0000366,1969.0,,CLD0
4908,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619353,,BAO_0000019,,,CLD0
4909,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619354,,BAO_0000366,1969.0,,CLD0
4910,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619355,495.0,BAO_0000219,,,CLD0
4911,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619356,495.0,BAO_0000219,,,CLD0
4912,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619357,495.0,BAO_0000219,,,CLD0
4913,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619358,495.0,BAO_0000219,,,CLD0
4914,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619359,495.0,BAO_0000219,,,CLD0
4915,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619360,495.0,BAO_0000219,,,CLD0
4916,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619361,495.0,BAO_0000219,,,CLD0
4917,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619362,495.0,BAO_0000219,,,CLD0
4918,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619363,495.0,BAO_0000219,,,CLD0
4919,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618942,,BAO_0000019,,,CLD0
4920,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618943,,BAO_0000366,1969.0,,CLD0
4921,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL618944,495.0,BAO_0000219,,,CLD0
4922,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618945,,BAO_0000221,1088.0,,CLD0
4923,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618946,,BAO_0000218,,,CLD0
4924,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876413,,BAO_0000218,,,CLD0
4925,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618947,,BAO_0000218,,,CLD0
4926,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618948,,BAO_0000218,1969.0,,CLD0
4927,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618949,,BAO_0000218,1969.0,,CLD0
4928,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618950,,BAO_0000218,,,CLD0
4929,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618951,,BAO_0000218,,,CLD0
4930,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618952,,BAO_0000218,,,CLD0
4931,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618953,,BAO_0000218,,,CLD0
4932,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618954,,BAO_0000218,955.0,,CLD0
4933,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618955,,BAO_0000218,2113.0,,CLD0
4934,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618956,,BAO_0000218,2107.0,,CLD0
4935,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618957,,BAO_0000218,2048.0,,CLD0
4936,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618958,,BAO_0000218,,,CLD0
4937,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618959,,BAO_0000218,,,CLD0
4938,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618960,,BAO_0000218,,,CLD0
4939,17764,Tmax in mice at 26 uM/kg i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876723,,BAO_0000218,,,CLD0
4940,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618961,,BAO_0000218,2106.0,,CLD0
4941,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618962,,BAO_0000218,,,CLD0
4942,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618963,,BAO_0000218,,,CLD0
4943,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618964,,BAO_0000218,,,CLD0
4944,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618965,,BAO_0000218,,,CLD0
4945,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618966,,BAO_0000218,,,CLD0
4946,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618967,,BAO_0000218,1088.0,,CLD0
4947,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618968,,BAO_0000218,1088.0,,CLD0
4948,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618969,,BAO_0000218,1088.0,,CLD0
4949,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618970,,BAO_0000218,,,CLD0
4950,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618971,,BAO_0000218,,,CLD0
4951,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618972,,BAO_0000218,,,CLD0
4952,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618973,,BAO_0000218,,,CLD0
4953,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618974,,BAO_0000218,,,CLD0
4954,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618975,,BAO_0000218,,,CLD0
4955,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618976,,BAO_0000218,,,CLD0
4956,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618977,,BAO_0000218,,,CLD0
4957,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876724,,BAO_0000218,,,CLD0
4958,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618978,,BAO_0000218,1969.0,,CLD0
4959,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618979,,BAO_0000218,1969.0,,CLD0
4960,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618980,,BAO_0000218,1969.0,,CLD0
4961,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618981,,BAO_0000218,,,CLD0
4962,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618982,,BAO_0000218,,,CLD0
4963,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620150,,BAO_0000218,,,CLD0
4964,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620151,,BAO_0000218,,,CLD0
4965,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620152,,BAO_0000218,,,CLD0
4966,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620153,,BAO_0000218,178.0,,CLD0
4967,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876395,,BAO_0000218,,,CLD0
4968,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620154,,BAO_0000218,,,CLD0
4969,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620155,,BAO_0000218,,,CLD0
4970,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620156,,BAO_0000218,,,CLD0
4971,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620157,,BAO_0000218,,,CLD0
4972,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620158,,BAO_0000218,2113.0,,CLD0
4973,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620159,,BAO_0000218,178.0,,CLD0
4974,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620160,,BAO_0000218,178.0,,CLD0
4975,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620161,,BAO_0000218,178.0,,CLD0
4976,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL620162,797.0,BAO_0000219,,,CLD0
4977,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620163,500.0,BAO_0000219,,,CLD0
4978,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620833,500.0,BAO_0000219,,,CLD0
4979,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876396,500.0,BAO_0000219,,,CLD0
4980,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620834,500.0,BAO_0000219,,,CLD0
4981,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620835,500.0,BAO_0000219,,,CLD0
4982,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620836,500.0,BAO_0000219,,,CLD0
4983,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL620837,500.0,BAO_0000219,,,CLD0
4984,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621017,500.0,BAO_0000219,,,CLD0
4985,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621018,500.0,BAO_0000218,,,CLD0
4986,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621019,500.0,BAO_0000219,,,CLD0
4987,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621020,500.0,BAO_0000219,,,CLD0
4988,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621021,500.0,BAO_0000219,,,CLD0
4989,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621022,500.0,BAO_0000219,,,CLD0
4990,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621023,500.0,BAO_0000219,,,CLD0
4991,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621024,500.0,BAO_0000219,,,CLD0
4992,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621025,500.0,BAO_0000219,,,CLD0
4993,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621026,500.0,BAO_0000219,,,CLD0
4994,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621027,500.0,BAO_0000219,,,CLD0
4995,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876397,500.0,BAO_0000219,,,CLD0
4996,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL883797,500.0,BAO_0000219,,,CLD0
4997,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621028,500.0,BAO_0000219,,,CLD0
4998,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621029,500.0,BAO_0000219,,,CLD0
4999,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621030,500.0,BAO_0000219,,,CLD0
5000,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621147,500.0,BAO_0000219,,,CLD0
5001,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621148,500.0,BAO_0000218,,,CLD0
5002,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621149,500.0,BAO_0000219,,,CLD0
5003,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621150,500.0,BAO_0000219,,,CLD0
5004,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621151,500.0,BAO_0000219,,,CLD0
5005,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621152,500.0,BAO_0000219,,,CLD0
5006,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621153,500.0,BAO_0000219,,,CLD0
5007,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL884000,500.0,BAO_0000219,,,CLD0
5008,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621154,500.0,BAO_0000219,,,CLD0
5009,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621155,500.0,BAO_0000219,,,CLD0
5010,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621156,500.0,BAO_0000219,,,CLD0
5011,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621157,500.0,BAO_0000219,,,CLD0
5012,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621158,500.0,BAO_0000219,,,CLD0
5013,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621159,500.0,BAO_0000219,,,CLD0
5014,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621160,500.0,BAO_0000219,,,CLD0
5015,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621161,500.0,BAO_0000219,,,CLD0
5016,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621162,500.0,BAO_0000219,,,CLD0
5017,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621163,500.0,BAO_0000219,,,CLD0
5018,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621164,500.0,BAO_0000219,,,CLD0
5019,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621165,500.0,BAO_0000219,,,CLD0
5020,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619159,,BAO_0000019,,,CLD0
5021,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619160,,BAO_0000366,1969.0,,CLD0
5022,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619161,,BAO_0000218,,,CLD0
5023,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619162,,BAO_0000366,1969.0,,CLD0
5024,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619163,,BAO_0000366,1969.0,,CLD0
5025,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619164,,BAO_0000218,1969.0,,CLD0
5026,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619320,,BAO_0000218,1969.0,,CLD0
5027,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619321,,BAO_0000218,,,CLD0
5028,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873336,,BAO_0000218,,,CLD0
5029,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619322,,BAO_0000218,,,CLD0
5030,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619323,,BAO_0000218,,,CLD0
5031,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619324,,BAO_0000218,,,CLD0
5032,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619325,,BAO_0000366,1969.0,,CLD0
5033,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL876411,,BAO_0000366,1969.0,,CLD0
5034,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619326,,BAO_0000366,1969.0,,CLD0
5035,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619327,,BAO_0000366,1969.0,,CLD0
5036,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619328,,BAO_0000366,1969.0,,CLD0
5037,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619329,,BAO_0000366,1969.0,,CLD0
5038,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619330,,BAO_0000366,1969.0,,CLD0
5039,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619331,,BAO_0000366,1969.0,,CLD0
5040,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619332,,BAO_0000366,1969.0,,CLD0
5041,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619333,,BAO_0000366,1969.0,,CLD0
5042,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619334,,BAO_0000366,1969.0,,CLD0
5043,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619335,,BAO_0000366,1969.0,,CLD0
5044,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619336,,BAO_0000366,1969.0,,CLD0
5045,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619337,,BAO_0000366,1969.0,,CLD0
5046,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619338,,BAO_0000366,1969.0,,CLD0
5047,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619339,,BAO_0000366,1969.0,,CLD0
5048,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619340,,BAO_0000218,,,CLD0
5049,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873496,,BAO_0000218,1969.0,,CLD0
5050,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619341,,BAO_0000218,1969.0,,CLD0
5051,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619342,,BAO_0000218,1969.0,,CLD0
5052,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619343,,BAO_0000218,,,CLD0
5053,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619344,,BAO_0000218,,,CLD0
5054,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619345,,BAO_0000218,,,CLD0
5055,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619346,,BAO_0000218,,,CLD0
5056,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619347,,BAO_0000218,,,CLD0
5057,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619348,,BAO_0000019,,,CLD0
5058,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619349,,BAO_0000366,1969.0,,CLD0
5059,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619350,,BAO_0000366,1969.0,,CLD0
5060,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619351,,BAO_0000366,1969.0,,CLD0
5061,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875953,,BAO_0000366,1969.0,,CLD0
5062,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621716,,BAO_0000366,1969.0,,CLD0
5063,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621717,,BAO_0000366,1969.0,,CLD0
5064,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621718,,BAO_0000019,,,CLD0
5065,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,Canis lupus familiaris,9615.0,Beagle,,,,22224,U,0,Autocuration,1,,CHEMBL621719,,BAO_0000019,,,CLD0
5066,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,Canis lupus familiaris,9615.0,Beagle,,,,22224,U,0,Autocuration,1,,CHEMBL621720,,BAO_0000019,,,CLD0
5067,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,Beagle,,,,22224,U,0,Autocuration,1,,CHEMBL621721,,BAO_0000218,,,CLD0
5068,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621722,,BAO_0000221,1088.0,,CLD0
5069,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621723,,BAO_0000221,1088.0,,CLD0
5070,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621724,,BAO_0000221,1088.0,,CLD0
5071,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623443,,BAO_0000221,1088.0,,CLD0
5072,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623444,,BAO_0000221,1088.0,,CLD0
5073,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623445,,BAO_0000221,1088.0,,CLD0
5074,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623446,,BAO_0000221,1088.0,,CLD0
5075,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL623447,,BAO_0000251,2107.0,,CLD0
5076,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623448,,BAO_0000019,,,CLD0
5077,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623449,,BAO_0000019,,,CLD0
5078,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623450,,BAO_0000019,,,CLD0
5079,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL623451,,BAO_0000251,2107.0,,CLD0
5080,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623452,,BAO_0000019,,,CLD0
5081,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,Liver,,Liver S9 fraction,22224,U,0,Autocuration,1,,CHEMBL623453,,BAO_0000220,2107.0,,CLD0
5082,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL623454,,BAO_0000251,2107.0,,CLD0
5083,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL623455,,BAO_0000251,2107.0,,CLD0
5084,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL624371,,BAO_0000251,2107.0,,CLD0
5085,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624372,,BAO_0000218,2107.0,,CLD0
5086,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624373,,BAO_0000366,1969.0,,CLD0
5087,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624374,,BAO_0000366,1969.0,,CLD0
5088,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624556,,BAO_0000366,1969.0,,CLD0
5089,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624557,,BAO_0000366,1969.0,,CLD0
5090,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624558,,BAO_0000366,1969.0,,CLD0
5091,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624559,,BAO_0000221,178.0,,CLD0
5092,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624560,,BAO_0000019,,,CLD0
5093,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL624561,,BAO_0000251,,,CLD0
5094,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624562,,BAO_0000366,1969.0,,CLD0
5095,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624563,,BAO_0000366,1969.0,,CLD0
5096,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624564,,BAO_0000218,,,CLD0
5097,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL624565,,BAO_0000251,2107.0,,CLD0
5098,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875152,,BAO_0000366,1969.0,,CLD0
5099,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624566,,BAO_0000366,1969.0,,CLD0
5100,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873805,,BAO_0000366,1969.0,,CLD0
5101,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL624567,,BAO_0000251,2107.0,,CLD0
5102,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624568,,BAO_0000218,,,CLD0
5103,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624569,,BAO_0000218,,,CLD0
5104,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624570,,BAO_0000218,,,CLD0
5105,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624571,,BAO_0000366,1969.0,,CLD0
5106,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624572,,BAO_0000366,1969.0,,CLD0
5107,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624573,,BAO_0000366,1969.0,,CLD0
5108,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875153,,BAO_0000366,1969.0,,CLD0
5109,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL624574,,BAO_0000251,2107.0,,CLD0
5110,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624575,,BAO_0000366,1969.0,,CLD0
5111,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624576,,BAO_0000366,1969.0,,CLD0
5112,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL624577,,BAO_0000251,2107.0,,CLD0
5113,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624578,,BAO_0000221,178.0,,CLD0
5114,4297,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622796,,BAO_0000366,1977.0,,CLD0
5115,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622797,,BAO_0000366,1977.0,,CLD0
5116,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,CEM-SS,,22224,U,0,Autocuration,1,,CHEMBL622798,638.0,BAO_0000219,,,CLD0
5117,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,CEM-SS,,22224,U,0,Autocuration,1,,CHEMBL622799,638.0,BAO_0000219,,,CLD0
5118,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622800,,BAO_0000366,1969.0,,CLD0
5119,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,S9,22224,U,0,Autocuration,1,,CHEMBL622801,,BAO_0000220,2107.0,,CLD0
5120,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL622802,,BAO_0000251,2107.0,,CLD0
5121,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622803,,BAO_0000019,,,CLD0
5122,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875154,,BAO_0000019,,,CLD0
5123,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622804,,BAO_0000366,1969.0,,CLD0
5124,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622805,,BAO_0000218,955.0,,CLD0
5125,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622611,,BAO_0000218,948.0,,CLD0
5126,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622612,,BAO_0000218,948.0,,CLD0
5127,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL875160,,BAO_0000218,2113.0,,CLD0
5128,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622613,,BAO_0000218,2113.0,,CLD0
5129,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622614,,BAO_0000218,2113.0,,CLD0
5130,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622615,,BAO_0000218,2107.0,,CLD0
5131,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622616,,BAO_0000218,2107.0,,CLD0
5132,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622617,,BAO_0000218,2107.0,,CLD0
5133,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622618,,BAO_0000218,2106.0,,CLD0
5134,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622619,,BAO_0000218,2106.0,,CLD0
5135,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622620,,BAO_0000218,2106.0,,CLD0
5136,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622621,,BAO_0000218,955.0,,CLD0
5137,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622622,,BAO_0000218,178.0,,CLD0
5138,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622623,,BAO_0000218,178.0,,CLD0
5139,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622624,,BAO_0000218,178.0,,CLD0
5140,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622625,,BAO_0000218,178.0,,CLD0
5141,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622626,,BAO_0000218,178.0,,CLD0
5142,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622627,,BAO_0000218,178.0,,CLD0
5143,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622628,,BAO_0000218,955.0,,CLD0
5144,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622629,,BAO_0000218,955.0,,CLD0
5145,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622630,,BAO_0000218,955.0,,CLD0
5146,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622631,,BAO_0000218,955.0,,CLD0
5147,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622632,,BAO_0000218,955.0,,CLD0
5148,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622633,,BAO_0000218,955.0,,CLD0
5149,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622634,,BAO_0000218,948.0,,CLD0
5150,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622635,,BAO_0000218,948.0,,CLD0
5151,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL875161,,BAO_0000218,948.0,,CLD0
5152,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622636,,BAO_0000218,948.0,,CLD0
5153,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623335,,BAO_0000218,948.0,,CLD0
5154,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623336,,BAO_0000218,948.0,,CLD0
5155,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623337,,BAO_0000218,2113.0,,CLD0
5156,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623338,,BAO_0000218,2113.0,,CLD0
5157,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623339,,BAO_0000218,2113.0,,CLD0
5158,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623524,,BAO_0000218,2113.0,,CLD0
5159,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623525,,BAO_0000218,2113.0,,CLD0
5160,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623526,,BAO_0000218,2107.0,,CLD0
5161,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623527,,BAO_0000218,2107.0,,CLD0
5162,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623528,,BAO_0000218,2107.0,,CLD0
5163,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL624615,500.0,BAO_0000219,,,CLD0
5164,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621672,500.0,BAO_0000219,,,CLD0
5165,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621673,500.0,BAO_0000218,,,CLD0
5166,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621674,500.0,BAO_0000218,,,CLD0
5167,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL884002,500.0,BAO_0000219,,,CLD0
5168,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621850,500.0,BAO_0000219,,,CLD0
5169,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621851,500.0,BAO_0000219,,,CLD0
5170,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621852,500.0,BAO_0000219,,,CLD0
5171,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621853,500.0,BAO_0000219,,,CLD0
5172,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621854,500.0,BAO_0000218,,,CLD0
5173,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621855,500.0,BAO_0000218,,,CLD0
5174,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623724,500.0,BAO_0000218,,,CLD0
5175,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623725,500.0,BAO_0000218,,,CLD0
5176,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623726,500.0,BAO_0000218,,,CLD0
5177,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL623727,500.0,BAO_0000219,,,CLD0
5178,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL623728,500.0,BAO_0000219,,,CLD0
5179,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623729,500.0,BAO_0000218,,,CLD0
5180,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623730,500.0,BAO_0000218,,,CLD0
5181,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623731,500.0,BAO_0000218,,,CLD0
5182,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623732,500.0,BAO_0000218,,,CLD0
5183,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623733,500.0,BAO_0000218,,,CLD0
5184,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623734,500.0,BAO_0000218,,,CLD0
5185,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623735,500.0,BAO_0000218,,,CLD0
5186,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623736,500.0,BAO_0000219,,,CLD0
5187,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623737,500.0,BAO_0000219,,,CLD0
5188,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623738,500.0,BAO_0000219,,,CLD0
5189,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL875168,500.0,BAO_0000219,,,CLD0
5190,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623739,646.0,BAO_0000219,,,CLD0
5191,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623740,646.0,BAO_0000219,,,CLD0
5192,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624424,646.0,BAO_0000219,,,CLD0
5193,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624425,624.0,BAO_0000219,,,CLD0
5194,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624426,624.0,BAO_0000219,,,CLD0
5195,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624427,624.0,BAO_0000219,,,CLD0
5196,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624428,624.0,BAO_0000219,,,CLD0
5197,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624429,624.0,BAO_0000219,,,CLD0
5198,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624620,624.0,BAO_0000219,,,CLD0
5199,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624621,624.0,BAO_0000219,,,CLD0
5200,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624622,624.0,BAO_0000219,,,CLD0
5201,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624623,624.0,BAO_0000219,,,CLD0
5202,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL874365,624.0,BAO_0000219,,,CLD0
5203,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624624,624.0,BAO_0000219,,,CLD0
5204,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624625,624.0,BAO_0000219,,,CLD0
5205,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624626,624.0,BAO_0000219,,,CLD0
5206,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624627,624.0,BAO_0000219,,,CLD0
5207,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883157,624.0,BAO_0000219,,,CLD0
5208,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL624628,624.0,BAO_0000219,,,CLD0
5209,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,Beagle,,,,22224,U,0,Autocuration,1,,CHEMBL624629,,BAO_0000218,,,CLD0
5210,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623551,,BAO_0000218,,,CLD0
5211,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623552,,BAO_0000218,,,CLD0
5212,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623553,,BAO_0000218,,,CLD0
5213,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623554,,BAO_0000019,,,CLD0
5214,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623555,,BAO_0000019,,,CLD0
5215,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623556,,BAO_0000019,,,CLD0
5216,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623557,,BAO_0000019,,,CLD0
5217,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623558,,BAO_0000019,,,CLD0
5218,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623559,,BAO_0000019,,,CLD0
5219,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623560,,BAO_0000221,2106.0,,CLD0
5220,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL623561,,BAO_0000366,1977.0,,CLD0
5221,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623562,,BAO_0000019,,,CLD0
5222,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623563,,BAO_0000019,,,CLD0
5223,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623564,,BAO_0000221,2106.0,,CLD0
5224,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873806,,BAO_0000019,,,CLD0
5225,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623565,,BAO_0000019,,,CLD0
5226,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623566,,BAO_0000019,,,CLD0
5227,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623567,,BAO_0000019,,,CLD0
5228,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL623568,,BAO_0000366,1977.0,,CLD0
5229,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623569,,BAO_0000218,1969.0,,CLD0
5230,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623570,,BAO_0000218,1969.0,,CLD0
5231,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624254,,BAO_0000218,1969.0,,CLD0
5232,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624255,,BAO_0000218,1969.0,,CLD0
5233,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624256,,BAO_0000218,1969.0,,CLD0
5234,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624257,,BAO_0000218,1969.0,,CLD0
5235,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624258,,BAO_0000218,1969.0,,CLD0
5236,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875277,,BAO_0000218,,,CLD0
5237,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622667,,BAO_0000218,,,CLD0
5238,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622668,,BAO_0000218,,,CLD0
5239,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622669,,BAO_0000218,,,CLD0
5240,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622670,,BAO_0000218,,,CLD0
5241,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622671,,BAO_0000218,,,CLD0
5242,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622672,,BAO_0000218,,,CLD0
5243,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622673,,BAO_0000218,,,CLD0
5244,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622674,,BAO_0000218,,,CLD0
5245,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622675,,BAO_0000218,,,CLD0
5246,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622676,,BAO_0000218,,,CLD0
5247,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622677,,BAO_0000218,,,CLD0
5248,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622678,,BAO_0000218,,,CLD0
5249,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622679,,BAO_0000218,,,CLD0
5250,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622680,,BAO_0000218,,,CLD0
5251,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622681,,BAO_0000218,,,CLD0
5252,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875278,,BAO_0000218,,,CLD0
5253,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622682,,BAO_0000218,,,CLD0
5254,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622683,,BAO_0000218,,,CLD0
5255,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622684,,BAO_0000218,,,CLD0
5256,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622685,,BAO_0000218,,,CLD0
5257,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622686,,BAO_0000218,,,CLD0
5258,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618344,,BAO_0000218,,,CLD0
5259,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875582,,BAO_0000218,,,CLD0
5260,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618345,,BAO_0000218,,,CLD0
5261,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618346,,BAO_0000218,,,CLD0
5262,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618347,,BAO_0000218,,,CLD0
5263,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618348,,BAO_0000218,,,CLD0
5264,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618349,,BAO_0000019,,,CLD0
5265,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618350,,BAO_0000019,,,CLD0
5266,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618351,,BAO_0000019,,,CLD0
5267,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618352,,BAO_0000019,,,CLD0
5268,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL873494,,BAO_0000221,178.0,,CLD0
5269,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618353,,BAO_0000366,1969.0,,CLD0
5270,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618354,,BAO_0000366,1969.0,,CLD0
5271,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875583,,BAO_0000366,1969.0,,CLD0
5272,6072,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL618355,,BAO_0000366,1977.0,,CLD0
5273,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618356,,BAO_0000366,1969.0,,CLD0
5274,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618357,,BAO_0000251,,,CLD0
5275,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618358,,BAO_0000366,1969.0,,CLD0
5276,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224,U,0,Autocuration,1,,CHEMBL618359,,BAO_0000221,14.0,,CLD0
5277,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618360,,BAO_0000366,1969.0,,CLD0
5278,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,CCRF-CEM,,22224,U,0,Autocuration,1,,CHEMBL618361,635.0,BAO_0000219,,,CLD0
5279,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618362,,BAO_0000251,2107.0,,CLD0
5280,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618363,,BAO_0000366,1969.0,,CLD0
5281,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618364,,BAO_0000366,1969.0,,CLD0
5282,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875584,,BAO_0000366,1969.0,,CLD0
5283,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,CCRF-CEM,,22224,U,0,Autocuration,1,,CHEMBL618365,635.0,BAO_0000219,,,CLD0
5284,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873495,,BAO_0000366,1969.0,,CLD0
5285,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618366,,BAO_0000366,1969.0,,CLD0
5286,5523,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618367,,BAO_0000019,,,CLD0
5287,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618368,,BAO_0000221,178.0,,CLD0
5288,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618369,,BAO_0000221,178.0,,CLD0
5289,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618370,,BAO_0000366,1969.0,,CLD0
5290,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618371,,BAO_0000019,,,CLD0
5291,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618372,,BAO_0000221,178.0,,CLD0
5292,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618373,,BAO_0000366,1969.0,,CLD0
5293,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618374,,BAO_0000366,1969.0,,CLD0
5294,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618375,,BAO_0000366,1969.0,,CLD0
5295,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618376,,BAO_0000366,1969.0,,CLD0
5296,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL618377,,BAO_0000251,2107.0,,CLD0
5297,993,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618378,,BAO_0000366,1969.0,,CLD0
5298,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618379,,BAO_0000366,1969.0,,CLD0
5299,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618380,,BAO_0000366,1969.0,,CLD0
5300,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618381,,BAO_0000366,1969.0,,CLD0
5301,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618382,,BAO_0000366,1969.0,,CLD0
5302,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618383,,BAO_0000019,,,CLD0
5303,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618384,,BAO_0000019,,,CLD0
5304,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618385,,BAO_0000019,,,CLD0
5305,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619099,,BAO_0000366,1969.0,,CLD0
5306,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619100,,BAO_0000366,1969.0,,CLD0
5307,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619101,,BAO_0000019,,,CLD0
5308,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619102,,BAO_0000019,,,CLD0
5309,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL619103,,BAO_0000251,2107.0,,CLD0
5310,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL619268,,BAO_0000218,178.0,,CLD0
5311,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL619269,,BAO_0000218,178.0,,CLD0
5312,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL619270,,BAO_0000218,955.0,,CLD0
5313,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL619271,,BAO_0000218,955.0,,CLD0
5314,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL875585,,BAO_0000218,2113.0,,CLD0
5315,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL619272,,BAO_0000218,2113.0,,CLD0
5316,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619273,391.0,BAO_0000219,,,CLD0
5317,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619274,391.0,BAO_0000219,,,CLD0
5318,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619275,391.0,BAO_0000219,,,CLD0
5319,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619276,391.0,BAO_0000219,,,CLD0
5320,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619277,391.0,BAO_0000219,,,CLD0
5321,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619278,391.0,BAO_0000219,,,CLD0
5322,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619279,391.0,BAO_0000219,,,CLD0
5323,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL858458,391.0,BAO_0000219,,,CLD0
5324,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619280,391.0,BAO_0000219,,,CLD0
5325,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619281,391.0,BAO_0000219,,,CLD0
5326,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619282,391.0,BAO_0000219,,,CLD0
5327,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619283,391.0,BAO_0000219,,,CLD0
5328,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619284,391.0,BAO_0000219,,,CLD0
5329,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619285,391.0,BAO_0000219,,,CLD0
5330,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619286,391.0,BAO_0000219,,,CLD0
5331,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619287,391.0,BAO_0000219,,,CLD0
5332,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857455,391.0,BAO_0000219,,,CLD0
5333,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883801,391.0,BAO_0000219,,,CLD0
5334,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619288,972.0,BAO_0000219,,,CLD0
5335,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619289,972.0,BAO_0000219,,,CLD0
5336,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619290,972.0,BAO_0000219,,,CLD0
5337,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619291,972.0,BAO_0000219,,,CLD0
5338,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619292,972.0,BAO_0000219,,,CLD0
5339,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619293,972.0,BAO_0000219,,,CLD0
5340,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619294,972.0,BAO_0000219,,,CLD0
5341,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619295,972.0,BAO_0000219,,,CLD0
5342,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619296,972.0,BAO_0000219,,,CLD0
5343,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619297,972.0,BAO_0000219,,,CLD0
5344,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619298,391.0,BAO_0000219,,,CLD0
5345,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,NCI,,22226,U,0,Intermediate,1,,CHEMBL619299,1188.0,BAO_0000219,,,CLD0
5346,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619300,741.0,BAO_0000219,,,CLD0
5347,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619301,741.0,BAO_0000219,,,CLD0
5348,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619302,741.0,BAO_0000219,,,CLD0
5349,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619303,741.0,BAO_0000219,,,CLD0
5350,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619304,741.0,BAO_0000219,,,CLD0
5351,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL857706,741.0,BAO_0000219,,,CLD0
5352,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619305,741.0,BAO_0000219,,,CLD0
5353,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619306,741.0,BAO_0000219,,,CLD0
5354,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619307,741.0,BAO_0000219,,,CLD0
5355,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619308,741.0,BAO_0000219,,,CLD0
5356,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619309,741.0,BAO_0000219,,,CLD0
5357,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619310,741.0,BAO_0000219,,,CLD0
5358,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619311,624.0,BAO_0000219,,,CLD0
5359,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619312,624.0,BAO_0000219,,,CLD0
5360,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619313,624.0,BAO_0000219,,,CLD0
5361,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619314,624.0,BAO_0000219,,,CLD0
5362,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619959,624.0,BAO_0000219,,,CLD0
5363,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619960,624.0,BAO_0000219,,,CLD0
5364,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619961,624.0,BAO_0000219,,,CLD0
5365,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619962,624.0,BAO_0000219,,,CLD0
5366,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL875586,624.0,BAO_0000219,,,CLD0
5367,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619963,624.0,BAO_0000219,,,CLD0
5368,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619964,624.0,BAO_0000219,,,CLD0
5369,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620108,624.0,BAO_0000219,,,CLD0
5370,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620109,624.0,BAO_0000219,,,CLD0
5371,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620110,624.0,BAO_0000219,,,CLD0
5372,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620111,624.0,BAO_0000219,,,CLD0
5373,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620112,624.0,BAO_0000219,,,CLD0
5374,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620113,624.0,BAO_0000219,,,CLD0
5375,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620114,624.0,BAO_0000219,,,CLD0
5376,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620115,624.0,BAO_0000219,,,CLD0
5377,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620116,624.0,BAO_0000219,,,CLD0
5378,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620117,624.0,BAO_0000219,,,CLD0
5379,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620118,624.0,BAO_0000219,,,CLD0
5380,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620119,624.0,BAO_0000219,,,CLD0
5381,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620120,624.0,BAO_0000219,,,CLD0
5382,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620121,646.0,BAO_0000219,,,CLD0
5383,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620122,646.0,BAO_0000219,,,CLD0
5384,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620123,646.0,BAO_0000219,,,CLD0
5385,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620124,646.0,BAO_0000219,,,CLD0
5386,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620125,646.0,BAO_0000219,,,CLD0
5387,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620126,646.0,BAO_0000219,,,CLD0
5388,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL883027,646.0,BAO_0000219,,,CLD0
5389,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620127,646.0,BAO_0000219,,,CLD0
5390,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620128,646.0,BAO_0000219,,,CLD0
5391,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620129,646.0,BAO_0000219,,,CLD0
5392,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620130,646.0,BAO_0000219,,,CLD0
5393,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620131,646.0,BAO_0000219,,,CLD0
5394,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620132,646.0,BAO_0000219,,,CLD0
5395,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620133,646.0,BAO_0000219,,,CLD0
5396,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620134,646.0,BAO_0000219,,,CLD0
5397,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620135,646.0,BAO_0000219,,,CLD0
5398,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620136,646.0,BAO_0000219,,,CLD0
5399,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620137,646.0,BAO_0000219,,,CLD0
5400,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620268,646.0,BAO_0000219,,,CLD0
5401,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620269,646.0,BAO_0000219,,,CLD0
5402,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620270,646.0,BAO_0000219,,,CLD0
5403,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620271,646.0,BAO_0000219,,,CLD0
5404,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620272,646.0,BAO_0000219,,,CLD0
5405,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620273,646.0,BAO_0000219,,,CLD0
5406,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620274,646.0,BAO_0000219,,,CLD0
5407,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620275,646.0,BAO_0000219,,,CLD0
5408,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620276,646.0,BAO_0000219,,,CLD0
5409,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620277,646.0,BAO_0000219,,,CLD0
5410,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620278,646.0,BAO_0000219,,,CLD0
5411,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620279,,BAO_0000218,,,CLD0
5412,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620280,,BAO_0000218,,,CLD0
5413,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620281,,BAO_0000218,,,CLD0
5414,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620282,,BAO_0000218,,,CLD0
5415,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL621134,,BAO_0000218,178.0,,CLD0
5416,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL621135,,BAO_0000218,178.0,,CLD0
5417,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL621136,,BAO_0000218,178.0,,CLD0
5418,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL621137,,BAO_0000218,178.0,,CLD0
5419,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621138,,BAO_0000218,1969.0,,CLD0
5420,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875587,,BAO_0000218,1969.0,,CLD0
5421,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621139,,BAO_0000218,,,CLD0
5422,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621140,,BAO_0000218,,,CLD0
5423,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621141,,BAO_0000218,,,CLD0
5424,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621142,,BAO_0000218,,,CLD0
5425,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621143,,BAO_0000218,,,CLD0
5426,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621144,,BAO_0000218,,,CLD0
5427,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621145,,BAO_0000218,,,CLD0
5428,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621146,,BAO_0000218,,,CLD0
5429,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622567,,BAO_0000218,,,CLD0
5430,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622568,,BAO_0000218,,,CLD0
5431,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622569,,BAO_0000218,,,CLD0
5432,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622570,,BAO_0000218,,,CLD0
5433,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622571,,BAO_0000218,1969.0,,CLD0
5434,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622572,,BAO_0000218,,,CLD0
5435,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622573,,BAO_0000218,,,CLD0
5436,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622574,,BAO_0000218,,,CLD0
5437,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622575,,BAO_0000218,,,CLD0
5438,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622576,,BAO_0000218,,,CLD0
5439,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622577,,BAO_0000218,,,CLD0
5440,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622578,,BAO_0000218,,,CLD0
5441,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622579,,BAO_0000218,,,CLD0
5442,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622580,,BAO_0000218,,,CLD0
5443,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622581,,BAO_0000218,,,CLD0
5444,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622582,,BAO_0000218,,,CLD0
5445,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622583,,BAO_0000218,,,CLD0
5446,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622584,,BAO_0000218,,,CLD0
5447,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622585,,BAO_0000218,,,CLD0
5448,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622586,,BAO_0000218,,,CLD0
5449,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,kidney,,50588,N,1,Intermediate,1,,CHEMBL623281,,BAO_0000218,,,CLD0
5450,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,kidney,,50588,N,1,Intermediate,1,,CHEMBL623282,,BAO_0000218,,,CLD0
5451,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,kidney,,50588,N,1,Intermediate,1,,CHEMBL623283,,BAO_0000218,,,CLD0
5452,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623284,,BAO_0000218,,,CLD0
5453,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623285,,BAO_0000218,,,CLD0
5454,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623463,,BAO_0000218,1969.0,,CLD0
5455,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875952,,BAO_0000218,1969.0,,CLD0
5456,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621705,,BAO_0000218,,,CLD0
5457,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621706,,BAO_0000218,,,CLD0
5458,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621707,,BAO_0000218,,,CLD0
5459,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621708,,BAO_0000218,,,CLD0
5460,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621709,,BAO_0000218,,,CLD0
5461,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621710,,BAO_0000218,,,CLD0
5462,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621711,,BAO_0000218,,,CLD0
5463,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621712,,BAO_0000218,,,CLD0
5464,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621713,,BAO_0000218,,,CLD0
5465,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621714,,BAO_0000218,,,CLD0
5466,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL621715,,BAO_0000218,2113.0,,CLD0
5467,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623717,,BAO_0000218,2107.0,,CLD0
5468,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623718,,BAO_0000218,2107.0,,CLD0
5469,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623719,,BAO_0000218,2107.0,,CLD0
5470,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623720,,BAO_0000218,,,CLD0
5471,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623721,,BAO_0000218,,,CLD0
5472,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623722,,BAO_0000218,2385.0,,CLD0
5473,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623723,,BAO_0000218,2385.0,,CLD0
5474,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL618543,,BAO_0000218,2385.0,,CLD0
5475,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL618544,,BAO_0000218,2106.0,,CLD0
5476,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875155,,BAO_0000218,2106.0,,CLD0
5477,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618545,,BAO_0000218,,,CLD0
5478,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618546,,BAO_0000218,,,CLD0
5479,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623529,,BAO_0000218,,,CLD0
5480,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Uveal tract,,,22224,U,0,Autocuration,1,,CHEMBL623530,,BAO_0000218,1768.0,,CLD0
5481,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Uveal tract,,,22224,U,0,Autocuration,1,,CHEMBL621764,,BAO_0000218,1768.0,,CLD0
5482,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL621765,,BAO_0000221,955.0,,CLD0
5483,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621766,,BAO_0000221,2037.0,,CLD0
5484,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621767,,BAO_0000221,1870.0,,CLD0
5485,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL621768,,BAO_0000221,1474.0,,CLD0
5486,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621769,,BAO_0000221,2435.0,,CLD0
5487,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL621770,,BAO_0000221,955.0,,CLD0
5488,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621771,,BAO_0000221,2037.0,,CLD0
5489,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621772,,BAO_0000221,1870.0,,CLD0
5490,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL621773,,BAO_0000221,1474.0,,CLD0
5491,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621774,,BAO_0000221,2435.0,,CLD0
5492,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621775,,BAO_0000218,,,CLD0
5493,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621776,,BAO_0000218,1969.0,,CLD0
5494,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621777,,BAO_0000019,,,CLD0
5495,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875162,,BAO_0000218,,,CLD0
5496,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621778,,BAO_0000218,1969.0,,CLD0
5497,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621779,,BAO_0000218,1969.0,,CLD0
5498,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622479,,BAO_0000218,1969.0,,CLD0
5499,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622480,,BAO_0000218,,,CLD0
5500,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622481,,BAO_0000218,,,CLD0
5501,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622482,,BAO_0000218,,,CLD0
5502,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622483,,BAO_0000218,,,CLD0
5503,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622484,,BAO_0000218,,,CLD0
5504,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622641,,BAO_0000218,,,CLD0
5505,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622642,,BAO_0000218,,,CLD0
5506,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622643,,BAO_0000218,,,CLD0
5507,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622644,,BAO_0000218,,,CLD0
5508,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622645,741.0,BAO_0000219,,,CLD0
5509,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622646,741.0,BAO_0000219,,,CLD0
5510,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621238,741.0,BAO_0000219,,,CLD0
5511,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621239,741.0,BAO_0000219,,,CLD0
5512,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621240,741.0,BAO_0000219,,,CLD0
5513,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621241,741.0,BAO_0000219,,,CLD0
5514,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621242,741.0,BAO_0000219,,,CLD0
5515,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620350,741.0,BAO_0000219,,,CLD0
5516,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620351,741.0,BAO_0000219,,,CLD0
5517,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620352,741.0,BAO_0000219,,,CLD0
5518,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620353,741.0,BAO_0000219,,,CLD0
5519,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620354,741.0,BAO_0000219,,,CLD0
5520,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620355,741.0,BAO_0000219,,,CLD0
5521,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620356,741.0,BAO_0000219,,,CLD0
5522,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620357,741.0,BAO_0000219,,,CLD0
5523,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620358,741.0,BAO_0000219,,,CLD0
5524,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL620359,741.0,BAO_0000219,,,CLD0
5525,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620360,741.0,BAO_0000219,,,CLD0
5526,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620361,741.0,BAO_0000219,,,CLD0
5527,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620362,741.0,BAO_0000219,,,CLD0
5528,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620363,741.0,BAO_0000219,,,CLD0
5529,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620364,741.0,BAO_0000219,,,CLD0
5530,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620365,854.0,BAO_0000219,,,CLD0
5531,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620366,854.0,BAO_0000219,,,CLD0
5532,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Expert,1,,CHEMBL620367,854.0,BAO_0000219,,,CLD0
5533,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620368,854.0,BAO_0000219,,,CLD0
5534,6608,Inhibitory activity against caspase-1,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620369,,BAO_0000019,,,CLD0
5535,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45,H,8,Autocuration,1,,CHEMBL620370,,BAO_0000357,,,CLD0
5536,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620371,705.0,BAO_0000219,,,CLD0
5537,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620372,705.0,BAO_0000219,,,CLD0
5538,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,Cancer cell lines,,22226,U,0,Intermediate,1,,CHEMBL876492,1015.0,BAO_0000219,,,CLD0
5539,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620373,,BAO_0000019,,,CLD0
5540,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,NCI,,22226,U,0,Intermediate,1,,CHEMBL620374,1188.0,BAO_0000219,,,CLD0
5541,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620375,,BAO_0000019,,,CLD0
5542,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22221,N,1,Autocuration,1,,CHEMBL857902,,BAO_0000019,,,CLD0
5543,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22221,N,1,Autocuration,1,,CHEMBL620376,,BAO_0000019,,,CLD0
5544,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922,H,8,Autocuration,1,,CHEMBL620377,,BAO_0000357,,,CLD0
5545,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB,,81115,N,1,Intermediate,1,,CHEMBL620378,324.0,BAO_0000219,,,CLD0
5546,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB,,81115,N,1,Intermediate,1,,CHEMBL620379,324.0,BAO_0000219,,,CLD0
5547,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,9KB,,22221,N,1,Autocuration,1,,CHEMBL620380,,BAO_0000219,,,CLD0
5548,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Intermediate,1,,CHEMBL884006,392.0,BAO_0000219,,,CLD0
5549,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620381,392.0,BAO_0000219,,,CLD0
5550,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620382,392.0,BAO_0000219,,,CLD0
5551,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620383,646.0,BAO_0000219,,,CLD0
5552,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876493,646.0,BAO_0000219,,,CLD0
5553,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620384,646.0,BAO_0000219,,,CLD0
5554,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620385,646.0,BAO_0000219,,,CLD0
5555,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620386,646.0,BAO_0000219,,,CLD0
5556,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL620387,646.0,BAO_0000219,,,CLD0
5557,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL621404,646.0,BAO_0000219,,,CLD0
5558,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621405,646.0,BAO_0000219,,,CLD0
5559,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621406,646.0,BAO_0000219,,,CLD0
5560,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621407,646.0,BAO_0000219,,,CLD0
5561,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621408,646.0,BAO_0000219,,,CLD0
5562,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885345,646.0,BAO_0000219,,,CLD0
5563,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621409,646.0,BAO_0000219,,,CLD0
5564,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL876034,646.0,BAO_0000219,,,CLD0
5565,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621410,646.0,BAO_0000219,,,CLD0
5566,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621411,646.0,BAO_0000219,,,CLD0
5567,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621412,646.0,BAO_0000219,,,CLD0
5568,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621413,646.0,BAO_0000219,,,CLD0
5569,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621414,646.0,BAO_0000219,,,CLD0
5570,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621415,646.0,BAO_0000219,,,CLD0
5571,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621416,646.0,BAO_0000219,,,CLD0
5572,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621417,646.0,BAO_0000219,,,CLD0
5573,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621418,646.0,BAO_0000219,,,CLD0
5574,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621419,646.0,BAO_0000219,,,CLD0
5575,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621420,646.0,BAO_0000219,,,CLD0
5576,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875823,646.0,BAO_0000219,,,CLD0
5577,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621421,646.0,BAO_0000219,,,CLD0
5578,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621422,646.0,BAO_0000219,,,CLD0
5579,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884014,646.0,BAO_0000219,,,CLD0
5580,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621423,646.0,BAO_0000219,,,CLD0
5581,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621424,646.0,BAO_0000219,,,CLD0
5582,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621425,646.0,BAO_0000219,,,CLD0
5583,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621426,646.0,BAO_0000219,,,CLD0
5584,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621427,646.0,BAO_0000219,,,CLD0
5585,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621428,646.0,BAO_0000219,,,CLD0
5586,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621429,646.0,BAO_0000219,,,CLD0
5587,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621430,646.0,BAO_0000219,,,CLD0
5588,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621431,646.0,BAO_0000219,,,CLD0
5589,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621432,646.0,BAO_0000219,,,CLD0
5590,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621433,646.0,BAO_0000219,,,CLD0
5591,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875824,646.0,BAO_0000219,,,CLD0
5592,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621434,646.0,BAO_0000219,,,CLD0
5593,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621435,646.0,BAO_0000219,,,CLD0
5594,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621436,646.0,BAO_0000219,,,CLD0
5595,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621437,646.0,BAO_0000219,,,CLD0
5596,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621438,646.0,BAO_0000219,,,CLD0
5597,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621439,646.0,BAO_0000219,,,CLD0
5598,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621440,646.0,BAO_0000219,,,CLD0
5599,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621441,,BAO_0000218,,,CLD0
5600,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621442,,BAO_0000218,,,CLD0
5601,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621443,,BAO_0000218,,,CLD0
5602,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621444,,BAO_0000218,,,CLD0
5603,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625133,,BAO_0000218,,,CLD0
5604,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625134,,BAO_0000218,,,CLD0
5605,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625135,,BAO_0000218,,,CLD0
5606,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625136,,BAO_0000218,,,CLD0
5607,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625137,,BAO_0000218,,,CLD0
5608,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625138,,BAO_0000218,,,CLD0
5609,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625139,,BAO_0000218,,,CLD0
5610,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872264,,BAO_0000218,,,CLD0
5611,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625140,,BAO_0000218,,,CLD0
5612,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624436,,BAO_0000218,,,CLD0
5613,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624437,,BAO_0000218,,,CLD0
5614,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872261,,BAO_0000218,,,CLD0
5615,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL624438,,BAO_0000218,178.0,,CLD0
5616,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624439,,BAO_0000218,1969.0,,CLD0
5617,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624440,,BAO_0000218,,,CLD0
5618,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624441,,BAO_0000218,,,CLD0
5619,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624442,,BAO_0000218,1969.0,,CLD0
5620,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624443,,BAO_0000218,,,CLD0
5621,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624444,,BAO_0000218,,,CLD0
5622,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624445,,BAO_0000218,,,CLD0
5623,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624446,,BAO_0000218,,,CLD0
5624,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624447,,BAO_0000218,,,CLD0
5625,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624448,,BAO_0000218,1969.0,,CLD0
5626,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624449,,BAO_0000218,1969.0,,CLD0
5627,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624450,,BAO_0000218,1969.0,,CLD0
5628,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875942,,BAO_0000218,1969.0,,CLD0
5629,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624451,,BAO_0000218,1969.0,,CLD0
5630,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624452,,BAO_0000218,1969.0,,CLD0
5631,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624453,,BAO_0000218,1969.0,,CLD0
5632,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624454,,BAO_0000218,1969.0,,CLD0
5633,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624455,,BAO_0000218,1969.0,,CLD0
5634,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624456,,BAO_0000218,,,CLD0
5635,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624457,,BAO_0000218,1969.0,,CLD0
5636,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624458,,BAO_0000218,,,CLD0
5637,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624459,,BAO_0000218,,,CLD0
5638,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,102164,S,2,Intermediate,1,,CHEMBL624460,,BAO_0000251,2107.0,,CLD0
5639,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsome,102164,S,2,Intermediate,1,,CHEMBL624461,,BAO_0000251,2107.0,,CLD0
5640,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875943,,BAO_0000218,,,CLD0
5641,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624462,,BAO_0000218,,,CLD0
5642,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624463,,BAO_0000218,,,CLD0
5643,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624464,,BAO_0000218,1969.0,,CLD0
5644,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624465,,BAO_0000218,1969.0,,CLD0
5645,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624466,,BAO_0000218,1969.0,,CLD0
5646,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624467,,BAO_0000218,1969.0,,CLD0
5647,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624468,,BAO_0000218,1969.0,,CLD0
5648,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624469,,BAO_0000218,1969.0,,CLD0
5649,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624470,,BAO_0000218,1969.0,,CLD0
5650,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624471,,BAO_0000218,,,CLD0
5651,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624472,,BAO_0000218,,,CLD0
5652,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622775,,BAO_0000218,,,CLD0
5653,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622776,,BAO_0000218,,,CLD0
5654,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622777,,BAO_0000218,,,CLD0
5655,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622778,,BAO_0000218,,,CLD0
5656,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622779,,BAO_0000218,,,CLD0
5657,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622780,,BAO_0000218,,,CLD0
5658,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622781,,BAO_0000218,1969.0,,CLD0
5659,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622782,,BAO_0000218,,,CLD0
5660,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622783,,BAO_0000218,1969.0,,CLD0
5661,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622784,,BAO_0000218,1969.0,,CLD0
5662,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622785,,BAO_0000218,,,CLD0
5663,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622786,,BAO_0000218,,,CLD0
5664,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622787,,BAO_0000218,,,CLD0
5665,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875949,,BAO_0000218,,,CLD0
5666,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622788,,BAO_0000218,,,CLD0
5667,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622789,,BAO_0000218,,,CLD0
5668,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622790,,BAO_0000218,,,CLD0
5669,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622791,,BAO_0000218,,,CLD0
5670,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622792,,BAO_0000218,,,CLD0
5671,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622793,,BAO_0000218,,,CLD0
5672,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622794,,BAO_0000218,,,CLD0
5673,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622795,,BAO_0000218,,,CLD0
5674,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621803,,BAO_0000218,,,CLD0
5675,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621804,,BAO_0000218,,,CLD0
5676,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621805,,BAO_0000218,,,CLD0
5677,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL621806,,BAO_0000218,178.0,,CLD0
5678,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL621807,,BAO_0000218,178.0,,CLD0
5679,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621808,,BAO_0000218,,,CLD0
5680,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621809,,BAO_0000218,,,CLD0
5681,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621810,,BAO_0000218,,,CLD0
5682,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875164,,BAO_0000218,,,CLD0
5683,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621811,,BAO_0000218,,,CLD0
5684,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621812,,BAO_0000218,,,CLD0
5685,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621813,,BAO_0000218,,,CLD0
5686,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621814,,BAO_0000218,,,CLD0
5687,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621815,,BAO_0000218,,,CLD0
5688,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621816,,BAO_0000218,,,CLD0
5689,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621817,,BAO_0000218,,,CLD0
5690,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621818,,BAO_0000218,,,CLD0
5691,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621819,,BAO_0000218,,,CLD0
5692,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621820,,BAO_0000218,,,CLD0
5693,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621821,,BAO_0000218,,,CLD0
5694,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621822,,BAO_0000218,,,CLD0
5695,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619474,,BAO_0000218,,,CLD0
5696,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619475,,BAO_0000218,,,CLD0
5697,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619476,,BAO_0000218,,,CLD0
5698,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619477,,BAO_0000218,,,CLD0
5699,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619478,,BAO_0000218,,,CLD0
5700,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619479,,BAO_0000218,,,CLD0
5701,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619480,,BAO_0000218,,,CLD0
5702,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL619481,,BAO_0000218,178.0,,CLD0
5703,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL619482,,BAO_0000218,178.0,,CLD0
5704,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619483,,BAO_0000218,,,CLD0
5705,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619484,,BAO_0000218,,,CLD0
5706,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619485,,BAO_0000218,1969.0,,CLD0
5707,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619486,,BAO_0000218,1969.0,,CLD0
5708,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619487,,BAO_0000218,,,CLD0
5709,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619488,,BAO_0000218,,,CLD0
5710,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620106,,BAO_0000218,178.0,,CLD0
5711,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653,N,1,Intermediate,1,,CHEMBL620107,392.0,BAO_0000219,,,CLD0
5712,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22221,N,1,Autocuration,1,,CHEMBL620283,,BAO_0000019,,,CLD0
5713,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL875176,,BAO_0000219,,,CLD0
5714,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620284,,BAO_0000219,,,CLD0
5715,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623515,,BAO_0000219,,,CLD0
5716,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22221,N,1,Autocuration,1,,CHEMBL623516,,BAO_0000019,,,CLD0
5717,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22221,N,1,Autocuration,1,,CHEMBL623517,,BAO_0000019,,,CLD0
5718,15508,Partition coefficient (logD6.5),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL857878,,BAO_0000100,,,CLD0
5719,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623518,478.0,BAO_0000219,,,CLD0
5720,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624195,455.0,BAO_0000219,,,CLD0
5721,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL624196,500.0,BAO_0000219,,,CLD0
5722,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL624197,500.0,BAO_0000219,,,CLD0
5723,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624198,624.0,BAO_0000219,,,CLD0
5724,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621287,624.0,BAO_0000219,,,CLD0
5725,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621288,624.0,BAO_0000219,,,CLD0
5726,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL876496,624.0,BAO_0000219,,,CLD0
5727,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621289,624.0,BAO_0000219,,,CLD0
5728,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Autocuration,1,,CHEMBL621290,,BAO_0000019,,,CLD0
5729,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Autocuration,1,,CHEMBL621291,,BAO_0000019,,,CLD0
5730,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Autocuration,1,,CHEMBL621292,,BAO_0000019,,,CLD0
5731,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Autocuration,1,,CHEMBL621293,,BAO_0000019,,,CLD0
5732,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621294,646.0,BAO_0000219,,,CLD0
5733,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621295,646.0,BAO_0000219,,,CLD0
5734,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884007,646.0,BAO_0000219,,,CLD0
5735,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621296,646.0,BAO_0000219,,,CLD0
5736,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621297,646.0,BAO_0000219,,,CLD0
5737,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839828,646.0,BAO_0000219,,,CLD0
5738,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620397,646.0,BAO_0000219,,,CLD0
5739,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620398,646.0,BAO_0000219,,,CLD0
5740,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620399,646.0,BAO_0000219,,,CLD0
5741,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620400,646.0,BAO_0000219,,,CLD0
5742,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620401,646.0,BAO_0000219,,,CLD0
5743,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620402,646.0,BAO_0000219,,,CLD0
5744,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620403,646.0,BAO_0000219,,,CLD0
5745,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620404,,BAO_0000218,,,CLD0
5746,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620405,,BAO_0000218,,,CLD0
5747,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620406,,BAO_0000218,,,CLD0
5748,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620407,,BAO_0000218,,,CLD0
5749,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620408,,BAO_0000218,,,CLD0
5750,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620409,,BAO_0000218,,,CLD0
5751,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620410,624.0,BAO_0000219,,,CLD0
5752,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620411,,BAO_0000019,,,CLD0
5753,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620412,,BAO_0000019,,,CLD0
5754,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL876596,,BAO_0000019,,,CLD0
5755,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL620413,622.0,BAO_0000219,,,CLD0
5756,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620414,622.0,BAO_0000219,,,CLD0
5757,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620415,622.0,BAO_0000219,,,CLD0
5758,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620416,646.0,BAO_0000219,,,CLD0
5759,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620417,646.0,BAO_0000219,,,CLD0
5760,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620418,646.0,BAO_0000219,,,CLD0
5761,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620419,646.0,BAO_0000219,,,CLD0
5762,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620420,646.0,BAO_0000219,,,CLD0
5763,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620421,646.0,BAO_0000219,,,CLD0
5764,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620422,646.0,BAO_0000219,,,CLD0
5765,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620423,646.0,BAO_0000219,,,CLD0
5766,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620424,646.0,BAO_0000219,,,CLD0
5767,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620425,646.0,BAO_0000219,,,CLD0
5768,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620426,646.0,BAO_0000219,,,CLD0
5769,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,Serum,A549,,80682,N,1,Intermediate,1,,CHEMBL620427,646.0,BAO_0000219,1977.0,,CLD0
5770,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620428,646.0,BAO_0000219,,,CLD0
5771,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620429,646.0,BAO_0000219,,,CLD0
5772,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620430,646.0,BAO_0000219,,,CLD0
5773,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839887,646.0,BAO_0000219,,,CLD0
5774,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620431,646.0,BAO_0000219,,,CLD0
5775,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884010,646.0,BAO_0000219,,,CLD0
5776,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620538,646.0,BAO_0000219,,,CLD0
5777,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620539,646.0,BAO_0000219,,,CLD0
5778,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623373,646.0,BAO_0000218,,,CLD0
5779,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623374,646.0,BAO_0000219,,,CLD0
5780,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623375,646.0,BAO_0000219,,,CLD0
5781,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623376,646.0,BAO_0000219,,,CLD0
5782,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623377,646.0,BAO_0000219,,,CLD0
5783,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623378,646.0,BAO_0000219,,,CLD0
5784,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623379,646.0,BAO_0000219,,,CLD0
5785,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623380,646.0,BAO_0000219,,,CLD0
5786,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623381,646.0,BAO_0000219,,,CLD0
5787,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623382,646.0,BAO_0000219,,,CLD0
5788,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623383,646.0,BAO_0000219,,,CLD0
5789,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623384,646.0,BAO_0000219,,,CLD0
5790,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623385,646.0,BAO_0000219,,,CLD0
5791,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623386,646.0,BAO_0000219,,,CLD0
5792,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884105,646.0,BAO_0000219,,,CLD0
5793,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623387,646.0,BAO_0000219,,,CLD0
5794,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621568,646.0,BAO_0000219,,,CLD0
5795,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621569,646.0,BAO_0000219,,,CLD0
5796,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621570,646.0,BAO_0000219,,,CLD0
5797,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621571,646.0,BAO_0000219,,,CLD0
5798,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621572,646.0,BAO_0000219,,,CLD0
5799,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621573,646.0,BAO_0000219,,,CLD0
5800,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621574,646.0,BAO_0000219,,,CLD0
5801,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621575,646.0,BAO_0000219,,,CLD0
5802,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621576,646.0,BAO_0000219,,,CLD0
5803,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621577,646.0,BAO_0000219,,,CLD0
5804,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621578,646.0,BAO_0000219,,,CLD0
5805,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621579,646.0,BAO_0000219,,,CLD0
5806,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621580,646.0,BAO_0000219,,,CLD0
5807,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621581,,BAO_0000218,1969.0,,CLD0
5808,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621582,,BAO_0000218,1969.0,,CLD0
5809,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621583,,BAO_0000218,1969.0,,CLD0
5810,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621584,,BAO_0000218,1969.0,,CLD0
5811,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621585,,BAO_0000218,1969.0,,CLD0
5812,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621586,,BAO_0000218,1969.0,,CLD0
5813,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875835,,BAO_0000218,,,CLD0
5814,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621587,,BAO_0000218,,,CLD0
5815,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621588,,BAO_0000218,1969.0,,CLD0
5816,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsome,50588,N,1,Intermediate,1,,CHEMBL621589,,BAO_0000218,2107.0,,CLD0
5817,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621590,,BAO_0000218,,,CLD0
5818,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621591,,BAO_0000218,,,CLD0
5819,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621592,,BAO_0000218,1969.0,,CLD0
5820,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621593,,BAO_0000218,,,CLD0
5821,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621594,,BAO_0000218,1969.0,,CLD0
5822,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621595,,BAO_0000218,,,CLD0
5823,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621596,,BAO_0000218,1969.0,,CLD0
5824,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621597,,BAO_0000218,1969.0,,CLD0
5825,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621598,,BAO_0000218,,,CLD0
5826,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621599,,BAO_0000218,1969.0,,CLD0
5827,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875836,,BAO_0000218,1969.0,,CLD0
5828,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621600,,BAO_0000218,1969.0,,CLD0
5829,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621601,,BAO_0000218,1969.0,,CLD0
5830,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618474,,BAO_0000218,1969.0,,CLD0
5831,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618475,,BAO_0000218,1969.0,,CLD0
5832,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624524,,BAO_0000218,1969.0,,CLD0
5833,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624525,,BAO_0000218,1969.0,,CLD0
5834,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624526,,BAO_0000218,1969.0,,CLD0
5835,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624527,,BAO_0000218,1969.0,,CLD0
5836,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624528,,BAO_0000218,1969.0,,CLD0
5837,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624529,,BAO_0000218,1969.0,,CLD0
5838,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624530,,BAO_0000218,1969.0,,CLD0
5839,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624531,,BAO_0000218,1969.0,,CLD0
5840,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624532,,BAO_0000218,1969.0,,CLD0
5841,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624533,,BAO_0000218,1969.0,,CLD0
5842,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624534,,BAO_0000218,1969.0,,CLD0
5843,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624535,,BAO_0000218,1969.0,,CLD0
5844,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624536,,BAO_0000218,1969.0,,CLD0
5845,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624537,,BAO_0000218,1969.0,,CLD0
5846,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624538,,BAO_0000218,1969.0,,CLD0
5847,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624539,,BAO_0000218,1969.0,,CLD0
5848,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624540,,BAO_0000218,1969.0,,CLD0
5849,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624541,,BAO_0000218,1969.0,,CLD0
5850,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624542,,BAO_0000218,1969.0,,CLD0
5851,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624543,,BAO_0000218,1969.0,,CLD0
5852,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624544,,BAO_0000218,,,CLD0
5853,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624545,,BAO_0000218,1969.0,,CLD0
5854,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624546,,BAO_0000218,,,CLD0
5855,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875957,,BAO_0000218,,,CLD0
5856,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624547,,BAO_0000218,,,CLD0
5857,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624548,,BAO_0000218,,,CLD0
5858,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624549,,BAO_0000218,,,CLD0
5859,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624550,,BAO_0000218,1969.0,,CLD0
5860,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621613,,BAO_0000218,,,CLD0
5861,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621614,,BAO_0000218,,,CLD0
5862,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623431,,BAO_0000218,,,CLD0
5863,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623432,,BAO_0000218,,,CLD0
5864,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623433,,BAO_0000218,,,CLD0
5865,17764,Cmax after peroral administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623434,,BAO_0000218,,,CLD0
5866,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623435,,BAO_0000218,,,CLD0
5867,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623436,,BAO_0000218,,,CLD0
5868,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875958,,BAO_0000218,,,CLD0
5869,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623437,,BAO_0000218,,,CLD0
5870,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623438,,BAO_0000218,178.0,,CLD0
5871,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623439,,BAO_0000218,178.0,,CLD0
5872,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL623440,,BAO_0000218,1474.0,,CLD0
5873,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL623441,,BAO_0000218,1474.0,,CLD0
5874,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL623442,,BAO_0000218,1474.0,,CLD0
5875,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Adipose tissue,,,50594,N,1,Intermediate,1,,CHEMBL623469,,BAO_0000218,1013.0,,CLD0
5876,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Adipose tissue,,,50594,N,1,Intermediate,1,,CHEMBL623470,,BAO_0000218,1013.0,,CLD0
5877,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Adipose tissue,,,50594,N,1,Intermediate,1,,CHEMBL623471,,BAO_0000218,1013.0,,CLD0
5878,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623472,,BAO_0000218,948.0,,CLD0
5879,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623473,,BAO_0000218,948.0,,CLD0
5880,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623474,,BAO_0000218,948.0,,CLD0
5881,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623475,,BAO_0000218,2113.0,,CLD0
5882,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623476,,BAO_0000218,2113.0,,CLD0
5883,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623477,,BAO_0000218,2113.0,,CLD0
5884,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Large intestine,,,50594,N,1,Intermediate,1,,CHEMBL621896,,BAO_0000218,59.0,,CLD0
5885,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Large intestine,,,50594,N,1,Intermediate,1,,CHEMBL621897,,BAO_0000218,59.0,,CLD0
5886,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Large intestine,,,50594,N,1,Intermediate,1,,CHEMBL621898,,BAO_0000218,59.0,,CLD0
5887,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621899,,BAO_0000218,2107.0,,CLD0
5888,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621900,,BAO_0000218,2107.0,,CLD0
5889,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621901,,BAO_0000218,2107.0,,CLD0
5890,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621902,,BAO_0000218,2048.0,,CLD0
5891,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621903,,BAO_0000218,2048.0,,CLD0
5892,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622587,,BAO_0000218,2048.0,,CLD0
5893,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620285,,BAO_0000218,2385.0,,CLD0
5894,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875285,,BAO_0000218,2385.0,,CLD0
5895,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620286,,BAO_0000218,2385.0,,CLD0
5896,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620287,,BAO_0000218,,,CLD0
5897,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620288,,BAO_0000218,,,CLD0
5898,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620289,,BAO_0000218,,,CLD0
5899,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Small intestine,,,50594,N,1,Intermediate,1,,CHEMBL620290,,BAO_0000218,2108.0,,CLD0
5900,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Small intestine,,,50594,N,1,Intermediate,1,,CHEMBL620291,,BAO_0000218,2108.0,,CLD0
5901,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Small intestine,,,50594,N,1,Intermediate,1,,CHEMBL620292,,BAO_0000218,2108.0,,CLD0
5902,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620293,,BAO_0000218,2106.0,,CLD0
5903,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620294,,BAO_0000218,2106.0,,CLD0
5904,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618614,,BAO_0000218,2106.0,,CLD0
5905,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618615,,BAO_0000218,945.0,,CLD0
5906,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618616,,BAO_0000218,945.0,,CLD0
5907,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL618617,622.0,BAO_0000219,,,CLD0
5908,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL618618,622.0,BAO_0000219,,,CLD0
5909,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Intermediate,1,,CHEMBL618619,623.0,BAO_0000219,,,CLD0
5910,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618620,478.0,BAO_0000219,,,CLD0
5911,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618621,455.0,BAO_0000219,,,CLD0
5912,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618622,455.0,BAO_0000219,,,CLD0
5913,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618623,797.0,BAO_0000219,,,CLD0
5914,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618624,797.0,BAO_0000219,,,CLD0
5915,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618625,797.0,BAO_0000219,,,CLD0
5916,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618626,797.0,BAO_0000219,,,CLD0
5917,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618627,797.0,BAO_0000219,,,CLD0
5918,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618628,797.0,BAO_0000219,,,CLD0
5919,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618629,797.0,BAO_0000219,,,CLD0
5920,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618630,797.0,BAO_0000219,,,CLD0
5921,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618631,797.0,BAO_0000219,,,CLD0
5922,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618632,797.0,BAO_0000219,,,CLD0
5923,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL618633,500.0,BAO_0000219,,,CLD0
5924,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619315,624.0,BAO_0000219,,,CLD0
5925,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL619316,624.0,BAO_0000219,,,CLD0
5926,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619317,624.0,BAO_0000219,,,CLD0
5927,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619318,624.0,BAO_0000219,,,CLD0
5928,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619319,624.0,BAO_0000219,,,CLD0
5929,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619739,624.0,BAO_0000219,,,CLD0
5930,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619740,624.0,BAO_0000219,,,CLD0
5931,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883158,624.0,BAO_0000219,,,CLD0
5932,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL884012,624.0,BAO_0000219,,,CLD0
5933,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619741,624.0,BAO_0000219,,,CLD0
5934,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619742,624.0,BAO_0000219,,,CLD0
5935,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876610,646.0,BAO_0000219,,,CLD0
5936,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619743,646.0,BAO_0000219,,,CLD0
5937,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619744,646.0,BAO_0000219,,,CLD0
5938,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619745,646.0,BAO_0000219,,,CLD0
5939,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619746,646.0,BAO_0000219,,,CLD0
5940,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619747,646.0,BAO_0000219,,,CLD0
5941,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619748,646.0,BAO_0000219,,,CLD0
5942,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619749,646.0,BAO_0000219,,,CLD0
5943,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619750,646.0,BAO_0000219,,,CLD0
5944,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624014,646.0,BAO_0000219,,,CLD0
5945,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624015,646.0,BAO_0000219,,,CLD0
5946,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885344,646.0,BAO_0000219,,,CLD0
5947,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623224,646.0,BAO_0000219,,,CLD0
5948,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623225,646.0,BAO_0000219,,,CLD0
5949,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622698,646.0,BAO_0000219,,,CLD0
5950,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622699,646.0,BAO_0000219,,,CLD0
5951,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622700,646.0,BAO_0000219,,,CLD0
5952,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622701,646.0,BAO_0000219,,,CLD0
5953,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622702,646.0,BAO_0000219,,,CLD0
5954,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622703,646.0,BAO_0000219,,,CLD0
5955,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622704,646.0,BAO_0000219,,,CLD0
5956,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622705,646.0,BAO_0000219,,,CLD0
5957,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622706,646.0,BAO_0000219,,,CLD0
5958,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622707,646.0,BAO_0000219,,,CLD0
5959,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622708,646.0,BAO_0000219,,,CLD0
5960,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622709,646.0,BAO_0000219,,,CLD0
5961,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622710,646.0,BAO_0000219,,,CLD0
5962,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622711,646.0,BAO_0000219,,,CLD0
5963,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622712,646.0,BAO_0000218,,,CLD0
5964,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622713,646.0,BAO_0000218,,,CLD0
5965,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622714,646.0,BAO_0000218,,,CLD0
5966,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622715,646.0,BAO_0000218,,,CLD0
5967,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622716,646.0,BAO_0000218,,,CLD0
5968,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622717,646.0,BAO_0000219,,,CLD0
5969,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622718,646.0,BAO_0000218,,,CLD0
5970,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622719,646.0,BAO_0000219,,,CLD0
5971,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622720,646.0,BAO_0000219,,,CLD0
5972,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622721,646.0,BAO_0000219,,,CLD0
5973,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622722,646.0,BAO_0000219,,,CLD0
5974,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876030,646.0,BAO_0000219,,,CLD0
5975,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620206,646.0,BAO_0000219,,,CLD0
5976,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620207,646.0,BAO_0000219,,,CLD0
5977,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620208,646.0,BAO_0000219,,,CLD0
5978,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620209,646.0,BAO_0000219,,,CLD0
5979,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620210,646.0,BAO_0000219,,,CLD0
5980,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621639,646.0,BAO_0000219,,,CLD0
5981,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621640,646.0,BAO_0000219,,,CLD0
5982,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621641,646.0,BAO_0000219,,,CLD0
5983,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621642,646.0,BAO_0000219,,,CLD0
5984,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621643,646.0,BAO_0000219,,,CLD0
5985,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621644,646.0,BAO_0000219,,,CLD0
5986,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621645,646.0,BAO_0000219,,,CLD0
5987,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621646,646.0,BAO_0000219,,,CLD0
5988,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621647,646.0,BAO_0000219,,,CLD0
5989,6630,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621648,646.0,BAO_0000219,,,CLD0
5990,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621649,646.0,BAO_0000219,,,CLD0
5991,6630,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621650,646.0,BAO_0000219,,,CLD0
5992,6630,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621651,646.0,BAO_0000219,,,CLD0
5993,6630,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621652,646.0,BAO_0000219,,,CLD0
5994,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621653,646.0,BAO_0000219,,,CLD0
5995,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621654,646.0,BAO_0000219,,,CLD0
5996,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621655,646.0,BAO_0000219,,,CLD0
5997,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621656,,BAO_0000218,,,CLD0
5998,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621657,,BAO_0000218,,,CLD0
5999,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621658,,BAO_0000218,,,CLD0
6000,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621659,,BAO_0000218,,,CLD0
6001,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621660,,BAO_0000218,,,CLD0
6002,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621661,,BAO_0000218,,,CLD0
6003,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621662,,BAO_0000218,,,CLD0
6004,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621663,,BAO_0000218,,,CLD0
6005,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621664,,BAO_0000218,,,CLD0
6006,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621665,,BAO_0000218,1969.0,,CLD0
6007,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621666,,BAO_0000218,1969.0,,CLD0
6008,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621667,,BAO_0000218,,,CLD0
6009,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876738,,BAO_0000218,,,CLD0
6010,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621668,,BAO_0000218,,,CLD0
6011,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621669,,BAO_0000218,,,CLD0
6012,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621670,,BAO_0000218,,,CLD0
6013,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621671,,BAO_0000218,,,CLD0
6014,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622360,,BAO_0000218,,,CLD0
6015,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622361,,BAO_0000218,,,CLD0
6016,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622362,,BAO_0000218,1969.0,,CLD0
6017,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622363,,BAO_0000218,1969.0,,CLD0
6018,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622364,,BAO_0000218,1969.0,,CLD0
6019,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622365,,BAO_0000218,1969.0,,CLD0
6020,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622533,,BAO_0000218,1969.0,,CLD0
6021,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622534,,BAO_0000218,,,CLD0
6022,4527,Maximum concentration by oral administration at a dose of 10 umol/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622535,,BAO_0000218,,,CLD0
6023,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876739,,BAO_0000218,,,CLD0
6024,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622536,,BAO_0000218,,,CLD0
6025,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622537,,BAO_0000218,1969.0,,CLD0
6026,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622538,,BAO_0000218,,,CLD0
6027,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627867,,BAO_0000218,,,CLD0
6028,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627868,,BAO_0000218,,,CLD0
6029,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627869,,BAO_0000218,1969.0,,CLD0
6030,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627870,,BAO_0000218,,,CLD0
6031,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627871,,BAO_0000218,1969.0,,CLD0
6032,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627872,,BAO_0000218,1969.0,,CLD0
6033,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627873,,BAO_0000218,1969.0,,CLD0
6034,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627874,,BAO_0000218,1969.0,,CLD0
6035,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627875,,BAO_0000218,1969.0,,CLD0
6036,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627876,,BAO_0000218,1969.0,,CLD0
6037,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627877,,BAO_0000218,1969.0,,CLD0
6038,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627878,,BAO_0000218,1969.0,,CLD0
6039,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627879,,BAO_0000218,1969.0,,CLD0
6040,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875355,,BAO_0000218,1969.0,,CLD0
6041,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627880,,BAO_0000218,1969.0,,CLD0
6042,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627881,,BAO_0000218,1969.0,,CLD0
6043,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 umol/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627882,,BAO_0000218,1969.0,,CLD0
6044,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627883,,BAO_0000218,1969.0,,CLD0
6045,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628526,,BAO_0000218,1969.0,,CLD0
6046,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628527,,BAO_0000218,1969.0,,CLD0
6047,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628528,,BAO_0000218,1969.0,,CLD0
6048,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628529,,BAO_0000218,1969.0,,CLD0
6049,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628530,,BAO_0000218,1969.0,,CLD0
6050,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625243,,BAO_0000218,1969.0,,CLD0
6051,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL625244,,BAO_0000218,1969.0,,CLD0
6052,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625245,,BAO_0000218,,,CLD0
6053,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625246,,BAO_0000218,,,CLD0
6054,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL625247,,BAO_0000218,945.0,,CLD0
6055,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625248,,BAO_0000218,1088.0,,CLD0
6056,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625249,,BAO_0000218,1088.0,,CLD0
6057,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625250,,BAO_0000218,1088.0,,CLD0
6058,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL625251,,BAO_0000218,1474.0,,CLD0
6059,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875356,,BAO_0000218,,,CLD0
6060,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625252,,BAO_0000218,,,CLD0
6061,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625253,,BAO_0000218,178.0,,CLD0
6062,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL625254,,BAO_0000218,1474.0,,CLD0
6063,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL625255,,BAO_0000218,1474.0,,CLD0
6064,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL625256,,BAO_0000218,1474.0,,CLD0
6065,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625257,,BAO_0000218,178.0,,CLD0
6066,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625258,,BAO_0000218,178.0,,CLD0
6067,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625259,,BAO_0000218,,,CLD0
6068,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625260,,BAO_0000218,,,CLD0
6069,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625261,,BAO_0000218,,,CLD0
6070,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625262,,BAO_0000218,,,CLD0
6071,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622639,,BAO_0000218,,,CLD0
6072,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622640,,BAO_0000218,1969.0,,CLD0
6073,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622812,,BAO_0000218,1969.0,,CLD0
6074,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622813,,BAO_0000218,1969.0,,CLD0
6075,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622814,,BAO_0000218,1969.0,,CLD0
6076,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622815,,BAO_0000218,,,CLD0
6077,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625342,,BAO_0000218,,,CLD0
6078,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625343,,BAO_0000218,,,CLD0
6079,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL877591,,BAO_0000218,1969.0,,CLD0
6080,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL625344,,BAO_0000218,1969.0,,CLD0
6081,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625345,,BAO_0000218,,,CLD0
6082,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625346,,BAO_0000218,,,CLD0
6083,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625347,,BAO_0000218,,,CLD0
6084,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625348,,BAO_0000218,,,CLD0
6085,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625349,,BAO_0000218,,,CLD0
6086,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625350,,BAO_0000218,,,CLD0
6087,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL882952,,BAO_0000218,,,CLD0
6088,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625351,,BAO_0000218,955.0,,CLD0
6089,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625352,,BAO_0000218,955.0,,CLD0
6090,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL877592,,BAO_0000218,955.0,,CLD0
6091,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625353,,BAO_0000218,955.0,,CLD0
6092,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625354,,BAO_0000218,955.0,,CLD0
6093,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626019,,BAO_0000218,955.0,,CLD0
6094,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626020,,BAO_0000218,948.0,,CLD0
6095,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626021,,BAO_0000218,948.0,,CLD0
6096,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626022,,BAO_0000218,948.0,,CLD0
6097,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626192,,BAO_0000218,948.0,,CLD0
6098,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626193,646.0,BAO_0000219,,,CLD0
6099,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL626194,646.0,BAO_0000219,,,CLD0
6100,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626195,646.0,BAO_0000219,,,CLD0
6101,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626196,646.0,BAO_0000219,,,CLD0
6102,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626197,646.0,BAO_0000219,,,CLD0
6103,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626198,646.0,BAO_0000219,,,CLD0
6104,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626199,646.0,BAO_0000219,,,CLD0
6105,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626200,646.0,BAO_0000219,,,CLD0
6106,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626201,646.0,BAO_0000219,,,CLD0
6107,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626202,646.0,BAO_0000219,,,CLD0
6108,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626203,646.0,BAO_0000219,,,CLD0
6109,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626204,646.0,BAO_0000219,,,CLD0
6110,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624701,646.0,BAO_0000219,,,CLD0
6111,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624702,646.0,BAO_0000219,,,CLD0
6112,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624703,646.0,BAO_0000219,,,CLD0
6113,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624704,646.0,BAO_0000219,,,CLD0
6114,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624705,646.0,BAO_0000219,,,CLD0
6115,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624706,646.0,BAO_0000219,,,CLD0
6116,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624707,646.0,BAO_0000219,,,CLD0
6117,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624708,646.0,BAO_0000219,,,CLD0
6118,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624709,646.0,BAO_0000219,,,CLD0
6119,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884107,646.0,BAO_0000219,,,CLD0
6120,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624710,646.0,BAO_0000219,,,CLD0
6121,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624711,646.0,BAO_0000219,,,CLD0
6122,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624712,646.0,BAO_0000219,,,CLD0
6123,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624713,646.0,BAO_0000219,,,CLD0
6124,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624714,646.0,BAO_0000219,,,CLD0
6125,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624715,646.0,BAO_0000219,,,CLD0
6126,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624716,646.0,BAO_0000219,,,CLD0
6127,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619505,646.0,BAO_0000219,,,CLD0
6128,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619506,646.0,BAO_0000219,,,CLD0
6129,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619507,646.0,BAO_0000219,,,CLD0
6130,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619508,646.0,BAO_0000219,,,CLD0
6131,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619509,646.0,BAO_0000219,,,CLD0
6132,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619510,646.0,BAO_0000219,,,CLD0
6133,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619511,646.0,BAO_0000219,,,CLD0
6134,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619512,646.0,BAO_0000219,,,CLD0
6135,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619513,646.0,BAO_0000219,,,CLD0
6136,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619514,646.0,BAO_0000219,,,CLD0
6137,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619515,646.0,BAO_0000219,,,CLD0
6138,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619516,646.0,BAO_0000219,,,CLD0
6139,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884005,646.0,BAO_0000219,,,CLD0
6140,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619517,646.0,BAO_0000219,,,CLD0
6141,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619518,646.0,BAO_0000219,,,CLD0
6142,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619519,646.0,BAO_0000219,,,CLD0
6143,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876489,646.0,BAO_0000219,,,CLD0
6144,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619520,646.0,BAO_0000219,,,CLD0
6145,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619521,646.0,BAO_0000219,,,CLD0
6146,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619522,646.0,BAO_0000219,,,CLD0
6147,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619523,646.0,BAO_0000219,,,CLD0
6148,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619524,646.0,BAO_0000219,,,CLD0
6149,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619525,646.0,BAO_0000219,,,CLD0
6150,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619526,646.0,BAO_0000219,,,CLD0
6151,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619527,646.0,BAO_0000219,,,CLD0
6152,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619528,646.0,BAO_0000219,,,CLD0
6153,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619529,646.0,BAO_0000219,,,CLD0
6154,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619530,646.0,BAO_0000219,,,CLD0
6155,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876490,646.0,BAO_0000219,,,CLD0
6156,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619531,646.0,BAO_0000219,,,CLD0
6157,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619532,646.0,BAO_0000219,,,CLD0
6158,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619533,646.0,BAO_0000219,,,CLD0
6159,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619534,646.0,BAO_0000219,,,CLD0
6160,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620164,646.0,BAO_0000219,,,CLD0
6161,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620165,646.0,BAO_0000219,,,CLD0
6162,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620166,646.0,BAO_0000219,,,CLD0
6163,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620167,646.0,BAO_0000219,,,CLD0
6164,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620168,646.0,BAO_0000219,,,CLD0
6165,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620338,646.0,BAO_0000219,,,CLD0
6166,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620339,646.0,BAO_0000219,,,CLD0
6167,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620340,646.0,BAO_0000219,,,CLD0
6168,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620341,646.0,BAO_0000219,,,CLD0
6169,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876491,646.0,BAO_0000219,,,CLD0
6170,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620342,646.0,BAO_0000219,,,CLD0
6171,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620343,646.0,BAO_0000219,,,CLD0
6172,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620344,646.0,BAO_0000219,,,CLD0
6173,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620345,646.0,BAO_0000219,,,CLD0
6174,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620346,646.0,BAO_0000219,,,CLD0
6175,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620347,646.0,BAO_0000219,,,CLD0
6176,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620348,646.0,BAO_0000219,,,CLD0
6177,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620349,646.0,BAO_0000219,,,CLD0
6178,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618667,646.0,BAO_0000219,,,CLD0
6179,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL618668,646.0,BAO_0000219,,,CLD0
6180,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876031,646.0,BAO_0000219,,,CLD0
6181,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618759,646.0,BAO_0000219,,,CLD0
6182,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618760,646.0,BAO_0000219,,,CLD0
6183,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619000,646.0,BAO_0000219,,,CLD0
6184,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619001,646.0,BAO_0000219,,,CLD0
6185,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619002,646.0,BAO_0000219,,,CLD0
6186,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619003,646.0,BAO_0000219,,,CLD0
6187,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619597,646.0,BAO_0000219,,,CLD0
6188,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619598,646.0,BAO_0000219,,,CLD0
6189,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619599,646.0,BAO_0000219,,,CLD0
6190,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619600,646.0,BAO_0000219,,,CLD0
6191,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619601,646.0,BAO_0000219,,,CLD0
6192,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619602,646.0,BAO_0000219,,,CLD0
6193,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619603,646.0,BAO_0000219,,,CLD0
6194,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619604,646.0,BAO_0000219,,,CLD0
6195,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619605,646.0,BAO_0000219,,,CLD0
6196,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619606,,BAO_0000218,,,CLD0
6197,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876032,,BAO_0000218,,,CLD0
6198,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (umol/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619607,,BAO_0000218,,,CLD0
6199,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619608,,BAO_0000218,,,CLD0
6200,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619609,,BAO_0000218,1969.0,,CLD0
6201,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619610,,BAO_0000218,1969.0,,CLD0
6202,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619611,,BAO_0000218,178.0,,CLD0
6203,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619612,,BAO_0000218,,,CLD0
6204,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619613,,BAO_0000218,,,CLD0
6205,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619614,,BAO_0000218,178.0,,CLD0
6206,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619615,,BAO_0000218,1969.0,,CLD0
6207,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619616,,BAO_0000218,1969.0,,CLD0
6208,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619617,,BAO_0000218,1969.0,,CLD0
6209,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619618,,BAO_0000218,1969.0,,CLD0
6210,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL876033,,BAO_0000218,1969.0,,CLD0
6211,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619619,,BAO_0000218,1969.0,,CLD0
6212,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,Urine/Feces,,,50588,N,1,Intermediate,1,,CHEMBL619620,,BAO_0000218,10000012.0,,CLD0
6213,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619621,,BAO_0000218,1088.0,,CLD0
6214,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619622,,BAO_0000218,1088.0,,CLD0
6215,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL618874,,BAO_0000218,1088.0,,CLD0
6216,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618875,,BAO_0000218,,,CLD0
6217,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618876,,BAO_0000218,,,CLD0
6218,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618877,,BAO_0000218,,,CLD0
6219,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618878,,BAO_0000218,,,CLD0
6220,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618879,,BAO_0000218,,,CLD0
6221,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618880,,BAO_0000218,,,CLD0
6222,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618881,,BAO_0000218,,,CLD0
6223,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618882,,BAO_0000218,,,CLD0
6224,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624226,,BAO_0000218,,,CLD0
6225,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624227,,BAO_0000218,1969.0,,CLD0
6226,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624228,,BAO_0000218,,,CLD0
6227,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624229,,BAO_0000218,,,CLD0
6228,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624230,,BAO_0000218,,,CLD0
6229,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624231,,BAO_0000218,,,CLD0
6230,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624232,,BAO_0000218,,,CLD0
6231,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625127,,BAO_0000218,,,CLD0
6232,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625128,,BAO_0000218,,,CLD0
6233,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621675,,BAO_0000218,,,CLD0
6234,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621676,,BAO_0000218,,,CLD0
6235,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621677,,BAO_0000218,,,CLD0
6236,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621678,,BAO_0000218,,,CLD0
6237,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621679,,BAO_0000218,,,CLD0
6238,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621680,,BAO_0000218,,,CLD0
6239,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621681,,BAO_0000218,,,CLD0
6240,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876740,,BAO_0000218,,,CLD0
6241,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621682,,BAO_0000218,,,CLD0
6242,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621683,,BAO_0000218,,,CLD0
6243,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621684,,BAO_0000218,,,CLD0
6244,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621685,,BAO_0000218,,,CLD0
6245,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621686,,BAO_0000218,,,CLD0
6246,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621687,,BAO_0000218,,,CLD0
6247,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621688,,BAO_0000218,,,CLD0
6248,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621689,,BAO_0000218,,,CLD0
6249,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621690,,BAO_0000218,,,CLD0
6250,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621691,,BAO_0000218,,,CLD0
6251,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875941,,BAO_0000218,,,CLD0
6252,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621692,,BAO_0000218,,,CLD0
6253,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621693,,BAO_0000218,,,CLD0
6254,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621694,,BAO_0000218,,,CLD0
6255,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621695,,BAO_0000218,948.0,,CLD0
6256,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621696,,BAO_0000218,948.0,,CLD0
6257,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621697,,BAO_0000218,2113.0,,CLD0
6258,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621698,,BAO_0000218,2113.0,,CLD0
6259,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623420,,BAO_0000218,2113.0,,CLD0
6260,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623421,,BAO_0000218,2113.0,,CLD0
6261,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623422,,BAO_0000218,2113.0,,CLD0
6262,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623423,,BAO_0000218,2113.0,,CLD0
6263,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623424,,BAO_0000218,2107.0,,CLD0
6264,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623425,,BAO_0000218,2107.0,,CLD0
6265,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623426,,BAO_0000218,2107.0,,CLD0
6266,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623427,,BAO_0000218,2107.0,,CLD0
6267,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623428,,BAO_0000218,2107.0,,CLD0
6268,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL875947,,BAO_0000218,2107.0,,CLD0
6269,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623429,,BAO_0000218,2048.0,,CLD0
6270,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623430,,BAO_0000218,2048.0,,CLD0
6271,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622588,,BAO_0000218,2048.0,,CLD0
6272,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622589,,BAO_0000218,2048.0,,CLD0
6273,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622751,,BAO_0000218,2048.0,,CLD0
6274,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622752,,BAO_0000218,2048.0,,CLD0
6275,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622753,42.0,BAO_0000218,178.0,,CLD0
6276,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622647,42.0,BAO_0000218,178.0,,CLD0
6277,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875163,42.0,BAO_0000218,178.0,,CLD0
6278,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622648,42.0,BAO_0000218,178.0,,CLD0
6279,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622649,42.0,BAO_0000218,178.0,,CLD0
6280,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622650,42.0,BAO_0000218,955.0,,CLD0
6281,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622651,42.0,BAO_0000218,955.0,,CLD0
6282,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622652,42.0,BAO_0000218,955.0,,CLD0
6283,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622653,42.0,BAO_0000218,955.0,,CLD0
6284,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622654,42.0,BAO_0000218,955.0,,CLD0
6285,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622655,42.0,BAO_0000218,948.0,,CLD0
6286,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622656,42.0,BAO_0000218,948.0,,CLD0
6287,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622657,42.0,BAO_0000218,948.0,,CLD0
6288,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622658,42.0,BAO_0000218,948.0,,CLD0
6289,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622659,42.0,BAO_0000218,948.0,,CLD0
6290,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,,CLD0
6291,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,,CLD0
6292,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,,CLD0
6293,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624633,646.0,BAO_0000219,,,CLD0
6294,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624634,646.0,BAO_0000219,,,CLD0
6295,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624635,646.0,BAO_0000219,,,CLD0
6296,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624636,646.0,BAO_0000219,,,CLD0
6297,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL857055,646.0,BAO_0000219,,,CLD0
6298,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624637,646.0,BAO_0000219,,,CLD0
6299,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624638,646.0,BAO_0000219,,,CLD0
6300,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL874366,646.0,BAO_0000219,,,CLD0
6301,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624639,646.0,BAO_0000219,,,CLD0
6302,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624640,646.0,BAO_0000219,,,CLD0
6303,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624641,646.0,BAO_0000219,,,CLD0
6304,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624642,646.0,BAO_0000219,,,CLD0
6305,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624643,646.0,BAO_0000219,,,CLD0
6306,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624644,646.0,BAO_0000219,,,CLD0
6307,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624645,646.0,BAO_0000219,,,CLD0
6308,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619445,646.0,BAO_0000219,,,CLD0
6309,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839886,646.0,BAO_0000219,,,CLD0
6310,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619446,646.0,BAO_0000219,,,CLD0
6311,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619447,646.0,BAO_0000219,,,CLD0
6312,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619448,646.0,BAO_0000219,,,CLD0
6313,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619449,646.0,BAO_0000219,,,CLD0
6314,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619450,646.0,BAO_0000219,,,CLD0
6315,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619451,646.0,BAO_0000219,,,CLD0
6316,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619452,646.0,BAO_0000219,,,CLD0
6317,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619453,646.0,BAO_0000219,,,CLD0
6318,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL874367,646.0,BAO_0000219,,,CLD0
6319,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619454,646.0,BAO_0000219,,,CLD0
6320,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619455,646.0,BAO_0000219,,,CLD0
6321,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619456,646.0,BAO_0000219,,,CLD0
6322,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191,N,1,Expert,1,,CHEMBL619457,,BAO_0000218,,,CLD0
6323,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL619458,,BAO_0000218,,,CLD0
6324,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619459,,BAO_0000218,,,CLD0
6325,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619460,,BAO_0000218,,,CLD0
6326,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619461,,BAO_0000218,,,CLD0
6327,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619462,,BAO_0000218,,,CLD0
6328,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620388,,BAO_0000218,,,CLD0
6329,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620389,,BAO_0000218,,,CLD0
6330,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620390,,BAO_0000218,,,CLD0
6331,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL620391,,BAO_0000218,,,CLD0
6332,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL621073,,BAO_0000218,,,CLD0
6333,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL621074,,BAO_0000218,,,CLD0
6334,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL621075,,BAO_0000218,,,CLD0
6335,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619554,,BAO_0000218,,,CLD0
6336,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619555,,BAO_0000218,,,CLD0
6337,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619556,,BAO_0000218,,,CLD0
6338,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619557,,BAO_0000218,,,CLD0
6339,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619558,,BAO_0000218,,,CLD0
6340,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619559,646.0,BAO_0000219,,,CLD0
6341,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619560,646.0,BAO_0000219,,,CLD0
6342,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619561,646.0,BAO_0000219,,,CLD0
6343,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619562,646.0,BAO_0000219,,,CLD0
6344,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619563,646.0,BAO_0000219,,,CLD0
6345,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL857457,646.0,BAO_0000219,,,CLD0
6346,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619564,646.0,BAO_0000219,,,CLD0
6347,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619565,646.0,BAO_0000219,,,CLD0
6348,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619566,646.0,BAO_0000218,,,CLD0
6349,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619567,646.0,BAO_0000218,,,CLD0
6350,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619568,646.0,BAO_0000219,,,CLD0
6351,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619569,646.0,BAO_0000219,,,CLD0
6352,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619570,646.0,BAO_0000219,,,CLD0
6353,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619571,646.0,BAO_0000218,,,CLD0
6354,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619572,646.0,BAO_0000219,,,CLD0
6355,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619573,646.0,BAO_0000219,,,CLD0
6356,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619574,646.0,BAO_0000219,,,CLD0
6357,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619575,646.0,BAO_0000219,,,CLD0
6358,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619576,646.0,BAO_0000219,,,CLD0
6359,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619577,646.0,BAO_0000219,,,CLD0
6360,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619578,646.0,BAO_0000219,,,CLD0
6361,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884009,646.0,BAO_0000219,,,CLD0
6362,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,Lung,A549,,80682,N,1,Intermediate,1,,CHEMBL619579,646.0,BAO_0000219,2048.0,,CLD0
6363,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619580,646.0,BAO_0000219,,,CLD0
6364,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619581,646.0,BAO_0000219,,,CLD0
6365,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619582,646.0,BAO_0000219,,,CLD0
6366,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619583,646.0,BAO_0000219,,,CLD0
6367,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876502,646.0,BAO_0000219,,,CLD0
6368,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619584,646.0,BAO_0000219,,,CLD0
6369,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619585,646.0,BAO_0000219,,,CLD0
6370,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619586,646.0,BAO_0000219,,,CLD0
6371,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619587,646.0,BAO_0000219,,,CLD0
6372,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619588,646.0,BAO_0000219,,,CLD0
6373,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619589,646.0,BAO_0000219,,,CLD0
6374,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619590,646.0,BAO_0000219,,,CLD0
6375,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619591,646.0,BAO_0000219,,,CLD0
6376,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619592,646.0,BAO_0000219,,,CLD0
6377,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619593,646.0,BAO_0000219,,,CLD0
6378,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620217,646.0,BAO_0000219,,,CLD0
6379,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620218,646.0,BAO_0000219,,,CLD0
6380,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620219,646.0,BAO_0000219,,,CLD0
6381,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620220,646.0,BAO_0000219,,,CLD0
6382,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625141,646.0,BAO_0000219,,,CLD0
6383,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL625142,646.0,BAO_0000219,,,CLD0
6384,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625143,646.0,BAO_0000219,,,CLD0
6385,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625144,646.0,BAO_0000219,,,CLD0
6386,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622474,646.0,BAO_0000219,,,CLD0
6387,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884104,646.0,BAO_0000219,,,CLD0
6388,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22221,N,1,Autocuration,1,,CHEMBL622475,,BAO_0000219,,,CLD0
6389,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Intermediate,1,,CHEMBL622476,,BAO_0000218,,,CLD0
6390,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875831,,BAO_0000218,,,CLD0
6391,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622477,,BAO_0000218,,,CLD0
6392,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622478,,BAO_0000218,,,CLD0
6393,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623172,,BAO_0000218,,,CLD0
6394,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623173,,BAO_0000218,,,CLD0
6395,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623174,,BAO_0000218,,,CLD0
6396,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623175,,BAO_0000218,,,CLD0
6397,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623340,,BAO_0000218,,,CLD0
6398,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623341,,BAO_0000218,,,CLD0
6399,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623342,,BAO_0000218,,,CLD0
6400,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623343,,BAO_0000218,,,CLD0
6401,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623344,,BAO_0000218,,,CLD0
6402,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623345,,BAO_0000218,,,CLD0
6403,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875832,,BAO_0000218,,,CLD0
6404,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623346,,BAO_0000218,,,CLD0
6405,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623347,,BAO_0000218,,,CLD0
6406,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623348,,BAO_0000218,,,CLD0
6407,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623349,,BAO_0000218,,,CLD0
6408,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623350,,BAO_0000218,,,CLD0
6409,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623351,,BAO_0000218,,,CLD0
6410,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623352,,BAO_0000218,,,CLD0
6411,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623353,,BAO_0000218,,,CLD0
6412,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875833,,BAO_0000218,,,CLD0
6413,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623354,,BAO_0000218,,,CLD0
6414,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623355,,BAO_0000218,,,CLD0
6415,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623356,,BAO_0000218,,,CLD0
6416,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623357,,BAO_0000218,,,CLD0
6417,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623358,,BAO_0000218,,,CLD0
6418,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623359,,BAO_0000218,,,CLD0
6419,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623360,,BAO_0000218,,,CLD0
6420,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623361,,BAO_0000218,,,CLD0
6421,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623362,,BAO_0000218,,,CLD0
6422,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623363,,BAO_0000218,,,CLD0
6423,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623364,,BAO_0000218,,,CLD0
6424,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875834,,BAO_0000218,,,CLD0
6425,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623365,,BAO_0000218,,,CLD0
6426,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623366,,BAO_0000218,,,CLD0
6427,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623367,,BAO_0000218,,,CLD0
6428,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623368,,BAO_0000218,,,CLD0
6429,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623369,,BAO_0000218,,,CLD0
6430,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623370,,BAO_0000218,,,CLD0
6431,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623371,,BAO_0000218,,,CLD0
6432,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623372,,BAO_0000218,,,CLD0
6433,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621351,,BAO_0000218,,,CLD0
6434,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621352,,BAO_0000218,,,CLD0
6435,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621353,,BAO_0000218,,,CLD0
6436,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621354,,BAO_0000218,,,CLD0
6437,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621355,,BAO_0000218,,,CLD0
6438,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621356,,BAO_0000218,,,CLD0
6439,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621357,,BAO_0000218,,,CLD0
6440,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621358,,BAO_0000218,,,CLD0
6441,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621359,,BAO_0000218,,,CLD0
6442,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621360,,BAO_0000218,,,CLD0
6443,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621361,,BAO_0000218,,,CLD0
6444,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621362,,BAO_0000218,,,CLD0
6445,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621363,,BAO_0000218,,,CLD0
6446,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621364,,BAO_0000218,,,CLD0
6447,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621166,,BAO_0000218,,,CLD0
6448,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621167,,BAO_0000218,,,CLD0
6449,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621168,,BAO_0000218,,,CLD0
6450,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621169,,BAO_0000218,,,CLD0
6451,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875950,,BAO_0000218,,,CLD0
6452,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621170,,BAO_0000218,,,CLD0
6453,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621171,,BAO_0000218,,,CLD0
6454,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621172,,BAO_0000218,,,CLD0
6455,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621173,,BAO_0000218,,,CLD0
6456,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,,CLD0
6457,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,,CLD0
6458,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,,CLD0
6459,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,,CLD0
6460,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,,CLD0
6461,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,,CLD0
6462,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,,CLD0
6463,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,,CLD0
6464,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,,CLD0
6465,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,,CLD0
6466,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,,CLD0
6467,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,,CLD0
6468,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621185,42.0,BAO_0000218,,,CLD0
6469,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621186,42.0,BAO_0000218,,,CLD0
6470,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621187,42.0,BAO_0000218,,,CLD0
6471,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621188,42.0,BAO_0000218,,,CLD0
6472,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621189,42.0,BAO_0000218,,,CLD0
6473,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,,CLD0
6474,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,,CLD0
6475,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,,CLD0
6476,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,,CLD0
6477,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,,CLD0
6478,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621742,42.0,BAO_0000218,,,CLD0
6479,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621743,42.0,BAO_0000218,,,CLD0
6480,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621744,42.0,BAO_0000218,,,CLD0
6481,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621745,42.0,BAO_0000218,,,CLD0
6482,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621746,42.0,BAO_0000218,,,CLD0
6483,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Tumor/Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621747,42.0,BAO_0000218,10000130.0,,CLD0
6484,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Tumor/Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621748,42.0,BAO_0000218,10000130.0,,CLD0
6485,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Tumor/Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621749,42.0,BAO_0000218,10000130.0,,CLD0
6486,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Tumor/Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621750,42.0,BAO_0000218,10000130.0,,CLD0
6487,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Tumor/Blood,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621751,42.0,BAO_0000218,10000130.0,,CLD0
6488,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621752,42.0,BAO_0000218,948.0,,CLD0
6489,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621753,42.0,BAO_0000218,948.0,,CLD0
6490,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875955,42.0,BAO_0000218,948.0,,CLD0
6491,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621754,42.0,BAO_0000218,948.0,,CLD0
6492,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621755,42.0,BAO_0000218,948.0,,CLD0
6493,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,,CLD0
6494,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,,CLD0
6495,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,,CLD0
6496,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,,CLD0
6497,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,,CLD0
6498,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,,CLD0
6499,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,,CLD0
6500,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL857901,,BAO_0000218,,,CLD0
6501,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL875274,,BAO_0000218,,,CLD0
6502,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624379,,BAO_0000218,,,CLD0
6503,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624380,,BAO_0000218,,,CLD0
6504,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL624381,,BAO_0000218,,,CLD0
6505,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624382,,BAO_0000218,,,CLD0
6506,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624383,,BAO_0000218,,,CLD0
6507,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624384,,BAO_0000218,,,CLD0
6508,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624385,,BAO_0000218,,,CLD0
6509,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624386,,BAO_0000218,,,CLD0
6510,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624387,,BAO_0000218,,,CLD0
6511,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624388,,BAO_0000218,,,CLD0
6512,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624389,,BAO_0000218,,,CLD0
6513,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624390,,BAO_0000218,,,CLD0
6514,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL875275,,BAO_0000218,,,CLD0
6515,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL624391,,BAO_0000218,,,CLD0
6516,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL623636,,BAO_0000218,,,CLD0
6517,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623637,,BAO_0000218,,,CLD0
6518,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623638,,BAO_0000218,,,CLD0
6519,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623639,,BAO_0000218,,,CLD0
6520,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623640,,BAO_0000218,,,CLD0
6521,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623641,,BAO_0000218,,,CLD0
6522,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623642,,BAO_0000218,,,CLD0
6523,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623643,,BAO_0000218,,,CLD0
6524,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623644,,BAO_0000218,,,CLD0
6525,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623645,,BAO_0000218,,,CLD0
6526,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623646,,BAO_0000218,,,CLD0
6527,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623647,,BAO_0000218,,,CLD0
6528,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,Mitochondria,50532,N,1,Intermediate,1,,CHEMBL623648,,BAO_0000218,,,CLD0
6529,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623649,,BAO_0000218,,,CLD0
6530,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623650,,BAO_0000218,,,CLD0
6531,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623651,,BAO_0000218,,,CLD0
6532,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623652,,BAO_0000218,,,CLD0
6533,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623653,,BAO_0000218,,,CLD0
6534,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623654,,BAO_0000218,,,CLD0
6535,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623655,,BAO_0000218,,,CLD0
6536,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623656,,BAO_0000218,,,CLD0
6537,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623657,,BAO_0000218,,,CLD0
6538,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623658,,BAO_0000218,,,CLD0
6539,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623659,,BAO_0000218,,,CLD0
6540,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623660,,BAO_0000218,,,CLD0
6541,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623661,,BAO_0000218,,,CLD0
6542,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL875281,,BAO_0000218,,,CLD0
6543,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623662,,BAO_0000218,,,CLD0
6544,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623663,,BAO_0000218,,,CLD0
6545,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623664,,BAO_0000218,,,CLD0
6546,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623665,,BAO_0000218,,,CLD0
6547,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673Mer+,,80023,N,1,Intermediate,1,,CHEMBL621856,,BAO_0000219,,,CLD0
6548,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704Rem,,80661,N,1,Intermediate,1,,CHEMBL620432,,BAO_0000219,,,CLD0
6549,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620433,,BAO_0000219,,,CLD0
6550,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9L,,80024,N,1,Intermediate,1,,CHEMBL620434,,BAO_0000219,,,CLD0
6551,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9L,,80024,N,1,Intermediate,1,,CHEMBL620435,,BAO_0000219,,,CLD0
6552,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9-PTX10,,80024,N,1,Intermediate,1,,CHEMBL620436,,BAO_0000219,,,CLD0
6553,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9-PTX10,,80024,N,1,Intermediate,1,,CHEMBL876597,,BAO_0000219,,,CLD0
6554,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Ovarian cancer cell line,,81035,N,1,Expert,1,,CHEMBL620437,872.0,BAO_0000219,,,CLD0
6555,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9L-m1,,80024,N,1,Expert,1,,CHEMBL620438,,BAO_0000219,,,CLD0
6556,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9L-m1,,80024,N,1,Expert,1,,CHEMBL620439,,BAO_0000219,,,CLD0
6557,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9L-m1,,80024,N,1,Expert,1,,CHEMBL619657,,BAO_0000219,,,CLD0
6558,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9L-m1,,80024,N,1,Intermediate,1,,CHEMBL619658,,BAO_0000219,,,CLD0
6559,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9L-m1,,80024,N,1,Intermediate,1,,CHEMBL619659,,BAO_0000219,,,CLD0
6560,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649,H,8,Expert,1,,CHEMBL619660,,BAO_0000019,,,CLD0
6561,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9L-m3,,80024,N,1,Intermediate,1,,CHEMBL619661,,BAO_0000219,,,CLD0
6562,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9L-m3,,80024,N,1,Intermediate,1,,CHEMBL619662,,BAO_0000219,,,CLD0
6563,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663,N,1,Intermediate,1,,CHEMBL619663,975.0,BAO_0000219,,,CLD0
6564,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619664,,BAO_0000219,,,CLD0
6565,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619665,,BAO_0000219,,,CLD0
6566,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,,,80662,N,1,Intermediate,1,,CHEMBL883244,,BAO_0000219,,,CLD0
6567,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,,,80662,N,1,Intermediate,1,,CHEMBL884011,,BAO_0000219,,,CLD0
6568,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL619666,974.0,BAO_0000219,,,CLD0
6569,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566,N,1,Intermediate,1,,CHEMBL619667,379.0,BAO_0000219,,,CLD0
6570,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578,N,1,Intermediate,1,,CHEMBL619668,274.0,BAO_0000219,,,CLD0
6571,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619669,185.0,BAO_0000219,,,CLD0
6572,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL876608,185.0,BAO_0000219,,,CLD0
6573,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619670,185.0,BAO_0000219,,,CLD0
6574,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619671,185.0,BAO_0000219,,,CLD0
6575,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619672,185.0,BAO_0000219,,,CLD0
6576,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619673,185.0,BAO_0000219,,,CLD0
6577,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619674,185.0,BAO_0000219,,,CLD0
6578,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619675,185.0,BAO_0000219,,,CLD0
6579,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619676,185.0,BAO_0000219,,,CLD0
6580,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619677,185.0,BAO_0000219,,,CLD0
6581,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619678,185.0,BAO_0000219,,,CLD0
6582,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619679,185.0,BAO_0000219,,,CLD0
6583,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619680,185.0,BAO_0000219,,,CLD0
6584,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621457,185.0,BAO_0000219,,,CLD0
6585,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL876609,185.0,BAO_0000219,,,CLD0
6586,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621458,185.0,BAO_0000219,,,CLD0
6587,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hamster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621459,185.0,BAO_0000219,,,CLD0
6588,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621460,185.0,BAO_0000219,,,CLD0
6589,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621461,185.0,BAO_0000219,,,CLD0
6590,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621462,185.0,BAO_0000219,,,CLD0
6591,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621463,,BAO_0000218,,,CLD0
6592,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621464,,BAO_0000218,,,CLD0
6593,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621465,,BAO_0000218,,,CLD0
6594,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621466,,BAO_0000218,,,CLD0
6595,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621467,,BAO_0000218,,,CLD0
6596,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621468,,BAO_0000218,,,CLD0
6597,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876734,,BAO_0000218,,,CLD0
6598,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618476,,BAO_0000218,,,CLD0
6599,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618477,,BAO_0000218,,,CLD0
6600,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618478,,BAO_0000218,,,CLD0
6601,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618479,,BAO_0000218,,,CLD0
6602,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618480,,BAO_0000218,,,CLD0
6603,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618481,,BAO_0000218,,,CLD0
6604,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618482,,BAO_0000218,1969.0,,CLD0
6605,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618483,,BAO_0000218,,,CLD0
6606,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618484,,BAO_0000218,,,CLD0
6607,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618485,,BAO_0000218,,,CLD0
6608,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618486,,BAO_0000218,,,CLD0
6609,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618487,,BAO_0000218,1969.0,,CLD0
6610,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618488,,BAO_0000218,1969.0,,CLD0
6611,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL876735,,BAO_0000218,1969.0,,CLD0
6612,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618489,,BAO_0000218,,,CLD0
6613,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618490,,BAO_0000218,,,CLD0
6614,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618491,,BAO_0000218,,,CLD0
6615,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618492,,BAO_0000218,,,CLD0
6616,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873354,,BAO_0000218,,,CLD0
6617,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618493,,BAO_0000218,,,CLD0
6618,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Bile,,,50588,N,1,Intermediate,1,,CHEMBL618494,,BAO_0000218,1970.0,,CLD0
6619,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588,N,1,Intermediate,1,,CHEMBL618495,,BAO_0000218,948.0,,CLD0
6620,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588,N,1,Intermediate,1,,CHEMBL618496,,BAO_0000218,2113.0,,CLD0
6621,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618497,,BAO_0000218,2107.0,,CLD0
6622,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL618498,,BAO_0000218,2048.0,,CLD0
6623,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL618499,,BAO_0000218,2106.0,,CLD0
6624,3639,Partition coefficient ( LogP) of the compound,P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL876736,,BAO_0000100,,,CLD0
6625,6227,Partition coefficient (logP) of the compound,P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL618500,,BAO_0000100,,,CLD0
6626,6227,Partition coefficient (logP) of the compound,P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL857831,,BAO_0000100,,,CLD0
6627,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618501,,BAO_0000218,,,CLD0
6628,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618502,,BAO_0000218,,,CLD0
6629,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL618503,,BAO_0000218,2107.0,,CLD0
6630,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,S9 Microsomes,50588,N,1,Intermediate,1,,CHEMBL618504,,BAO_0000218,,,CLD0
6631,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,S9 Microsomes,50588,N,1,Intermediate,1,,CHEMBL618505,,BAO_0000218,,,CLD0
6632,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,S9 Microsomes,50588,N,1,Intermediate,1,,CHEMBL618506,,BAO_0000218,,,CLD0
6633,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL618507,,BAO_0000218,2107.0,,CLD0
6634,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876737,,BAO_0000218,,,CLD0
6635,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618508,,BAO_0000218,,,CLD0
6636,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618509,,BAO_0000218,,,CLD0
6637,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618510,,BAO_0000218,,,CLD0
6638,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618511,,BAO_0000218,,,CLD0
6639,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618512,,BAO_0000218,,,CLD0
6640,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618513,,BAO_0000218,,,CLD0
6641,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618514,,BAO_0000218,,,CLD0
6642,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620052,,BAO_0000218,,,CLD0
6643,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620053,,BAO_0000218,1969.0,,CLD0
6644,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620054,,BAO_0000218,1969.0,,CLD0
6645,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620055,,BAO_0000218,1969.0,,CLD0
6646,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620056,,BAO_0000218,1969.0,,CLD0
6647,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL620057,,BAO_0000218,2107.0,,CLD0
6648,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618939,,BAO_0000218,,,CLD0
6649,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618940,,BAO_0000218,,,CLD0
6650,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618941,,BAO_0000218,,,CLD0
6651,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,,CLD0
6652,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,,CLD0
6653,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,,CLD0
6654,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Tumor/Muscle,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624476,42.0,BAO_0000218,10000137.0,,CLD0
6655,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Tumor/Muscle,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623478,42.0,BAO_0000218,10000137.0,,CLD0
6656,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Tumor/Muscle,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623479,42.0,BAO_0000218,10000137.0,,CLD0
6657,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Tumor/Muscle,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623480,42.0,BAO_0000218,10000137.0,,CLD0
6658,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Tumor/Muscle,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623481,42.0,BAO_0000218,10000137.0,,CLD0
6659,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623482,,BAO_0000218,955.0,,CLD0
6660,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623483,,BAO_0000218,2113.0,,CLD0
6661,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623484,,BAO_0000218,2107.0,,CLD0
6662,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623485,,BAO_0000218,2048.0,,CLD0
6663,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623486,,BAO_0000218,2106.0,,CLD0
6664,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623487,,BAO_0000218,1969.0,,CLD0
6665,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623488,,BAO_0000218,,,CLD0
6666,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623489,,BAO_0000218,178.0,,CLD0
6667,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875157,,BAO_0000218,,,CLD0
6668,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623490,,BAO_0000218,,,CLD0
6669,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623491,,BAO_0000218,1969.0,,CLD0
6670,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623492,,BAO_0000218,1969.0,,CLD0
6671,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623493,,BAO_0000218,1969.0,,CLD0
6672,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623494,,BAO_0000218,1969.0,,CLD0
6673,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623495,,BAO_0000218,1969.0,,CLD0
6674,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623496,,BAO_0000218,1969.0,,CLD0
6675,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623497,,BAO_0000218,1969.0,,CLD0
6676,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623498,,BAO_0000218,1969.0,,CLD0
6677,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623499,,BAO_0000218,,,CLD0
6678,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623500,,BAO_0000218,,,CLD0
6679,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623501,,BAO_0000218,1969.0,,CLD0
6680,17384,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL875158,,BAO_0000100,,,CLD0
6681,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623502,,BAO_0000218,1969.0,,CLD0
6682,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623503,,BAO_0000218,1969.0,,CLD0
6683,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623504,,BAO_0000218,1969.0,,CLD0
6684,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623505,,BAO_0000218,,,CLD0
6685,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623506,,BAO_0000218,,,CLD0
6686,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623507,,BAO_0000218,,,CLD0
6687,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623508,,BAO_0000218,,,CLD0
6688,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623509,,BAO_0000218,,,CLD0
6689,17764,Cmax after peroral administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875159,,BAO_0000218,,,CLD0
6690,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623510,,BAO_0000218,955.0,,CLD0
6691,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623511,,BAO_0000218,2113.0,,CLD0
6692,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623512,,BAO_0000218,2107.0,,CLD0
6693,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623513,,BAO_0000218,2048.0,,CLD0
6694,17764,Cmax in mice at 18 umol/kg i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623514,,BAO_0000218,,,CLD0
6695,17764,Cmax in mice at 23 umol/kg i.v. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622609,,BAO_0000218,,,CLD0
6696,17764,Cmax in mice at 24 umol/kg i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622610,,BAO_0000218,,,CLD0
6697,17764,Cmax in mice at 25 umol/kg i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621823,,BAO_0000218,,,CLD0
6698,17764,Cmax in mice at 26 umol/kg i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621824,,BAO_0000218,,,CLD0
6699,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621825,,BAO_0000218,2106.0,,CLD0
6700,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621826,,BAO_0000218,,,CLD0
6701,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621827,,BAO_0000218,,,CLD0
6702,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621828,,BAO_0000218,,,CLD0
6703,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621829,,BAO_0000218,,,CLD0
6704,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621830,,BAO_0000218,,,CLD0
6705,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621831,,BAO_0000218,,,CLD0
6706,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621832,,BAO_0000218,1969.0,,CLD0
6707,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624579,,BAO_0000218,1969.0,,CLD0
6708,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624580,,BAO_0000218,,,CLD0
6709,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624581,,BAO_0000218,,,CLD0
6710,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624582,,BAO_0000218,,,CLD0
6711,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624583,,BAO_0000218,,,CLD0
6712,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624584,455.0,BAO_0000219,,,CLD0
6713,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512,D,9,Expert,1,,CHEMBL624585,,BAO_0000249,,,CLD0
6714,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114,D,9,Expert,1,,CHEMBL875165,,BAO_0000019,,,CLD0
6715,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619490,449.0,BAO_0000219,,,CLD0
6716,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619491,449.0,BAO_0000219,,,CLD0
6717,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619492,449.0,BAO_0000219,,,CLD0
6718,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619493,449.0,BAO_0000219,,,CLD0
6719,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619494,449.0,BAO_0000219,,,CLD0
6720,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619495,449.0,BAO_0000219,,,CLD0
6721,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619496,449.0,BAO_0000219,,,CLD0
6722,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114,D,9,Expert,1,,CHEMBL619497,449.0,BAO_0000219,,,CLD0
6723,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619498,449.0,BAO_0000219,,,CLD0
6724,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619499,449.0,BAO_0000219,,,CLD0
6725,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619500,449.0,BAO_0000219,,,CLD0
6726,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619501,449.0,BAO_0000219,,,CLD0
6727,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619502,449.0,BAO_0000219,,,CLD0
6728,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619503,449.0,BAO_0000219,,,CLD0
6729,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619504,449.0,BAO_0000219,,,CLD0
6730,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621298,449.0,BAO_0000219,,,CLD0
6731,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621299,449.0,BAO_0000219,,,CLD0
6732,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621300,449.0,BAO_0000219,,,CLD0
6733,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621301,449.0,BAO_0000219,,,CLD0
6734,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621302,449.0,BAO_0000219,,,CLD0
6735,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621303,164.0,BAO_0000219,,,CLD0
6736,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621304,164.0,BAO_0000219,,,CLD0
6737,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621305,164.0,BAO_0000219,,,CLD0
6738,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621306,164.0,BAO_0000219,,,CLD0
6739,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618444,164.0,BAO_0000219,,,CLD0
6740,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618445,164.0,BAO_0000219,,,CLD0
6741,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618446,185.0,BAO_0000219,,,CLD0
6742,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618447,185.0,BAO_0000219,,,CLD0
6743,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618448,185.0,BAO_0000219,,,CLD0
6744,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618449,185.0,BAO_0000219,,,CLD0
6745,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618637,185.0,BAO_0000219,,,CLD0
6746,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618638,185.0,BAO_0000219,,,CLD0
6747,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618639,185.0,BAO_0000219,,,CLD0
6748,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618640,185.0,BAO_0000219,,,CLD0
6749,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618641,185.0,BAO_0000219,,,CLD0
6750,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618642,185.0,BAO_0000219,,,CLD0
6751,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618643,185.0,BAO_0000219,,,CLD0
6752,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL884013,185.0,BAO_0000219,,,CLD0
6753,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622723,185.0,BAO_0000219,,,CLD0
6754,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622724,185.0,BAO_0000219,,,CLD0
6755,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622725,185.0,BAO_0000219,,,CLD0
6756,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622726,185.0,BAO_0000219,,,CLD0
6757,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622727,185.0,BAO_0000219,,,CLD0
6758,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622728,185.0,BAO_0000219,,,CLD0
6759,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622729,185.0,BAO_0000219,,,CLD0
6760,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622730,185.0,BAO_0000219,,,CLD0
6761,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622731,185.0,BAO_0000219,,,CLD0
6762,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622732,185.0,BAO_0000219,,,CLD0
6763,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622733,185.0,BAO_0000219,,,CLD0
6764,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622734,,BAO_0000218,,,CLD0
6765,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622735,185.0,BAO_0000219,,,CLD0
6766,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618746,185.0,BAO_0000219,,,CLD0
6767,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618747,185.0,BAO_0000219,,,CLD0
6768,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620540,185.0,BAO_0000219,,,CLD0
6769,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620541,185.0,BAO_0000219,,,CLD0
6770,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620542,185.0,BAO_0000219,,,CLD0
6771,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620543,185.0,BAO_0000219,,,CLD0
6772,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618832,185.0,BAO_0000219,,,CLD0
6773,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618833,185.0,BAO_0000219,,,CLD0
6774,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618834,185.0,BAO_0000219,,,CLD0
6775,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618835,185.0,BAO_0000219,,,CLD0
6776,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618836,185.0,BAO_0000219,,,CLD0
6777,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618837,185.0,BAO_0000219,,,CLD0
6778,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618838,185.0,BAO_0000219,,,CLD0
6779,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618839,185.0,BAO_0000219,,,CLD0
6780,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618840,185.0,BAO_0000219,,,CLD0
6781,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618841,,BAO_0000019,,,CLD0
6782,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618842,185.0,BAO_0000219,,,CLD0
6783,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618843,185.0,BAO_0000219,,,CLD0
6784,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618844,,BAO_0000218,,,CLD0
6785,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618845,,BAO_0000218,,,CLD0
6786,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618846,,BAO_0000218,,,CLD0
6787,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618847,,BAO_0000218,,,CLD0
6788,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618848,,BAO_0000218,,,CLD0
6789,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618849,,BAO_0000218,,,CLD0
6790,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618850,,BAO_0000218,,,CLD0
6791,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618851,,BAO_0000218,,,CLD0
6792,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873815,,BAO_0000218,,,CLD0
6793,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618852,,BAO_0000218,1969.0,,CLD0
6794,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618853,,BAO_0000218,,,CLD0
6795,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618854,,BAO_0000218,,,CLD0
6796,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618855,,BAO_0000218,,,CLD0
6797,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618856,,BAO_0000218,178.0,,CLD0
6798,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875827,,BAO_0000218,,,CLD0
6799,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618857,,BAO_0000218,,,CLD0
6800,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618858,,BAO_0000218,,,CLD0
6801,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618859,,BAO_0000218,,,CLD0
6802,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618860,,BAO_0000218,,,CLD0
6803,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618861,,BAO_0000218,,,CLD0
6804,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622539,,BAO_0000218,,,CLD0
6805,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622540,,BAO_0000218,,,CLD0
6806,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873803,,BAO_0000218,,,CLD0
6807,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873804,,BAO_0000218,,,CLD0
6808,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624311,,BAO_0000218,,,CLD0
6809,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624312,,BAO_0000218,,,CLD0
6810,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624313,,BAO_0000218,,,CLD0
6811,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624314,,BAO_0000218,,,CLD0
6812,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624315,,BAO_0000218,,,CLD0
6813,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624316,,BAO_0000218,1969.0,,CLD0
6814,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624317,,BAO_0000218,,,CLD0
6815,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624318,,BAO_0000218,,,CLD0
6816,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624319,,BAO_0000218,,,CLD0
6817,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624496,,BAO_0000218,,,CLD0
6818,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624497,,BAO_0000218,,,CLD0
6819,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624498,,BAO_0000218,,,CLD0
6820,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624499,,BAO_0000218,,,CLD0
6821,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624500,,BAO_0000218,1969.0,,CLD0
6822,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624501,,BAO_0000218,1969.0,,CLD0
6823,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623666,,BAO_0000218,1969.0,,CLD0
6824,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623667,,BAO_0000218,1969.0,,CLD0
6825,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623668,,BAO_0000218,,,CLD0
6826,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623669,,BAO_0000218,,,CLD0
6827,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623670,,BAO_0000218,,,CLD0
6828,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623671,,BAO_0000218,,,CLD0
6829,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL875945,,BAO_0000218,178.0,,CLD0
6830,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL623672,,BAO_0000218,178.0,,CLD0
6831,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623673,,BAO_0000218,,,CLD0
6832,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623674,,BAO_0000218,,,CLD0
6833,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623675,,BAO_0000218,,,CLD0
6834,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872526,,BAO_0000218,,,CLD0
6835,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623676,,BAO_0000218,,,CLD0
6836,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623677,,BAO_0000218,1969.0,,CLD0
6837,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623678,,BAO_0000218,1969.0,,CLD0
6838,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623679,,BAO_0000218,1969.0,,CLD0
6839,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623680,,BAO_0000218,,,CLD0
6840,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623681,,BAO_0000218,1969.0,,CLD0
6841,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623682,,BAO_0000218,,,CLD0
6842,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623683,,BAO_0000218,,,CLD0
6843,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623684,,BAO_0000218,,,CLD0
6844,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622745,,BAO_0000218,,,CLD0
6845,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622746,,BAO_0000218,,,CLD0
6846,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622747,,BAO_0000218,,,CLD0
6847,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622748,,BAO_0000218,,,CLD0
6848,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622749,,BAO_0000218,,,CLD0
6849,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622750,,BAO_0000218,1969.0,,CLD0
6850,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623411,,BAO_0000218,1969.0,,CLD0
6851,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL875946,,BAO_0000218,1969.0,,CLD0
6852,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623412,,BAO_0000218,1969.0,,CLD0
6853,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623413,,BAO_0000218,1969.0,,CLD0
6854,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623414,,BAO_0000218,1969.0,,CLD0
6855,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623415,,BAO_0000218,1969.0,,CLD0
6856,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623416,,BAO_0000218,1969.0,,CLD0
6857,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623417,,BAO_0000218,1969.0,,CLD0
6858,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623418,,BAO_0000218,1969.0,,CLD0
6859,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623419,,BAO_0000218,1969.0,,CLD0
6860,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622816,,BAO_0000218,,,CLD0
6861,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623313,,BAO_0000218,,,CLD0
6862,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623314,,BAO_0000218,,,CLD0
6863,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876788,,BAO_0000218,,,CLD0
6864,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623315,,BAO_0000218,,,CLD0
6865,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623316,,BAO_0000218,,,CLD0
6866,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623317,,BAO_0000218,,,CLD0
6868,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623319,,BAO_0000218,,,CLD0
6869,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623320,,BAO_0000218,1969.0,,CLD0
6870,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623321,,BAO_0000218,,,CLD0
6871,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623322,,BAO_0000218,1969.0,,CLD0
6872,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623323,,BAO_0000218,1969.0,,CLD0
6873,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623324,,BAO_0000218,1969.0,,CLD0
6874,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623325,,BAO_0000218,1969.0,,CLD0
6875,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623326,,BAO_0000218,1969.0,,CLD0
6876,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623327,,BAO_0000218,1969.0,,CLD0
6877,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623328,,BAO_0000218,1969.0,,CLD0
6878,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623329,,BAO_0000218,1969.0,,CLD0
6879,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623330,,BAO_0000218,1969.0,,CLD0
6880,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,Feces,,,50594,N,1,Intermediate,1,,CHEMBL876789,,BAO_0000218,1988.0,,CLD0
6893,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623333,164.0,BAO_0000219,,,CLD0
6894,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623334,164.0,BAO_0000219,,,CLD0
6895,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627536,164.0,BAO_0000219,,,CLD0
6896,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627537,164.0,BAO_0000219,,,CLD0
6897,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL627538,164.0,BAO_0000219,,,CLD0
6898,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL884106,393.0,BAO_0000219,,,CLD0
6899,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625294,393.0,BAO_0000219,,,CLD0
6900,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625295,393.0,BAO_0000219,,,CLD0
6901,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625296,393.0,BAO_0000219,,,CLD0
6902,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625297,393.0,BAO_0000219,,,CLD0
6903,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625298,393.0,BAO_0000219,,,CLD0
6904,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625960,393.0,BAO_0000219,,,CLD0
6905,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625961,393.0,BAO_0000219,,,CLD0
6906,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625962,393.0,BAO_0000219,,,CLD0
6907,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624717,393.0,BAO_0000219,,,CLD0
6908,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624718,393.0,BAO_0000219,,,CLD0
6909,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624719,393.0,BAO_0000219,,,CLD0
6910,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624720,393.0,BAO_0000219,,,CLD0
6911,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624721,622.0,BAO_0000219,,,CLD0
6912,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL624722,622.0,BAO_0000219,,,CLD0
6913,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL877597,622.0,BAO_0000219,,,CLD0
6914,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624723,622.0,BAO_0000219,,,CLD0
6915,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624724,622.0,BAO_0000219,,,CLD0
6916,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729,H,4,Autocuration,1,,CHEMBL624725,,BAO_0000224,,,CLD0
6917,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656,N,1,Intermediate,1,,CHEMBL624726,1085.0,BAO_0000219,,,CLD0
6918,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713,D,5,Autocuration,1,,CHEMBL857535,,BAO_0000224,,,CLD0
6919,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624727,623.0,BAO_0000219,,,CLD0
6920,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624728,623.0,BAO_0000219,,,CLD0
6921,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015,N,1,Intermediate,1,,CHEMBL624729,404.0,BAO_0000219,,,CLD0
6922,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624730,973.0,BAO_0000219,,,CLD0
6923,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624731,973.0,BAO_0000219,,,CLD0
6924,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624732,973.0,BAO_0000219,,,CLD0
6925,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL883245,973.0,BAO_0000219,,,CLD0
6926,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624733,973.0,BAO_0000219,,,CLD0
6927,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624734,973.0,BAO_0000219,,,CLD0
6928,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624735,973.0,BAO_0000219,,,CLD0
6929,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621780,478.0,BAO_0000219,,,CLD0
6930,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL877598,478.0,BAO_0000219,,,CLD0
6931,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621781,478.0,BAO_0000219,,,CLD0
6932,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621782,478.0,BAO_0000219,,,CLD0
6933,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621783,478.0,BAO_0000219,,,CLD0
6934,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621784,478.0,BAO_0000219,,,CLD0
6935,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621785,478.0,BAO_0000219,,,CLD0
6936,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621968,478.0,BAO_0000219,,,CLD0
6937,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621969,478.0,BAO_0000219,,,CLD0
6938,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621970,478.0,BAO_0000219,,,CLD0
6939,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621971,478.0,BAO_0000219,,,CLD0
6940,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621972,478.0,BAO_0000219,,,CLD0
6941,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884108,478.0,BAO_0000219,,,CLD0
6942,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,AA8,,22224,U,0,Autocuration,1,,CHEMBL623826,,BAO_0000219,,,CLD0
6943,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623827,185.0,BAO_0000219,,,CLD0
6944,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623828,185.0,BAO_0000219,,,CLD0
6945,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623829,185.0,BAO_0000219,,,CLD0
6946,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623830,185.0,BAO_0000219,,,CLD0
6947,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-derived,,22224,U,0,Autocuration,1,,CHEMBL623831,,BAO_0000219,,,CLD0
6948,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623832,185.0,BAO_0000219,,,CLD0
6949,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hamster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623833,185.0,BAO_0000219,,,CLD0
6950,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623834,185.0,BAO_0000219,,,CLD0
6951,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623835,185.0,BAO_0000219,,,CLD0
6952,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623836,185.0,BAO_0000219,,,CLD0
6953,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623837,185.0,BAO_0000219,,,CLD0
6954,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623838,185.0,BAO_0000219,,,CLD0
6955,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623839,,BAO_0000019,,,CLD0
6956,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623840,,BAO_0000019,,,CLD0
6957,16037,Association constant for binding to AATT duplex,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL623841,,BAO_0000225,,,CLD0
6958,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090,N,1,Expert,1,,CHEMBL623842,416.0,BAO_0000219,,,CLD0
6959,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,Breast,AC755,,80668,N,1,Intermediate,1,,CHEMBL623843,1064.0,BAO_0000218,310.0,,CLD0
6960,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618669,,BAO_0000218,,,CLD0
6961,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618670,,BAO_0000218,,,CLD0
6962,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618671,,BAO_0000357,,,CLD0
6963,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618672,,BAO_0000357,,,CLD0
6964,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618673,978.0,BAO_0000219,,,CLD0
6965,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618674,978.0,BAO_0000219,,,CLD0
6966,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618675,998.0,BAO_0000219,,,CLD0
6967,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618676,998.0,BAO_0000219,,,CLD0
6968,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618677,998.0,BAO_0000219,,,CLD0
6969,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618678,626.0,BAO_0000219,,,CLD0
6970,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618679,626.0,BAO_0000219,,,CLD0
6971,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618680,626.0,BAO_0000219,,,CLD0
6972,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618681,626.0,BAO_0000219,,,CLD0
6973,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618682,626.0,BAO_0000219,,,CLD0
6974,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618683,626.0,BAO_0000219,,,CLD0
6975,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618684,626.0,BAO_0000219,,,CLD0
6976,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618685,626.0,BAO_0000219,,,CLD0
6977,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL876499,626.0,BAO_0000219,,,CLD0
6978,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618686,626.0,BAO_0000219,,,CLD0
6979,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618687,626.0,BAO_0000219,,,CLD0
6980,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618688,626.0,BAO_0000219,,,CLD0
6981,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618689,626.0,BAO_0000219,,,CLD0
6982,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618690,626.0,BAO_0000219,,,CLD0
6983,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618691,626.0,BAO_0000219,,,CLD0
6984,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619373,626.0,BAO_0000219,,,CLD0
6985,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL884008,626.0,BAO_0000219,,,CLD0
6986,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,Feces,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619374,626.0,BAO_0000219,1988.0,,CLD0
6987,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619375,626.0,BAO_0000219,,,CLD0
6988,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619376,626.0,BAO_0000219,,,CLD0
6989,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619377,626.0,BAO_0000219,,,CLD0
6990,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619378,626.0,BAO_0000219,,,CLD0
6991,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872527,,BAO_0000218,,,CLD0
6992,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876500,,BAO_0000218,,,CLD0
6993,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619379,,BAO_0000218,1969.0,,CLD0
6994,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619538,,BAO_0000218,,,CLD0
6995,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619539,,BAO_0000218,,,CLD0
6996,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619540,,BAO_0000218,,,CLD0
6997,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619541,,BAO_0000218,,,CLD0
6998,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619542,,BAO_0000218,,,CLD0
6999,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619543,,BAO_0000218,,,CLD0
7000,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL619544,,BAO_0000218,1969.0,,CLD0
7001,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619545,,BAO_0000218,,,CLD0
7002,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619546,,BAO_0000218,,,CLD0
7003,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619547,,BAO_0000218,,,CLD0
7004,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619548,,BAO_0000218,,,CLD0
7005,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619549,,BAO_0000218,,,CLD0
7006,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619550,,BAO_0000218,,,CLD0
7007,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876501,,BAO_0000218,,,CLD0
7008,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619551,,BAO_0000218,,,CLD0
7009,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619552,,BAO_0000218,,,CLD0
7010,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619553,,BAO_0000218,,,CLD0
7011,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618722,,BAO_0000218,,,CLD0
7012,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618723,,BAO_0000218,,,CLD0
7013,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618724,,BAO_0000218,,,CLD0
7014,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618725,,BAO_0000218,,,CLD0
7015,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618726,,BAO_0000218,,,CLD0
7016,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618727,,BAO_0000218,,,CLD0
7017,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624233,,BAO_0000218,,,CLD0
7018,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624234,,BAO_0000218,,,CLD0
7019,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624235,,BAO_0000218,,,CLD0
7020,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624236,,BAO_0000218,,,CLD0
7021,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624237,,BAO_0000218,,,CLD0
7022,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624238,,BAO_0000218,,,CLD0
7023,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624239,,BAO_0000218,,,CLD0
7024,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875829,,BAO_0000218,,,CLD0
7025,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624240,,BAO_0000218,,,CLD0
7026,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624241,,BAO_0000218,,,CLD0
7027,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624242,,BAO_0000218,,,CLD0
7028,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624243,,BAO_0000218,,,CLD0
7029,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624244,,BAO_0000218,,,CLD0
7030,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624245,,BAO_0000218,,,CLD0
7031,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624246,,BAO_0000218,,,CLD0
7032,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624247,,BAO_0000218,,,CLD0
7033,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624248,,BAO_0000218,,,CLD0
7034,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624249,,BAO_0000218,,,CLD0
7035,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624250,,BAO_0000218,,,CLD0
7036,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624251,,BAO_0000218,,,CLD0
7037,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624252,,BAO_0000218,,,CLD0
7038,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624253,,BAO_0000218,,,CLD0
7039,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624950,,BAO_0000218,,,CLD0
7040,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624951,,BAO_0000218,,,CLD0
7041,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875830,,BAO_0000218,,,CLD0
7042,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624952,,BAO_0000218,,,CLD0
7043,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624953,,BAO_0000218,,,CLD0
7044,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624954,,BAO_0000218,,,CLD0
7045,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624955,,BAO_0000218,,,CLD0
7046,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624956,,BAO_0000218,,,CLD0
7047,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625129,,BAO_0000218,,,CLD0
7048,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625130,,BAO_0000218,,,CLD0
7049,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625131,,BAO_0000218,,,CLD0
7050,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625132,,BAO_0000218,,,CLD0
7051,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872263,,BAO_0000218,,,CLD0
7060,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL624336,,BAO_0000218,178.0,,CLD0
7061,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624337,,BAO_0000218,,,CLD0
7062,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624338,,BAO_0000218,,,CLD0
7063,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624339,,BAO_0000218,,,CLD0
7064,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624340,,BAO_0000218,,,CLD0
7065,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624341,,BAO_0000218,,,CLD0
7066,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624342,,BAO_0000218,,,CLD0
7067,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624343,,BAO_0000218,,,CLD0
7068,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624344,,BAO_0000218,,,CLD0
7069,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624345,,BAO_0000218,,,CLD0
7070,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624346,,BAO_0000218,,,CLD0
7071,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Expert,1,,CHEMBL624347,,BAO_0000218,,,CLD0
7072,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624348,,BAO_0000218,,,CLD0
7074,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622754,,BAO_0000218,,,CLD0
7075,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622755,,BAO_0000218,,,CLD0
7076,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622756,,BAO_0000218,,,CLD0
7077,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622757,,BAO_0000218,,,CLD0
7078,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622758,,BAO_0000218,,,CLD0
7079,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622759,,BAO_0000218,,,CLD0
7080,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622760,,BAO_0000218,,,CLD0
7081,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622761,,BAO_0000218,1969.0,,CLD0
7082,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622762,,BAO_0000218,1969.0,,CLD0
7083,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622763,,BAO_0000218,1969.0,,CLD0
7084,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622764,,BAO_0000218,1969.0,,CLD0
7085,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622765,,BAO_0000218,1969.0,,CLD0
7086,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622766,,BAO_0000218,,,CLD0
7087,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622767,,BAO_0000218,,,CLD0
7088,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622768,,BAO_0000218,,,CLD0
7089,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL875948,,BAO_0000218,178.0,,CLD0
7090,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622769,,BAO_0000218,178.0,,CLD0
7091,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622770,,BAO_0000218,178.0,,CLD0
7092,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622771,,BAO_0000218,178.0,,CLD0
7093,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622772,,BAO_0000218,178.0,,CLD0
7094,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622773,,BAO_0000218,178.0,,CLD0
7095,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622774,,BAO_0000218,178.0,,CLD0
7096,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL621725,,BAO_0000218,1474.0,,CLD0
7097,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL621726,,BAO_0000218,1474.0,,CLD0
7098,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621727,478.0,BAO_0000219,,,CLD0
7099,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622413,478.0,BAO_0000219,,,CLD0
7100,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622414,478.0,BAO_0000219,,,CLD0
7101,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622415,478.0,BAO_0000219,,,CLD0
7102,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL884001,478.0,BAO_0000219,,,CLD0
7103,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622416,478.0,BAO_0000219,,,CLD0
7104,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622417,478.0,BAO_0000219,,,CLD0
7105,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622590,478.0,BAO_0000219,,,CLD0
7106,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622591,478.0,BAO_0000219,,,CLD0
7107,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622592,478.0,BAO_0000219,,,CLD0
7108,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622593,478.0,BAO_0000219,,,CLD0
7109,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622594,478.0,BAO_0000219,,,CLD0
7110,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622595,478.0,BAO_0000219,,,CLD0
7111,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622596,478.0,BAO_0000219,,,CLD0
7112,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622597,478.0,BAO_0000219,,,CLD0
7113,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622598,478.0,BAO_0000219,,,CLD0
7114,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,Cancer cell lines,,104766,D,5,Autocuration,1,,CHEMBL622599,1015.0,BAO_0000219,,,CLD0
7115,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622600,478.0,BAO_0000219,,,CLD0
7116,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622601,478.0,BAO_0000219,,,CLD0
7117,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622602,478.0,BAO_0000219,,,CLD0
7118,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622603,478.0,BAO_0000219,,,CLD0
7119,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622604,478.0,BAO_0000219,,,CLD0
7120,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622605,478.0,BAO_0000219,,,CLD0
7121,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622606,478.0,BAO_0000219,,,CLD0
7122,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619463,478.0,BAO_0000219,,,CLD0
7123,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619464,478.0,BAO_0000219,,,CLD0
7124,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619465,478.0,BAO_0000219,,,CLD0
7125,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619466,478.0,BAO_0000219,,,CLD0
7126,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619467,478.0,BAO_0000219,,,CLD0
7127,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619468,478.0,BAO_0000219,,,CLD0
7128,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619469,478.0,BAO_0000219,,,CLD0
7129,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619470,478.0,BAO_0000219,,,CLD0
7130,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619471,478.0,BAO_0000219,,,CLD0
7131,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619472,478.0,BAO_0000219,,,CLD0
7132,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619473,478.0,BAO_0000219,,,CLD0
7133,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL874368,478.0,BAO_0000219,,,CLD0
7134,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884003,478.0,BAO_0000219,,,CLD0
7135,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622690,478.0,BAO_0000219,,,CLD0
7136,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622691,478.0,BAO_0000219,,,CLD0
7137,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622692,478.0,BAO_0000219,,,CLD0
7138,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623406,478.0,BAO_0000219,,,CLD0
7139,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884004,478.0,BAO_0000219,,,CLD0
7140,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623407,478.0,BAO_0000219,,,CLD0
7141,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623408,478.0,BAO_0000219,,,CLD0
7142,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623409,478.0,BAO_0000219,,,CLD0
7143,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623410,478.0,BAO_0000219,,,CLD0
7144,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623576,478.0,BAO_0000219,,,CLD0
7145,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623577,626.0,BAO_0000219,,,CLD0
7146,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623578,626.0,BAO_0000219,,,CLD0
7147,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623579,626.0,BAO_0000219,,,CLD0
7148,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623580,626.0,BAO_0000219,,,CLD0
7149,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623581,626.0,BAO_0000219,,,CLD0
7150,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL857456,626.0,BAO_0000219,,,CLD0
7151,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623582,626.0,BAO_0000219,,,CLD0
7152,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623583,626.0,BAO_0000219,,,CLD0
7153,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623584,626.0,BAO_0000219,,,CLD0
7154,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623585,626.0,BAO_0000219,,,CLD0
7155,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623586,626.0,BAO_0000219,,,CLD0
7156,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623587,626.0,BAO_0000219,,,CLD0
7157,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875279,626.0,BAO_0000219,,,CLD0
7158,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623588,626.0,BAO_0000219,,,CLD0
7159,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623589,626.0,BAO_0000219,,,CLD0
7160,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623590,626.0,BAO_0000219,,,CLD0
7161,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623591,626.0,BAO_0000219,,,CLD0
7162,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623592,626.0,BAO_0000219,,,CLD0
7163,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623593,626.0,BAO_0000219,,,CLD0
7164,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623594,626.0,BAO_0000219,,,CLD0
7165,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL621833,626.0,BAO_0000219,,,CLD0
7166,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621834,626.0,BAO_0000219,,,CLD0
7167,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621835,626.0,BAO_0000219,,,CLD0
7168,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621836,626.0,BAO_0000219,,,CLD0
7169,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621837,626.0,BAO_0000219,,,CLD0
7170,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875280,626.0,BAO_0000219,,,CLD0
7171,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621838,626.0,BAO_0000219,,,CLD0
7172,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621839,626.0,BAO_0000219,,,CLD0
7173,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621840,,BAO_0000019,,,CLD0
7174,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647,H,8,Autocuration,1,,CHEMBL621841,,BAO_0000019,,,CLD0
7175,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529,N,1,Expert,1,,CHEMBL622979,468.0,BAO_0000218,,,CLD0
7176,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529,N,1,Intermediate,1,,CHEMBL876595,,BAO_0000218,,,CLD0
7177,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620221,,BAO_0000357,,,CLD0
7178,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620222,,BAO_0000357,,,CLD0
7179,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670,N,1,Intermediate,1,,CHEMBL620506,979.0,BAO_0000219,,,CLD0
7180,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,Plasma,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620507,980.0,BAO_0000219,1969.0,,CLD0
7181,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,Plasma,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620508,980.0,BAO_0000219,1969.0,,CLD0
7182,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,Plasma,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620509,980.0,BAO_0000219,1969.0,,CLD0
7183,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,Plasma,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620510,980.0,BAO_0000219,1969.0,,CLD0
7184,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,Plasma,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620511,980.0,BAO_0000219,1969.0,,CLD0
7185,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620512,980.0,BAO_0000219,,,CLD0
7186,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620513,,BAO_0000366,1969.0,,CLD0
7187,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620514,,BAO_0000366,1969.0,,CLD0
7188,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620515,,BAO_0000366,1969.0,,CLD0
7189,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620516,,BAO_0000218,,,CLD0
7190,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620517,,BAO_0000218,1969.0,,CLD0
7191,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620518,,BAO_0000218,1969.0,,CLD0
7192,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620519,,BAO_0000218,,,CLD0
7193,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621386,,BAO_0000218,,,CLD0
7194,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621387,,BAO_0000218,,,CLD0
7195,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621388,,BAO_0000218,,,CLD0
7196,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621389,,BAO_0000218,1969.0,,CLD0
7197,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621390,,BAO_0000218,1969.0,,CLD0
7198,4219,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621391,,BAO_0000100,,,CLD0
7199,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621392,,BAO_0000218,,,CLD0
7200,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621393,,BAO_0000218,,,CLD0
7201,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621394,,BAO_0000218,,,CLD0
7202,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL621395,,BAO_0000218,2107.0,,CLD0
7203,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621396,,BAO_0000218,,,CLD0
7204,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621397,,BAO_0000218,,,CLD0
7205,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621398,,BAO_0000218,,,CLD0
7206,3639,pKa was evaluated,P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL618818,,BAO_0000100,,,CLD0
7207,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618819,,BAO_0000218,,,CLD0
7208,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618820,,BAO_0000218,,,CLD0
7209,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873810,,BAO_0000218,,,CLD0
7210,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876606,,BAO_0000218,,,CLD0
7211,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618821,,BAO_0000218,,,CLD0
7212,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618822,,BAO_0000218,178.0,,CLD0
7213,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618823,,BAO_0000218,178.0,,CLD0
7214,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618824,,BAO_0000218,,,CLD0
7215,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618825,,BAO_0000218,,,CLD0
7216,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618826,,BAO_0000218,,,CLD0
7217,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618827,,BAO_0000218,,,CLD0
7218,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618828,,BAO_0000218,,,CLD0
7219,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618829,,BAO_0000218,,,CLD0
7220,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618830,,BAO_0000218,,,CLD0
7221,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618831,,BAO_0000218,,,CLD0
7222,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619489,,BAO_0000218,1969.0,,CLD0
7223,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619649,,BAO_0000218,,,CLD0
7224,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876607,,BAO_0000218,,,CLD0
7225,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619650,,BAO_0000218,,,CLD0
7226,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619651,,BAO_0000218,,,CLD0
7227,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619652,,BAO_0000218,,,CLD0
7228,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619653,,BAO_0000218,,,CLD0
7229,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619654,,BAO_0000218,,,CLD0
7230,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619655,,BAO_0000218,,,CLD0
7231,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619656,,BAO_0000218,178.0,,CLD0
7232,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL873812,,BAO_0000218,1969.0,,CLD0
7233,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621365,,BAO_0000218,1969.0,,CLD0
7234,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621366,,BAO_0000218,,,CLD0
7235,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621367,,BAO_0000218,1969.0,,CLD0
7236,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621368,,BAO_0000218,1969.0,,CLD0
7237,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621369,,BAO_0000218,1969.0,,CLD0
7238,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621370,,BAO_0000218,1969.0,,CLD0
7239,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621371,,BAO_0000218,,,CLD0
7240,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621372,,BAO_0000218,,,CLD0
7241,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621373,,BAO_0000218,1969.0,,CLD0
7242,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621374,,BAO_0000218,,,CLD0
7243,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621375,,BAO_0000218,,,CLD0
7244,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621376,,BAO_0000218,,,CLD0
7245,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619624,,BAO_0000218,,,CLD0
7246,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875840,,BAO_0000218,,,CLD0
7247,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619625,,BAO_0000218,,,CLD0
7248,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619626,,BAO_0000218,,,CLD0
7249,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619627,,BAO_0000218,,,CLD0
7250,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873817,,BAO_0000218,,,CLD0
7251,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619628,,BAO_0000218,,,CLD0
7252,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619629,,BAO_0000218,,,CLD0
7253,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619630,,BAO_0000218,,,CLD0
7254,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619631,,BAO_0000218,,,CLD0
7255,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619632,,BAO_0000218,,,CLD0
7256,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL619633,,BAO_0000218,1474.0,,CLD0
7257,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL875841,,BAO_0000218,1474.0,,CLD0
7258,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL619634,,BAO_0000218,1474.0,,CLD0
7259,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL619635,,BAO_0000218,1474.0,,CLD0
7260,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone element,,,50594,N,1,Intermediate,1,,CHEMBL619636,,BAO_0000218,1474.0,,CLD0
7261,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619637,,BAO_0000218,10000004.0,,CLD0
7262,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619638,,BAO_0000218,10000004.0,,CLD0
7263,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619639,,BAO_0000218,10000004.0,,CLD0
7264,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619640,,BAO_0000218,10000004.0,,CLD0
7265,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619641,,BAO_0000218,10000004.0,,CLD0
7266,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619642,,BAO_0000218,10000004.0,,CLD0
7267,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619643,,BAO_0000218,10000004.0,,CLD0
7268,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL619644,,BAO_0000218,948.0,,CLD0
7269,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621112,,BAO_0000218,948.0,,CLD0
7270,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621113,,BAO_0000218,948.0,,CLD0
7271,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621114,,BAO_0000218,948.0,,CLD0
7272,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621115,,BAO_0000218,948.0,,CLD0
7273,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621116,,BAO_0000218,948.0,,CLD0
7274,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621117,,BAO_0000218,948.0,,CLD0
7275,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621118,,BAO_0000218,2113.0,,CLD0
7276,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621119,,BAO_0000218,2113.0,,CLD0
7277,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621120,,BAO_0000218,2113.0,,CLD0
7278,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621757,,BAO_0000218,2113.0,,CLD0
7279,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621758,,BAO_0000218,2113.0,,CLD0
7280,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621759,,BAO_0000218,2113.0,,CLD0
7281,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621760,,BAO_0000218,2113.0,,CLD0
7282,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621761,,BAO_0000218,2107.0,,CLD0
7283,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621762,,BAO_0000218,2107.0,,CLD0
7284,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621763,,BAO_0000218,2107.0,,CLD0
7285,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624502,,BAO_0000218,2107.0,,CLD0
7286,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624503,,BAO_0000218,2107.0,,CLD0
7287,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624504,,BAO_0000218,2107.0,,CLD0
7288,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624505,,BAO_0000218,2107.0,,CLD0
7289,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624506,,BAO_0000218,2048.0,,CLD0
7290,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624507,478.0,BAO_0000219,,,CLD0
7291,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624508,478.0,BAO_0000219,,,CLD0
7292,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624509,478.0,BAO_0000219,,,CLD0
7293,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624510,478.0,BAO_0000219,,,CLD0
7294,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL875956,478.0,BAO_0000219,,,CLD0
7295,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL839885,478.0,BAO_0000219,,,CLD0
7296,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL624511,478.0,BAO_0000219,,,CLD0
7297,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624512,478.0,BAO_0000219,,,CLD0
7298,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624513,478.0,BAO_0000219,,,CLD0
7299,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624514,478.0,BAO_0000219,,,CLD0
7300,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618547,478.0,BAO_0000218,,,CLD0
7301,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618548,478.0,BAO_0000219,,,CLD0
7302,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618549,478.0,BAO_0000219,,,CLD0
7303,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618550,478.0,BAO_0000219,,,CLD0
7304,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618551,478.0,BAO_0000219,,,CLD0
7305,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618552,478.0,BAO_0000219,,,CLD0
7306,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618553,478.0,BAO_0000219,,,CLD0
7307,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618554,478.0,BAO_0000219,,,CLD0
7308,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618555,478.0,BAO_0000219,,,CLD0
7309,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618556,481.0,BAO_0000219,,,CLD0
7310,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618557,481.0,BAO_0000219,,,CLD0
7311,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618558,481.0,BAO_0000219,,,CLD0
7312,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618559,481.0,BAO_0000219,,,CLD0
7313,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618560,478.0,BAO_0000218,,,CLD0
7314,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618561,478.0,BAO_0000218,,,CLD0
7315,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618562,478.0,BAO_0000219,,,CLD0
7316,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618563,478.0,BAO_0000219,,,CLD0
7317,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618564,478.0,BAO_0000219,,,CLD0
7318,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618565,478.0,BAO_0000219,,,CLD0
7319,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618566,478.0,BAO_0000218,,,CLD0
7320,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618567,478.0,BAO_0000219,,,CLD0
7321,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618568,478.0,BAO_0000219,,,CLD0
7322,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618569,478.0,BAO_0000219,,,CLD0
7323,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621857,478.0,BAO_0000219,,,CLD0
7324,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621858,478.0,BAO_0000219,,,CLD0
7325,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621859,478.0,BAO_0000219,,,CLD0
7326,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621860,478.0,BAO_0000219,,,CLD0
7327,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621861,478.0,BAO_0000219,,,CLD0
7328,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621862,478.0,BAO_0000219,,,CLD0
7329,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621863,478.0,BAO_0000219,,,CLD0
7330,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621864,478.0,BAO_0000219,,,CLD0
7331,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621865,478.0,BAO_0000219,,,CLD0
7332,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621866,478.0,BAO_0000219,,,CLD0
7333,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621867,478.0,BAO_0000219,,,CLD0
7334,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621868,478.0,BAO_0000219,,,CLD0
7335,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875282,478.0,BAO_0000219,,,CLD0
7336,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621869,,BAO_0000218,,,CLD0
7337,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621870,,BAO_0000218,,,CLD0
7338,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621871,,BAO_0000019,,,CLD0
7339,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621243,,BAO_0000218,1969.0,,CLD0
7340,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621244,,BAO_0000218,1969.0,,CLD0
7341,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621245,,BAO_0000218,,,CLD0
7342,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621246,,BAO_0000218,,,CLD0
7343,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621247,,BAO_0000218,,,CLD0
7344,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618386,,BAO_0000218,,,CLD0
7345,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618387,,BAO_0000218,,,CLD0
7346,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618388,,BAO_0000218,,,CLD0
7347,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618389,,BAO_0000218,,,CLD0
7348,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618574,,BAO_0000019,,,CLD0
7349,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618575,,BAO_0000019,,,CLD0
7350,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618576,,BAO_0000019,,,CLD0
7351,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618577,,BAO_0000218,,,CLD0
7352,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876487,,BAO_0000218,,,CLD0
7353,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618578,,BAO_0000218,,,CLD0
7354,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618579,,BAO_0000218,,,CLD0
7355,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618580,,BAO_0000019,,,CLD0
7356,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618581,,BAO_0000218,,,CLD0
7357,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618582,,BAO_0000218,,,CLD0
7358,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618583,,BAO_0000218,,,CLD0
7359,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618584,,BAO_0000218,,,CLD0
7360,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618585,,BAO_0000218,,,CLD0
7361,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618586,,BAO_0000218,,,CLD0
7362,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618587,,BAO_0000218,,,CLD0
7363,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618588,,BAO_0000218,,,CLD0
7364,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618589,,BAO_0000366,1969.0,,CLD0
7365,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618590,,BAO_0000366,1969.0,,CLD0
7366,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872262,,BAO_0000218,,,CLD0
7367,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618591,,BAO_0000218,,,CLD0
7368,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618592,,BAO_0000218,,,CLD0
7369,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876488,,BAO_0000218,,,CLD0
7370,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618593,,BAO_0000218,,,CLD0
7371,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618594,,BAO_0000218,,,CLD0
7372,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618595,,BAO_0000218,,,CLD0
7373,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621469,,BAO_0000019,,,CLD0
7374,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621470,,BAO_0000218,,,CLD0
7375,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621471,,BAO_0000218,,,CLD0
7376,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621472,,BAO_0000218,1969.0,,CLD0
7377,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621473,,BAO_0000218,1969.0,,CLD0
7378,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621474,,BAO_0000218,1969.0,,CLD0
7379,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621475,,BAO_0000218,1969.0,,CLD0
7380,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621476,,BAO_0000218,1969.0,,CLD0
7381,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624290,,BAO_0000218,1969.0,,CLD0
7382,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624291,,BAO_0000218,,,CLD0
7383,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624292,,BAO_0000218,,,CLD0
7384,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624293,,BAO_0000218,,,CLD0
7385,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624294,,BAO_0000218,,,CLD0
7386,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624295,,BAO_0000218,,,CLD0
7387,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624296,,BAO_0000218,,,CLD0
7388,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624297,,BAO_0000218,,,CLD0
7389,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624298,,BAO_0000218,,,CLD0
7390,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624299,,BAO_0000218,,,CLD0
7391,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624300,,BAO_0000218,,,CLD0
7392,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624301,,BAO_0000218,,,CLD0
7393,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624302,,BAO_0000218,,,CLD0
7394,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876026,,BAO_0000218,,,CLD0
7395,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624303,,BAO_0000218,,,CLD0
7396,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624304,,BAO_0000218,,,CLD0
7397,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624305,,BAO_0000218,,,CLD0
7398,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624306,,BAO_0000218,,,CLD0
7399,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624307,,BAO_0000218,,,CLD0
7400,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624308,,BAO_0000218,,,CLD0
7401,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624309,,BAO_0000218,,,CLD0
7402,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624310,,BAO_0000218,,,CLD0
7403,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625003,,BAO_0000218,,,CLD0
7404,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625004,,BAO_0000218,,,CLD0
7405,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625005,,BAO_0000218,,,CLD0
7406,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873813,,BAO_0000218,,,CLD0
7407,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625006,,BAO_0000218,,,CLD0
7408,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625007,,BAO_0000218,,,CLD0
7409,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876027,,BAO_0000218,,,CLD0
7410,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625008,,BAO_0000218,,,CLD0
7411,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625009,,BAO_0000218,,,CLD0
7412,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625010,,BAO_0000218,1969.0,,CLD0
7413,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625011,,BAO_0000218,,,CLD0
7414,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621553,,BAO_0000218,,,CLD0
7415,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621554,,BAO_0000218,,,CLD0
7416,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621555,,BAO_0000218,,,CLD0
7417,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621556,,BAO_0000218,,,CLD0
7418,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621557,,BAO_0000218,,,CLD0
7419,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621558,,BAO_0000218,,,CLD0
7420,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621559,,BAO_0000218,,,CLD0
7421,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621560,,BAO_0000218,,,CLD0
7422,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876028,,BAO_0000218,,,CLD0
7423,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621561,,BAO_0000218,1969.0,,CLD0
7424,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621562,,BAO_0000218,1969.0,,CLD0
7425,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621563,,BAO_0000218,,,CLD0
7426,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621564,,BAO_0000218,,,CLD0
7427,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621565,,BAO_0000218,,,CLD0
7428,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621566,,BAO_0000218,,,CLD0
7429,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621567,,BAO_0000218,,,CLD0
7430,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622978,,BAO_0000218,,,CLD0
7431,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873814,,BAO_0000218,,,CLD0
7432,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623219,,BAO_0000218,,,CLD0
7433,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624477,,BAO_0000218,,,CLD0
7434,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624478,,BAO_0000218,,,CLD0
7435,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624479,,BAO_0000218,,,CLD0
7436,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624480,,BAO_0000218,,,CLD0
7437,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623595,,BAO_0000218,,,CLD0
7438,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623596,,BAO_0000218,,,CLD0
7439,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623597,,BAO_0000218,1969.0,,CLD0
7440,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623598,,BAO_0000218,,,CLD0
7441,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623599,,BAO_0000218,,,CLD0
7442,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623600,,BAO_0000218,,,CLD0
7443,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623601,,BAO_0000218,,,CLD0
7444,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623602,,BAO_0000218,,,CLD0
7445,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623603,,BAO_0000218,,,CLD0
7446,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623604,,BAO_0000218,,,CLD0
7447,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623605,,BAO_0000218,2048.0,,CLD0
7448,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623606,,BAO_0000218,2048.0,,CLD0
7449,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623607,,BAO_0000218,2048.0,,CLD0
7450,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623608,,BAO_0000218,2048.0,,CLD0
7451,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623609,,BAO_0000218,2048.0,,CLD0
7452,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623610,,BAO_0000218,2048.0,,CLD0
7453,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623611,,BAO_0000218,2385.0,,CLD0
7454,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623612,,BAO_0000218,2385.0,,CLD0
7455,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623613,,BAO_0000218,2385.0,,CLD0
7456,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623614,,BAO_0000218,2385.0,,CLD0
7457,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623615,,BAO_0000218,2385.0,,CLD0
7458,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623616,,BAO_0000218,2385.0,,CLD0
7459,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623617,,BAO_0000218,2385.0,,CLD0
7460,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL875944,,BAO_0000218,14.0,,CLD0
7461,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623618,,BAO_0000218,14.0,,CLD0
7462,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623619,,BAO_0000218,14.0,,CLD0
7463,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623620,,BAO_0000218,14.0,,CLD0
7464,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623621,,BAO_0000218,14.0,,CLD0
7465,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623622,,BAO_0000218,14.0,,CLD0
7466,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623623,,BAO_0000218,14.0,,CLD0
7467,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623624,,BAO_0000218,2106.0,,CLD0
7468,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618521,,BAO_0000218,2106.0,,CLD0
7469,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618522,,BAO_0000218,2106.0,,CLD0
7470,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618523,,BAO_0000218,2106.0,,CLD0
7471,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618524,,BAO_0000218,2106.0,,CLD0
7472,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618525,,BAO_0000218,2106.0,,CLD0
7473,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL624586,,BAO_0000218,2106.0,,CLD0
7474,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624587,,BAO_0000218,945.0,,CLD0
7475,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624588,,BAO_0000218,945.0,,CLD0
7476,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624589,,BAO_0000218,945.0,,CLD0
7477,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624590,,BAO_0000218,945.0,,CLD0
7478,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624591,,BAO_0000218,945.0,,CLD0
7479,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624592,,BAO_0000218,945.0,,CLD0
7480,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624593,,BAO_0000218,945.0,,CLD0
7481,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624594,,BAO_0000218,,,CLD0
7482,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624595,,BAO_0000218,,,CLD0
7483,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624596,,BAO_0000218,,,CLD0
7484,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624597,,BAO_0000218,,,CLD0
7485,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624598,,BAO_0000218,,,CLD0
7486,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624599,,BAO_0000218,,,CLD0
7487,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875166,,BAO_0000218,,,CLD0
7488,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624600,,BAO_0000218,1969.0,,CLD0
7489,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624601,,BAO_0000218,1969.0,,CLD0
7490,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624602,,BAO_0000218,,,CLD0
7491,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624603,,BAO_0000218,,,CLD0
7492,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624604,,BAO_0000218,,,CLD0
7493,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624605,,BAO_0000218,1969.0,,CLD0
7494,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624606,,BAO_0000218,,,CLD0
7495,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624607,,BAO_0000218,178.0,,CLD0
7496,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624608,,BAO_0000218,,,CLD0
7497,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624609,,BAO_0000218,178.0,,CLD0
7498,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624610,,BAO_0000218,178.0,,CLD0
7499,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624611,,BAO_0000218,178.0,,CLD0
7500,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624612,,BAO_0000218,178.0,,CLD0
7501,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875167,,BAO_0000218,178.0,,CLD0
7502,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624613,,BAO_0000218,178.0,,CLD0
7503,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624614,,BAO_0000218,178.0,,CLD0
7504,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624392,,BAO_0000218,1969.0,,CLD0
7505,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624393,,BAO_0000218,955.0,,CLD0
7506,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624394,,BAO_0000218,955.0,,CLD0
7507,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624395,,BAO_0000218,955.0,,CLD0
7508,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624396,,BAO_0000218,955.0,,CLD0
7509,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624397,,BAO_0000218,955.0,,CLD0
7510,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624398,,BAO_0000218,2046.0,,CLD0
7511,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624399,,BAO_0000218,2046.0,,CLD0
7512,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624400,,BAO_0000218,2046.0,,CLD0
7513,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624401,,BAO_0000218,2046.0,,CLD0
7514,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624402,,BAO_0000218,2046.0,,CLD0
7515,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624403,,BAO_0000218,178.0,,CLD0
7516,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624404,,BAO_0000218,178.0,,CLD0
7517,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624405,,BAO_0000218,178.0,,CLD0
7518,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624406,,BAO_0000218,1474.0,,CLD0
7519,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624407,,BAO_0000218,1474.0,,CLD0
7520,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624408,,BAO_0000218,1474.0,,CLD0
7521,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618644,,BAO_0000218,948.0,,CLD0
7522,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618645,,BAO_0000218,948.0,,CLD0
7523,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618646,,BAO_0000218,948.0,,CLD0
7524,9866,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL618647,,BAO_0000218,2113.0,,CLD0
7525,9866,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL618648,,BAO_0000218,2113.0,,CLD0
7526,9866,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL618649,,BAO_0000218,2113.0,,CLD0
7527,9866,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618650,,BAO_0000218,2107.0,,CLD0
7528,9866,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618651,,BAO_0000218,2107.0,,CLD0
7529,9866,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876497,,BAO_0000218,2107.0,,CLD0
7530,9866,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618652,,BAO_0000218,2048.0,,CLD0
7531,9866,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618653,,BAO_0000218,2048.0,,CLD0
7532,9866,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618654,,BAO_0000218,2048.0,,CLD0
7533,6351,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL618655,,BAO_0000218,1970.0,,CLD0
7534,1465,Compound was tested for solubility in water,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618656,,BAO_0000218,,,CLD0
7535,5182,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL618657,,BAO_0000100,,,CLD0
7536,17847,Solubility was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618658,,BAO_0000218,,,CLD0
7537,15339,solubility in water (ug/mL) at 37 degree C.,P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL618659,,BAO_0000100,,,CLD0
7538,5202,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL618660,,BAO_0000218,2107.0,,CLD0
7539,1088,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,,,Rattus norvegicus,10116.0,,,Hepatocyte,,50597,N,1,Intermediate,1,,CHEMBL618661,395.0,BAO_0000218,,,CLD0
7540,3169,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873807,,BAO_0000218,,,CLD0
7541,5353,Half life in Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618662,,BAO_0000218,,,CLD0
7542,2864,Half life period after 3 mg/kg iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618663,,BAO_0000218,,,CLD0
7543,2864,Half life period after 3 mg/kg iv administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618664,,BAO_0000218,,,CLD0
7544,2864,Half life period after 3 mg/kg iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618665,,BAO_0000218,,,CLD0
7545,6362,Half life period in female Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876498,,BAO_0000218,,,CLD0
7546,6249,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618666,,BAO_0000218,,,CLD0
7547,3169,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620440,,BAO_0000218,,,CLD0
7548,3169,Half-life in rats with metabolic oxidation,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620441,,BAO_0000218,,,CLD0
7549,3169,Half-life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620442,,BAO_0000218,,,CLD0
7550,17260,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620443,,BAO_0000218,,,CLD0
7551,17260,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620444,,BAO_0000218,,,CLD0
7552,17260,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620445,,BAO_0000218,,,CLD0
7553,17260,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620446,,BAO_0000218,,,CLD0
7554,2879,Biological half-life measured in plasma of rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620447,,BAO_0000218,1969.0,,CLD0
7555,2879,Biological half-life measured in plasma of rat; 22-25,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621129,,BAO_0000218,1969.0,,CLD0
7556,2879,Biological half-life measured in plasma of rat; 9-16,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621130,,BAO_0000218,1969.0,,CLD0
7557,3184,Compound was evaluated for its half life when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873808,,BAO_0000218,,,CLD0
7558,4891,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876598,,BAO_0000218,,,CLD0
7559,429,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621131,,BAO_0000218,,,CLD0
7560,5656,Half life (T1/2) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621132,,BAO_0000218,,,CLD0
7561,4413,Half life of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621133,,BAO_0000218,,,CLD0
7562,3598,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL621312,,BAO_0000218,,,CLD0
7563,17267,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621313,,BAO_0000218,,,CLD0
7564,4727,Half life of compound was determined in rat blood,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621314,,BAO_0000218,178.0,,CLD0
7565,17651,Half life at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621315,,BAO_0000218,,,CLD0
7566,17651,Half life at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621316,,BAO_0000218,,,CLD0
7567,401,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621317,,BAO_0000218,,,CLD0
7568,4942,Half life in rats in hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621318,,BAO_0000218,,,CLD0
7569,17735,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621319,,BAO_0000218,,,CLD0
7570,6056,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621377,,BAO_0000218,,,CLD0
7571,5213,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621378,,BAO_0000218,,,CLD0
7572,6616,Half life after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876599,,BAO_0000218,,,CLD0
7573,5937,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621379,,BAO_0000218,,,CLD0
7574,5819,Half life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621380,,BAO_0000218,1969.0,,CLD0
7575,5819,Half life in rat plasma; Not detected,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621381,,BAO_0000218,1969.0,,CLD0
7576,6803,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618515,,BAO_0000218,,,CLD0
7577,17804,Half life period of compound was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618516,,BAO_0000218,,,CLD0
7578,17804,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618517,,BAO_0000218,,,CLD0
7579,5948,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618518,,BAO_0000218,,,CLD0
7580,1916,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618519,,BAO_0000218,,,CLD0
7581,1916,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618698,,BAO_0000218,,,CLD0
7582,1916,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618862,,BAO_0000218,,,CLD0
7583,4890,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618863,,BAO_0000218,,,CLD0
7584,17764,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618864,,BAO_0000218,,,CLD0
7585,4727,Half life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618865,,BAO_0000218,,,CLD0
7586,17509,Half-life 24 hr after 10 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618866,,BAO_0000218,,,CLD0
7587,17509,Half-life 24 hr after 2 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618867,,BAO_0000218,,,CLD0
7588,6597,Half-life consistent with the observed metabolic steady state in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875828,,BAO_0000218,,,CLD0
7589,17735,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618868,,BAO_0000218,,,CLD0
7590,6597,Half-life for oxidative metabolic stability was determined using male human,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618869,,BAO_0000218,,,CLD0
7591,17670,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618870,,BAO_0000218,,,CLD0
7592,1696,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618871,,BAO_0000218,1969.0,,CLD0
7593,1742,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618872,,BAO_0000218,1969.0,,CLD0
7594,17800,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873816,,BAO_0000218,,,CLD0
7595,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618873,,BAO_0000218,,,CLD0
7596,11954,Area under curve after oral dose of 0.1 mg//kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621602,,BAO_0000019,,,CLD0
7597,11954,Area under curve after oral dose of 0.3 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621603,,BAO_0000218,,,CLD0
7598,11954,Area under curve after oral dose of 1 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621604,,BAO_0000218,,,CLD0
7599,11954,Area under curve after oral dose of 10 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621605,,BAO_0000218,,,CLD0
7600,11954,Area under curve after oral dose of 23.4 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621606,,BAO_0000218,,,CLD0
7601,11954,Area under curve after oral dose of 3 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621607,,BAO_0000218,,,CLD0
7602,11954,Area under curve after oral dose of 3.87 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621608,,BAO_0000218,,,CLD0
7603,5237,Area under curve was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621609,,BAO_0000019,,,CLD0
7604,4026,Area under curve at a dose of 10 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621610,,BAO_0000218,,,CLD0
7605,5237,Area under curve was determined; ND=No data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621611,,BAO_0000218,,,CLD0
7606,14793,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621612,,BAO_0000218,955.0,,CLD0
7607,14793,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622308,,BAO_0000218,955.0,,CLD0
7608,14793,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622309,,BAO_0000218,955.0,,CLD0
7609,14793,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622310,,BAO_0000218,955.0,,CLD0
7610,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622311,,BAO_0000218,955.0,,CLD0
7611,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622312,,BAO_0000218,955.0,,CLD0
7612,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622931,,BAO_0000218,955.0,,CLD0
7613,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622932,,BAO_0000218,955.0,,CLD0
7614,14793,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622736,,BAO_0000218,1969.0,,CLD0
7615,14793,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622737,,BAO_0000218,1969.0,,CLD0
7616,14793,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622738,,BAO_0000218,1969.0,,CLD0
7617,14793,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622739,,BAO_0000218,1969.0,,CLD0
7618,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622740,,BAO_0000218,1969.0,,CLD0
7619,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622741,,BAO_0000218,1969.0,,CLD0
7620,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622742,,BAO_0000218,1969.0,,CLD0
7621,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622743,,BAO_0000218,1969.0,,CLD0
7622,11637,AUC in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622744,,BAO_0000218,1969.0,,CLD0
7623,11149,Area under curve was measured from the graph obtained from concentration Vs time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624134,,BAO_0000019,,,CLD0
7624,10016,Area under curve value of compound per hour after oral administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624135,,BAO_0000019,,,CLD0
7625,17796,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624136,,BAO_0000218,,,CLD0
7626,17796,Area under curve was determined after oral administration in rats; No data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624137,,BAO_0000218,,,CLD0
7627,17796,Area under curve was determined after oral administration in rats;No data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624320,,BAO_0000218,,,CLD0
7628,12923,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624321,,BAO_0000218,,,CLD0
7629,15372,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624322,,BAO_0000218,,,CLD0
7630,15372,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624323,,BAO_0000218,,,CLD0
7631,15372,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624324,,BAO_0000218,,,CLD0
7632,15372,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624325,,BAO_0000218,,,CLD0
7633,15372,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624326,,BAO_0000218,,,CLD0
7634,15372,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624327,,BAO_0000218,,,CLD0
7635,15372,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624328,,BAO_0000218,,,CLD0
7636,14169,Area under curve was determined in Dogs after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627848,,BAO_0000218,,,CLD0
7637,14169,Area under curve was determined in Rats after peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627849,,BAO_0000218,,,CLD0
7638,14258,Area under curve was determined in carotid blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627850,,BAO_0000218,178.0,,CLD0
7639,14258,Area under curve was determined in portal blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627851,,BAO_0000218,178.0,,CLD0
7640,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627852,,BAO_0000218,,,CLD0
7641,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627853,,BAO_0000218,,,CLD0
7642,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627854,,BAO_0000218,,,CLD0
7643,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627855,,BAO_0000218,,,CLD0
7644,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627856,,BAO_0000218,,,CLD0
7645,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875339,,BAO_0000218,,,CLD0
7646,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627857,,BAO_0000218,,,CLD0
7647,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627858,,BAO_0000218,2106.0,,CLD0
7648,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627859,,BAO_0000218,178.0,,CLD0
7649,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627860,,BAO_0000218,955.0,,CLD0
7650,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627019,,BAO_0000218,948.0,,CLD0
7651,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627020,,BAO_0000218,2107.0,,CLD0
7652,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627021,,BAO_0000218,2048.0,,CLD0
7653,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627022,,BAO_0000218,2385.0,,CLD0
7654,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627023,,BAO_0000218,,,CLD0
7655,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627024,,BAO_0000218,2106.0,,CLD0
7656,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627025,,BAO_0000218,2046.0,,CLD0
7657,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627026,,BAO_0000218,2113.0,,CLD0
7658,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627027,,BAO_0000218,178.0,,CLD0
7659,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627028,,BAO_0000218,955.0,,CLD0
7660,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627029,,BAO_0000218,948.0,,CLD0
7661,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627030,,BAO_0000218,2113.0,,CLD0
7662,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627031,,BAO_0000218,2107.0,,CLD0
7663,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627032,,BAO_0000218,2048.0,,CLD0
7664,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627033,,BAO_0000218,2385.0,,CLD0
7665,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627034,,BAO_0000218,,,CLD0
7666,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627035,,BAO_0000218,2106.0,,CLD0
7667,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627036,,BAO_0000218,2046.0,,CLD0
7668,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875340,,BAO_0000218,178.0,,CLD0
7669,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627037,,BAO_0000218,948.0,,CLD0
7670,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627038,,BAO_0000218,2113.0,,CLD0
7671,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627039,,BAO_0000218,2107.0,,CLD0
7672,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627040,,BAO_0000218,2385.0,,CLD0
7673,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL624663,,BAO_0000218,2106.0,,CLD0
7674,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL625963,,BAO_0000218,2046.0,,CLD0
7675,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL876799,,BAO_0000218,955.0,,CLD0
7676,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626133,,BAO_0000218,2048.0,,CLD0
7677,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626134,,BAO_0000218,,,CLD0
7678,6295,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626135,,BAO_0000218,2107.0,,CLD0
7679,6296,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626136,,BAO_0000218,2107.0,,CLD0
7680,6296,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626137,,BAO_0000218,2107.0,,CLD0
7681,6295,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626138,,BAO_0000218,1969.0,,CLD0
7682,6296,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626139,,BAO_0000218,1969.0,,CLD0
7683,17260,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626140,,BAO_0000218,,,CLD0
7684,17260,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626141,,BAO_0000218,,,CLD0
7685,17686,C24h in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626142,,BAO_0000218,,,CLD0
7686,9866,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627930,,BAO_0000218,2385.0,,CLD0
7687,9866,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627931,,BAO_0000218,2385.0,,CLD0
7688,9866,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627932,,BAO_0000218,2385.0,,CLD0
7689,9866,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627933,,BAO_0000218,2106.0,,CLD0
7690,9866,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627934,,BAO_0000218,2106.0,,CLD0
7691,9866,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627935,,BAO_0000218,2106.0,,CLD0
7692,9866,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627936,,BAO_0000218,178.0,,CLD0
7693,9866,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627937,,BAO_0000218,178.0,,CLD0
7694,9866,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627938,,BAO_0000218,178.0,,CLD0
7695,9866,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627939,,BAO_0000218,178.0,,CLD0
7696,9866,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627940,,BAO_0000218,178.0,,CLD0
7697,9866,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627941,,BAO_0000218,178.0,,CLD0
7698,9866,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL876800,,BAO_0000218,178.0,,CLD0
7699,9866,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627942,,BAO_0000218,178.0,,CLD0
7700,9866,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627943,,BAO_0000218,178.0,,CLD0
7701,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627944,,BAO_0000218,178.0,,CLD0
7702,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627945,,BAO_0000218,178.0,,CLD0
7703,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628584,,BAO_0000218,178.0,,CLD0
7704,9866,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628585,,BAO_0000218,178.0,,CLD0
7705,9866,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628586,,BAO_0000218,178.0,,CLD0
7706,9866,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628587,,BAO_0000218,178.0,,CLD0
7707,9866,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628588,,BAO_0000218,178.0,,CLD0
7708,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628589,,BAO_0000218,178.0,,CLD0
7709,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625304,,BAO_0000218,178.0,,CLD0
7710,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625305,,BAO_0000218,178.0,,CLD0
7711,9866,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625306,,BAO_0000218,178.0,,CLD0
7712,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625307,,BAO_0000218,178.0,,CLD0
7713,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625308,,BAO_0000218,178.0,,CLD0
7714,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627740,,BAO_0000218,178.0,,CLD0
7715,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627741,,BAO_0000218,178.0,,CLD0
7716,9866,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627742,,BAO_0000218,178.0,,CLD0
7717,9866,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627743,,BAO_0000218,178.0,,CLD0
7718,9866,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627744,,BAO_0000218,178.0,,CLD0
7719,9866,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627745,,BAO_0000218,1474.0,,CLD0
7720,9866,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627746,,BAO_0000218,1474.0,,CLD0
7721,9866,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627747,,BAO_0000218,1474.0,,CLD0
7722,9866,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL876810,,BAO_0000218,1474.0,,CLD0
7723,9866,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627748,,BAO_0000218,1474.0,,CLD0
7724,9866,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627749,,BAO_0000218,1474.0,,CLD0
7725,9866,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627750,,BAO_0000218,1474.0,,CLD0
7726,9866,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618728,,BAO_0000218,1474.0,,CLD0
7727,9866,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618729,,BAO_0000218,1474.0,,CLD0
7728,9866,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618730,,BAO_0000218,1474.0,,CLD0
7729,9866,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618731,,BAO_0000218,1474.0,,CLD0
7730,9866,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618732,,BAO_0000218,1474.0,,CLD0
7731,9866,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618733,,BAO_0000218,1474.0,,CLD0
7732,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618734,,BAO_0000218,1474.0,,CLD0
7733,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618735,,BAO_0000218,1474.0,,CLD0
7734,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL876602,,BAO_0000218,1474.0,,CLD0
7735,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618736,,BAO_0000218,1474.0,,CLD0
7736,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618737,,BAO_0000218,1474.0,,CLD0
7737,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618738,,BAO_0000218,1474.0,,CLD0
7738,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618739,,BAO_0000218,1474.0,,CLD0
7739,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618740,,BAO_0000218,1474.0,,CLD0
7740,9866,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618741,,BAO_0000218,1474.0,,CLD0
7741,9866,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618742,,BAO_0000218,1474.0,,CLD0
7742,9866,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL618743,,BAO_0000218,1474.0,,CLD0
7743,17752,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618744,,BAO_0000218,1969.0,,CLD0
7744,5610,Half-life in male rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618745,,BAO_0000218,,,CLD0
7745,5939,Half-life in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620479,,BAO_0000218,,,CLD0
7746,5939,Half-life in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620480,,BAO_0000218,,,CLD0
7747,17771,Half-life in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620481,,BAO_0000218,,,CLD0
7748,1974,Half-life was evaluated in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620482,,BAO_0000218,,,CLD0
7749,4239,Half-life was measured in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876603,,BAO_0000218,,,CLD0
7750,6681,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620483,,BAO_0000218,,,CLD0
7751,17752,Half-life period in rats after intravenous administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620484,,BAO_0000218,,,CLD0
7752,6046,Half-life period in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620485,,BAO_0000218,,,CLD0
7753,6685,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620486,,BAO_0000218,,,CLD0
7754,6685,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620487,,BAO_0000218,,,CLD0
7755,6685,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620488,,BAO_0000218,,,CLD0
7756,4727,Half-life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620489,,BAO_0000218,,,CLD0
7757,1088,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620490,,BAO_0000218,,,CLD0
7758,5610,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620491,,BAO_0000218,,,CLD0
7759,3032,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876604,,BAO_0000218,1969.0,,CLD0
7760,5199,Oral half life was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620492,,BAO_0000218,,,CLD0
7761,14941,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620493,,BAO_0000218,,,CLD0
7762,4408,Pharmacokinetic property (t1/2) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620494,,BAO_0000218,,,CLD0
7763,2552,Plasma elimination half-life was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620495,,BAO_0000218,1969.0,,CLD0
7764,5199,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620496,,BAO_0000218,1969.0,,CLD0
7765,15662,Plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620497,,BAO_0000218,1969.0,,CLD0
7766,1465,Plasma half-life was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620498,,BAO_0000218,1969.0,,CLD0
7767,1446,Plasma half-life following oral administration in Fisher rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620499,,BAO_0000218,1969.0,,CLD0
7768,6824,Plasma half-life in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620500,,BAO_0000218,1969.0,,CLD0
7769,17533,Plasmatic Half-life after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873809,,BAO_0000218,1969.0,,CLD0
7770,5979,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620501,,BAO_0000218,,,CLD0
7771,4689,Terminal half life after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620502,,BAO_0000218,,,CLD0
7772,4689,Terminal half life in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620503,,BAO_0000218,,,CLD0
7773,2463,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620504,,BAO_0000218,,,CLD0
7774,4883,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876605,,BAO_0000218,,,CLD0
7775,4883,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620505,,BAO_0000218,,,CLD0
7776,15662,plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873811,,BAO_0000218,1969.0,,CLD0
7777,3598,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL624016,,BAO_0000218,,,CLD0
7778,4576,Half life of compound determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624017,,BAO_0000218,,,CLD0
7779,4576,Mean residence time determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624018,,BAO_0000218,,,CLD0
7780,4576,Plasma half life determined in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624019,,BAO_0000218,1969.0,,CLD0
7781,4910,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624020,,BAO_0000218,955.0,,CLD0
7782,4891,Compound was evaluated for pharmacokinetic parameter maximum time period,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624201,,BAO_0000218,,,CLD0
7783,429,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL872528,,BAO_0000218,,,CLD0
7784,5974,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624202,,BAO_0000218,,,CLD0
7785,5974,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624203,,BAO_0000218,,,CLD0
7786,5974,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624350,,BAO_0000218,,,CLD0
7787,5974,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621320,,BAO_0000218,,,CLD0
7788,17582,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621321,,BAO_0000218,,,CLD0
7789,4026,Maximum time (Tmax) required to reach Cmax in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621322,,BAO_0000218,,,CLD0
7790,4890,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621323,,BAO_0000218,,,CLD0
7791,6571,Maximum time of clearance of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621324,,BAO_0000218,,,CLD0
7792,4727,Maximum time at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621325,,BAO_0000218,,,CLD0
7793,17651,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875837,,BAO_0000218,1969.0,,CLD0
7794,17651,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621326,,BAO_0000218,1969.0,,CLD0
7795,14465,Tmax in Guinea pig (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621327,,BAO_0000218,,,CLD0
7796,14941,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621328,,BAO_0000218,,,CLD0
7797,5960,Pharmacokinetic parameter (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621329,,BAO_0000218,,,CLD0
7798,5022,Pharmacokinetic parameter (Tmax) was estimated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621330,,BAO_0000218,,,CLD0
7799,4408,Pharmacokinetic property (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621331,,BAO_0000218,,,CLD0
7800,5983,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621332,,BAO_0000218,,,CLD0
7801,4689,T max in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621333,,BAO_0000218,,,CLD0
7802,2792,T max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621334,,BAO_0000218,,,CLD0
7803,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621335,,BAO_0000218,,,CLD0
7804,14180,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621336,,BAO_0000218,,,CLD0
7805,14180,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621337,,BAO_0000218,,,CLD0
7806,14599,Area under curve was measured after i.v. administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621338,,BAO_0000218,,,CLD0
7807,14599,Area under curve was measured after iv administration into Beagle dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875838,,BAO_0000218,,,CLD0
7808,14599,Area under curve was measured after po administration into Beagle dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621339,,BAO_0000218,,,CLD0
7809,14599,Area under curve was measured after po administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621340,,BAO_0000218,,,CLD0
7810,15675,Area under curve was measured at peroral dose of 3 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621341,,BAO_0000218,,,CLD0
7811,12706,Area under curve was measured by using concentration Vs time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621342,,BAO_0000019,,,CLD0
7812,12706,Area under curve was measured by using concentration Vs time; not tested,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621343,,BAO_0000019,,,CLD0
7813,9750,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621344,,BAO_0000218,,,CLD0
7814,9750,Area under curve(AUC) was measured in mice after oral administration.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621345,,BAO_0000218,,,CLD0
7815,14691,Area under curve(AUC) value of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621346,,BAO_0000019,,,CLD0
7816,14691,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621347,,BAO_0000218,,,CLD0
7817,14691,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621348,,BAO_0000218,,,CLD0
7818,2939,Area under curve(carotid artery) was determined by the availability in blood,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL621349,,BAO_0000221,178.0,,CLD0
7819,2939,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL621350,,BAO_0000221,178.0,,CLD0
7820,2939,Area under curve(carotid artery) was determined by the availability in blood; No data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL875839,,BAO_0000221,178.0,,CLD0
7821,2939,Area under curve(portal vein) was determined by the availability in blood,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620211,,BAO_0000221,178.0,,CLD0
7822,2939,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620212,,BAO_0000221,178.0,,CLD0
7823,2939,Area under curve(portal vein) was determined by the availability in blood; No data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620213,,BAO_0000221,178.0,,CLD0
7824,9552,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL620214,,BAO_0000218,1969.0,,CLD0
7825,9552,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL620215,,BAO_0000218,1969.0,,CLD0
7826,9552,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL620216,,BAO_0000218,1969.0,,CLD0
7827,9552,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620888,,BAO_0000218,1969.0,,CLD0
7828,9552,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620889,,BAO_0000218,1969.0,,CLD0
7829,9552,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620890,,BAO_0000366,1969.0,,CLD0
7830,11911,Area under plasma time curve determined in male rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620891,,BAO_0000218,1969.0,,CLD0
7831,16618,Area under the MAP curve measured over 5 min.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL620892,,BAO_0000019,,,CLD0
7832,14387,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621079,,BAO_0000218,,,CLD0
7833,14387,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621080,,BAO_0000218,,,CLD0
7834,12836,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621081,,BAO_0000218,,,CLD0
7835,12836,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL621082,,BAO_0000218,,,CLD0
7836,12836,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621083,,BAO_0000218,,,CLD0
7837,14339,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621084,,BAO_0000218,,,CLD0
7838,14339,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621085,,BAO_0000218,,,CLD0
7839,14339,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621086,,BAO_0000218,,,CLD0
7840,10524,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621087,,BAO_0000218,,,CLD0
7841,9994,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622607,,BAO_0000218,1969.0,,CLD0
7842,11325,Serum AUC in marmosets (IV dose),A,,,Canis lupus familiaris,9615.0,,Serum,,,50588,N,1,Intermediate,1,,CHEMBL622608,,BAO_0000218,1977.0,,CLD0
7843,12536,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624481,,BAO_0000019,,,CLD0
7844,12536,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624482,,BAO_0000019,,,CLD0
7845,12536,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624483,,BAO_0000019,,,CLD0
7846,12536,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624484,,BAO_0000019,,,CLD0
7847,12536,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624485,,BAO_0000019,,,CLD0
7848,15556,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624486,,BAO_0000218,,,CLD0
7849,2809,Area under the curve for the compound was calculated.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624487,,BAO_0000019,,,CLD0
7850,9511,Area under the curve in concentration/ time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624488,,BAO_0000019,,,CLD0
7851,12818,Area under the curve administered intraintestinal in rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624489,,BAO_0000218,,,CLD0
7852,12818,Area under the curve administered intravenously in rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625184,,BAO_0000218,,,CLD0
7853,15118,Area under the curve during intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625185,,BAO_0000019,,,CLD0
7854,15118,Area under the curve during intravenous administration; Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875954,,BAO_0000019,,,CLD0
7855,15118,Area under the curve during systemic administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625186,,BAO_0000019,,,CLD0
7856,15118,Area under the curve during systemic administration; Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625187,,BAO_0000019,,,CLD0
7857,2632,Area under the curve was calculated for the compound.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625188,,BAO_0000019,,,CLD0
7858,14346,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625189,,BAO_0000218,,,CLD0
7859,14346,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625190,,BAO_0000218,,,CLD0
7860,14346,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621733,,BAO_0000218,,,CLD0
7861,14346,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621734,,BAO_0000218,,,CLD0
7862,11149,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621735,,BAO_0000218,,,CLD0
7863,17796,Clearance of the drug was measured in the plasma of rat; No data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621736,,BAO_0000218,1969.0,,CLD0
7864,5247,The pharmacokinetic parameter plasma clearance in vivo in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621737,,BAO_0000218,1969.0,,CLD0
7865,4727,Plasma clearance at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621738,,BAO_0000218,1969.0,,CLD0
7866,5654,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622806,,BAO_0000218,,,CLD0
7867,5654,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623519,,BAO_0000218,,,CLD0
7868,17260,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623520,,BAO_0000218,,,CLD0
7869,17065,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623521,,BAO_0000218,,,CLD0
7870,17671,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623522,,BAO_0000218,,,CLD0
7871,6672,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623523,,BAO_0000218,,,CLD0
7872,6673,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623690,,BAO_0000218,,,CLD0
7873,5978,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623691,,BAO_0000218,,,CLD0
7874,5978,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623692,,BAO_0000218,,,CLD0
7875,5978,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623693,,BAO_0000218,,,CLD0
7876,5978,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623694,,BAO_0000218,,,CLD0
7877,4413,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623695,,BAO_0000218,,,CLD0
7878,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623696,,BAO_0000218,,,CLD0
7879,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623697,,BAO_0000218,,,CLD0
7880,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL623698,,BAO_0000218,1969.0,,CLD0
7881,5005,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL623699,,BAO_0000218,1969.0,,CLD0
7882,15765,Mean (%CV) PK parameters for CL(mL/min/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623700,,BAO_0000218,,,CLD0
7883,3747,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623701,,BAO_0000218,,,CLD0
7884,16366,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623702,,BAO_0000218,1969.0,,CLD0
7885,4199,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623703,,BAO_0000218,1969.0,,CLD0
7886,17267,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623704,,BAO_0000218,1969.0,,CLD0
7887,6535,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623705,,BAO_0000218,1969.0,,CLD0
7888,6535,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623706,,BAO_0000218,1969.0,,CLD0
7889,5041,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623707,,BAO_0000218,1969.0,,CLD0
7890,5960,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623708,,BAO_0000218,1969.0,,CLD0
7891,5937,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623709,,BAO_0000218,1969.0,,CLD0
7892,5871,Plasma clearance in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623710,,BAO_0000218,1969.0,,CLD0
7893,5874,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623711,,BAO_0000218,1969.0,,CLD0
7894,6504,Plasma clearance in rat p.o.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623712,,BAO_0000218,1969.0,,CLD0
7895,6803,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623713,,BAO_0000218,1969.0,,CLD0
7896,5041,Plasma clearance was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623714,,BAO_0000218,1969.0,,CLD0
7897,5041,Plasma clearance was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623715,,BAO_0000218,1969.0,,CLD0
7898,1916,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623716,,BAO_0000218,1969.0,,CLD0
7899,5199,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622980,,BAO_0000218,1969.0,,CLD0
7900,16367,Plasma administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622981,,BAO_0000218,,,CLD0
7901,6362,Plasma clearance of the compound in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622982,,BAO_0000218,1969.0,,CLD0
7902,15662,Plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622983,,BAO_0000218,1969.0,,CLD0
7903,6215,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622984,,BAO_0000218,,,CLD0
7904,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622985,,BAO_0000218,,,CLD0
7905,15662,plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623631,,BAO_0000218,1969.0,,CLD0
7906,4723,In vivo CL/F determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623632,,BAO_0000218,,,CLD0
7907,2792,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623633,,BAO_0000218,1969.0,,CLD0
7908,2792,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623634,,BAO_0000218,1969.0,,CLD0
7909,5213,Compound was tested for the lower blood clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623635,,BAO_0000218,178.0,,CLD0
7910,4687,Evaluated for the low clearance in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621195,,BAO_0000218,,,CLD0
7911,3371,Pharmacokinetic property (CLb)of the compound was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621196,,BAO_0000218,,,CLD0
7912,4690,Rapid clearance after intravenous administration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875287,,BAO_0000218,,,CLD0
7913,5702,Clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621197,,BAO_0000218,,,CLD0
7914,740,Compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621198,,BAO_0000218,1969.0,,CLD0
7915,4853,Low plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621199,,BAO_0000218,1969.0,,CLD0
7916,5789,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621200,,BAO_0000218,,,CLD0
7917,4527,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621201,,BAO_0000218,1969.0,,CLD0
7918,4527,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621202,,BAO_0000218,1969.0,,CLD0
7919,6518,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621203,,BAO_0000218,1969.0,,CLD0
7920,6518,Plasma clearance after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621204,,BAO_0000218,1969.0,,CLD0
7921,9866,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621205,,BAO_0000218,948.0,,CLD0
7922,9866,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621206,,BAO_0000218,948.0,,CLD0
7923,9866,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621207,,BAO_0000218,948.0,,CLD0
7924,9866,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621208,,BAO_0000218,948.0,,CLD0
7925,9866,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621209,,BAO_0000218,948.0,,CLD0
7926,9866,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL876484,,BAO_0000218,948.0,,CLD0
7927,9866,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621210,,BAO_0000218,948.0,,CLD0
7928,9866,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621211,,BAO_0000218,948.0,,CLD0
7929,9866,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621212,,BAO_0000218,948.0,,CLD0
7930,9866,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621213,,BAO_0000218,948.0,,CLD0
7931,9866,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621214,,BAO_0000218,948.0,,CLD0
7932,9866,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621215,,BAO_0000218,948.0,,CLD0
7933,9866,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621216,,BAO_0000218,948.0,,CLD0
7934,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621217,,BAO_0000218,948.0,,CLD0
7935,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621218,,BAO_0000218,948.0,,CLD0
7936,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621219,,BAO_0000218,948.0,,CLD0
7937,9866,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621220,,BAO_0000218,948.0,,CLD0
7938,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621221,,BAO_0000218,948.0,,CLD0
7939,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621222,,BAO_0000218,948.0,,CLD0
7940,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621223,,BAO_0000218,948.0,,CLD0
7941,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL876485,,BAO_0000218,948.0,,CLD0
7942,9866,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621224,,BAO_0000218,948.0,,CLD0
7943,9866,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621225,,BAO_0000218,948.0,,CLD0
7944,9866,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621226,,BAO_0000218,948.0,,CLD0
7945,9866,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621227,,BAO_0000218,2113.0,,CLD0
7946,9866,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621228,,BAO_0000218,2113.0,,CLD0
7947,9866,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621229,,BAO_0000218,2113.0,,CLD0
7948,9866,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621230,,BAO_0000218,2113.0,,CLD0
7949,9866,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621231,,BAO_0000218,2113.0,,CLD0
7950,9866,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621232,,BAO_0000218,2113.0,,CLD0
7951,9866,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621233,,BAO_0000218,2113.0,,CLD0
7952,9866,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621234,,BAO_0000218,2113.0,,CLD0
7953,9866,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621235,,BAO_0000218,2113.0,,CLD0
7954,9866,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621236,,BAO_0000218,2113.0,,CLD0
7955,9866,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621237,,BAO_0000218,2113.0,,CLD0
7956,9866,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL876486,,BAO_0000218,2113.0,,CLD0
7957,9866,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622436,,BAO_0000218,160.0,,CLD0
7958,9866,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622437,,BAO_0000218,160.0,,CLD0
7959,9866,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622438,,BAO_0000218,160.0,,CLD0
7960,9866,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622439,,BAO_0000218,2107.0,,CLD0
7961,9866,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622440,,BAO_0000218,2107.0,,CLD0
7962,9866,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622441,,BAO_0000218,2107.0,,CLD0
7963,9866,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622442,,BAO_0000218,2107.0,,CLD0
7964,9866,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622443,,BAO_0000218,2107.0,,CLD0
7965,9866,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622444,,BAO_0000218,2107.0,,CLD0
7966,9866,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622445,,BAO_0000218,2107.0,,CLD0
7967,9866,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622446,,BAO_0000218,2107.0,,CLD0
7968,9866,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622447,,BAO_0000218,2107.0,,CLD0
7969,9866,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622448,,BAO_0000218,2107.0,,CLD0
7970,9866,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622449,,BAO_0000218,2107.0,,CLD0
7971,9866,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622450,,BAO_0000218,2107.0,,CLD0
7972,9866,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622451,,BAO_0000218,2107.0,,CLD0
7973,9866,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622452,,BAO_0000218,2107.0,,CLD0
7974,9866,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622453,,BAO_0000218,2107.0,,CLD0
7975,9866,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622454,,BAO_0000218,2107.0,,CLD0
7976,9866,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622455,,BAO_0000218,2107.0,,CLD0
7977,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876024,,BAO_0000218,2107.0,,CLD0
7978,2792,T max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622456,,BAO_0000218,,,CLD0
7979,15078,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622457,,BAO_0000218,,,CLD0
7980,15078,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622458,,BAO_0000218,,,CLD0
7981,15022,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622459,,BAO_0000218,,,CLD0
7982,15022,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873343,,BAO_0000218,,,CLD0
7983,15022,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622460,,BAO_0000218,,,CLD0
7984,4576,Time for maximum plasma concentration determined in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622461,,BAO_0000218,1969.0,,CLD0
7985,6681,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622462,,BAO_0000218,1969.0,,CLD0
7986,16365,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622463,,BAO_0000218,,,CLD0
7987,16365,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622464,,BAO_0000218,,,CLD0
7988,16365,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622465,,BAO_0000218,,,CLD0
7989,16365,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622466,,BAO_0000218,,,CLD0
7990,16365,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622467,,BAO_0000218,,,CLD0
7991,6824,Time of maximum plasma concentration in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622468,,BAO_0000218,1969.0,,CLD0
7992,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876025,,BAO_0000218,1969.0,,CLD0
7993,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622469,,BAO_0000218,1969.0,,CLD0
7994,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622470,,BAO_0000218,1969.0,,CLD0
7995,15662,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622471,,BAO_0000218,,,CLD0
7996,1742,Time required to reach maximum concentration in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622472,,BAO_0000218,1969.0,,CLD0
7997,2774,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622473,,BAO_0000218,1969.0,,CLD0
7998,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624282,,BAO_0000218,1969.0,,CLD0
7999,12873,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624283,,BAO_0000218,1969.0,,CLD0
8000,12873,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624284,,BAO_0000218,1969.0,,CLD0
8001,1916,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624285,,BAO_0000218,1969.0,,CLD0
8002,16367,Time to reach Cmax after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624286,,BAO_0000218,,,CLD0
8003,16366,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624287,,BAO_0000218,,,CLD0
8004,216,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624288,,BAO_0000218,,,CLD0
8005,6410,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624289,,BAO_0000218,1969.0,,CLD0
8006,6410,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873344,,BAO_0000218,1969.0,,CLD0
8007,6215,Tmax after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619623,,BAO_0000218,,,CLD0
8008,3598,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL621399,,BAO_0000218,,,CLD0
8009,4527,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621400,,BAO_0000218,,,CLD0
8010,17670,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621401,,BAO_0000218,,,CLD0
8011,1465,Tmax was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621402,,BAO_0000218,,,CLD0
8012,2552,Tmax was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621403,,BAO_0000218,,,CLD0
8013,5656,Tmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621121,,BAO_0000218,,,CLD0
8014,17764,Tmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL872525,,BAO_0000218,,,CLD0
8015,5610,Tmax in male rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621122,,BAO_0000218,,,CLD0
8016,6046,Tmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621123,,BAO_0000218,,,CLD0
8017,5874,Tmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621124,,BAO_0000218,,,CLD0
8018,17596,Tmax in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621125,,BAO_0000218,,,CLD0
8019,17804,Tmax was measured in rats after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621126,,BAO_0000218,,,CLD0
8020,1908,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621127,,BAO_0000218,,,CLD0
8021,2959,Tmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621128,,BAO_0000218,,,CLD0
8022,6757,Tmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618263,,BAO_0000218,,,CLD0
8023,6757,Tmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618264,,BAO_0000218,,,CLD0
8024,6757,Tmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618265,,BAO_0000218,,,CLD0
8025,4186,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618266,,BAO_0000218,1969.0,,CLD0
8026,15662,time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618267,,BAO_0000218,,,CLD0
8027,429,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618450,,BAO_0000218,1088.0,,CLD0
8028,429,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618451,,BAO_0000218,1088.0,,CLD0
8029,5546,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618452,,BAO_0000218,1969.0,,CLD0
8030,3173,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618453,,BAO_0000218,1088.0,,CLD0
8031,3173,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618454,,BAO_0000218,1088.0,,CLD0
8032,3173,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618455,,BAO_0000218,1088.0,,CLD0
8033,4257,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618456,,BAO_0000218,,,CLD0
8034,6011,Compound distribution in rat tissues was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618457,,BAO_0000218,,,CLD0
8035,5472,Volume of distribution was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618458,,BAO_0000218,,,CLD0
8036,14346,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618459,,BAO_0000218,,,CLD0
8037,14346,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876733,,BAO_0000218,,,CLD0
8038,14346,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618460,,BAO_0000218,,,CLD0
8039,14346,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618461,,BAO_0000218,,,CLD0
8040,15469,Area under the curve was determined after oral administration (300 uM/Kg),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618462,,BAO_0000019,,,CLD0
8041,14346,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618463,,BAO_0000218,,,CLD0
8042,14346,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618464,,BAO_0000218,,,CLD0
8043,14346,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618465,,BAO_0000218,,,CLD0
8044,14346,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618466,,BAO_0000218,,,CLD0
8045,14346,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618467,,BAO_0000218,,,CLD0
8046,15372,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618468,,BAO_0000218,,,CLD0
8047,12935,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618469,,BAO_0000218,1969.0,,CLD0
8048,12935,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618470,,BAO_0000218,1969.0,,CLD0
8049,14813,Plasma drug AUC in rat (PO dose),A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618471,,BAO_0000218,1969.0,,CLD0
8050,15792,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618472,,BAO_0000218,,,CLD0
8051,3579,Area under was determined at a dose of 30 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618473,,BAO_0000218,,,CLD0
8052,12487,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL621699,,BAO_0000218,,,CLD0
8053,12487,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621700,,BAO_0000218,,,CLD0
8054,12487,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621701,,BAO_0000218,,,CLD0
8055,12487,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL621702,,BAO_0000218,,,CLD0
8056,12487,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621703,,BAO_0000218,,,CLD0
8057,12487,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621704,,BAO_0000218,,,CLD0
8058,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624259,,BAO_0000218,,,CLD0
8059,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624260,,BAO_0000218,,,CLD0
8060,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624430,,BAO_0000218,,,CLD0
8061,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624431,,BAO_0000218,,,CLD0
8062,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624432,,BAO_0000218,,,CLD0
8063,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624433,,BAO_0000218,,,CLD0
8064,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624434,,BAO_0000218,,,CLD0
8065,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624435,,BAO_0000218,,,CLD0
8066,12745,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618570,,BAO_0000218,955.0,,CLD0
8067,12745,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618571,,BAO_0000218,955.0,,CLD0
8068,12745,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618572,,BAO_0000218,955.0,,CLD0
8069,12745,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618573,,BAO_0000218,955.0,,CLD0
8070,12745,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619267,,BAO_0000218,1977.0,,CLD0
8071,12745,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619431,,BAO_0000218,1977.0,,CLD0
8072,12745,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619432,,BAO_0000218,1977.0,,CLD0
8073,12745,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619433,,BAO_0000218,1977.0,,CLD0
8074,13298,AUC in mice after oral dose (50 mg/kg),A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619434,,BAO_0000218,1969.0,,CLD0
8075,12226,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619435,,BAO_0000218,1977.0,,CLD0
8076,12634,AUC (0-4 hr) ug/ml/h,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619436,,BAO_0000366,1969.0,,CLD0
8077,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619437,,BAO_0000218,,,CLD0
8078,13889,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619438,,BAO_0000218,,,CLD0
8079,10018,Compound was evaluated for Area under curve in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619439,,BAO_0000218,,,CLD0
8080,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619440,,BAO_0000218,,,CLD0
8081,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619441,,BAO_0000218,,,CLD0
8082,8758,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619442,,BAO_0000218,,,CLD0
8083,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875156,,BAO_0000019,,,CLD0
8084,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619443,,BAO_0000019,,,CLD0
8085,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619444,,BAO_0000019,,,CLD0
8086,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623464,,BAO_0000019,,,CLD0
8087,15115,Compound was evaluated for area under curve when administered through oral route in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623465,,BAO_0000218,,,CLD0
8088,6518,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623466,,BAO_0000218,1969.0,,CLD0
8089,6518,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623467,,BAO_0000218,1969.0,,CLD0
8090,6249,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623468,,BAO_0000218,1969.0,,CLD0
8091,2463,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622660,,BAO_0000218,1969.0,,CLD0
8092,4969,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622661,,BAO_0000218,1969.0,,CLD0
8093,17720,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622662,,BAO_0000218,1969.0,,CLD0
8094,3457,Pharmacokinetic property (total body clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622663,,BAO_0000218,,,CLD0
8095,5983,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622664,,BAO_0000218,,,CLD0
8096,6295,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622665,,BAO_0000218,2107.0,,CLD0
8097,6296,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622666,,BAO_0000218,2107.0,,CLD0
8098,17686,Cl in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621615,,BAO_0000218,,,CLD0
8099,17764,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621616,,BAO_0000218,,,CLD0
8100,5503,Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621617,,BAO_0000218,,,CLD0
8101,4368,Clearance by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621618,,BAO_0000218,,,CLD0
8102,6005,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621619,,BAO_0000218,,,CLD0
8103,5031,Clearance rate after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621620,,BAO_0000218,,,CLD0
8104,4890,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621786,,BAO_0000218,,,CLD0
8105,5182,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621787,,BAO_0000218,,,CLD0
8106,5979,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621788,,BAO_0000218,,,CLD0
8107,5656,Clearance (Cl) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621789,,BAO_0000218,,,CLD0
8108,17804,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621790,,BAO_0000218,,,CLD0
8109,4839,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621791,,BAO_0000218,1969.0,,CLD0
8110,5041,In vitro microsome metabolism clearance in rat was determined,A,In vitro,,Rattus norvegicus,10116.0,,,,Microsome,50597,N,1,Intermediate,1,,CHEMBL621792,,BAO_0000218,,,CLD0
8111,5041,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,In vitro,,Rattus norvegicus,10116.0,,,,Microsome,50597,N,1,Intermediate,1,,CHEMBL621793,,BAO_0000218,,,CLD0
8112,5974,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621794,,BAO_0000218,,,CLD0
8113,5496,In vivo plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621795,,BAO_0000218,1969.0,,CLD0
8114,5739,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621796,,BAO_0000218,,,CLD0
8115,5676,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,Hepatocyte,,50597,N,1,Intermediate,1,,CHEMBL621797,401.0,BAO_0000218,2107.0,,CLD0
8116,4239,Pharmacokinetic property (Plasma clearance) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621798,,BAO_0000218,1969.0,,CLD0
8117,5676,Pharmacokinetic property (clearance) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621799,,BAO_0000218,,,CLD0
8118,1918,"Plasma Clearance was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621800,,BAO_0000218,1969.0,,CLD0
8119,17800,Plasma clearance (in vivo) in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621801,,BAO_0000218,1969.0,,CLD0
8120,6056,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621802,,BAO_0000218,1969.0,,CLD0
8121,5496,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618596,,BAO_0000218,1969.0,,CLD0
8122,5939,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618597,,BAO_0000218,1969.0,,CLD0
8123,5939,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618598,,BAO_0000218,1969.0,,CLD0
8124,17752,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618599,,BAO_0000218,1969.0,,CLD0
8125,4576,Plasma clearance rate determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618600,,BAO_0000218,1969.0,,CLD0
8126,6011,Plasma clearance was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618601,,BAO_0000218,1969.0,,CLD0
8127,5510,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618602,,BAO_0000218,1969.0,,CLD0
8128,5948,Plasma clearance value in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618603,,BAO_0000218,1969.0,,CLD0
8129,6125,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618604,,BAO_0000218,2107.0,,CLD0
8130,4839,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618605,,BAO_0000218,,,CLD0
8131,17686,Total body clearance in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618606,,BAO_0000218,,,CLD0
8132,6571,Clearance of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618607,,BAO_0000218,,,CLD0
8133,3364,Clearance after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618608,,BAO_0000218,,,CLD0
8134,13569,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618609,,BAO_0000218,,,CLD0
8135,13569,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618610,,BAO_0000218,,,CLD0
8136,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618611,,BAO_0000218,,,CLD0
8137,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618612,,BAO_0000218,,,CLD0
8138,13569,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618613,,BAO_0000218,,,CLD0
8139,13569,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621076,,BAO_0000218,,,CLD0
8140,13569,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621077,,BAO_0000218,,,CLD0
8141,17670,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621078,,BAO_0000218,,,CLD0
8142,5970,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621251,,BAO_0000218,,,CLD0
8143,6495,Clearance in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621252,,BAO_0000218,,,CLD0
8144,4590,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621253,,BAO_0000218,,,CLD0
8145,6193,Clearance rate following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621254,,BAO_0000218,,,CLD0
8146,2832,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621255,,BAO_0000218,,,CLD0
8147,1052,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621256,,BAO_0000218,1969.0,,CLD0
8148,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621257,,BAO_0000218,2107.0,,CLD0
8149,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621258,,BAO_0000218,2107.0,,CLD0
8150,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621259,,BAO_0000218,2107.0,,CLD0
8151,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621260,,BAO_0000218,2107.0,,CLD0
8152,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876494,,BAO_0000218,2107.0,,CLD0
8153,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621261,,BAO_0000218,2107.0,,CLD0
8154,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621262,,BAO_0000218,2107.0,,CLD0
8155,9866,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621263,,BAO_0000218,2107.0,,CLD0
8156,9866,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621264,,BAO_0000218,2107.0,,CLD0
8157,9866,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621265,,BAO_0000218,2385.0,,CLD0
8158,9866,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621266,,BAO_0000218,2385.0,,CLD0
8159,9866,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621267,,BAO_0000218,2385.0,,CLD0
8160,9866,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621268,,BAO_0000218,2385.0,,CLD0
8161,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621269,,BAO_0000218,2385.0,,CLD0
8162,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621270,,BAO_0000218,2385.0,,CLD0
8163,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621271,,BAO_0000218,2385.0,,CLD0
8164,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621272,,BAO_0000218,2385.0,,CLD0
8165,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621273,,BAO_0000218,2385.0,,CLD0
8166,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621274,,BAO_0000218,2385.0,,CLD0
8167,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL876495,,BAO_0000218,2385.0,,CLD0
8168,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621275,,BAO_0000218,2385.0,,CLD0
8169,9866,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621276,,BAO_0000218,2385.0,,CLD0
8170,9866,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621277,,BAO_0000218,2385.0,,CLD0
8171,9866,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621278,,BAO_0000218,160.0,,CLD0
8172,9866,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621279,,BAO_0000218,160.0,,CLD0
8173,9866,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621280,,BAO_0000218,160.0,,CLD0
8174,9866,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621281,,BAO_0000218,2106.0,,CLD0
8175,9866,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621282,,BAO_0000218,2106.0,,CLD0
8176,9866,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621283,,BAO_0000218,2106.0,,CLD0
8177,9866,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621284,,BAO_0000218,2106.0,,CLD0
8178,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621285,,BAO_0000218,2106.0,,CLD0
8179,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621286,,BAO_0000218,2106.0,,CLD0
8180,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL623220,,BAO_0000218,2106.0,,CLD0
8181,9866,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL623221,,BAO_0000218,2106.0,,CLD0
8182,9866,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL876029,,BAO_0000218,2106.0,,CLD0
8183,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623222,,BAO_0000218,945.0,,CLD0
8184,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623223,,BAO_0000218,945.0,,CLD0
8185,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL621445,,BAO_0000218,945.0,,CLD0
8186,13950,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621446,,BAO_0000218,178.0,,CLD0
8187,13950,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621447,,BAO_0000218,178.0,,CLD0
8188,13950,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL619681,,BAO_0000218,178.0,,CLD0
8189,13950,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL619682,,BAO_0000218,178.0,,CLD0
8190,13950,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL619683,,BAO_0000218,178.0,,CLD0
8191,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619684,,BAO_0000218,955.0,,CLD0
8192,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619685,,BAO_0000218,955.0,,CLD0
8193,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619686,,BAO_0000218,955.0,,CLD0
8194,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619687,,BAO_0000218,955.0,,CLD0
8195,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619688,,BAO_0000218,955.0,,CLD0
8196,13950,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619689,,BAO_0000218,948.0,,CLD0
8197,13950,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619690,,BAO_0000218,948.0,,CLD0
8198,13950,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619691,,BAO_0000218,948.0,,CLD0
8199,6062,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619692,,BAO_0000218,,,CLD0
8200,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Expert,1,,CHEMBL619693,,BAO_0000218,1969.0,,CLD0
8201,1908,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619694,,BAO_0000218,,,CLD0
8202,17596,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619695,,BAO_0000218,,,CLD0
8203,4891,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619696,,BAO_0000218,,,CLD0
8204,740,Compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619697,,BAO_0000218,,,CLD0
8205,16366,Steady state volume distribution was determined; steady state(ss),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619698,,BAO_0000218,,,CLD0
8206,3364,Steady state volume of distribution after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619699,,BAO_0000218,,,CLD0
8207,2552,Steady state volume of distribution dosing at 3 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619700,,BAO_0000218,,,CLD0
8208,406,The compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619701,,BAO_0000218,,,CLD0
8209,12500,The compound was tested for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619702,,BAO_0000218,,,CLD0
8210,12500,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620335,,BAO_0000218,,,CLD0
8211,5656,Volume distribution (VD) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620336,,BAO_0000218,,,CLD0
8212,17671,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620337,,BAO_0000218,,,CLD0
8213,1094,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620520,,BAO_0000218,,,CLD0
8214,5833,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620521,,BAO_0000218,,,CLD0
8215,5939,Volume distribution in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875825,,BAO_0000218,,,CLD0
8216,5939,Volume distribution in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620522,,BAO_0000218,,,CLD0
8217,6005,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620523,,BAO_0000218,,,CLD0
8218,1696,Volume of distribution in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620524,,BAO_0000218,,,CLD0
8219,6672,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620525,,BAO_0000218,,,CLD0
8220,6673,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620526,,BAO_0000218,,,CLD0
8221,5871,Volume of distribution in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620527,,BAO_0000218,,,CLD0
8222,6803,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620528,,BAO_0000218,,,CLD0
8223,5199,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620529,,BAO_0000218,,,CLD0
8224,4727,Volume distribution at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620530,,BAO_0000218,,,CLD0
8225,16367,Steady state volume of distribution was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620531,,BAO_0000218,,,CLD0
8226,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL620532,,BAO_0000218,1969.0,,CLD0
8227,5005,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL620533,,BAO_0000218,1969.0,,CLD0
8228,5005,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL620534,,BAO_0000218,1969.0,,CLD0
8229,15765,Mean (%CV) PK parameters for Vdss(mL/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620535,,BAO_0000218,,,CLD0
8230,2792,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875826,,BAO_0000218,,,CLD0
8231,2792,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620536,,BAO_0000218,,,CLD0
8232,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620537,,BAO_0000218,,,CLD0
8233,5334,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618526,,BAO_0000218,,,CLD0
8234,5739,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618527,,BAO_0000218,,,CLD0
8235,5789,Pharmacokinetic property (Vdss) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618528,,BAO_0000218,,,CLD0
8236,4239,Pharmacokinetic property (vdss) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618529,,BAO_0000218,,,CLD0
8237,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618530,,BAO_0000218,,,CLD0
8238,6642,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618531,,BAO_0000218,,,CLD0
8239,5247,The pharmacokinetic parameter volume of distribution in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618532,,BAO_0000218,,,CLD0
8240,17720,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618533,,BAO_0000218,1969.0,,CLD0
8241,17686,Vdss in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618534,,BAO_0000218,,,CLD0
8242,4689,Volume distribution after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618535,,BAO_0000218,,,CLD0
8243,5654,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618536,,BAO_0000218,,,CLD0
8244,5654,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618537,,BAO_0000218,,,CLD0
8245,4527,Volume distribution at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618538,,BAO_0000218,,,CLD0
8246,4521,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618539,,BAO_0000218,,,CLD0
8247,6057,Volume distribution was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618540,,BAO_0000218,,,CLD0
8248,5510,Volume distribution was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618541,,BAO_0000218,,,CLD0
8249,2938,Volume of distribution after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618542,,BAO_0000218,,,CLD0
8250,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622544,,BAO_0000218,,,CLD0
8251,6685,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622545,,BAO_0000218,,,CLD0
8252,6685,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622546,,BAO_0000218,,,CLD0
8253,6685,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622547,,BAO_0000218,,,CLD0
8254,5145,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622548,,BAO_0000218,,,CLD0
8255,6467,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622549,,BAO_0000218,,,CLD0
8256,6467,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622550,,BAO_0000218,,,CLD0
8257,15115,Compound was evaluated for area under curve when administered through oral route to mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622551,,BAO_0000218,,,CLD0
8258,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622552,,BAO_0000218,,,CLD0
8259,8758,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622553,,BAO_0000218,,,CLD0
8260,8267,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622554,,BAO_0000218,,,CLD0
8261,8267,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622555,,BAO_0000218,,,CLD0
8262,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622556,,BAO_0000218,,,CLD0
8263,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622557,,BAO_0000218,,,CLD0
8264,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622558,,BAO_0000218,178.0,,CLD0
8265,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622559,,BAO_0000218,178.0,,CLD0
8266,10754,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622560,,BAO_0000218,,,CLD0
8267,14681,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622561,,BAO_0000218,,,CLD0
8268,14681,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622562,,BAO_0000218,,,CLD0
8269,14681,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622563,,BAO_0000218,,,CLD0
8270,13118,Concentration of compound in Central nervous system,A,,,,,,Central nervous system,,,22224,U,0,Autocuration,1,,CHEMBL622564,,BAO_0000221,1017.0,,CLD0
8271,13118,Concentration of compound in Central nervous system; Not detectable,A,,,,,,Central nervous system,,,22224,U,0,Autocuration,1,,CHEMBL622565,,BAO_0000221,1017.0,,CLD0
8272,13318,"Concentration of diester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622566,,BAO_0000218,,,CLD0
8273,13318,"Concentration of monoester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL624515,,BAO_0000218,178.0,,CLD0
8274,13318,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL624516,,BAO_0000218,178.0,,CLD0
8275,15692,Evaluated for Pharmacokinetic property: Area under the curve,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624517,,BAO_0000019,,,CLD0
8276,14839,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624518,,BAO_0000218,1969.0,,CLD0
8277,14839,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL624519,,BAO_0000218,1969.0,,CLD0
8278,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624520,,BAO_0000218,,,CLD0
8279,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624521,,BAO_0000218,,,CLD0
8280,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624522,,BAO_0000218,,,CLD0
8281,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624523,,BAO_0000218,,,CLD0
8282,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624409,,BAO_0000218,,,CLD0
8283,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624410,,BAO_0000218,,,CLD0
8284,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624411,,BAO_0000218,,,CLD0
8285,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623531,,BAO_0000218,,,CLD0
8286,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623532,,BAO_0000218,,,CLD0
8287,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623533,,BAO_0000218,,,CLD0
8288,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623534,,BAO_0000218,,,CLD0
8289,14839,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623535,,BAO_0000218,,,CLD0
8290,14839,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623536,,BAO_0000218,,,CLD0
8291,14839,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623537,,BAO_0000218,,,CLD0
8292,14839,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623538,,BAO_0000218,,,CLD0
8293,14839,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623539,,BAO_0000218,,,CLD0
8294,14839,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623540,,BAO_0000218,,,CLD0
8295,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623541,,BAO_0000218,,,CLD0
8296,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623542,,BAO_0000218,,,CLD0
8297,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623543,,BAO_0000218,,,CLD0
8298,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623544,,BAO_0000218,,,CLD0
8299,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623545,,BAO_0000218,,,CLD0
8300,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623546,,BAO_0000218,,,CLD0
8301,5408,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623547,,BAO_0000218,1969.0,,CLD0
8302,6827,High i.v. clearance in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623548,,BAO_0000218,,,CLD0
8303,17538,In vitro clearance in rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsome,50597,N,1,Intermediate,1,,CHEMBL623549,,BAO_0000218,2107.0,,CLD0
8304,6331,Intrinsic clearance in rat liver microsomes was determined,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsome,50597,N,1,Intermediate,1,,CHEMBL623550,,BAO_0000218,2107.0,,CLD0
8305,5948,Intrinsic clearance in rat hepatocytes was determined,A,In vitro,,Rattus norvegicus,10116.0,,Liver,Hepatocyte,,50597,N,1,Intermediate,1,,CHEMBL875276,401.0,BAO_0000218,2107.0,,CLD0
8306,4026,Plasma Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621872,,BAO_0000218,1969.0,,CLD0
8307,6647,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621873,,BAO_0000218,1969.0,,CLD0
8308,1696,Plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621874,,BAO_0000218,1969.0,,CLD0
8309,6597,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621875,,BAO_0000218,1969.0,,CLD0
8310,347,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621876,,BAO_0000218,1969.0,,CLD0
8311,16423,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621877,,BAO_0000218,1969.0,,CLD0
8312,2879,Plasma clearance was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621878,,BAO_0000218,1969.0,,CLD0
8313,4883,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621879,,BAO_0000218,,,CLD0
8314,5328,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621880,,BAO_0000218,1969.0,,CLD0
8315,5160,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621881,,BAO_0000218,,,CLD0
8316,17582,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621882,,BAO_0000218,,,CLD0
8317,17651,Total clearance at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875283,,BAO_0000218,,,CLD0
8318,17651,Total clearance at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621883,,BAO_0000218,,,CLD0
8319,6596,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621884,,BAO_0000218,,,CLD0
8320,4796,Plasma clearance rate determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621885,,BAO_0000218,1969.0,,CLD0
8321,6850,Clearance of compound in rat was evaluated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621886,,BAO_0000218,,,CLD0
8322,5932,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621887,,BAO_0000218,1969.0,,CLD0
8323,3371,Pharmacokinetic property (blood clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621888,,BAO_0000218,178.0,,CLD0
8324,2083,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621889,,BAO_0000218,1969.0,,CLD0
8325,4942,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621890,,BAO_0000218,1969.0,,CLD0
8326,6838,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsome,50597,N,1,Intermediate,1,,CHEMBL621891,,BAO_0000218,2107.0,,CLD0
8327,5353,Clearance in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621892,,BAO_0000218,,,CLD0
8328,6641,Clearance rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621893,,BAO_0000218,,,CLD0
8329,6641,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621894,,BAO_0000218,,,CLD0
8330,6641,Clearance rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621895,,BAO_0000218,,,CLD0
8331,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875284,,BAO_0000218,,,CLD0
8332,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618699,,BAO_0000218,,,CLD0
8333,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618700,,BAO_0000218,,,CLD0
8334,6211,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618701,,BAO_0000218,,,CLD0
8335,12873,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876600,,BAO_0000218,1969.0,,CLD0
8336,6570,Clearance of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618702,,BAO_0000218,,,CLD0
8337,3341,Compound was evaluated for Hepatic clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618703,,BAO_0000218,2107.0,,CLD0
8338,4891,In vivo clearance after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618704,,BAO_0000218,,,CLD0
8339,1094,Compound was tested for plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618705,,BAO_0000218,1969.0,,CLD0
8340,2938,Hepatic clearance after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618706,,BAO_0000218,2107.0,,CLD0
8341,17853,Lower clearance in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618707,,BAO_0000218,,,CLD0
8342,6049,Pharmacokinetic parameter expressed as plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618708,,BAO_0000218,1969.0,,CLD0
8343,5789,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618709,,BAO_0000218,,,CLD0
8344,4514,Plasma clearance in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618710,,BAO_0000218,1969.0,,CLD0
8345,6448,Plasma clearance (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618711,,BAO_0000218,1969.0,,CLD0
8346,6062,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618712,,BAO_0000218,1969.0,,CLD0
8347,5710,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618713,,BAO_0000218,1969.0,,CLD0
8348,4709,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618714,,BAO_0000218,1969.0,,CLD0
8349,4521,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618715,,BAO_0000218,1969.0,,CLD0
8350,1742,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618716,,BAO_0000218,1969.0,,CLD0
8351,6057,Plasma clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876601,,BAO_0000218,1969.0,,CLD0
8352,6057,Plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618717,,BAO_0000218,1969.0,,CLD0
8353,5145,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618718,,BAO_0000218,1969.0,,CLD0
8354,5833,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618719,,BAO_0000218,1969.0,,CLD0
8355,6453,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618720,,BAO_0000218,1969.0,,CLD0
8356,6640,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618721,,BAO_0000218,1969.0,,CLD0
8357,6305,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621477,,BAO_0000218,1969.0,,CLD0
8358,6642,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621478,,BAO_0000218,1969.0,,CLD0
8359,5472,Plasma clearance was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621479,,BAO_0000218,1969.0,,CLD0
8360,5472,Plasma clearance was evaluated in rat; Not tested,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621480,,BAO_0000218,1969.0,,CLD0
8361,5144,Plasma clearance rate was determined for the compound in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621481,,BAO_0000218,1969.0,,CLD0
8362,6685,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621482,,BAO_0000218,1969.0,,CLD0
8363,6685,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621483,,BAO_0000218,1969.0,,CLD0
8364,6685,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621484,,BAO_0000218,1969.0,,CLD0
8365,13950,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621485,,BAO_0000218,948.0,,CLD0
8366,13950,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621486,,BAO_0000218,948.0,,CLD0
8367,13950,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621487,,BAO_0000218,160.0,,CLD0
8368,13950,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621488,,BAO_0000218,160.0,,CLD0
8369,13950,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621489,,BAO_0000218,160.0,,CLD0
8370,13950,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621490,,BAO_0000218,160.0,,CLD0
8371,13950,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621491,,BAO_0000218,160.0,,CLD0
8372,13950,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621492,,BAO_0000218,2113.0,,CLD0
8373,13950,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621493,,BAO_0000218,2113.0,,CLD0
8374,13950,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621494,,BAO_0000218,2113.0,,CLD0
8375,13950,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621495,,BAO_0000218,2113.0,,CLD0
8376,13950,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621496,,BAO_0000218,2113.0,,CLD0
8377,13950,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621497,,BAO_0000218,2107.0,,CLD0
8378,13950,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621498,,BAO_0000218,2107.0,,CLD0
8379,13950,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621499,,BAO_0000218,2107.0,,CLD0
8380,13950,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618634,,BAO_0000218,2107.0,,CLD0
8381,13950,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618635,,BAO_0000218,2107.0,,CLD0
8382,13950,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618636,,BAO_0000218,2048.0,,CLD0
8383,13950,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL619737,,BAO_0000218,2048.0,,CLD0
8384,13950,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL619738,,BAO_0000218,2048.0,,CLD0
8385,13950,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624329,,BAO_0000218,2048.0,,CLD0
8386,13950,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624330,,BAO_0000218,2048.0,,CLD0
8387,13950,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624331,,BAO_0000218,2385.0,,CLD0
8388,13950,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624332,,BAO_0000218,2385.0,,CLD0
8389,13950,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624333,,BAO_0000218,2385.0,,CLD0
8390,13950,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624334,,BAO_0000218,2385.0,,CLD0
8391,13950,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624335,,BAO_0000218,2385.0,,CLD0
8392,13950,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620016,,BAO_0000218,2106.0,,CLD0
8393,13950,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620169,,BAO_0000218,2106.0,,CLD0
8394,13950,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620170,,BAO_0000218,2106.0,,CLD0
8395,13950,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620171,,BAO_0000218,2106.0,,CLD0
8396,13950,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620172,,BAO_0000218,2106.0,,CLD0
8397,13950,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620173,,BAO_0000218,945.0,,CLD0
8398,13950,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620174,,BAO_0000218,945.0,,CLD0
8399,13950,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620175,,BAO_0000218,945.0,,CLD0
8400,13950,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620176,,BAO_0000218,945.0,,CLD0
8401,13950,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620177,,BAO_0000218,945.0,,CLD0
8402,13950,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL620178,,BAO_0000218,2037.0,,CLD0
8403,13950,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL620179,,BAO_0000218,2037.0,,CLD0
8404,13950,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL620180,,BAO_0000218,955.0,,CLD0
8405,6570,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620181,,BAO_0000218,,,CLD0
8406,6571,Volume of distribution of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620182,,BAO_0000218,,,CLD0
8407,6453,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620183,,BAO_0000218,,,CLD0
8408,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620184,,BAO_0000218,,,CLD0
8409,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620185,,BAO_0000218,,,CLD0
8410,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620186,,BAO_0000218,,,CLD0
8411,5353,Volume of distribution was determined in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620187,,BAO_0000218,,,CLD0
8412,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620188,,BAO_0000218,,,CLD0
8413,5334,Volume of distribution was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620189,,BAO_0000218,,,CLD0
8414,6641,Volumes of distribution in rat after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620190,,BAO_0000218,,,CLD0
8415,6641,Volumes of distribution in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620191,,BAO_0000218,,,CLD0
8416,6641,Volumes of distribution in rat after po administration; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620192,,BAO_0000218,,,CLD0
8417,5676,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620193,,BAO_0000218,,,CLD0
8418,6410,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620194,,BAO_0000218,,,CLD0
8419,17670,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876730,,BAO_0000218,,,CLD0
8420,6495,Volume distribution in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620195,,BAO_0000218,,,CLD0
8421,5408,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620196,,BAO_0000218,,,CLD0
8422,4883,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620197,,BAO_0000218,,,CLD0
8423,6647,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620198,,BAO_0000218,,,CLD0
8424,6495,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620199,,BAO_0000218,,,CLD0
8425,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620200,,BAO_0000218,,,CLD0
8426,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620201,,BAO_0000218,,,CLD0
8427,5974,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620202,,BAO_0000218,,,CLD0
8428,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620203,,BAO_0000218,,,CLD0
8429,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620204,,BAO_0000218,,,CLD0
8430,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620205,,BAO_0000218,,,CLD0
8431,5960,Pharmacokinetic parameter (Vss) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624664,,BAO_0000218,,,CLD0
8432,5676,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624665,,BAO_0000218,,,CLD0
8433,5948,Pharmacokinetic property (Vss) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624666,,BAO_0000218,,,CLD0
8434,5979,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624667,,BAO_0000218,,,CLD0
8435,5978,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624668,,BAO_0000218,,,CLD0
8436,5978,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624669,,BAO_0000218,,,CLD0
8437,5978,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624670,,BAO_0000218,,,CLD0
8438,5978,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624671,,BAO_0000218,,,CLD0
8439,6448,Steady state volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624672,,BAO_0000218,,,CLD0
8440,12873,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624673,,BAO_0000218,1969.0,,CLD0
8441,4576,Steady state volume of distribution determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624674,,BAO_0000218,,,CLD0
8442,17582,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624675,,BAO_0000218,,,CLD0
8443,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621728,,BAO_0000218,,,CLD0
8444,5182,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621729,,BAO_0000218,,,CLD0
8445,5182,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621730,,BAO_0000218,,,CLD0
8446,6535,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621731,,BAO_0000218,,,CLD0
8447,6535,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621732,,BAO_0000218,,,CLD0
8448,5041,Volume in steady state distribution value was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621908,,BAO_0000218,,,CLD0
8449,5041,Volume in steady state distribution value was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875347,,BAO_0000218,,,CLD0
8450,5041,Volume in steady state distribution value was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621909,,BAO_0000218,,,CLD0
8451,17065,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621910,,BAO_0000218,,,CLD0
8452,6597,Volume of distribution at steady state was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621911,,BAO_0000218,,,CLD0
8453,15662,Volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621912,,BAO_0000218,,,CLD0
8454,6485,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621913,,BAO_0000218,,,CLD0
8455,17655,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621914,,BAO_0000218,,,CLD0
8456,6616,Volume of distribution after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621915,,BAO_0000218,,,CLD0
8457,1916,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621916,,BAO_0000218,,,CLD0
8458,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621917,,BAO_0000218,2107.0,,CLD0
8459,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621918,,BAO_0000218,2107.0,,CLD0
8460,16438,Biodistribution of compound (oxidized form) in spleen tissue,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621919,,BAO_0000218,2106.0,,CLD0
8461,16438,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621920,,BAO_0000218,2106.0,,CLD0
8462,16438,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621921,,BAO_0000218,2106.0,,CLD0
8463,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622401,,BAO_0000218,2106.0,,CLD0
8464,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL875348,,BAO_0000218,2106.0,,CLD0
8465,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622402,,BAO_0000218,2106.0,,CLD0
8466,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622403,,BAO_0000218,178.0,,CLD0
8467,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622404,,BAO_0000218,178.0,,CLD0
8468,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622405,,BAO_0000218,955.0,,CLD0
8469,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622406,,BAO_0000218,955.0,,CLD0
8470,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622407,,BAO_0000218,955.0,,CLD0
8471,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622408,,BAO_0000218,948.0,,CLD0
8472,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622409,,BAO_0000218,948.0,,CLD0
8473,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622410,,BAO_0000218,948.0,,CLD0
8474,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622411,,BAO_0000218,2113.0,,CLD0
8475,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627864,,BAO_0000218,2113.0,,CLD0
8476,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627865,,BAO_0000218,2113.0,,CLD0
8477,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627866,,BAO_0000218,2107.0,,CLD0
8478,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627751,,BAO_0000218,2107.0,,CLD0
8479,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627752,,BAO_0000218,2106.0,,CLD0
8480,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627753,,BAO_0000218,2106.0,,CLD0
8481,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627754,,BAO_0000218,2106.0,,CLD0
8482,12467,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627755,,BAO_0000218,,,CLD0
8483,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627756,,BAO_0000218,955.0,,CLD0
8484,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627757,,BAO_0000218,955.0,,CLD0
8485,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627758,,BAO_0000218,955.0,,CLD0
8486,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627759,,BAO_0000218,955.0,,CLD0
8487,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627760,,BAO_0000218,955.0,,CLD0
8488,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627761,,BAO_0000218,955.0,,CLD0
8489,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL876811,,BAO_0000218,948.0,,CLD0
8490,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627762,,BAO_0000218,948.0,,CLD0
8491,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627763,,BAO_0000218,948.0,,CLD0
8492,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627764,,BAO_0000218,948.0,,CLD0
8493,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627765,,BAO_0000218,948.0,,CLD0
8494,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627766,,BAO_0000218,948.0,,CLD0
8495,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627767,,BAO_0000218,2113.0,,CLD0
8496,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627768,,BAO_0000218,2113.0,,CLD0
8497,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL628422,,BAO_0000218,2113.0,,CLD0
8498,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL628423,,BAO_0000218,2113.0,,CLD0
8499,5089,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628424,,BAO_0000218,1969.0,,CLD0
8500,5089,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628425,,BAO_0000218,1969.0,,CLD0
8501,4257,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628426,,BAO_0000218,1969.0,,CLD0
8502,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628427,,BAO_0000218,1969.0,,CLD0
8503,5546,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626938,,BAO_0000218,1969.0,,CLD0
8504,6141,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626939,,BAO_0000218,1969.0,,CLD0
8505,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626940,,BAO_0000218,1969.0,,CLD0
8506,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626941,,BAO_0000218,1969.0,,CLD0
8507,5334,Plasma clearance was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626942,,BAO_0000218,1969.0,,CLD0
8508,4689,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876812,,BAO_0000218,1969.0,,CLD0
8509,6848,Plasma clearance of compound in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626943,,BAO_0000218,1969.0,,CLD0
8510,6848,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626944,,BAO_0000218,1969.0,,CLD0
8511,6467,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626945,,BAO_0000218,1969.0,,CLD0
8512,6467,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626946,,BAO_0000218,1969.0,,CLD0
8513,4956,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626856,,BAO_0000218,1969.0,,CLD0
8514,5529,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626857,,BAO_0000218,1969.0,,CLD0
8515,406,The compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626858,,BAO_0000218,1969.0,,CLD0
8516,17655,Total plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627018,,BAO_0000218,1969.0,,CLD0
8517,3293,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625331,,BAO_0000218,178.0,,CLD0
8518,4075,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625332,,BAO_0000218,178.0,,CLD0
8519,2792,C max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877590,,BAO_0000218,,,CLD0
8520,2792,C max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625333,,BAO_0000218,,,CLD0
8521,17594,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625334,,BAO_0000218,,,CLD0
8522,17594,Cmax after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625335,,BAO_0000218,,,CLD0
8523,4762,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625336,,BAO_0000218,,,CLD0
8524,17509,Cmax 24 hr after 10 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625337,,BAO_0000218,,,CLD0
8525,17509,Cmax 24 hr after 2 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625338,,BAO_0000218,,,CLD0
8526,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625339,,BAO_0000218,1969.0,,CLD0
8527,6535,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625340,,BAO_0000218,,,CLD0
8528,6535,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625341,,BAO_0000218,,,CLD0
8529,3169,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622687,,BAO_0000218,,,CLD0
8530,6515,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622688,,BAO_0000218,1969.0,,CLD0
8531,11149,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622689,,BAO_0000218,178.0,,CLD0
8532,11149,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL620295,,BAO_0000218,178.0,,CLD0
8533,17858,Cmax after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620296,,BAO_0000218,,,CLD0
8534,6518,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620297,,BAO_0000218,,,CLD0
8535,6518,Cmax after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620298,,BAO_0000218,,,CLD0
8536,4426,Cmax after oral administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620299,,BAO_0000218,,,CLD0
8537,4426,Cmax after oral administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620300,,BAO_0000218,,,CLD0
8538,4426,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620301,,BAO_0000218,,,CLD0
8539,5656,Cmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620302,,BAO_0000218,,,CLD0
8540,6518,Cmax after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620303,,BAO_0000218,,,CLD0
8541,6518,Cmax after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620304,,BAO_0000218,,,CLD0
8542,6113,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620305,,BAO_0000218,,,CLD0
8543,17764,Cmax after peroral administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620306,,BAO_0000218,,,CLD0
8544,4756,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620307,,BAO_0000218,,,CLD0
8545,4756,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620308,,BAO_0000218,,,CLD0
8546,6402,Cmax by administering at 20 mg/kg p.o. in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620309,,BAO_0000218,,,CLD0
8547,5610,Cmax in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620310,,BAO_0000218,,,CLD0
8548,5207,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620311,,BAO_0000218,,,CLD0
8549,6011,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620312,,BAO_0000218,,,CLD0
8550,6504,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620313,,BAO_0000218,,,CLD0
8551,6046,Cmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620314,,BAO_0000218,,,CLD0
8552,6504,Cmax in rat at the dose of 1 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620315,,BAO_0000218,,,CLD0
8553,5874,Cmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620316,,BAO_0000218,,,CLD0
8554,17686,Cmax in rat p.o. at 20 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620317,,BAO_0000218,,,CLD0
8555,5836,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620318,,BAO_0000218,,,CLD0
8556,17596,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620319,,BAO_0000218,,,CLD0
8557,16423,Cmax was evaluated after 20 umol/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620320,,BAO_0000218,,,CLD0
8558,17804,Cmax was measured in rats after peroral administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620321,,BAO_0000218,,,CLD0
8559,1908,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620322,,BAO_0000218,,,CLD0
8560,13950,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL620323,,BAO_0000218,955.0,,CLD0
8561,13950,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Frontal cortex,,,50597,N,1,Intermediate,1,,CHEMBL620324,,BAO_0000218,1870.0,,CLD0
8562,13950,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Frontal cortex,,,50597,N,1,Intermediate,1,,CHEMBL620325,,BAO_0000218,1870.0,,CLD0
8563,13950,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL620326,,BAO_0000218,10000000.0,,CLD0
8564,13950,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL620327,,BAO_0000218,10000000.0,,CLD0
8565,13950,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL620328,,BAO_0000218,955.0,,CLD0
8566,13950,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL620329,,BAO_0000218,955.0,,CLD0
8567,13950,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Midbrain,,,50597,N,1,Intermediate,1,,CHEMBL620330,,BAO_0000218,1891.0,,CLD0
8568,13950,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Midbrain,,,50597,N,1,Intermediate,1,,CHEMBL875286,,BAO_0000218,1891.0,,CLD0
8569,13950,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL620331,,BAO_0000218,955.0,,CLD0
8570,13950,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL620332,,BAO_0000218,955.0,,CLD0
8571,13950,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL620333,,BAO_0000218,2435.0,,CLD0
8572,13950,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL620334,,BAO_0000218,2435.0,,CLD0
8573,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621015,,BAO_0000218,178.0,,CLD0
8574,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621016,,BAO_0000218,178.0,,CLD0
8575,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621191,,BAO_0000218,178.0,,CLD0
8576,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621192,,BAO_0000218,178.0,,CLD0
8577,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621193,,BAO_0000218,178.0,,CLD0
8578,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621194,,BAO_0000218,178.0,,CLD0
8579,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624204,,BAO_0000218,178.0,,CLD0
8580,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624205,,BAO_0000218,178.0,,CLD0
8581,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624206,,BAO_0000218,178.0,,CLD0
8582,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624207,,BAO_0000218,178.0,,CLD0
8583,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624208,,BAO_0000218,178.0,,CLD0
8584,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624209,,BAO_0000218,178.0,,CLD0
8585,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624210,,BAO_0000218,178.0,,CLD0
8586,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624211,,BAO_0000218,178.0,,CLD0
8587,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624212,,BAO_0000218,178.0,,CLD0
8588,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624213,,BAO_0000218,178.0,,CLD0
8589,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL876611,,BAO_0000218,178.0,,CLD0
8590,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624214,,BAO_0000218,178.0,,CLD0
8591,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624215,,BAO_0000218,178.0,,CLD0
8592,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624216,,BAO_0000218,178.0,,CLD0
8593,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624217,,BAO_0000218,178.0,,CLD0
8594,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624218,,BAO_0000218,178.0,,CLD0
8595,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624219,,BAO_0000218,178.0,,CLD0
8596,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624220,,BAO_0000218,178.0,,CLD0
8597,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624221,,BAO_0000218,178.0,,CLD0
8598,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624222,,BAO_0000218,1474.0,,CLD0
8599,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624223,,BAO_0000218,1474.0,,CLD0
8600,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624224,,BAO_0000218,1474.0,,CLD0
8601,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624225,,BAO_0000218,1474.0,,CLD0
8602,17764,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622420,,BAO_0000218,,,CLD0
8603,5031,Volume of steady state distribution after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622421,,BAO_0000218,,,CLD0
8604,6215,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622422,,BAO_0000218,,,CLD0
8605,17671,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622423,,BAO_0000218,,,CLD0
8606,17752,Vss was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622424,,BAO_0000218,,,CLD0
8607,6596,Vss in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622425,,BAO_0000218,,,CLD0
8608,16423,Vss was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876612,,BAO_0000218,,,CLD0
8609,15662,volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622426,,BAO_0000218,,,CLD0
8610,6062,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622427,,BAO_0000218,,,CLD0
8611,5874,Pharmacokinetic (PK) parameter Vz in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622428,,BAO_0000218,,,CLD0
8612,4942,Volume distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622429,,BAO_0000218,,,CLD0
8613,17796,Volume of distribution in rat; No data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622430,,BAO_0000218,,,CLD0
8614,4890,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622431,,BAO_0000218,,,CLD0
8615,15765,% absorption predicted from in vitro rat ileum transport studies,A,,,Rattus norvegicus,10116.0,,Ileum,,,50597,N,1,Intermediate,1,,CHEMBL622432,,BAO_0000218,2116.0,,CLD0
8616,13569,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622433,,BAO_0000218,,,CLD0
8617,13569,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622434,,BAO_0000218,,,CLD0
8618,13569,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622435,,BAO_0000218,,,CLD0
8619,13569,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618748,,BAO_0000218,,,CLD0
8620,13569,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618749,,BAO_0000218,,,CLD0
8621,13569,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618750,,BAO_0000218,,,CLD0
8622,13569,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618751,,BAO_0000218,,,CLD0
8623,13569,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618752,,BAO_0000218,,,CLD0
8624,4576,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618753,,BAO_0000218,,,CLD0
8625,750,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618754,,BAO_0000218,1969.0,,CLD0
8626,750,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618755,,BAO_0000218,,,CLD0
8627,4590,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618756,,BAO_0000218,,,CLD0
8628,1716,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618757,,BAO_0000218,,,CLD0
8629,1974,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618758,,BAO_0000218,,,CLD0
8630,4502,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621088,,BAO_0000218,,,CLD0
8631,3371,Partition coefficient  (cLogP) of the compound,P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621089,,BAO_0000100,,,CLD0
8632,9099,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621090,,BAO_0000218,178.0,,CLD0
8633,9099,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621091,,BAO_0000218,178.0,,CLD0
8634,4590,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876731,,BAO_0000218,,,CLD0
8635,3184,Compound was evaluated for its clearance when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621092,,BAO_0000218,,,CLD0
8636,16456,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621093,,BAO_0000218,1969.0,,CLD0
8637,4199,Blood: Brain distribution ratio is determined in rat,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621094,,BAO_0000218,178.0,,CLD0
8638,4199,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621095,,BAO_0000218,178.0,,CLD0
8639,4199,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621096,,BAO_0000218,178.0,,CLD0
8640,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621097,,BAO_0000218,2113.0,,CLD0
8641,7449,Percent dose excreted in 0-48 hours administered ip to male rat,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621098,,BAO_0000218,,,CLD0
8642,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621099,,BAO_0000218,2037.0,,CLD0
8643,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621100,,BAO_0000218,2037.0,,CLD0
8644,11977,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621101,,BAO_0000218,2037.0,,CLD0
8645,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621102,,BAO_0000218,2037.0,,CLD0
8646,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL876732,,BAO_0000218,2037.0,,CLD0
8647,11977,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cortex,,,50597,N,1,Intermediate,1,,CHEMBL621103,,BAO_0000218,1851.0,,CLD0
8648,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cortex,,,50597,N,1,Intermediate,1,,CHEMBL621104,,BAO_0000218,1851.0,,CLD0
8649,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,Cortex,,,50597,N,1,Intermediate,1,,CHEMBL621105,,BAO_0000218,1851.0,,CLD0
8650,11977,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cortex,,,50597,N,1,Intermediate,1,,CHEMBL621106,,BAO_0000218,1851.0,,CLD0
8651,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cortex,,,50597,N,1,Intermediate,1,,CHEMBL621107,,BAO_0000218,1851.0,,CLD0
8652,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621108,,BAO_0000218,,,CLD0
8653,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621109,,BAO_0000218,,,CLD0
8654,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621110,,BAO_0000218,2113.0,,CLD0
8655,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621111,,BAO_0000218,2113.0,,CLD0
8656,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622541,,BAO_0000218,2107.0,,CLD0
8657,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622542,,BAO_0000218,2107.0,,CLD0
8658,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622543,,BAO_0000218,2107.0,,CLD0
8659,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624412,,BAO_0000218,2107.0,,CLD0
8660,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624413,,BAO_0000218,2107.0,,CLD0
8661,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624414,,BAO_0000218,2107.0,,CLD0
8662,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624415,,BAO_0000218,2048.0,,CLD0
8663,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624416,,BAO_0000218,2048.0,,CLD0
8664,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624417,,BAO_0000218,2048.0,,CLD0
8665,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624418,,BAO_0000218,2048.0,,CLD0
8666,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624419,,BAO_0000218,2048.0,,CLD0
8667,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624420,,BAO_0000218,2048.0,,CLD0
8668,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL624421,,BAO_0000218,2385.0,,CLD0
8669,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL624422,,BAO_0000218,2385.0,,CLD0
8670,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL624423,,BAO_0000218,2385.0,,CLD0
8671,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL625123,,BAO_0000218,2385.0,,CLD0
8672,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL625124,,BAO_0000218,2385.0,,CLD0
8673,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL625125,,BAO_0000218,2385.0,,CLD0
8674,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL625126,,BAO_0000218,14.0,,CLD0
8675,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626947,,BAO_0000218,14.0,,CLD0
8676,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626948,,BAO_0000218,14.0,,CLD0
8677,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626949,,BAO_0000218,14.0,,CLD0
8678,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626950,,BAO_0000218,14.0,,CLD0
8679,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626951,,BAO_0000218,14.0,,CLD0
8680,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626952,,BAO_0000218,2106.0,,CLD0
8681,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626953,,BAO_0000218,2106.0,,CLD0
8682,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626954,,BAO_0000218,2106.0,,CLD0
8683,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626955,,BAO_0000218,2106.0,,CLD0
8684,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626956,,BAO_0000218,2106.0,,CLD0
8685,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626957,,BAO_0000218,2106.0,,CLD0
8686,17208,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626958,,BAO_0000218,178.0,,CLD0
8687,17208,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626959,,BAO_0000218,178.0,,CLD0
8688,17208,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626960,,BAO_0000218,178.0,,CLD0
8689,17208,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626961,,BAO_0000218,178.0,,CLD0
8690,17208,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL627589,,BAO_0000218,178.0,,CLD0
8691,17208,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL627590,,BAO_0000218,178.0,,CLD0
8692,3132,Time taken for EC90 was determined when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627591,,BAO_0000218,,,CLD0
8693,3132,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627592,,BAO_0000218,,,CLD0
8694,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627593,,BAO_0000218,,,CLD0
8695,5727,Half life in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627594,,BAO_0000218,,,CLD0
8696,5302,Half life period in mouse after 10 mg/Kg dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876813,,BAO_0000218,,,CLD0
8697,5302,Half life period in mouse after 10 mg/kg dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627595,,BAO_0000218,,,CLD0
8698,6348,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627596,,BAO_0000218,,,CLD0
8699,5964,Cmax value at 5 mg/kg po was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627597,,BAO_0000218,,,CLD0
8700,6078,Cmax value evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627598,,BAO_0000218,,,CLD0
8701,5206,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627599,,BAO_0000218,955.0,,CLD0
8702,2959,Cmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627600,,BAO_0000218,,,CLD0
8703,5964,Cmax value at 1 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627601,,BAO_0000218,,,CLD0
8704,5964,Cmax value at 5 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627776,,BAO_0000218,,,CLD0
8705,6757,Cmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627777,,BAO_0000218,,,CLD0
8706,6757,Cmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627778,,BAO_0000218,,,CLD0
8707,6757,Cmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627779,,BAO_0000218,,,CLD0
8708,17617,Cmax value in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876814,,BAO_0000218,,,CLD0
8709,1445,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627780,,BAO_0000218,,,CLD0
8710,6082,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627781,,BAO_0000218,,,CLD0
8711,1446,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627782,,BAO_0000218,,,CLD0
8712,5407,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627783,,BAO_0000218,1969.0,,CLD0
8713,2690,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627784,,BAO_0000218,1969.0,,CLD0
8714,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627785,,BAO_0000218,,,CLD0
8715,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627786,,BAO_0000218,,,CLD0
8716,4891,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627787,,BAO_0000218,1969.0,,CLD0
8717,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627788,,BAO_0000218,1969.0,,CLD0
8718,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626579,,BAO_0000218,1969.0,,CLD0
8719,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626580,,BAO_0000218,1969.0,,CLD0
8720,3634,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876815,,BAO_0000218,,,CLD0
8721,1881,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626581,,BAO_0000218,1969.0,,CLD0
8722,1881,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626582,,BAO_0000218,1969.0,,CLD0
8723,429,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626583,,BAO_0000218,,,CLD0
8724,5974,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626205,,BAO_0000218,,,CLD0
8725,5974,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626206,,BAO_0000218,,,CLD0
8726,5974,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626207,,BAO_0000218,,,CLD0
8727,5974,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623882,,BAO_0000218,,,CLD0
8728,17582,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623883,,BAO_0000218,,,CLD0
8729,17582,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623884,,BAO_0000218,,,CLD0
8730,3032,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623885,,BAO_0000218,1969.0,,CLD0
8731,6295,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623886,,BAO_0000218,1969.0,,CLD0
8732,6619,Maximal concentration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623887,,BAO_0000218,,,CLD0
8733,6616,Maximal concentration after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623888,,BAO_0000218,,,CLD0
8734,3249,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623889,,BAO_0000218,1969.0,,CLD0
8735,17791,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623890,,BAO_0000218,1969.0,,CLD0
8736,17791,Cmax in rat plasma after oral dose (50 mg/Kg),A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623891,,BAO_0000218,1969.0,,CLD0
8737,1360,Maximal plasma concentration was determined.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623892,,BAO_0000218,1969.0,,CLD0
8738,2552,Maximal plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623893,,BAO_0000218,1969.0,,CLD0
8739,6571,Maximal concentration in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877616,,BAO_0000218,,,CLD0
8740,6570,Maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623894,,BAO_0000218,,,CLD0
8741,6567,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623895,,BAO_0000218,1969.0,,CLD0
8742,3031,Maximum concentration of compound in rat was evaluated.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623896,,BAO_0000218,,,CLD0
8743,3436,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623897,,BAO_0000218,,,CLD0
8744,3436,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623898,,BAO_0000218,,,CLD0
8745,2083,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623899,,BAO_0000218,,,CLD0
8746,3436,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623900,,BAO_0000218,,,CLD0
8747,4527,Maximum concentration by oral administration at a dose of 100 umol/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623901,,BAO_0000218,,,CLD0
8748,1974,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623902,,BAO_0000218,,,CLD0
8749,3307,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Cerebrospinal fluid,,,50597,N,1,Intermediate,1,,CHEMBL623903,,BAO_0000218,1359.0,,CLD0
8750,3307,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623904,,BAO_0000218,1969.0,,CLD0
8751,1916,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL877617,,BAO_0000218,1969.0,,CLD0
8752,1500,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Portal vein,,,50597,N,1,Intermediate,1,,CHEMBL623905,,BAO_0000218,2017.0,,CLD0
8753,1500,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Portal vein,,,50597,N,1,Intermediate,1,,CHEMBL623906,,BAO_0000218,2017.0,,CLD0
8754,4186,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623907,,BAO_0000218,1969.0,,CLD0
8755,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623908,,BAO_0000218,1474.0,,CLD0
8756,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623909,,BAO_0000218,1474.0,,CLD0
8757,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623910,,BAO_0000218,1474.0,,CLD0
8758,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623911,,BAO_0000218,1474.0,,CLD0
8759,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623912,,BAO_0000218,1474.0,,CLD0
8760,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624616,,BAO_0000218,1474.0,,CLD0
8761,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624617,,BAO_0000218,1474.0,,CLD0
8762,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624618,,BAO_0000218,1474.0,,CLD0
8763,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624619,,BAO_0000218,1474.0,,CLD0
8764,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624794,,BAO_0000218,1474.0,,CLD0
8765,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL624795,,BAO_0000218,1474.0,,CLD0
8766,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623921,,BAO_0000218,1474.0,,CLD0
8767,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623922,,BAO_0000218,1474.0,,CLD0
8768,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623923,,BAO_0000218,1474.0,,CLD0
8769,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623924,,BAO_0000218,1474.0,,CLD0
8770,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623925,,BAO_0000218,1474.0,,CLD0
8771,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623926,,BAO_0000218,1474.0,,CLD0
8772,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623927,,BAO_0000218,1474.0,,CLD0
8773,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623928,,BAO_0000218,1474.0,,CLD0
8774,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623929,,BAO_0000218,1474.0,,CLD0
8775,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL623930,,BAO_0000218,1474.0,,CLD0
8776,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623931,,BAO_0000218,955.0,,CLD0
8777,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622165,,BAO_0000218,955.0,,CLD0
8778,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621249,,BAO_0000218,955.0,,CLD0
8779,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621250,,BAO_0000218,955.0,,CLD0
8780,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621448,,BAO_0000218,955.0,,CLD0
8781,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621449,,BAO_0000218,955.0,,CLD0
8782,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621450,,BAO_0000218,955.0,,CLD0
8783,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621451,,BAO_0000218,955.0,,CLD0
8784,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621452,,BAO_0000218,955.0,,CLD0
8785,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621453,,BAO_0000218,955.0,,CLD0
8786,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621454,,BAO_0000218,955.0,,CLD0
8787,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621455,,BAO_0000218,955.0,,CLD0
8788,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621456,,BAO_0000218,955.0,,CLD0
8789,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625145,,BAO_0000218,955.0,,CLD0
8790,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL875847,,BAO_0000218,955.0,,CLD0
8791,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625146,,BAO_0000218,955.0,,CLD0
8792,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625147,,BAO_0000218,955.0,,CLD0
8793,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625148,,BAO_0000218,955.0,,CLD0
8794,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625149,,BAO_0000218,955.0,,CLD0
8795,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625150,,BAO_0000218,955.0,,CLD0
8796,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625151,,BAO_0000218,955.0,,CLD0
8797,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625152,,BAO_0000218,955.0,,CLD0
8798,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625153,,BAO_0000218,955.0,,CLD0
8799,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625154,,BAO_0000218,955.0,,CLD0
8800,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625155,,BAO_0000218,955.0,,CLD0
8801,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625156,,BAO_0000218,,,CLD0
8802,11977,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624354,,BAO_0000218,,,CLD0
8803,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624355,,BAO_0000218,10000000.0,,CLD0
8804,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624356,,BAO_0000218,10000000.0,,CLD0
8805,11977,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624357,,BAO_0000218,10000000.0,,CLD0
8806,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624358,,BAO_0000218,10000000.0,,CLD0
8807,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624359,,BAO_0000218,2435.0,,CLD0
8808,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624360,,BAO_0000218,2435.0,,CLD0
8809,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624361,,BAO_0000218,2435.0,,CLD0
8810,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624362,,BAO_0000218,2435.0,,CLD0
8811,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624363,,BAO_0000218,2435.0,,CLD0
8812,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624364,,BAO_0000218,178.0,,CLD0
8813,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624365,,BAO_0000218,178.0,,CLD0
8814,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624366,,BAO_0000218,178.0,,CLD0
8815,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624367,,BAO_0000218,178.0,,CLD0
8816,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624368,,BAO_0000218,955.0,,CLD0
8817,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624369,,BAO_0000218,955.0,,CLD0
8818,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624370,,BAO_0000218,955.0,,CLD0
8819,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625069,,BAO_0000218,955.0,,CLD0
8820,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625070,,BAO_0000218,955.0,,CLD0
8821,11977,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626051,,BAO_0000218,948.0,,CLD0
8822,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626052,,BAO_0000218,948.0,,CLD0
8823,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626053,,BAO_0000218,948.0,,CLD0
8824,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626054,,BAO_0000218,948.0,,CLD0
8825,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626055,,BAO_0000218,948.0,,CLD0
8826,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626056,,BAO_0000218,2113.0,,CLD0
8827,11977,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626057,,BAO_0000218,2113.0,,CLD0
8828,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625193,,BAO_0000218,2113.0,,CLD0
8829,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625194,,BAO_0000218,2113.0,,CLD0
8830,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625195,,BAO_0000218,2107.0,,CLD0
8831,11977,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625196,,BAO_0000218,2107.0,,CLD0
8832,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625197,,BAO_0000218,2107.0,,CLD0
8833,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625198,,BAO_0000218,2107.0,,CLD0
8834,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627929,,BAO_0000218,2107.0,,CLD0
8835,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627074,,BAO_0000218,2048.0,,CLD0
8836,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627075,,BAO_0000218,2048.0,,CLD0
8837,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627076,,BAO_0000218,2048.0,,CLD0
8838,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627077,,BAO_0000218,2048.0,,CLD0
8839,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627078,,BAO_0000218,2048.0,,CLD0
8840,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627079,,BAO_0000218,2385.0,,CLD0
8841,4573,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL873824,,BAO_0000218,,,CLD0
8842,3132,Half life in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627080,,BAO_0000218,1969.0,,CLD0
8843,17718,Half life was determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627081,,BAO_0000218,,,CLD0
8844,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627082,,BAO_0000218,,,CLD0
8845,5961,Half-life in male mice after 1 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627083,,BAO_0000218,,,CLD0
8847,17731,Half life in mice plasma,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627085,,BAO_0000218,1969.0,,CLD0
8848,17592,Half life in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627086,,BAO_0000218,,,CLD0
8849,3132,Half life in mouse plasma at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627087,,BAO_0000218,1969.0,,CLD0
8850,17729,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627088,,BAO_0000218,,,CLD0
8851,17729,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627089,,BAO_0000218,,,CLD0
8852,17729,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627090,,BAO_0000218,,,CLD0
8853,3277,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627091,,BAO_0000218,,,CLD0
8854,3760,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627092,,BAO_0000218,,,CLD0
8855,3760,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876785,,BAO_0000218,,,CLD0
8856,2862,Half-life by iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627093,,BAO_0000218,,,CLD0
8857,2862,Half-life by oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627094,,BAO_0000218,,,CLD0
8858,5980,Half-life in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627095,,BAO_0000218,,,CLD0
8859,6159,Half-life using mouse brain homogenate,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627096,,BAO_0000218,955.0,,CLD0
8860,6254,Half-life was measured in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627097,,BAO_0000218,,,CLD0
8861,6062,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627098,,BAO_0000218,,,CLD0
8862,1574,Half-life period was determined in mouse blood,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL627099,,BAO_0000218,178.0,,CLD0
8863,56,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627100,,BAO_0000218,955.0,,CLD0
8864,993,Plasma half life in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627101,,BAO_0000218,1969.0,,CLD0
8865,6652,Stability of the peptide in the presence of mouse serum,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627102,,BAO_0000218,,,CLD0
8866,17852,Terminal half life of compound was determined in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627103,,BAO_0000218,,,CLD0
8867,2675,Terminal half life was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627104,,BAO_0000218,,,CLD0
8868,2675,Terminal half life was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627105,,BAO_0000218,,,CLD0
8869,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876786,,BAO_0000218,,,CLD0
8870,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL873825,,BAO_0000218,,,CLD0
8871,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627106,,BAO_0000218,,,CLD0
8872,14239,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626336,,BAO_0000218,,,CLD0
8873,5506,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877462,,BAO_0000218,,,CLD0
8874,5506,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626337,,BAO_0000218,,,CLD0
8875,17734,Half life after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626338,,BAO_0000218,,,CLD0
8876,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626339,,BAO_0000218,,,CLD0
8877,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626340,,BAO_0000218,,,CLD0
8878,17728,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625377,,BAO_0000218,,,CLD0
8879,17728,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625378,,BAO_0000218,,,CLD0
8880,17728,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625379,,BAO_0000218,,,CLD0
8881,14294,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,,,Sus scrofa,9823.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL625380,,BAO_0000251,,,CLD0
8882,14294,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,,,Sus scrofa,9823.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL625381,,BAO_0000251,,,CLD0
8883,6056,Stability to porcine renal DHP-I,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625382,,BAO_0000019,,,CLD0
8884,1317,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,In vivo,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873828,,BAO_0000218,,,CLD0
8885,1317,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,In vivo,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625383,,BAO_0000218,,,CLD0
8886,5229,Half-life of the parent prodrug in porcine esterase solution,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625384,,BAO_0000019,,,CLD0
8887,4231,"First order rate constant, k was determined in in pig liver Esterase",A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL625385,,BAO_0000221,2107.0,,CLD0
8888,4231,Half life of the in pig liver Esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL625386,,BAO_0000221,2107.0,,CLD0
8889,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623571,,BAO_0000221,2107.0,,CLD0
8890,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623572,,BAO_0000221,2107.0,,CLD0
8891,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623573,,BAO_0000221,2107.0,,CLD0
8892,3305,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623574,,BAO_0000221,2107.0,,CLD0
8893,3305,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623575,,BAO_0000221,2107.0,,CLD0
8894,2842,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623749,,BAO_0000221,2107.0,,CLD0
8895,2842,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623750,,BAO_0000221,2107.0,,CLD0
8896,889,Half-life in vitro in pig liver,A,In vitro,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623751,,BAO_0000221,2107.0,,CLD0
8897,1904,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623752,,BAO_0000221,2107.0,,CLD0
8898,4186,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623753,,BAO_0000218,1969.0,,CLD0
8899,2774,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623754,,BAO_0000218,1969.0,,CLD0
8900,1742,Maximum concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623755,,BAO_0000218,1969.0,,CLD0
8901,3169,Maximum concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623756,,BAO_0000218,,,CLD0
8902,3169,Maximum concentration in rats at 1-2 hours,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623757,,BAO_0000218,,,CLD0
8903,2081,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623758,,BAO_0000218,,,CLD0
8904,3307,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623759,,BAO_0000218,955.0,,CLD0
8905,4727,Maximum concentration at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623760,,BAO_0000218,,,CLD0
8906,6597,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623761,,BAO_0000218,,,CLD0
8907,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623762,,BAO_0000218,1969.0,,CLD0
8908,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL877594,,BAO_0000218,1969.0,,CLD0
8909,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623763,,BAO_0000218,1969.0,,CLD0
8910,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623764,,BAO_0000218,1969.0,,CLD0
8911,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623765,,BAO_0000218,1969.0,,CLD0
8912,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623766,,BAO_0000218,178.0,,CLD0
8913,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623767,,BAO_0000218,178.0,,CLD0
8914,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623768,,BAO_0000218,178.0,,CLD0
8915,5978,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623769,,BAO_0000218,1969.0,,CLD0
8916,5978,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623770,,BAO_0000218,1969.0,,CLD0
8917,5978,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623771,,BAO_0000218,1969.0,,CLD0
8918,5978,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623772,,BAO_0000218,1969.0,,CLD0
8919,5978,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623773,,BAO_0000218,1969.0,,CLD0
8920,5978,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623774,,BAO_0000218,1969.0,,CLD0
8921,5978,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623775,,BAO_0000218,1969.0,,CLD0
8922,14465,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623776,,BAO_0000218,,,CLD0
8923,4723,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622191,,BAO_0000218,1969.0,,CLD0
8924,4723,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622192,,BAO_0000218,1969.0,,CLD0
8925,4576,Maximum plasma concentration determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622193,,BAO_0000218,1969.0,,CLD0
8926,12873,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622194,,BAO_0000218,1969.0,,CLD0
8927,12873,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622195,,BAO_0000218,1969.0,,CLD0
8928,6824,Maximum plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622196,,BAO_0000218,1969.0,,CLD0
8929,17065,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622197,,BAO_0000218,1969.0,,CLD0
8930,2932,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622198,,BAO_0000218,1969.0,,CLD0
8931,2932,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622199,,BAO_0000218,1969.0,,CLD0
8932,2879,Maximum plasma concentration of compound was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622200,,BAO_0000218,1969.0,,CLD0
8933,2864,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622201,,BAO_0000218,1969.0,,CLD0
8934,16367,Maximum plasma concentration after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623990,,BAO_0000218,1969.0,,CLD0
8935,17717,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623991,,BAO_0000218,1969.0,,CLD0
8936,17717,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623992,,BAO_0000218,1969.0,,CLD0
8937,17717,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623993,,BAO_0000218,1969.0,,CLD0
8938,17717,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623994,,BAO_0000218,1969.0,,CLD0
8939,17720,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623995,,BAO_0000218,1969.0,,CLD0
8940,17720,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623996,,BAO_0000218,1969.0,,CLD0
8941,17720,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623997,,BAO_0000218,1969.0,,CLD0
8942,4516,Maximum plasma concentration dosed orally in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623998,,BAO_0000218,1969.0,,CLD0
8943,4516,Maximum plasma concentration dosed orally in rats after 6 hours,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623999,,BAO_0000218,1969.0,,CLD0
8944,4516,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624000,,BAO_0000218,1969.0,,CLD0
8945,5199,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624001,,BAO_0000218,1969.0,,CLD0
8946,17538,Maximum plasma concentration in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624002,,BAO_0000218,1969.0,,CLD0
8947,6685,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624003,,BAO_0000218,1969.0,,CLD0
8948,6685,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624004,,BAO_0000218,1969.0,,CLD0
8949,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624005,,BAO_0000218,948.0,,CLD0
8950,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624006,,BAO_0000218,948.0,,CLD0
8951,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624007,,BAO_0000218,948.0,,CLD0
8952,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624008,,BAO_0000218,948.0,,CLD0
8953,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624009,,BAO_0000218,948.0,,CLD0
8954,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL874387,,BAO_0000218,948.0,,CLD0
8955,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624010,,BAO_0000218,948.0,,CLD0
8956,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624011,,BAO_0000218,948.0,,CLD0
8957,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624012,,BAO_0000218,948.0,,CLD0
8958,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624013,,BAO_0000218,948.0,,CLD0
8959,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624736,,BAO_0000218,948.0,,CLD0
8960,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624737,,BAO_0000218,948.0,,CLD0
8961,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624738,,BAO_0000218,948.0,,CLD0
8962,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624739,,BAO_0000218,948.0,,CLD0
8963,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624740,,BAO_0000218,948.0,,CLD0
8964,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624896,,BAO_0000218,948.0,,CLD0
8965,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624897,,BAO_0000218,948.0,,CLD0
8966,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624108,,BAO_0000218,948.0,,CLD0
8967,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624109,,BAO_0000218,948.0,,CLD0
8968,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624110,,BAO_0000218,948.0,,CLD0
8969,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624111,,BAO_0000218,948.0,,CLD0
8970,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624112,,BAO_0000218,948.0,,CLD0
8971,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624113,,BAO_0000218,948.0,,CLD0
8972,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619709,,BAO_0000218,948.0,,CLD0
8973,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619710,,BAO_0000218,948.0,,CLD0
8974,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619711,,BAO_0000218,2113.0,,CLD0
8975,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619712,,BAO_0000218,2113.0,,CLD0
8976,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619713,,BAO_0000218,2113.0,,CLD0
8977,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619714,,BAO_0000218,2113.0,,CLD0
8978,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619715,,BAO_0000218,2113.0,,CLD0
8979,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619716,,BAO_0000218,2113.0,,CLD0
8980,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619717,,BAO_0000218,2113.0,,CLD0
8981,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619718,,BAO_0000218,2113.0,,CLD0
8982,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619719,,BAO_0000218,2113.0,,CLD0
8983,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL875329,,BAO_0000218,2113.0,,CLD0
8984,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619720,,BAO_0000218,2113.0,,CLD0
8985,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619721,,BAO_0000218,2113.0,,CLD0
8986,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619722,,BAO_0000218,2113.0,,CLD0
8987,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619723,,BAO_0000218,2113.0,,CLD0
8988,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619724,,BAO_0000218,2113.0,,CLD0
8989,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619725,,BAO_0000218,2113.0,,CLD0
8990,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619726,,BAO_0000218,2113.0,,CLD0
8991,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619727,,BAO_0000218,2113.0,,CLD0
8992,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619728,,BAO_0000218,2113.0,,CLD0
8993,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619729,,BAO_0000218,2113.0,,CLD0
8994,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619730,,BAO_0000218,2385.0,,CLD0
8995,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619731,,BAO_0000218,2385.0,,CLD0
8996,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619732,,BAO_0000218,2385.0,,CLD0
8997,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619733,,BAO_0000218,2385.0,,CLD0
8998,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619734,,BAO_0000218,2385.0,,CLD0
8999,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL619735,,BAO_0000218,14.0,,CLD0
9000,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL875330,,BAO_0000218,14.0,,CLD0
9001,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL628465,,BAO_0000218,14.0,,CLD0
9002,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL628466,,BAO_0000218,14.0,,CLD0
9003,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL628467,,BAO_0000218,14.0,,CLD0
9004,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628468,,BAO_0000218,2106.0,,CLD0
9005,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628469,,BAO_0000218,2106.0,,CLD0
9006,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628470,,BAO_0000218,2106.0,,CLD0
9007,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628471,,BAO_0000218,2106.0,,CLD0
9008,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628472,,BAO_0000218,2106.0,,CLD0
9009,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL625191,,BAO_0000218,2046.0,,CLD0
9010,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL625192,,BAO_0000218,2046.0,,CLD0
9011,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL875337,,BAO_0000218,2046.0,,CLD0
9012,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626341,,BAO_0000218,2046.0,,CLD0
9013,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626342,,BAO_0000218,2046.0,,CLD0
9014,11977,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621943,,BAO_0000218,2107.0,,CLD0
9015,3748,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621944,,BAO_0000218,,,CLD0
9016,15765,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621945,,BAO_0000218,,,CLD0
9017,4871,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621946,,BAO_0000218,,,CLD0
9018,4871,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621947,,BAO_0000218,,,CLD0
9019,4872,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621948,,BAO_0000218,,,CLD0
9020,4872,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621949,,BAO_0000218,,,CLD0
9021,5413,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621950,,BAO_0000218,2107.0,,CLD0
9022,5413,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621951,,BAO_0000218,2107.0,,CLD0
9023,15272,Maximal blood concentration after oral administration of a 30 umol/kg dose of compound,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621952,,BAO_0000218,178.0,,CLD0
9024,4689,Stability (%) in rat liver microsomes,A,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL621953,,BAO_0000218,2107.0,,CLD0
9025,6057,Area under curve was calculated after intravenous administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621954,,BAO_0000218,,,CLD0
9026,6057,Area under the curve was calculated after iv administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621955,,BAO_0000218,,,CLD0
9027,6057,Area under the curve was calculated in rat after peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621956,,BAO_0000218,,,CLD0
9028,6211,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621957,,BAO_0000218,,,CLD0
9029,5710,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621958,,BAO_0000218,,,CLD0
9030,5710,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621959,,BAO_0000218,,,CLD0
9031,17853,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621960,,BAO_0000218,,,CLD0
9032,17853,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621961,,BAO_0000218,,,CLD0
9033,15765,p value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621962,,BAO_0000218,,,CLD0
9034,15765,p value of the compound,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876787,,BAO_0000218,,,CLD0
9035,15765,p value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621963,,BAO_0000218,,,CLD0
9036,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL622637,,BAO_0000218,1971.0,,CLD0
9037,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL622638,,BAO_0000218,1971.0,,CLD0
9038,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL626561,,BAO_0000218,1971.0,,CLD0
9039,7991,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626562,,BAO_0000019,,,CLD0
9040,429,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626563,,BAO_0000218,,,CLD0
9041,429,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626564,,BAO_0000218,,,CLD0
9042,6253,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626565,,BAO_0000218,178.0,,CLD0
9043,6253,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626566,,BAO_0000218,178.0,,CLD0
9044,3615,Clearance rate in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626567,,BAO_0000218,,,CLD0
9045,4059,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626568,,BAO_0000218,1969.0,,CLD0
9046,5124,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626569,,BAO_0000218,,,CLD0
9047,5124,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626570,,BAO_0000218,,,CLD0
9048,5124,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626571,,BAO_0000218,,,CLD0
9049,429,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626572,,BAO_0000218,,,CLD0
9050,4059,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626573,,BAO_0000218,1969.0,,CLD0
9051,9659,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,,,Oryctolagus cuniculus,9986.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL626574,,BAO_0000251,2107.0,,CLD0
9052,9659,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,,,Oryctolagus cuniculus,9986.0,,Liver,,Microsome,22224,U,0,Autocuration,1,,CHEMBL626575,,BAO_0000251,2107.0,,CLD0
9053,3639,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626576,,BAO_0000218,,,CLD0
9054,3639,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626577,,BAO_0000218,,,CLD0
9055,3639,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626578,,BAO_0000218,,,CLD0
9056,5124,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625263,,BAO_0000218,,,CLD0
9057,5124,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625264,,BAO_0000218,,,CLD0
9058,5124,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625265,,BAO_0000218,,,CLD0
9059,14294,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,,,Oryctolagus cuniculus,9986.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL625266,,BAO_0000251,,,CLD0
9060,14294,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,,,Oryctolagus cuniculus,9986.0,,,,Microsome,22224,U,0,Autocuration,1,,CHEMBL876796,,BAO_0000251,,,CLD0
9061,429,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625267,,BAO_0000218,,,CLD0
9062,5124,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL625268,,BAO_0000218,1969.0,,CLD0
9063,5124,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL625269,,BAO_0000218,1969.0,,CLD0
9064,5124,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624689,,BAO_0000218,1969.0,,CLD0
9065,429,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624690,,BAO_0000218,,,CLD0
9066,429,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,,,Oryctolagus cuniculus,9986.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL624691,,BAO_0000218,1088.0,,CLD0
9067,429,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,,,Oryctolagus cuniculus,9986.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL624692,,BAO_0000218,1088.0,,CLD0
9068,4059,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624693,,BAO_0000218,,,CLD0
9069,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624694,,BAO_0000218,,,CLD0
9070,11672,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,In vitro,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL877596,,BAO_0000221,,,CLD0
9071,12886,Time within which only 10% of the drug was degraded,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624695,,BAO_0000019,,,CLD0
9072,3853,Half life period in rabbit liver homogenate,A,,,Oryctolagus cuniculus,9986.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL624696,,BAO_0000221,2107.0,,CLD0
9073,3615,Half life value in rabbits,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624697,,BAO_0000019,,,CLD0
9074,6253,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624698,,BAO_0000218,178.0,,CLD0
9075,6253,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624699,,BAO_0000218,178.0,,CLD0
9076,6077,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624700,,BAO_0000218,,,CLD0
9077,17617,AUC 0-8 hr value in rats at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622903,,BAO_0000218,1969.0,,CLD0
9078,17594,AUC after administration at 2000 mg/kg/day in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622904,,BAO_0000218,1969.0,,CLD0
9079,6149,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622905,,BAO_0000218,1969.0,,CLD0
9080,17260,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622906,,BAO_0000218,1969.0,,CLD0
9081,17260,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622907,,BAO_0000218,1969.0,,CLD0
9082,6644,AUC in rat after oral administration at 10.5 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622908,,BAO_0000218,1969.0,,CLD0
9083,6644,AUC in rat after oral administration at 11.2 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622909,,BAO_0000218,1969.0,,CLD0
9084,6644,AUC in rat after oral administration at 9.7 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622910,,BAO_0000218,1969.0,,CLD0
9085,6495,AUC in rat brain after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622911,,BAO_0000218,955.0,,CLD0
9086,6504,AUC in rat p.o.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622912,,BAO_0000218,1969.0,,CLD0
9087,17686,AUC in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622913,,BAO_0000218,1969.0,,CLD0
9088,6495,AUC in rat plasma after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622914,,BAO_0000218,1969.0,,CLD0
9089,216,AUC in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622915,,BAO_0000218,1969.0,,CLD0
9090,1908,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622916,,BAO_0000218,1969.0,,CLD0
9091,1908,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622917,,BAO_0000218,1969.0,,CLD0
9092,6685,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622918,,BAO_0000218,1969.0,,CLD0
9093,216,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622919,,BAO_0000218,1969.0,,CLD0
9094,6049,Maximum plasma concentration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622920,,BAO_0000218,1969.0,,CLD0
9095,2463,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622921,,BAO_0000218,1969.0,,CLD0
9096,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622922,,BAO_0000218,1969.0,,CLD0
9097,6681,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622923,,BAO_0000218,1969.0,,CLD0
9098,4890,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL877604,,BAO_0000218,1969.0,,CLD0
9099,6410,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622924,,BAO_0000218,1969.0,,CLD0
9100,6410,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622925,,BAO_0000218,1969.0,,CLD0
9101,16366,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622926,,BAO_0000218,1969.0,,CLD0
9102,6227,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623625,,BAO_0000218,1969.0,,CLD0
9103,3598,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Expert,1,,CHEMBL623626,,BAO_0000218,1969.0,,CLD0
9104,1465,Maximum plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623627,,BAO_0000218,1969.0,,CLD0
9105,4368,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623628,,BAO_0000218,,,CLD0
9106,15662,Mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623629,,BAO_0000218,1969.0,,CLD0
9107,15662,Mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623630,,BAO_0000218,1969.0,,CLD0
9108,5355,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623804,,BAO_0000218,,,CLD0
9109,5355,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623805,,BAO_0000218,,,CLD0
9110,1567,Peak oral plasma concentration was determined in rats by oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623806,,BAO_0000218,1969.0,,CLD0
9111,4026,Peak plasma concentration (Cmax) was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623807,,BAO_0000218,1969.0,,CLD0
9112,6193,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623808,,BAO_0000218,1969.0,,CLD0
9113,4026,Peak plasma concentration (Cmax) in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623809,,BAO_0000218,1969.0,,CLD0
9114,6485,Peak plasma concentration at 1 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623810,,BAO_0000218,1969.0,,CLD0
9115,17655,Peak plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623811,,BAO_0000218,1969.0,,CLD0
9116,14941,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623812,,BAO_0000218,1969.0,,CLD0
9117,5394,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877605,,BAO_0000218,,,CLD0
9118,4408,Pharmacokinetic property (Cmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623813,,BAO_0000218,,,CLD0
9119,5983,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623814,,BAO_0000218,,,CLD0
9120,4878,Cmax in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623815,,BAO_0000218,,,CLD0
9121,5862,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,Sprague-Dawley,,,,50597,N,1,Intermediate,1,,CHEMBL623816,,BAO_0000218,,,CLD0
9122,4517,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623145,,BAO_0000218,,,CLD0
9123,5932,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623146,,BAO_0000218,1969.0,,CLD0
9124,5436,Plasma concentration after oral administration of 100 mg/kg to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623147,,BAO_0000218,1969.0,,CLD0
9125,4910,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623042,,BAO_0000218,955.0,,CLD0
9126,4950,Tested for the Cmax in rat at 10 mg/kg per orally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623043,,BAO_0000218,,,CLD0
9127,15078,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623044,,BAO_0000218,,,CLD0
9128,15078,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623045,,BAO_0000218,,,CLD0
9129,3360,Bioavailability as oral Cmax in rats at 30 mins,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623046,,BAO_0000218,,,CLD0
9130,3360,Bioavailability as oral Cmax in rats at 6hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623226,,BAO_0000218,,,CLD0
9131,15022,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623227,,BAO_0000218,,,CLD0
9132,15022,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623228,,BAO_0000218,,,CLD0
9133,15022,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623229,,BAO_0000218,,,CLD0
9134,5160,The maximum plasma levels for the compounds were determined by LC-MS.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623230,,BAO_0000218,1969.0,,CLD0
9135,15662,mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623231,,BAO_0000218,1969.0,,CLD0
9136,15662,mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623232,,BAO_0000218,1969.0,,CLD0
9137,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623233,,BAO_0000218,1969.0,,CLD0
9138,3535,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623234,,BAO_0000218,1969.0,,CLD0
9139,3535,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623235,,BAO_0000218,1969.0,,CLD0
9140,3535,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623236,,BAO_0000218,1969.0,,CLD0
9141,3535,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623237,,BAO_0000218,1969.0,,CLD0
9142,3535,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623238,,BAO_0000218,1969.0,,CLD0
9143,3535,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623239,,BAO_0000218,1969.0,,CLD0
9144,5005,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL623240,,BAO_0000218,1969.0,,CLD0
9145,6326,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL623241,,BAO_0000218,1898.0,,CLD0
9146,6326,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL623242,,BAO_0000218,1898.0,,CLD0
9147,6326,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874394,,BAO_0000218,1969.0,,CLD0
9148,6326,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623243,,BAO_0000218,1969.0,,CLD0
9149,17411,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623244,,BAO_0000218,2113.0,,CLD0
9150,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623245,,BAO_0000218,2113.0,,CLD0
9151,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623246,,BAO_0000218,2113.0,,CLD0
9152,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623247,,BAO_0000218,2113.0,,CLD0
9153,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623248,,BAO_0000218,2113.0,,CLD0
9154,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623249,,BAO_0000218,2113.0,,CLD0
9155,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625072,,BAO_0000218,2107.0,,CLD0
9156,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625073,,BAO_0000218,2107.0,,CLD0
9157,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625074,,BAO_0000218,2107.0,,CLD0
9158,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625075,,BAO_0000218,2107.0,,CLD0
9159,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625076,,BAO_0000218,2107.0,,CLD0
9160,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625077,,BAO_0000218,2107.0,,CLD0
9161,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625078,,BAO_0000218,2107.0,,CLD0
9162,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL874395,,BAO_0000218,2107.0,,CLD0
9163,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625079,,BAO_0000218,2107.0,,CLD0
9164,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625080,,BAO_0000218,2107.0,,CLD0
9165,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625081,,BAO_0000218,2107.0,,CLD0
9166,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625082,,BAO_0000218,2107.0,,CLD0
9167,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625083,,BAO_0000218,2107.0,,CLD0
9168,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625084,,BAO_0000218,2107.0,,CLD0
9169,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625085,,BAO_0000218,2107.0,,CLD0
9170,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625086,,BAO_0000218,2107.0,,CLD0
9171,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625087,,BAO_0000218,2107.0,,CLD0
9172,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625088,,BAO_0000218,2107.0,,CLD0
9173,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622205,,BAO_0000218,2107.0,,CLD0
9174,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622206,,BAO_0000218,2107.0,,CLD0
9175,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622207,,BAO_0000218,2107.0,,CLD0
9176,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622366,,BAO_0000218,2107.0,,CLD0
9177,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622367,,BAO_0000218,2107.0,,CLD0
9178,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL875331,,BAO_0000218,2107.0,,CLD0
9179,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622368,,BAO_0000218,2107.0,,CLD0
9180,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622369,,BAO_0000218,2048.0,,CLD0
9181,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622370,,BAO_0000218,2048.0,,CLD0
9182,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622371,,BAO_0000218,2048.0,,CLD0
9183,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622372,,BAO_0000218,2048.0,,CLD0
9184,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622373,,BAO_0000218,2048.0,,CLD0
9185,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622374,,BAO_0000218,2048.0,,CLD0
9186,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622375,,BAO_0000218,2048.0,,CLD0
9187,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622376,,BAO_0000218,2048.0,,CLD0
9188,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622377,,BAO_0000218,2048.0,,CLD0
9189,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622378,,BAO_0000218,2048.0,,CLD0
9190,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622379,,BAO_0000218,2048.0,,CLD0
9191,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622380,,BAO_0000218,2048.0,,CLD0
9192,16435,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622381,,BAO_0000218,2048.0,,CLD0
9193,16435,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622382,,BAO_0000218,2048.0,,CLD0
9194,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622383,,BAO_0000218,2048.0,,CLD0
9195,6175,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL875332,,BAO_0000218,1971.0,,CLD0
9196,6175,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL622384,,BAO_0000218,1971.0,,CLD0
9197,6175,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL622385,,BAO_0000218,1971.0,,CLD0
9198,6175,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Gastric juice,,,50597,N,1,Intermediate,1,,CHEMBL622386,,BAO_0000218,1971.0,,CLD0
9199,10839,The compound was tested for the plasma binding in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622387,,BAO_0000218,1969.0,,CLD0
9200,16459,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622388,,BAO_0000218,1969.0,,CLD0
9201,16459,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622389,,BAO_0000218,1969.0,,CLD0
9202,16459,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622390,,BAO_0000218,1969.0,,CLD0
9203,16459,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622391,,BAO_0000218,1969.0,,CLD0
9204,16459,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622392,,BAO_0000218,1969.0,,CLD0
9205,16459,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622393,,BAO_0000218,1969.0,,CLD0
9206,3278,Plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622394,,BAO_0000218,1969.0,,CLD0
9207,3278,plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622395,,BAO_0000218,1969.0,,CLD0
9208,4684,Stability in rat serum measured as % recovery at 1 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL622396,,BAO_0000218,1977.0,,CLD0
9209,4684,Stability in rat serum measured as % recovery at 10 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624894,,BAO_0000218,1977.0,,CLD0
9210,4684,Stability in rat serum measured as % recovery at 10 mins,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624895,,BAO_0000218,1977.0,,CLD0
9211,4684,Stability in rat serum measured as % recovery at 2 hr,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624058,,BAO_0000218,1977.0,,CLD0
9212,4684,Stability in rat serum measured as % recovery at 3 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624059,,BAO_0000218,1977.0,,CLD0
9213,4684,Stability in rat serum measured as % recovery at 3 mins,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624060,,BAO_0000218,1977.0,,CLD0
9214,4684,Stability in rat serum measured as % recovery at 5 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624061,,BAO_0000218,1977.0,,CLD0
9215,4684,Stability in rat serum measured as % recovery at 5 mins,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624062,,BAO_0000218,1977.0,,CLD0
9216,16456,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624063,,BAO_0000218,,,CLD0
9217,16456,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624064,,BAO_0000218,,,CLD0
9218,723,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624065,,BAO_0000218,1969.0,,CLD0
9219,723,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624066,,BAO_0000218,1969.0,,CLD0
9220,5160,Half life tested in mature male rat at a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877490,,BAO_0000218,,,CLD0
9221,4709,Half life after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874442,,BAO_0000218,,,CLD0
9222,5633,Half life period after administration (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626890,,BAO_0000218,,,CLD0
9223,5302,Half life period in rat after 5 mg/Kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626891,,BAO_0000218,,,CLD0
9224,5302,Half life period in rat after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626892,,BAO_0000218,,,CLD0
9225,17791,Half life period was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626893,,BAO_0000218,,,CLD0
9226,17791,Half life period was evaluated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626894,,BAO_0000218,,,CLD0
9227,17791,Half life period was evaluated in rat; 0.5-1.0,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626895,,BAO_0000218,,,CLD0
9228,17791,Half life period was evaluated in rat; 5.9-7.5,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626896,,BAO_0000218,,,CLD0
9229,14512,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626897,,BAO_0000218,1969.0,,CLD0
9230,6230,Half-life time in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626898,,BAO_0000218,,,CLD0
9231,3364,Terminal half-life after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626899,,BAO_0000218,,,CLD0
9232,6874,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626900,,BAO_0000218,,,CLD0
9233,857,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626901,,BAO_0000218,,,CLD0
9234,858,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626902,,BAO_0000218,,,CLD0
9235,858,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626903,,BAO_0000218,,,CLD0
9236,5355,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874443,,BAO_0000218,,,CLD0
9237,5355,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626904,,BAO_0000218,,,CLD0
9238,6305,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626905,,BAO_0000218,,,CLD0
9239,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873830,,BAO_0000218,1969.0,,CLD0
9240,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626906,,BAO_0000218,,,CLD0
9241,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631076,,BAO_0000218,1969.0,,CLD0
9242,2932,Biological half-life was measured in plasma of rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631077,,BAO_0000218,1969.0,,CLD0
9243,17065,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631078,,BAO_0000218,,,CLD0
9244,15765,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631079,,BAO_0000218,,,CLD0
9245,2713,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631080,,BAO_0000218,,,CLD0
9246,2661,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631081,,BAO_0000218,,,CLD0
9247,2661,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631239,,BAO_0000218,,,CLD0
9248,740,Compound was evaluated for plasma half life in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631240,,BAO_0000218,1969.0,,CLD0
9249,6597,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631241,,BAO_0000218,1969.0,,CLD0
9250,2959,AUC value after administration of 20 mg/Kg oral dose in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631242,,BAO_0000218,1969.0,,CLD0
9251,17594,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631243,,BAO_0000218,1969.0,,CLD0
9252,17596,AUC0-96 after administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874444,,BAO_0000218,1969.0,,CLD0
9253,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631244,,BAO_0000218,1969.0,,CLD0
9254,3293,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631245,,BAO_0000218,,,CLD0
9255,6757,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627162,,BAO_0000218,,,CLD0
9256,6757,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627163,,BAO_0000218,,,CLD0
9257,6757,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627164,,BAO_0000218,,,CLD0
9258,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627165,,BAO_0000218,2113.0,,CLD0
9259,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627166,,BAO_0000218,2107.0,,CLD0
9260,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627167,,BAO_0000218,2048.0,,CLD0
9261,4026,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627822,,BAO_0000218,,,CLD0
9262,5355,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627823,,BAO_0000218,,,CLD0
9263,5355,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627824,,BAO_0000218,,,CLD0
9264,5355,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627825,,BAO_0000218,,,CLD0
9265,5633,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627826,,BAO_0000218,,,CLD0
9266,1716,Area under curve (Pharmacokinetic property) was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627827,,BAO_0000218,,,CLD0
9267,1716,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627828,,BAO_0000218,,,CLD0
9268,4689,Area under curve after intravenous administration (1 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627829,,BAO_0000218,,,CLD0
9269,4527,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627830,,BAO_0000218,,,CLD0
9270,4527,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627831,,BAO_0000218,,,CLD0
9271,15662,Area under curve in male SD rats was observed after oral administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627832,,BAO_0000218,,,CLD0
9272,4413,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627833,,BAO_0000218,,,CLD0
9273,3598,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL627834,,BAO_0000218,,,CLD0
9274,3598,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL628004,,BAO_0000218,,,CLD0
9275,5964,Area under curve at 5 mg/kg po was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628005,,BAO_0000218,,,CLD0
9276,4689,Area under curve in Rat at a oral dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628006,,BAO_0000218,,,CLD0
9277,4186,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628007,,BAO_0000218,1969.0,,CLD0
9278,5510,Area under curve was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625676,,BAO_0000218,,,CLD0
9279,17858,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631309,,BAO_0000218,,,CLD0
9280,17804,Area under curve after intravenous administration at 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631310,,BAO_0000218,,,CLD0
9281,6106,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631311,,BAO_0000218,,,CLD0
9282,5964,Area under curve at 4 hr in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631312,,BAO_0000218,,,CLD0
9283,4026,Area under curve at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631313,,BAO_0000218,,,CLD0
9284,4756,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631314,,BAO_0000218,,,CLD0
9285,4756,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631315,,BAO_0000218,,,CLD0
9286,5862,Area under curve for a 2-mpk po dose in SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631316,,BAO_0000218,,,CLD0
9287,5862,Area under curve in SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631317,,BAO_0000218,,,CLD0
9288,6644,Area under curve in rat after oral administration at 13 mg/kg dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874471,,BAO_0000218,,,CLD0
9289,5871,Area under curve in rat by po administration at 0-24 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631318,,BAO_0000218,,,CLD0
9290,5919,Area under curve in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631319,,BAO_0000218,1969.0,,CLD0
9291,5939,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631320,,BAO_0000218,1969.0,,CLD0
9292,5939,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631321,,BAO_0000218,1969.0,,CLD0
9293,10,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631322,,BAO_0000218,,,CLD0
9294,11149,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631323,,BAO_0000218,,,CLD0
9295,5302,Area under curve value in rat at a dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631324,,BAO_0000218,,,CLD0
9296,17796,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631325,,BAO_0000218,,,CLD0
9297,4890,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631326,,BAO_0000218,,,CLD0
9298,6011,Area under curve was determined after peroral administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631327,,BAO_0000218,,,CLD0
9299,5375,Area under curve was determined at a dose 30 mpk administered orally.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631328,,BAO_0000218,,,CLD0
9300,17764,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631329,,BAO_0000218,,,CLD0
9301,4368,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627217,,BAO_0000218,,,CLD0
9302,5610,Area under curve was determined in male rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626352,,BAO_0000218,,,CLD0
9303,5833,Area under curve was determined in rat after PO administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626353,,BAO_0000218,,,CLD0
9304,4257,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626354,,BAO_0000218,,,CLD0
9305,5937,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626355,,BAO_0000218,,,CLD0
9306,5932,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626356,,BAO_0000218,,,CLD0
9307,5932,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626357,,BAO_0000218,,,CLD0
9308,17411,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626358,,BAO_0000218,2107.0,,CLD0
9309,17411,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626359,,BAO_0000218,2048.0,,CLD0
9310,17771,Peak plasma concentration in rat at a dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626360,,BAO_0000218,1969.0,,CLD0
9311,1628,Plasma concentration at 2 hr in rats was evaluated.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626361,,BAO_0000218,1969.0,,CLD0
9312,1628,Plasma concentration at 2 hr in rats was evaluated; Not available,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626362,,BAO_0000218,1969.0,,CLD0
9313,17411,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL626363,,BAO_0000218,1977.0,,CLD0
9314,4910,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL626970,,BAO_0000218,955.0,,CLD0
9315,4910,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL626971,,BAO_0000218,955.0,,CLD0
9316,4910,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626972,,BAO_0000218,1969.0,,CLD0
9317,4910,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626973,,BAO_0000218,1969.0,,CLD0
9318,4910,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626974,,BAO_0000218,1969.0,,CLD0
9319,4910,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874592,,BAO_0000218,1969.0,,CLD0
9320,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626975,,BAO_0000218,1969.0,,CLD0
9321,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626976,,BAO_0000218,1969.0,,CLD0
9322,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626977,,BAO_0000218,1969.0,,CLD0
9323,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626978,,BAO_0000218,1969.0,,CLD0
9324,16427,PK study was carried to determine the relative absorption ranking in rat.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626979,,BAO_0000218,,,CLD0
9325,4689,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626980,,BAO_0000218,1969.0,,CLD0
9326,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626981,,BAO_0000218,178.0,,CLD0
9327,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626982,,BAO_0000218,178.0,,CLD0
9328,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626983,,BAO_0000218,178.0,,CLD0
9329,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622522,,BAO_0000218,178.0,,CLD0
9330,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622523,,BAO_0000218,178.0,,CLD0
9331,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622524,,BAO_0000218,178.0,,CLD0
9332,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622525,,BAO_0000218,955.0,,CLD0
9333,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622526,,BAO_0000218,955.0,,CLD0
9334,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619849,,BAO_0000218,955.0,,CLD0
9335,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619850,,BAO_0000218,955.0,,CLD0
9336,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623864,,BAO_0000218,955.0,,CLD0
9337,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623865,,BAO_0000218,955.0,,CLD0
9338,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623866,,BAO_0000218,948.0,,CLD0
9339,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623867,,BAO_0000218,948.0,,CLD0
9340,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL877615,,BAO_0000218,948.0,,CLD0
9341,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623868,,BAO_0000218,948.0,,CLD0
9342,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623869,,BAO_0000218,948.0,,CLD0
9343,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623870,,BAO_0000218,948.0,,CLD0
9344,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL623871,,BAO_0000218,2048.0,,CLD0
9345,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL623872,,BAO_0000218,2048.0,,CLD0
9346,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622129,,BAO_0000218,2048.0,,CLD0
9347,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622130,,BAO_0000218,2048.0,,CLD0
9348,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622131,,BAO_0000218,2048.0,,CLD0
9349,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622132,,BAO_0000218,2048.0,,CLD0
9350,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622133,,BAO_0000218,2048.0,,CLD0
9351,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622134,,BAO_0000218,2048.0,,CLD0
9352,16435,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622135,,BAO_0000218,2048.0,,CLD0
9353,16435,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622136,,BAO_0000218,2048.0,,CLD0
9354,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622137,,BAO_0000218,2385.0,,CLD0
9355,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622138,,BAO_0000218,2385.0,,CLD0
9356,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623017,,BAO_0000218,2385.0,,CLD0
9357,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623018,,BAO_0000218,2385.0,,CLD0
9358,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623019,,BAO_0000218,2385.0,,CLD0
9359,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623020,,BAO_0000218,2385.0,,CLD0
9360,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623021,,BAO_0000218,2385.0,,CLD0
9361,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623022,,BAO_0000218,2385.0,,CLD0
9362,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623023,,BAO_0000218,2385.0,,CLD0
9363,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623024,,BAO_0000218,2385.0,,CLD0
9364,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623025,,BAO_0000218,2385.0,,CLD0
9365,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620545,,BAO_0000218,2385.0,,CLD0
9366,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620546,,BAO_0000218,2385.0,,CLD0
9367,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620547,,BAO_0000218,2385.0,,CLD0
9368,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620548,,BAO_0000218,2385.0,,CLD0
9369,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620549,,BAO_0000218,2385.0,,CLD0
9370,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620550,,BAO_0000218,2385.0,,CLD0
9371,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620551,,BAO_0000218,2385.0,,CLD0
9372,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620552,,BAO_0000218,2385.0,,CLD0
9373,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620553,,BAO_0000218,2385.0,,CLD0
9374,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620554,,BAO_0000218,2385.0,,CLD0
9375,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL875845,,BAO_0000218,2385.0,,CLD0
9376,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620555,,BAO_0000218,2385.0,,CLD0
9377,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620556,,BAO_0000218,2385.0,,CLD0
9378,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620557,,BAO_0000218,2385.0,,CLD0
9379,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL620558,,BAO_0000218,1264.0,,CLD0
9380,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL620559,,BAO_0000218,1264.0,,CLD0
9381,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622939,,BAO_0000218,1264.0,,CLD0
9382,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622940,,BAO_0000218,1264.0,,CLD0
9383,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622941,,BAO_0000218,1264.0,,CLD0
9384,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622942,,BAO_0000218,1264.0,,CLD0
9385,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622943,,BAO_0000218,1264.0,,CLD0
9386,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622944,,BAO_0000218,1264.0,,CLD0
9387,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622945,,BAO_0000218,1264.0,,CLD0
9388,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622946,,BAO_0000218,1264.0,,CLD0
9389,3341,Compound was evaluated for terminal half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622947,,BAO_0000218,,,CLD0
9390,3634,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622948,,BAO_0000218,1969.0,,CLD0
9391,3634,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622949,,BAO_0000218,1969.0,,CLD0
9392,4839,Compound was tested for its half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622950,,BAO_0000218,,,CLD0
9393,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL622951,,BAO_0000218,1969.0,,CLD0
9394,5005,Compound was tested for its plasma half life in Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL622952,,BAO_0000366,1969.0,,CLD0
9395,5005,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL622953,,BAO_0000366,1969.0,,CLD0
9396,1094,Compound was tested for plasma half-life period in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873818,,BAO_0000218,1969.0,,CLD0
9397,5031,Elimination half life after i.v. administration of compound in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622954,,BAO_0000218,,,CLD0
9398,6518,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622955,,BAO_0000218,,,CLD0
9399,6518,Elimination half-life after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875229,,BAO_0000218,,,CLD0
9400,6518,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622956,,BAO_0000218,,,CLD0
9401,6518,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622957,,BAO_0000218,,,CLD0
9402,5408,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622958,,BAO_0000218,955.0,,CLD0
9403,5408,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622959,,BAO_0000218,1969.0,,CLD0
9404,5408,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622960,,BAO_0000218,955.0,,CLD0
9405,5408,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622961,,BAO_0000218,1969.0,,CLD0
9406,4687,Evaluated for the half life in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622962,,BAO_0000218,,,CLD0
9407,6640,Hafl life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622963,,BAO_0000218,,,CLD0
9408,6640,Hafl life rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622964,,BAO_0000218,,,CLD0
9409,6641,Hafl life rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622965,,BAO_0000218,,,CLD0
9410,6640,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622966,,BAO_0000218,,,CLD0
9411,6641,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622967,,BAO_0000218,,,CLD0
9412,17411,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622968,,BAO_0000218,2113.0,,CLD0
9413,17411,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622969,,BAO_0000218,2107.0,,CLD0
9414,17411,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL875327,,BAO_0000218,2048.0,,CLD0
9415,6570,Half life in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628638,,BAO_0000218,,,CLD0
9416,6570,Half life in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628639,,BAO_0000218,,,CLD0
9417,17411,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL625840,,BAO_0000218,1977.0,,CLD0
9418,4722,Half life of 10 mg/kg oral dose determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625841,,BAO_0000218,,,CLD0
9419,5978,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625842,,BAO_0000218,,,CLD0
9420,5978,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625843,,BAO_0000218,,,CLD0
9421,5978,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625844,,BAO_0000218,,,CLD0
9422,5978,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873822,,BAO_0000218,,,CLD0
9423,5978,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625845,,BAO_0000218,,,CLD0
9424,5978,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627059,,BAO_0000218,,,CLD0
9425,5978,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627060,,BAO_0000218,,,CLD0
9426,5978,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627061,,BAO_0000218,,,CLD0
9427,4762,Half life of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627709,,BAO_0000218,,,CLD0
9428,5327,Half life of compound determined after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627710,,BAO_0000218,,,CLD0
9429,4847,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627711,,BAO_0000218,,,CLD0
9430,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627712,,BAO_0000218,1969.0,,CLD0
9431,4723,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627713,,BAO_0000218,,,CLD0
9432,4723,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627714,,BAO_0000218,,,CLD0
9433,4256,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627889,,BAO_0000218,,,CLD0
9434,4256,Half life determined in rat by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627890,,BAO_0000218,,,CLD0
9435,4722,Half life determined in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627891,,BAO_0000218,,,CLD0
9436,6535,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627892,,BAO_0000218,1969.0,,CLD0
9437,6535,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627893,,BAO_0000218,1969.0,,CLD0
9438,1435,Half life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627894,,BAO_0000218,1969.0,,CLD0
9439,1435,Half life in rat plasma was determined; NA means not applicable,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627895,,BAO_0000218,1969.0,,CLD0
9440,5206,Half life in rat was tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627896,,BAO_0000218,,,CLD0
9441,6080,Half life measured in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627897,,BAO_0000218,1969.0,,CLD0
9442,4449,Half life recorded in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627898,,BAO_0000218,,,CLD0
9443,6057,Half life was calculated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627899,,BAO_0000218,,,CLD0
9444,6057,Half life was calculated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873823,,BAO_0000218,,,CLD0
9445,3747,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627900,,BAO_0000218,,,CLD0
9446,17858,Half life after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627901,,BAO_0000218,,,CLD0
9447,16365,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627902,,BAO_0000218,,,CLD0
9448,16365,Half life after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627903,,BAO_0000218,,,CLD0
9449,5031,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627904,,BAO_0000218,,,CLD0
9450,4722,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627905,,BAO_0000218,,,CLD0
9451,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627906,,BAO_0000218,,,CLD0
9452,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627907,,BAO_0000218,,,CLD0
9453,6078,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876783,,BAO_0000218,,,CLD0
9454,6078,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627908,,BAO_0000218,,,CLD0
9455,17065,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627909,,BAO_0000218,,,CLD0
9456,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627910,,BAO_0000218,1969.0,,CLD0
9457,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627911,,BAO_0000218,1969.0,,CLD0
9458,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627912,,BAO_0000218,1969.0,,CLD0
9459,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627913,,BAO_0000218,1969.0,,CLD0
9460,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627914,,BAO_0000218,1969.0,,CLD0
9461,16423,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627915,,BAO_0000218,,,CLD0
9462,16423,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627916,,BAO_0000218,,,CLD0
9463,6062,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627917,,BAO_0000218,,,CLD0
9464,6056,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627918,,BAO_0000218,,,CLD0
9465,5182,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627919,,BAO_0000218,,,CLD0
9466,6410,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627920,,BAO_0000218,,,CLD0
9467,6410,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627921,,BAO_0000218,,,CLD0
9468,4723,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627922,,BAO_0000218,,,CLD0
9469,4723,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876784,,BAO_0000218,,,CLD0
9470,4723,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627923,,BAO_0000218,,,CLD0
9471,4723,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626208,,BAO_0000218,,,CLD0
9472,4723,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626209,,BAO_0000218,,,CLD0
9473,4723,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626210,,BAO_0000218,,,CLD0
9474,2463,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627994,,BAO_0000218,1969.0,,CLD0
9475,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627995,,BAO_0000218,,,CLD0
9476,4075,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627996,,BAO_0000218,178.0,,CLD0
9477,5394,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627997,,BAO_0000218,,,CLD0
9478,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627998,,BAO_0000218,,,CLD0
9479,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628640,,BAO_0000218,,,CLD0
9480,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628641,,BAO_0000218,,,CLD0
9481,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628642,,BAO_0000218,,,CLD0
9482,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628643,,BAO_0000218,,,CLD0
9483,2591,Compound was tested for area under curve in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628644,,BAO_0000218,,,CLD0
9484,6567,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628645,,BAO_0000218,1969.0,,CLD0
9485,6211,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628646,,BAO_0000218,,,CLD0
9486,5529,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628647,,BAO_0000218,,,CLD0
9487,5408,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL628648,,BAO_0000218,955.0,,CLD0
9488,5408,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625358,,BAO_0000218,1969.0,,CLD0
9489,5408,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625359,,BAO_0000218,955.0,,CLD0
9490,5408,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625360,,BAO_0000218,1969.0,,CLD0
9491,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625361,,BAO_0000218,,,CLD0
9492,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625362,,BAO_0000218,,,CLD0
9493,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625363,,BAO_0000218,,,CLD0
9494,4796,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625364,,BAO_0000218,,,CLD0
9495,5974,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625365,,BAO_0000218,,,CLD0
9496,5974,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625366,,BAO_0000218,,,CLD0
9497,5974,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625367,,BAO_0000218,,,CLD0
9498,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625368,,BAO_0000218,2113.0,,CLD0
9499,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625369,,BAO_0000218,2113.0,,CLD0
9500,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625370,,BAO_0000218,2113.0,,CLD0
9501,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625371,,BAO_0000218,2113.0,,CLD0
9502,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625372,,BAO_0000218,2113.0,,CLD0
9503,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625373,,BAO_0000218,2113.0,,CLD0
9504,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625374,,BAO_0000218,2107.0,,CLD0
9505,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL877593,,BAO_0000218,2107.0,,CLD0
9506,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625375,,BAO_0000218,2107.0,,CLD0
9507,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625376,,BAO_0000218,2107.0,,CLD0
9508,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621973,,BAO_0000218,2107.0,,CLD0
9509,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621974,,BAO_0000218,2107.0,,CLD0
9510,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL621975,,BAO_0000218,2048.0,,CLD0
9511,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622166,,BAO_0000218,2048.0,,CLD0
9512,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622167,,BAO_0000218,2048.0,,CLD0
9513,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622168,,BAO_0000218,2048.0,,CLD0
9514,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622169,,BAO_0000218,2048.0,,CLD0
9515,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622170,,BAO_0000218,2048.0,,CLD0
9516,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622171,,BAO_0000218,2046.0,,CLD0
9517,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622172,,BAO_0000218,2046.0,,CLD0
9518,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622173,,BAO_0000218,2046.0,,CLD0
9519,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622174,,BAO_0000218,2046.0,,CLD0
9520,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622175,,BAO_0000218,2046.0,,CLD0
9521,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622176,,BAO_0000218,2046.0,,CLD0
9522,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622177,,BAO_0000218,2046.0,,CLD0
9523,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622178,,BAO_0000218,2046.0,,CLD0
9524,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622179,,BAO_0000218,2046.0,,CLD0
9525,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622180,,BAO_0000218,2046.0,,CLD0
9526,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622181,,BAO_0000218,1264.0,,CLD0
9527,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622182,,BAO_0000218,1264.0,,CLD0
9528,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622183,,BAO_0000218,1264.0,,CLD0
9529,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622184,,BAO_0000218,1264.0,,CLD0
9530,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622185,,BAO_0000218,1264.0,,CLD0
9531,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622186,,BAO_0000218,1264.0,,CLD0
9532,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622187,,BAO_0000218,1264.0,,CLD0
9533,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL625002,,BAO_0000218,1264.0,,CLD0
9534,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622090,,BAO_0000218,1264.0,,CLD0
9535,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622091,,BAO_0000218,1264.0,,CLD0
9536,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622092,,BAO_0000218,1264.0,,CLD0
9537,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622093,,BAO_0000218,1264.0,,CLD0
9538,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622094,,BAO_0000218,1264.0,,CLD0
9539,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622095,,BAO_0000218,1264.0,,CLD0
9540,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Pancreas,,,50597,N,1,Intermediate,1,,CHEMBL622264,,BAO_0000218,1264.0,,CLD0
9541,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622265,,BAO_0000218,2106.0,,CLD0
9542,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622266,,BAO_0000218,2106.0,,CLD0
9543,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622267,,BAO_0000218,2106.0,,CLD0
9544,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622268,,BAO_0000218,2106.0,,CLD0
9545,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622269,,BAO_0000218,2106.0,,CLD0
9546,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625071,,BAO_0000218,2106.0,,CLD0
9547,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621621,,BAO_0000218,2106.0,,CLD0
9548,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621622,,BAO_0000218,2106.0,,CLD0
9549,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621623,,BAO_0000218,2106.0,,CLD0
9550,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621624,,BAO_0000218,2106.0,,CLD0
9551,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621625,,BAO_0000218,2106.0,,CLD0
9552,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621626,,BAO_0000218,2106.0,,CLD0
9553,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621627,,BAO_0000218,2106.0,,CLD0
9554,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621628,,BAO_0000218,2106.0,,CLD0
9555,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL875328,,BAO_0000218,2106.0,,CLD0
9556,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621629,,BAO_0000218,2106.0,,CLD0
9557,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621630,,BAO_0000218,2106.0,,CLD0
9558,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621631,,BAO_0000218,2106.0,,CLD0
9559,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621632,,BAO_0000218,2106.0,,CLD0
9560,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621633,,BAO_0000218,2106.0,,CLD0
9561,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621634,,BAO_0000218,2106.0,,CLD0
9562,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621635,,BAO_0000218,2106.0,,CLD0
9563,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621636,,BAO_0000218,2106.0,,CLD0
9564,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621637,,BAO_0000218,2106.0,,CLD0
9565,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621638,,BAO_0000218,2106.0,,CLD0
9566,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL618883,,BAO_0000218,473.0,,CLD0
9567,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL618884,,BAO_0000218,473.0,,CLD0
9568,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL628627,,BAO_0000218,473.0,,CLD0
9569,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL628628,,BAO_0000218,473.0,,CLD0
9570,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL628629,,BAO_0000218,473.0,,CLD0
9571,16365,Half life after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628630,,BAO_0000218,,,CLD0
9572,16365,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628631,,BAO_0000218,,,CLD0
9573,16365,Half life after administering intravenously a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628632,,BAO_0000218,,,CLD0
9574,526,Half life after oral dosing in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628633,,BAO_0000218,,,CLD0
9575,16365,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628634,,BAO_0000218,,,CLD0
9576,4368,Half life by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627789,,BAO_0000218,,,CLD0
9577,3371,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627790,,BAO_0000218,,,CLD0
9578,6448,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627791,,BAO_0000218,,,CLD0
9579,6453,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627792,,BAO_0000218,,,CLD0
9580,4353,Half life in rat after intravenous administration of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627793,,BAO_0000218,,,CLD0
9581,4353,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627794,,BAO_0000218,1969.0,,CLD0
9582,4353,Half life in rat after po administration of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627795,,BAO_0000218,,,CLD0
9583,4353,Half life in rat after po administration of the compound; ND means Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627796,,BAO_0000218,,,CLD0
9584,4353,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875335,,BAO_0000218,1969.0,,CLD0
9585,4353,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627797,,BAO_0000218,1969.0,,CLD0
9586,5789,Half life in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627798,,BAO_0000218,,,CLD0
9587,17686,Half life in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627799,,BAO_0000218,,,CLD0
9588,6495,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627800,,BAO_0000218,,,CLD0
9589,484,Half life in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627801,,BAO_0000218,,,CLD0
9590,6467,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627802,,BAO_0000218,,,CLD0
9591,6642,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL627803,,BAO_0000218,,,CLD0
9592,16367,Half life was evaluated after intravenous administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873820,,BAO_0000218,,,CLD0
9593,1369,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627804,,BAO_0000218,,,CLD0
9594,5472,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627805,,BAO_0000218,,,CLD0
9595,6049,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627806,,BAO_0000218,,,CLD0
9596,5472,Half life was evaluated in rat; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627107,,BAO_0000218,,,CLD0
9597,16366,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627108,,BAO_0000218,,,CLD0
9598,11149,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627109,,BAO_0000218,,,CLD0
9599,11149,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627110,,BAO_0000218,178.0,,CLD0
9600,2891,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627111,,BAO_0000218,,,CLD0
9601,2891,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627112,,BAO_0000218,,,CLD0
9602,2891,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627113,,BAO_0000218,,,CLD0
9603,2891,Half life was measured in rat at dose of 30 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627114,,BAO_0000218,,,CLD0
9604,4026,Half life (t1/2) was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627115,,BAO_0000218,,,CLD0
9605,4527,Half life period at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627116,,BAO_0000218,,,CLD0
9606,4527,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627117,,BAO_0000218,,,CLD0
9607,5503,Half life period was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627118,,BAO_0000218,,,CLD0
9608,4426,Half life period after intravenous administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627119,,BAO_0000218,,,CLD0
9609,4426,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627120,,BAO_0000218,,,CLD0
9610,6109,Half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626922,,BAO_0000218,,,CLD0
9611,5654,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626923,,BAO_0000218,,,CLD0
9612,5654,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626924,,BAO_0000218,,,CLD0
9613,4755,Half life period in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626925,,BAO_0000218,1969.0,,CLD0
9614,5862,Half life period in SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626926,,BAO_0000218,,,CLD0
9615,1515,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626927,,BAO_0000218,1969.0,,CLD0
9616,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626928,,BAO_0000218,1969.0,,CLD0
9617,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626929,,BAO_0000218,1969.0,,CLD0
9618,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626930,,BAO_0000218,1969.0,,CLD0
9619,5960,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626931,,BAO_0000218,,,CLD0
9620,6103,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626932,,BAO_0000218,,,CLD0
9621,6317,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626933,,BAO_0000218,,,CLD0
9622,6644,Half life period in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873826,,BAO_0000218,,,CLD0
9623,6644,Half life period in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626934,,BAO_0000218,,,CLD0
9624,6644,Half life period in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626935,,BAO_0000218,,,CLD0
9625,6644,Half life period in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626936,,BAO_0000218,,,CLD0
9626,5974,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626937,,BAO_0000218,,,CLD0
9627,6295,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625906,,BAO_0000218,1969.0,,CLD0
9628,6296,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625907,,BAO_0000218,1969.0,,CLD0
9629,16427,PK study was carried to determine AUC (area under curve) value in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625908,,BAO_0000218,,,CLD0
9630,16367,Pharmacokinetic parameter AUC after intravenous administration to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625909,,BAO_0000218,,,CLD0
9631,16367,Pharmacokinetic parameter AUC after oral administration to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625910,,BAO_0000218,,,CLD0
9632,16365,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625911,,BAO_0000218,,,CLD0
9633,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625912,,BAO_0000218,,,CLD0
9634,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626538,,BAO_0000218,,,CLD0
9635,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876794,,BAO_0000218,,,CLD0
9636,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626539,,BAO_0000218,,,CLD0
9637,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626540,,BAO_0000218,,,CLD0
9638,5394,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626541,,BAO_0000218,,,CLD0
9639,5394,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626542,,BAO_0000218,,,CLD0
9640,2792,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626543,,BAO_0000218,,,CLD0
9641,2792,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626544,,BAO_0000218,,,CLD0
9642,2792,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626545,,BAO_0000218,,,CLD0
9643,2792,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626546,,BAO_0000218,,,CLD0
9644,5334,Pharmacokinetic parameter area under curve was reported,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626547,,BAO_0000218,,,CLD0
9645,4408,Pharmacokinetic property (AUC) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626548,,BAO_0000218,,,CLD0
9646,5983,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626549,,BAO_0000218,,,CLD0
9647,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626550,,BAO_0000218,,,CLD0
9648,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626551,,BAO_0000218,,,CLD0
9649,5491,Pharmacokinetic property was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623777,,BAO_0000218,,,CLD0
9650,5491,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623778,,BAO_0000218,,,CLD0
9651,5491,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623779,,BAO_0000218,,,CLD0
9652,4199,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623780,,BAO_0000218,1969.0,,CLD0
9653,4199,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622015,,BAO_0000218,1969.0,,CLD0
9654,4199,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622016,,BAO_0000218,1969.0,,CLD0
9655,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622017,,BAO_0000218,,,CLD0
9656,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622018,,BAO_0000218,,,CLD0
9657,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622019,,BAO_0000218,,,CLD0
9658,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622020,,BAO_0000218,,,CLD0
9659,16366,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622021,,BAO_0000218,,,CLD0
9660,16366,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622022,,BAO_0000218,,,CLD0
9661,5327,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622023,,BAO_0000218,1969.0,,CLD0
9662,6681,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622024,,BAO_0000218,1969.0,,CLD0
9663,12873,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622693,,BAO_0000218,1969.0,,CLD0
9664,12873,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622694,,BAO_0000218,1969.0,,CLD0
9665,6685,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622695,,BAO_0000218,1969.0,,CLD0
9666,6685,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622696,,BAO_0000218,1969.0,,CLD0
9667,6685,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622697,,BAO_0000218,1969.0,,CLD0
9668,6619,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622874,,BAO_0000218,,,CLD0
9669,6619,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622875,,BAO_0000218,,,CLD0
9670,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622876,,BAO_0000218,,,CLD0
9671,4796,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622877,,BAO_0000218,,,CLD0
9672,4910,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622878,,BAO_0000218,955.0,,CLD0
9673,4910,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622879,,BAO_0000218,1969.0,,CLD0
9674,4839,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877602,,BAO_0000218,,,CLD0
9675,15078,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622880,,BAO_0000218,,,CLD0
9676,15078,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622881,,BAO_0000218,,,CLD0
9677,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622882,,BAO_0000218,,,CLD0
9678,15078,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622883,,BAO_0000218,,,CLD0
9679,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622884,,BAO_0000218,2046.0,,CLD0
9680,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622885,,BAO_0000218,2046.0,,CLD0
9681,8151,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622886,,BAO_0000218,1088.0,,CLD0
9682,8151,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622887,,BAO_0000218,1088.0,,CLD0
9683,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622888,,BAO_0000218,1088.0,,CLD0
9684,8677,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622889,,BAO_0000218,178.0,,CLD0
9685,8677,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622890,,BAO_0000218,178.0,,CLD0
9686,8677,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622891,,BAO_0000218,178.0,,CLD0
9687,8677,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL877603,,BAO_0000218,178.0,,CLD0
9688,8677,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622892,,BAO_0000218,955.0,,CLD0
9689,8677,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622893,,BAO_0000218,955.0,,CLD0
9690,8677,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622894,,BAO_0000218,955.0,,CLD0
9691,8677,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622895,,BAO_0000218,955.0,,CLD0
9692,8677,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622896,,BAO_0000218,955.0,,CLD0
9693,8677,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622897,,BAO_0000218,948.0,,CLD0
9694,8677,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622898,,BAO_0000218,948.0,,CLD0
9695,8677,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622899,,BAO_0000218,948.0,,CLD0
9696,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622900,,BAO_0000218,2113.0,,CLD0
9697,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624114,,BAO_0000218,2113.0,,CLD0
9698,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624115,,BAO_0000218,2113.0,,CLD0
9699,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624116,,BAO_0000218,2113.0,,CLD0
9700,8677,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624117,,BAO_0000218,2107.0,,CLD0
9701,8677,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624118,,BAO_0000218,2107.0,,CLD0
9702,8677,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624119,,BAO_0000218,2107.0,,CLD0
9703,8677,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624120,,BAO_0000218,2107.0,,CLD0
9704,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624121,,BAO_0000218,2048.0,,CLD0
9705,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624122,,BAO_0000218,2048.0,,CLD0
9706,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624123,,BAO_0000218,2048.0,,CLD0
9707,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624124,,BAO_0000218,2048.0,,CLD0
9708,8677,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624125,,BAO_0000218,2385.0,,CLD0
9709,8677,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624126,,BAO_0000218,2385.0,,CLD0
9710,8677,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624127,,BAO_0000218,2385.0,,CLD0
9711,8677,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624128,,BAO_0000218,2385.0,,CLD0
9712,8677,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL624129,,BAO_0000218,14.0,,CLD0
9713,8677,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL624130,,BAO_0000218,14.0,,CLD0
9714,8677,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622340,,BAO_0000218,14.0,,CLD0
9715,8677,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622341,,BAO_0000218,14.0,,CLD0
9716,8677,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Small intestine,,,50597,N,1,Intermediate,1,,CHEMBL622342,,BAO_0000218,2108.0,,CLD0
9717,8677,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Small intestine,,,50597,N,1,Intermediate,1,,CHEMBL622343,,BAO_0000218,2108.0,,CLD0
9718,8677,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Small intestine,,,50597,N,1,Intermediate,1,,CHEMBL622344,,BAO_0000218,2108.0,,CLD0
9719,8677,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Small intestine,,,50597,N,1,Intermediate,1,,CHEMBL622345,,BAO_0000218,2108.0,,CLD0
9720,8677,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622346,,BAO_0000218,2106.0,,CLD0
9721,8677,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622347,,BAO_0000218,2106.0,,CLD0
9722,8677,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622348,,BAO_0000218,2106.0,,CLD0
9723,8677,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622349,,BAO_0000218,2106.0,,CLD0
9724,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622350,,BAO_0000218,473.0,,CLD0
9725,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622351,,BAO_0000218,473.0,,CLD0
9726,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622352,,BAO_0000218,473.0,,CLD0
9727,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622353,,BAO_0000218,473.0,,CLD0
9728,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622354,,BAO_0000218,473.0,,CLD0
9729,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622355,,BAO_0000218,473.0,,CLD0
9730,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622356,,BAO_0000218,473.0,,CLD0
9731,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622357,,BAO_0000218,473.0,,CLD0
9732,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622358,,BAO_0000218,473.0,,CLD0
9733,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622359,,BAO_0000218,473.0,,CLD0
9734,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL874393,,BAO_0000218,473.0,,CLD0
9735,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622872,,BAO_0000218,473.0,,CLD0
9736,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL622873,,BAO_0000218,473.0,,CLD0
9737,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL623047,,BAO_0000218,473.0,,CLD0
9738,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL623048,,BAO_0000218,473.0,,CLD0
9739,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL623049,,BAO_0000218,473.0,,CLD0
9740,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL623050,,BAO_0000218,473.0,,CLD0
9741,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL623051,,BAO_0000218,473.0,,CLD0
9742,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL623052,,BAO_0000218,473.0,,CLD0
9743,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Testis,,,50597,N,1,Intermediate,1,,CHEMBL626343,,BAO_0000218,473.0,,CLD0
9744,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626344,,BAO_0000218,,,CLD0
9745,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626345,,BAO_0000218,,,CLD0
9746,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626346,,BAO_0000218,,,CLD0
9747,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626347,,BAO_0000218,,,CLD0
9748,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626348,,BAO_0000218,,,CLD0
9749,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626349,,BAO_0000218,,,CLD0
9750,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626350,,BAO_0000218,,,CLD0
9751,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626351,,BAO_0000218,,,CLD0
9752,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627650,,BAO_0000218,,,CLD0
9753,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627651,,BAO_0000218,,,CLD0
9754,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627652,,BAO_0000218,,,CLD0
9755,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627653,,BAO_0000218,,,CLD0
9756,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627654,,BAO_0000218,178.0,,CLD0
9757,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627835,,BAO_0000218,178.0,,CLD0
9758,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627836,,BAO_0000218,178.0,,CLD0
9759,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627837,,BAO_0000218,178.0,,CLD0
9760,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627838,,BAO_0000218,1474.0,,CLD0
9761,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL875338,,BAO_0000218,1474.0,,CLD0
9762,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627839,,BAO_0000218,1474.0,,CLD0
9763,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Bone element,,,50597,N,1,Intermediate,1,,CHEMBL627840,,BAO_0000218,1474.0,,CLD0
9764,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627841,,BAO_0000218,955.0,,CLD0
9765,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627842,,BAO_0000218,955.0,,CLD0
9766,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627843,,BAO_0000218,955.0,,CLD0
9767,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627844,,BAO_0000218,955.0,,CLD0
9768,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Adipose tissue,,,50597,N,1,Intermediate,1,,CHEMBL627845,,BAO_0000218,1013.0,,CLD0
9769,5874,Half life period in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627846,,BAO_0000218,,,CLD0
9770,1515,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627847,,BAO_0000218,1969.0,,CLD0
9771,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873821,,BAO_0000218,1969.0,,CLD0
9772,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626079,,BAO_0000218,1969.0,,CLD0
9773,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626080,,BAO_0000218,1969.0,,CLD0
9774,5491,Half life period was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626081,,BAO_0000218,1969.0,,CLD0
9775,5491,Half life period was evaluated in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875344,,BAO_0000218,1969.0,,CLD0
9776,1918,Half life period was evaluated in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626082,,BAO_0000218,,,CLD0
9777,1918,"Half life period was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626250,,BAO_0000218,,,CLD0
9778,6113,Half life period after intravenous administration at 5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626251,,BAO_0000218,,,CLD0
9779,5546,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626252,,BAO_0000218,,,CLD0
9780,5553,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626253,,BAO_0000218,,,CLD0
9781,4188,Half life stability of compound was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626254,,BAO_0000218,1969.0,,CLD0
9782,6215,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626255,,BAO_0000218,,,CLD0
9783,6141,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626256,,BAO_0000218,,,CLD0
9784,5182,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626257,,BAO_0000218,,,CLD0
9785,5182,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626258,,BAO_0000218,,,CLD0
9786,5710,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626259,,BAO_0000218,,,CLD0
9787,5789,Half in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626260,,BAO_0000218,,,CLD0
9788,6011,Half period in rat after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875345,,BAO_0000218,,,CLD0
9789,17594,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626261,,BAO_0000218,,,CLD0
9790,12357,Half-life measured in in vitro Cathepsin B assay in rat liver,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626262,,BAO_0000218,2107.0,,CLD0
9791,5210,Half-life of compound was determined in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626263,,BAO_0000218,,,CLD0
9792,17596,Half-life at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625270,,BAO_0000218,,,CLD0
9793,6672,Half-life determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625271,,BAO_0000218,,,CLD0
9794,6673,Half-life determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625272,,BAO_0000218,,,CLD0
9795,4910,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625273,,BAO_0000218,955.0,,CLD0
9796,3741,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625274,,BAO_0000218,1969.0,,CLD0
9797,17671,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625275,,BAO_0000218,,,CLD0
9798,4910,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625276,,BAO_0000218,1969.0,,CLD0
9799,17537,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625277,,BAO_0000218,1969.0,,CLD0
9800,4965,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625278,,BAO_0000218,1969.0,,CLD0
9801,17537,Half-life in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625279,,BAO_0000218,1969.0,,CLD0
9802,6124,Half-life in rat serum,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL625280,,BAO_0000218,1977.0,,CLD0
9803,6124,Half-life in rat serum; na is not available,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL876797,,BAO_0000218,1977.0,,CLD0
9804,6078,Half-life was calculated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625281,,BAO_0000218,,,CLD0
9805,17668,Half-life was calculated in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873827,,BAO_0000218,1969.0,,CLD0
9806,3185,Half-life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625282,,BAO_0000218,,,CLD0
9807,4883,Half-life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625283,,BAO_0000218,,,CLD0
9808,2959,Half-life after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625284,,BAO_0000218,,,CLD0
9809,4029,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625285,,BAO_0000218,,,CLD0
9810,4029,Half-life after intravenous administration in female rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625286,,BAO_0000218,,,CLD0
9811,4029,Half-life after intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625287,,BAO_0000218,,,CLD0
9812,6180,Half-life after intravenous dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625288,,BAO_0000218,,,CLD0
9813,1557,Half-life in a rat liver homogenate preparation,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625289,,BAO_0000218,2107.0,,CLD0
9814,12500,Half-life in plasma of rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625290,,BAO_0000218,1969.0,,CLD0
9815,12500,Half-life in plasma of rat at dose of 3-10 mgkg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876798,,BAO_0000218,1969.0,,CLD0
9816,5064,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625291,,BAO_0000218,,,CLD0
9817,5145,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625292,,BAO_0000218,,,CLD0
9818,5147,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625293,,BAO_0000218,,,CLD0
9819,5833,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622832,,BAO_0000218,,,CLD0
9820,6596,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622833,,BAO_0000218,,,CLD0
9821,17655,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622834,,BAO_0000218,,,CLD0
9822,6495,Half-life in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622835,,BAO_0000218,,,CLD0
9823,17538,Half-life in rat after po administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622836,,BAO_0000218,,,CLD0
9824,17538,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622837,,BAO_0000218,,,CLD0
9825,10,Half-life in rat at 3 mg/kg dose administered intravenously,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622838,,BAO_0000218,,,CLD0
9826,17669,Half-life in rat brain homogenate,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622839,,BAO_0000218,955.0,,CLD0
9827,17065,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622840,,BAO_0000218,1969.0,,CLD0
9828,4333,Half-life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622841,,BAO_0000218,,,CLD0
9829,6827,Half-life in Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622842,,BAO_0000218,,,CLD0
9830,889,Half-life in vitro in rat plasma,A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622843,,BAO_0000218,1969.0,,CLD0
9831,889,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622844,,BAO_0000218,1969.0,,CLD0
9832,3747,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622845,,BAO_0000218,,,CLD0
9833,15022,The area under the curve of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622846,,BAO_0000218,,,CLD0
9834,15022,The area under the curve of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622847,,BAO_0000218,,,CLD0
9835,15022,The area under the curve of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622848,,BAO_0000218,,,CLD0
9836,3360,Bioavailability as oral AUC in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622849,,BAO_0000218,,,CLD0
9837,5334,The plasma concentration versus time curve (AUC) was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622850,,BAO_0000218,1969.0,,CLD0
9838,17411,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL876807,,BAO_0000218,2113.0,,CLD0
9839,17411,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622851,,BAO_0000218,2107.0,,CLD0
9840,17411,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622852,,BAO_0000218,2048.0,,CLD0
9841,6570,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622853,,BAO_0000218,,,CLD0
9842,6570,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622854,,BAO_0000218,,,CLD0
9843,17411,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL622855,,BAO_0000218,1977.0,,CLD0
9844,14941,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622856,,BAO_0000218,1969.0,,CLD0
9845,14941,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622857,,BAO_0000218,1969.0,,CLD0
9846,17538,AUC in rat after po administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622858,,BAO_0000218,1969.0,,CLD0
9847,17752,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622859,,BAO_0000218,1969.0,,CLD0
9848,17509,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622860,,BAO_0000218,,,CLD0
9849,17509,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622861,,BAO_0000218,,,CLD0
9850,17509,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622862,,BAO_0000218,,,CLD0
9851,17509,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622863,,BAO_0000218,,,CLD0
9852,17509,Area under curve value 6 hr after po administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623817,,BAO_0000218,,,CLD0
9853,17717,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623818,,BAO_0000218,,,CLD0
9854,17717,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623819,,BAO_0000218,,,CLD0
9855,17717,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623820,,BAO_0000218,,,CLD0
9856,17717,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623821,,BAO_0000218,,,CLD0
9857,6642,AUC normalized for dose (AUCN) in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623822,,BAO_0000218,1969.0,,CLD0
9858,6640,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623823,,BAO_0000218,,,CLD0
9859,6641,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623824,,BAO_0000218,,,CLD0
9860,6641,Area under curve in rat after p.o. administration; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623825,,BAO_0000218,,,CLD0
9861,6641,Area under curve in rat after peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622070,,BAO_0000218,,,CLD0
9862,3603,Area under curve (carotid artery) value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622071,,BAO_0000218,,,CLD0
9863,3550,Bioavailability expressed as the area under curve of rat carotid artery,A,,,Rattus norvegicus,10116.0,,Artery,,,50597,N,1,Intermediate,1,,CHEMBL622072,,BAO_0000218,1637.0,,CLD0
9864,15662,Area under curve in male SD rats was observed after intravenous administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622073,,BAO_0000218,,,CLD0
9865,17720,Area under curve of the compound was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622074,,BAO_0000218,,,CLD0
9866,5407,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622075,,BAO_0000218,,,CLD0
9867,17752,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622076,,BAO_0000218,1969.0,,CLD0
9868,17752,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622077,,BAO_0000218,1969.0,,CLD0
9869,3603,Area under curve (portal vein) value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622078,,BAO_0000218,,,CLD0
9870,3550,Bioavailability expressed as the area under curve of rat portal vein,A,,,Rattus norvegicus,10116.0,,Portal vein,,,50597,N,1,Intermediate,1,,CHEMBL622079,,BAO_0000218,2017.0,,CLD0
9871,17655,Area Under plasma concentration time curve in rat upon peroral administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622080,,BAO_0000218,1969.0,,CLD0
9872,17582,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877612,,BAO_0000218,,,CLD0
9873,17582,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622081,,BAO_0000218,,,CLD0
9874,17791,Compound was evaluated for oral bioavailability in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622082,,BAO_0000218,,,CLD0
9875,17791,Compound was evaluated for oral bioavailability in rats after iv administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622083,,BAO_0000218,,,CLD0
9876,17791,Compound was evaluated for oral bioavailability in rats; 30-80,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622084,,BAO_0000218,,,CLD0
9877,17791,Compound was evaluated for oral bioavailability in rats; 50-60,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622085,,BAO_0000218,,,CLD0
9878,17791,Compound was evaluated for oral bioavailability in rats; no data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622086,,BAO_0000218,,,CLD0
9879,17791,Compound was evaluated for oral bioavailability in rats; peptide,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622087,,BAO_0000218,,,CLD0
9880,7768,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622088,,BAO_0000218,178.0,,CLD0
9881,7768,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622089,,BAO_0000218,178.0,,CLD0
9882,7768,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623685,,BAO_0000218,178.0,,CLD0
9883,7768,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623686,,BAO_0000218,178.0,,CLD0
9884,8677,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623687,,BAO_0000218,945.0,,CLD0
9885,8677,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623688,,BAO_0000218,945.0,,CLD0
9886,8677,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623689,,BAO_0000218,945.0,,CLD0
9887,8677,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622485,,BAO_0000218,945.0,,CLD0
9888,8677,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622486,,BAO_0000218,2046.0,,CLD0
9889,8677,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL877613,,BAO_0000218,2046.0,,CLD0
9890,8677,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622487,,BAO_0000218,2046.0,,CLD0
9891,8677,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622488,,BAO_0000218,2046.0,,CLD0
9892,8677,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622489,,BAO_0000218,948.0,,CLD0
9893,6899,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622490,,BAO_0000218,1088.0,,CLD0
9894,6899,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622491,,BAO_0000218,1088.0,,CLD0
9895,6899,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622492,,BAO_0000218,2107.0,,CLD0
9896,6899,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622493,,BAO_0000218,1088.0,,CLD0
9897,6899,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622494,,BAO_0000218,1088.0,,CLD0
9898,8677,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622495,,BAO_0000218,2385.0,,CLD0
9899,6899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL622496,,BAO_0000218,1988.0,,CLD0
9900,6899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622497,,BAO_0000218,1088.0,,CLD0
9901,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0,,Urine/Feces,,,50597,N,1,Intermediate,1,,CHEMBL622498,,BAO_0000218,10000012.0,,CLD0
9902,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624918,,BAO_0000218,1088.0,,CLD0
9903,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624919,,BAO_0000218,1088.0,,CLD0
9904,10839,Biodistribution of compound in rat blood after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624920,,BAO_0000218,178.0,,CLD0
9905,10839,Biodistribution of compound in rat blood after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624921,,BAO_0000218,178.0,,CLD0
9906,10839,Biodistribution of compound in rat brain after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624922,,BAO_0000218,955.0,,CLD0
9907,10839,Biodistribution of compound in rat heart after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624923,,BAO_0000218,948.0,,CLD0
9908,10839,Biodistribution of compound in rat heart after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624924,,BAO_0000218,948.0,,CLD0
9909,10839,Biodistribution of compound in rat kidney after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624925,,BAO_0000218,2113.0,,CLD0
9910,10839,Biodistribution of compound in rat kidney after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624926,,BAO_0000218,2113.0,,CLD0
9911,10839,Biodistribution of compound in rat liver after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624927,,BAO_0000218,2107.0,,CLD0
9912,10839,Biodistribution of compound in rat liver after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL874402,,BAO_0000218,2107.0,,CLD0
9913,10839,Biodistribution of compound in rat lung after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624928,,BAO_0000218,2048.0,,CLD0
9914,10839,Biodistribution of compound in rat lung after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624929,,BAO_0000218,2048.0,,CLD0
9915,10839,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624930,,BAO_0000218,2385.0,,CLD0
9916,10839,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624931,,BAO_0000218,2385.0,,CLD0
9917,4043,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Heart,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624932,,BAO_0000218,948.0,,CLD0
9918,4043,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Heart,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624933,,BAO_0000218,948.0,,CLD0
9919,4043,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Liver,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624934,,BAO_0000218,2107.0,,CLD0
9920,4043,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Liver,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624935,,BAO_0000218,2107.0,,CLD0
9921,4043,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624936,,BAO_0000218,,,CLD0
9922,4043,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Plasma,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624937,,BAO_0000218,1969.0,,CLD0
9923,4043,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Spleen,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624938,,BAO_0000218,2106.0,,CLD0
9924,4043,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Spleen,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624939,,BAO_0000218,2106.0,,CLD0
9925,4043,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL624940,,BAO_0000218,,,CLD0
9926,4043,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,Walker 256,,50597,N,1,Intermediate,1,,CHEMBL874403,,BAO_0000218,,,CLD0
9927,1446,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624941,,BAO_0000218,1969.0,,CLD0
9928,9971,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624942,,BAO_0000218,1088.0,,CLD0
9929,9971,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624943,,BAO_0000218,1088.0,,CLD0
9930,5765,% Bioavailability after 1 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624944,,BAO_0000218,,,CLD0
9931,5765,% Bioavailability after 4 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624945,,BAO_0000218,,,CLD0
9932,4257,Absolute bioavailability was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624946,,BAO_0000218,,,CLD0
9933,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Adipose tissue,,,50597,N,1,Intermediate,1,,CHEMBL624947,,BAO_0000218,1013.0,,CLD0
9934,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Adipose tissue,,,50597,N,1,Intermediate,1,,CHEMBL624948,,BAO_0000218,1013.0,,CLD0
9935,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Adipose tissue,,,50597,N,1,Intermediate,1,,CHEMBL624949,,BAO_0000218,1013.0,,CLD0
9936,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622025,,BAO_0000218,2113.0,,CLD0
9937,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622026,,BAO_0000218,2113.0,,CLD0
9938,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622027,,BAO_0000218,2113.0,,CLD0
9939,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622028,,BAO_0000218,2113.0,,CLD0
9940,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622029,,BAO_0000218,2107.0,,CLD0
9941,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622208,,BAO_0000218,2107.0,,CLD0
9942,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622209,,BAO_0000218,2107.0,,CLD0
9943,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622210,,BAO_0000218,2107.0,,CLD0
9944,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622211,,BAO_0000218,2048.0,,CLD0
9945,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622212,,BAO_0000218,2048.0,,CLD0
9946,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622213,,BAO_0000218,2048.0,,CLD0
9947,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL874404,,BAO_0000218,2048.0,,CLD0
9948,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620452,,BAO_0000218,2385.0,,CLD0
9949,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620453,,BAO_0000218,2385.0,,CLD0
9950,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620454,,BAO_0000218,2385.0,,CLD0
9951,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624067,,BAO_0000218,2385.0,,CLD0
9952,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624068,,BAO_0000218,,,CLD0
9953,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL624069,,BAO_0000218,992.0,,CLD0
9954,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL624070,,BAO_0000218,992.0,,CLD0
9955,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL624071,,BAO_0000218,992.0,,CLD0
9956,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624072,,BAO_0000218,995.0,,CLD0
9957,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624073,,BAO_0000218,995.0,,CLD0
9958,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624788,,BAO_0000218,995.0,,CLD0
9959,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624789,,BAO_0000218,995.0,,CLD0
9960,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Blood/Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624790,,BAO_0000218,10000011.0,,CLD0
9961,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Blood/Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624791,,BAO_0000218,10000011.0,,CLD0
9962,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Blood/Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624792,,BAO_0000218,10000011.0,,CLD0
9963,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Blood/Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624793,,BAO_0000218,10000011.0,,CLD0
9964,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL877491,,BAO_0000218,2385.0,,CLD0
9965,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624957,,BAO_0000218,2385.0,,CLD0
9966,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624958,,BAO_0000218,2385.0,,CLD0
9967,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624959,,BAO_0000218,2385.0,,CLD0
9968,11977,Dissociation constant was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624960,,BAO_0000218,,,CLD0
9969,14941,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624961,,BAO_0000218,,,CLD0
9970,15078,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624962,,BAO_0000218,,,CLD0
9971,15078,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624963,,BAO_0000218,,,CLD0
9972,4755,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624964,,BAO_0000218,1969.0,,CLD0
9973,589,Partition coefficient (LogP) value was evaluated,P,,,,,,Gut,,,22229,U,0,Intermediate,1,,CHEMBL624965,,BAO_0000100,10000004.0,,CLD0
9974,17582,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624966,,BAO_0000218,,,CLD0
9975,5031,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624967,,BAO_0000218,,,CLD0
9976,17764,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624968,,BAO_0000218,,,CLD0
9977,17720,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624969,,BAO_0000218,1969.0,,CLD0
9978,2862,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL624970,,BAO_0000218,,,CLD0
9979,16423,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624971,,BAO_0000218,,,CLD0
9980,16423,Half-life was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624972,,BAO_0000218,,,CLD0
9981,6005,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624973,,BAO_0000218,,,CLD0
9982,2938,Half-life was evaluated in plasma of rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624974,,BAO_0000218,1969.0,,CLD0
9983,6410,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624975,,BAO_0000218,,,CLD0
9984,6410,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877492,,BAO_0000218,,,CLD0
9985,6062,Half-life was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624976,,BAO_0000218,,,CLD0
9986,6571,Half-life period of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624977,,BAO_0000218,,,CLD0
9987,3136,Half-life period of compound was measured in rat plasma.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626848,,BAO_0000218,1969.0,,CLD0
9988,3136,Half-life period of compound was measured in rat plasma; ND is not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626849,,BAO_0000218,1969.0,,CLD0
9989,3136,Half-life period of compound was measured in rat plasma; not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626850,,BAO_0000218,1969.0,,CLD0
9990,4521,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626851,,BAO_0000218,,,CLD0
9991,5871,Half-life period in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626852,,BAO_0000218,,,CLD0
9992,6077,Half-life period in rats following intravenous administration at 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626853,,BAO_0000218,,,CLD0
9993,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626854,,BAO_0000218,,,CLD0
9994,5144,Half-life period was determined for the compound in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627486,,BAO_0000218,,,CLD0
9995,4498,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627487,,BAO_0000218,,,CLD0
9996,4498,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627488,,BAO_0000218,,,CLD0
9997,1908,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627489,,BAO_0000218,,,CLD0
9998,6211,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627490,,BAO_0000218,,,CLD0
9999,5529,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873829,,BAO_0000218,,,CLD0
10000,6444,Half-life was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627655,,BAO_0000218,,,CLD0
10001,6444,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625994,,BAO_0000218,,,CLD0
10002,6444,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625995,,BAO_0000218,,,CLD0
10003,5207,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625996,,BAO_0000218,,,CLD0
10004,530,In vitro half life in rat plasma,A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625850,,BAO_0000218,1969.0,,CLD0
10005,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625851,,BAO_0000218,1969.0,,CLD0
10006,3219,In vitro half life in rat,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625852,,BAO_0000218,,,CLD0
10007,6109,In vivo half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625853,,BAO_0000218,,,CLD0
10008,17582,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625854,,BAO_0000218,,,CLD0
10009,17582,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874450,,BAO_0000218,,,CLD0
10010,5974,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625855,,BAO_0000218,,,CLD0
10011,5974,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625856,,BAO_0000218,,,CLD0
10012,5974,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625857,,BAO_0000218,,,CLD0
10013,5974,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873831,,BAO_0000218,,,CLD0
10014,17853,Longer half-life in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625858,,BAO_0000218,,,CLD0
10015,17853,Longer half-life in rat (p.o.) at 2.0 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625859,,BAO_0000218,,,CLD0
10016,3457,Pharmacokinetic property (half life) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625860,,BAO_0000218,,,CLD0
10017,2792,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625861,,BAO_0000218,,,CLD0
10018,2792,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625862,,BAO_0000218,,,CLD0
10019,2792,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625863,,BAO_0000218,,,CLD0
10020,2792,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625864,,BAO_0000218,,,CLD0
10021,5739,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625865,,BAO_0000218,,,CLD0
10022,15765,Pharmacokinetic half time was determined intravenously in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625866,,BAO_0000218,,,CLD0
10023,6567,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625867,,BAO_0000218,1969.0,,CLD0
10024,2448,Plasma half life of hydrolysis of the compound,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625868,,BAO_0000218,1969.0,,CLD0
